CPDD 76th Annual Scientific Meeting Program

June 14-19, 2014
Caribe Hilton
San Juan, Puerto Rico
Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Temple University School of Medicine and The College on Problems of Drug Dependence. Temple University School of Medicine is accredited by the ACCME to sponsor Continuing Medical Education for physicians.

Certification Statement:

Temple University School of Medicine designates this live activity for a maximum of 21.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:

It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

Target Audience:

Physicians, Residents/Fellows, Physician Assistants, Nurses, Medical Students

Objectives:

Upon completion of this course, participants should be able to:

1. Critically evaluate current treatments for drug dependence

2. Be informed of the latest findings in epidemiology, prevention and advances in treatment of drug abuse and dependence

3. Select appropriate therapeutic approaches to dealing with issues of dependence to a variety of abused substances
### Qualifying Symposia and Workshops for CME Credit

**Sunday, June 15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30-4:30PM</td>
<td>Stress and Relapse to Drug Use: From Animal Models to Clinical Trials</td>
<td>2</td>
</tr>
<tr>
<td>2:30-4:30PM</td>
<td>Up in Smoke: Cannabis and Tobacco, Linked at the Hip and Double Trouble</td>
<td>2</td>
</tr>
<tr>
<td>5:00-6:00PM</td>
<td>Translational is Behavioral Research in Addiction</td>
<td>1</td>
</tr>
<tr>
<td>5:00-6:00PM</td>
<td>DSM-5 Substance-Related and Addictive Disorders: Rationale and Controversies</td>
<td>1</td>
</tr>
<tr>
<td>7:00-9:00PM</td>
<td>Integration of Addiction Care into Medical Settings: The State of Science</td>
<td>2</td>
</tr>
<tr>
<td>7:00-9:00PM</td>
<td>Go/No-Go Decisions in Medication Development: Why Some Compounds Should NOT Go Forward and How Do We Identify Them?</td>
<td>2</td>
</tr>
</tbody>
</table>

**Monday, June 16**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00AM-12:00PM</td>
<td>Acute and Chronic Stimulant Effects on Motivation and Behavioral Control</td>
<td>2</td>
</tr>
<tr>
<td>10:00AM-12:00PM</td>
<td>Neuropeptidergic Targets for CNS Disorders</td>
<td>2</td>
</tr>
<tr>
<td>2:00-4:00PM</td>
<td>The Effects, Use Patterns and Youth Perception of Electronic Cigarettes</td>
<td>2</td>
</tr>
<tr>
<td>2:00-4:00PM</td>
<td>Novel Approaches to Examining the Intertwining Epidemics of HIV and Drug Abuse: From Decision-Making to Viral Load</td>
<td>2</td>
</tr>
<tr>
<td>7:00-9:00PM</td>
<td>Knowledge Translation in Addiction Sciences: Why and How to Share Research Knowledge Beyond the Academic Community</td>
<td>2</td>
</tr>
<tr>
<td>7:00-9:00PM</td>
<td>High Risk and Understudied: Assessing Abuse Liability in Opioid-Dependent Subjects</td>
<td>2</td>
</tr>
<tr>
<td>7:00-9:00PM</td>
<td>Eating Disorders, Addictions and Substance Use Disorders: Research, Clinical and Treatment Aspects</td>
<td>2</td>
</tr>
</tbody>
</table>
### Tuesday, June 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>SX: (10:00AM-12:00PM)</td>
<td>CB2 Functions in the Brain and the Periphery</td>
<td>2</td>
</tr>
<tr>
<td>SXI: (10:00AM-12:00PM)</td>
<td>Trajectories of Heroin Use: Insights from Longitudinal Studies</td>
<td>2</td>
</tr>
<tr>
<td>WXI: (7:00-9:00PM)</td>
<td>Improving the Writing of Emerging Investigators in Addiction Science: Innovative Training, Evaluation Methods, and Resources</td>
<td>2</td>
</tr>
<tr>
<td>WXIII: (7:00-9:00PM)</td>
<td>Addiction Treatment Research vs. Usual Care: What are the Foreseeable Risks?</td>
<td>2</td>
</tr>
</tbody>
</table>

### Wednesday, June 18

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>SXII: (10:00AM-12:00PM)</td>
<td>Bill Woolverton’s Greatest Hits: Drugs, Choices, and Consequences</td>
<td>2</td>
</tr>
<tr>
<td>SXIII: (2:30-4:30PM)</td>
<td>Environmental and Physiological Factors Predisposing Susceptibility to Drug Abuse</td>
<td>2</td>
</tr>
</tbody>
</table>

### Thursday, June 19

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>SXIV: (10:00AM-12:00PM)</td>
<td>Medications for Drug Addictions: Sex Differences in Outcomes in Animal and Human Laboratory Studies and in Clinical Trials</td>
<td>2</td>
</tr>
<tr>
<td>SXV: (10:00AM-12:00PM)</td>
<td>Demystifying Medicinal Chemistry and Drug Design</td>
<td>2</td>
</tr>
</tbody>
</table>

Registration for CME credit is $100. The fee includes 1.00-21.00 credits maximum.
## Faculty Disclosures:

It is the policy of Temple University School of Medicine, Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in any Temple University sponsored programs are expected to disclose to the program audience ANY real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. **ALL** faculty for the **CPDD 76th Annual Meeting** being held **June 14-19, 2014** have provided disclosure information. Listed below are those faculty who have identified a relationship with a commercial company. Such disclosure should not be construed as a conflict of interest, but, rather as a disclosure of a current or previous financial arrangement. All other faculty have indicated they do not have a financial relationship to disclose.

<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Role/Support Type</th>
<th>Disclosure Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marc Auriacombe</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>RBK Pharma, Ferrer Int, Lundbeck, Mundipharma, DA Pharma</td>
</tr>
<tr>
<td>Sudie Back</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>NIDA, Dept. of Defense</td>
</tr>
<tr>
<td>Robert L. Balster</td>
<td><strong>Consultant</strong>:</td>
<td>Inflexxion, Newton, MA</td>
</tr>
<tr>
<td>Warren K. Bickel</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>NIH/NIDA (R01DA024080), NIH/NIDA (R01DA030241), NIH/NIMHD (R01MD007054), NIH/NCI (U19CA157345), NIH/NIDA (R01DA036017), Virginia Youth Tobacco Projects, NIH/NIDA (R01DA034755), NIH/NIAAA (R01AA021529), NIH (DP&amp;DDE024068), Medical University of South Carolina <strong>Consultant</strong>: General Genetics Corporation, ProPhase, LLC, AstraZeneca Pharmaceuticals, LP, ADial Pharmaceuticals, LLC, Vermont Center on Behavior and Health <strong>Other</strong>: Principal of HealthSim, LLC, a software development company</td>
</tr>
<tr>
<td>Laura Bohn</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>Eli Lilly &amp; Co.</td>
</tr>
<tr>
<td></td>
<td><strong>Consultant</strong>:</td>
<td>Mencuro Therapeutics, Inc.</td>
</tr>
<tr>
<td></td>
<td><strong>Stockholder</strong>:</td>
<td>Mencuro Therapeutics, Inc.</td>
</tr>
<tr>
<td>Kathleen T. Brady</td>
<td><strong>Consultant</strong>:</td>
<td>Embra Pharmaceuticals, Ovation Pharmaceuticals</td>
</tr>
<tr>
<td>Timothy D. Brewerton</td>
<td><strong>Other: Book Royalties</strong>:</td>
<td>Springer Publishing Co.</td>
</tr>
<tr>
<td>Michael R. Bruchas</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>NIH – NIDA, Directors Award NIH</td>
</tr>
<tr>
<td>Sandra D. Comer</td>
<td><strong>Grant/Research Support</strong>:</td>
<td>Rechitt Benckiser</td>
</tr>
<tr>
<td></td>
<td><strong>Consultant</strong>:</td>
<td>AstraZeneca, Salix, Pfizer, Guidepoint Global</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Details</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Wilson M. Compton</td>
<td>Stockholder</td>
<td>Pfizer, General Electric (less than $10,000 stock holdings in each)</td>
</tr>
<tr>
<td>Andrew Coop</td>
<td>Grant/Research Support</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Jonathan Foulds</td>
<td>Grant/Research Support</td>
<td>Pfizer, Inc.</td>
</tr>
<tr>
<td></td>
<td>Consultant</td>
<td>Pfizer, Inc., GSK</td>
</tr>
<tr>
<td>Kevin Freeman</td>
<td>Grant/Research Support</td>
<td>NIDA</td>
</tr>
<tr>
<td>Christine Grella</td>
<td>Grant/Research Support</td>
<td>NIDA</td>
</tr>
<tr>
<td></td>
<td>Consultant</td>
<td>Chestnut Health Systems</td>
</tr>
<tr>
<td>Margaret Haney</td>
<td>Consultant</td>
<td>Insys Pharmaceuticals</td>
</tr>
<tr>
<td>Colleen A. Hanlon</td>
<td>Grant/Research Support</td>
<td>National Institute of Health Career Development Award</td>
</tr>
<tr>
<td>Andrea G. Hohmann</td>
<td>Grant/Research Support</td>
<td>National Institutes of Health, NIDA</td>
</tr>
<tr>
<td></td>
<td>Consultant</td>
<td>Speaker for Cannabidiol Scientific Exchange</td>
</tr>
<tr>
<td></td>
<td>Stockholder</td>
<td>Pfizer Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>G.W. Pharmaceuticals provided Sativex but no</td>
</tr>
<tr>
<td></td>
<td></td>
<td>financial support for pilot double blind placebo controlled crossover</td>
</tr>
<tr>
<td></td>
<td></td>
<td>trial I published with Mary Lynch on which I was collaborator</td>
</tr>
<tr>
<td>Sally L. Huskinson</td>
<td>Grant/Research Support</td>
<td>R01-DA-027666 to KBF from the National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Iliyan Ivanov</td>
<td>Other: DSUB member</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Kathleen M. Kantak</td>
<td>Grant/Research Support</td>
<td>DA 011716</td>
</tr>
<tr>
<td>Marc J. Kaufman</td>
<td>Grant/Research Support</td>
<td>PhotoThera, Inc.</td>
</tr>
<tr>
<td>Frances Kay-Lambkin</td>
<td>Grant/Research Support</td>
<td>Research fellowship – National Health and</td>
</tr>
<tr>
<td></td>
<td>Consultant</td>
<td>Medical Research Council (AUST)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cobalt Therapeutics, LLC</td>
</tr>
<tr>
<td>Therese K. Killeen</td>
<td>Consultant</td>
<td>Rosewood Institute for Eating Disorder Training and Education</td>
</tr>
<tr>
<td>Naama Levy-Cooperman</td>
<td>Consultant</td>
<td>Consultant to pharmaceutical companies and biotech.</td>
</tr>
<tr>
<td>Aron Lichtman</td>
<td>Scientific Advisory Board</td>
<td>Abide Therapeutics</td>
</tr>
<tr>
<td>Bertha Madras</td>
<td>Consultant</td>
<td>RiverMend Health, National Football League</td>
</tr>
<tr>
<td>John Mantsch</td>
<td>Consultant</td>
<td>Promentis Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Stockholder</td>
<td>Promentis Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Other: Co-founder</td>
<td>Promentis Pharmaceuticals</td>
</tr>
</tbody>
</table>
F. Joseph McClernon  
**Grant/Research Support:** Consultant on a Pfizer, Inc. investigator initiated GRAND award to Marcus Munafó

Sherry McKee  
**Grant/Research Support:** Investigator initiated grant support, Pfizer

Yann Mineur  
**Grant/Research Support:** NIMH, NIDA

F. Gerard Moeller  
**Consultant:** Boehringer Ingelheim

Michael A. Nader  
**Grant/Research Support:** NIH/NIDA (DA017763)

Thomas E. Prisinzano  
**Grant/Research Support:** NIDA (DA018151), NIGMS (GM008545) National Institutes of Health

Paula Riggs  
**Grant/Research Support:** NIDA

Andrew Saxon  
**Speakers’ Bureau** Reckitt Benckiser  
**Other:** UpToDate, Inc.

Steven Shoptaw  
**Grant/Research Support:** MediciNova, Inc.  
**Consultant:** Pfizer, Inc.

Rajita Sinha  
**Grant/Research Support:** NIH  
**Scientific Advisory Board:** Embra Neurotherapeutics, LLC

Eric C. Strain  
**Consultant:** DemeRx, Jazz, Zogenix, Reckitt-Benckiser, The Oak Group

Sharon L. Walsh  
**Consultant:** Sun Pharma, AstraZeneca, Equinox Group, Jazz Pharmaceuticals, MedSignals, Inc., Camurus PCM Scientific  
**Speaker/Chair:** PCM Scientific  
**Development of Teaching Materials**

Laurie Zawertailo  
**Grant/Research Support:** Current unrestricted grant funding from Pfizer Canada and Pfizer International  
**Stockholder:** GlaxoSmithKline

The planning committee and staff of the Office for Continuing Medical Education have provided disclosure information and indicated they do not have any financial relationships to disclose. All conflicts have been resolved.
## BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Vocci, Jr., PhD</td>
<td>President</td>
</tr>
<tr>
<td>Richard De La Garza, II, PhD</td>
<td>Past-President</td>
</tr>
<tr>
<td>Eric Strain, M.D.</td>
<td>President-Elect</td>
</tr>
<tr>
<td>Theodore J. Cicero, PhD</td>
<td>Treasurer</td>
</tr>
<tr>
<td>Michael T. Bardo, PhD</td>
<td></td>
</tr>
<tr>
<td>Alan J. Budney, PhD</td>
<td></td>
</tr>
<tr>
<td>Andrew Coop, PhD</td>
<td></td>
</tr>
<tr>
<td>Linda B. Cottler, PhD, MPH</td>
<td></td>
</tr>
<tr>
<td>Linda P. Dwoskin, PhD</td>
<td></td>
</tr>
<tr>
<td>Linda A. Dykstra, PhD</td>
<td></td>
</tr>
<tr>
<td>Toby Eisenstein, PhD</td>
<td></td>
</tr>
<tr>
<td>Margaret Haney, PhD</td>
<td></td>
</tr>
<tr>
<td>Carl L. Hart, PhD</td>
<td></td>
</tr>
<tr>
<td>Stephen T. Higgins, PhD</td>
<td></td>
</tr>
<tr>
<td>Marc J. Kaufman, PhD</td>
<td></td>
</tr>
<tr>
<td>Mary Jeanne Kreek, MD</td>
<td></td>
</tr>
<tr>
<td>A. Thomas McLellan, PhD</td>
<td></td>
</tr>
<tr>
<td>Gregory M. Miller, PhD</td>
<td></td>
</tr>
<tr>
<td>Charles O’Keeffe, M.B.A.</td>
<td></td>
</tr>
<tr>
<td>Roger D. Spealman, PhD</td>
<td></td>
</tr>
</tbody>
</table>

## EXECUTIVE OFFICER

- **Martin W. Adler, PhD**

## DIRECTOR, EXECUTIVE OFFICE

- **Ellen B. Geller, MA**

## SCIENTIFIC PROGRAM COMMITTEE

- Elise Weerts, PhD, Chair
- Martin W. Adler, PhD, *ex officio*
- Ellen B. Geller, MA, *ex officio*
- Mary E. Abood, PhD
- Linda B. Cottler, PhD, MPH
- Kelly Dunn, PhD
- Linda P. Dwoskin, PhD
- William E. Fantegrossi, PhD
- Deborah S. Hasin, PhD
- Michael Kuhar, PhD
- Wendy Lynch, PhD
- F. Gerald Moeller, MD
- William W. Stoops, PhD
- George E. Woody, MD
PRE-MEETING SATELLITES

7th Meeting of the International Women’s and Children’s and Gender Group
Chaired by Wendee Wechsberg
San Cristobal B/C/D
June 13

The 2014 NIDA International Forum: Building International Collaborative Research on Drug Abuse
Chaired by Steven Gust
San Geronomio A/C
June 13 and June 14

Preconference Workshop—AAAP’s PCSS-MAT Buprenorphine Waiver Training
(supported in part by SAMHSA)
Las Olas
June 14
(8:00 AM – 5:30 PM)

The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)
Chaired by Morgan Drake
San Cristobal E/G
June 14

13th Annual Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment (CSAT) Pre-Conference Session
Chaired by Suzan Swanton
San Cristobal A/D
June 14

CPDD REGISTRATION

Saturday, June 14 Peacock Alley 1:30 PM - 5:30 PM
Sunday, June 15 Peacock Alley 7:30 AM - 5:00 PM
Mon, Tues, Wed (16/17/18) Conference Room 3 7:30 AM - 5:00 PM
Thursday, June 19 Conference Room 3 7:30 AM - 3:00 PM

OPENING RECEPTION
Pool Area (Cash Bar)

Saturday, June 14 7:00 PM - 9:00 PM
(Pre-registrants can pick up badges only)
Sunday, June 15, 2014

Plenary Session

SAN GERONIMO
8:00 - 11:00 AM

8:00 Welcome
CPDD President Frank Vocci, Jr.

8:10 In Memoriam

8:20 Report from the National Institute on Drug Abuse
Nora D. Volkow, NIDA/NIAAA, Bethesda, MD

8:40 Report from the National Institute on Alcohol Abuse and Alcoholism
George F. Koob, The Scripps Research Institute, La Jolla, CA

9:00 Presentation of the CPDD/NIDA Media Award to Charles Evans, Jr.
Introduction by Bertha Madras

9:15 Presentation of the Martin and Toby Adler Distinguished Service Award to David Shurtleff
Introduction by Frank Vocci, Jr.

9:25 Presentation of the Joseph Cochin Young Investigator Award to C. Debra Furr-Holden
Introduction by James Anthony

9:35 Presentation of the Mentorship Award to Michael Bardo
Introduction by Janet Neisewander

9:45 Presentation of the Nathan B. Eddy Award to Nora D. Volkow
Introduction by Anna Rose Childress

10:00 Nathan B. Eddy Award Lecture: Fronto-striatal circuitry in addiction
Nora D. Volkow, NIDA Bethesda, MD

Film Screening:
Addiction Incorporated

AUDITORIUM
11:15 - 12:00 PM

Town Hall Industry/Academia Forum

SAN CRISTOBAL
11:15 - 1:15 PM

PHARMACOTHERAPY RESEARCH - OPPORTUNITIES, CHALLENGES AND SUCCESSES IN THE CROSS-TALK OF INDUSTRY, ACADEMIA, AND GOVERNMENT

Chair: Beatriz Rocha

Challenges and unique advantages of using academic medical centers in conducting pharmacotherapy research
Charles P. O’Brien, University of Pennsylvania, Philadelphia, PA

Perspective of a government funding source
David McCann, National Institutes of Health, Bethesda, MD

Experience in collaborating with the private sector and smaller firms
Linda P. Dwoskin, University of Kentucky, Lexington, KY

Pharma perspective and experience in collaborating with academia
Beatrice Setnik, INC Research., Durham, NC

Challenges on collaborations between industry and academic institutions (Part 1)
Jean M. Bidlack, University of Rochester, Rochester, NY

Challenges on collaborations between industry and academic institutions (Part 2)
Margaret Haney, Columbia University, New York, NY
Sunday, June 15, 2014

CPDD Travel Awards Luncheon
(By Invitation Only)
LAS OLAS
11:45 - 1:00 PM

President’s Lecture
BALLROOM B
1:15 - 2:15 PM

The Harrison Act at 100. Past, present and future science behind the search for new opioid analgesics
Andrew Coop, University of Maryland

Symposium I
SAN CRISTOBAL
2:30 - 4:30 PM

STRESS AND RELAPSE TO DRUG USE:
FROM ANIMAL MODELS TO CLINICAL TRIALS

Chairs: John R. Mantsch and Yavin Shaham

2:30 Neurobiological mechanisms that contribute to stress-related cocaine use: Results of preclinical animal studies
John R. Mantsch, Marquette University, Milwaukee, WI

2:55 Stress-induced reinstatement of drug seeking—19 years of progress
Yavin Shaham, Intramural Research Program/NIDA, Baltimore, MD

3:20 Stress mechanisms increasing addiction relapse risk in humans: Potential for new addiction therapeutics
Rajita Sinha, Yale University School of Medicine, New Haven, CT

3:45 The neurokinin 1 receptor as a treatment target in addiction and other stress-related disorders
Markus Heilig, NIAAA/NIDA, Bethesda, MD

4:10 Stress and substance use disorders: The role of early life trauma
Sudie E. Back, Medical University of South Carolina, Charleston, SC

Symposium II
BALLROOM B
2:30 - 4:30 PM

UP IN SMOKE: CANNABIS AND TOBACCO,
LINKED AT THE HIP AND DOUBLE TROUBLE

Chairs: Alan J. Budney and Frances Kay-Lambkin

2:30 Genetic pathways to cannabis and tobacco co-use and misuse
Lauren Few, Washington University School of Medicine, Saint Louis, MO

2:55 Effect of tobacco use on marijuana withdrawal and relapse in the human laboratory
Margaret Haney, Columbia University, New York, NY

3:20 Tobacco use among those with cannabis use disorders: Clinical approaches to co-occurring use
Dustin C. Lee, Geisel School of Medicine at Dartmouth, Lebanon, NH
Sunday, June 15, 2014

3:45  The interaction between cannabis use, tobacco use and psychiatric disorders: Implications for treatment
Frances Kay-Lambkin, University of New South Wales, New South Wales, NSW, Australia

4:10 DISCUSSANT: Implications of co-use for adolescents, with focus on how rising national trends in marijuana use and marijuana legislation may moderate these concerns
Paula D. Riggs, University of Colorado School of Medicine, Aurora, CO

Oral Communications 1

HIV/HCV: DRUGS/INFECTION INTERSECTION

BALLROOM C
2:30 - 4:30 PM

Chairs: Don C. Des Jarlais and Jeffrey Samet

2:30 Knowledge about the transmission of HIV and HCV: A comparison between injection drug users and non-injection drug users

2:45 Hepatitis C virus incidence among HIV+ men who have sex with men: The role of non-injection drug use
H. Hagan1, J. Neurer1, A. E. Jordan1, D. C. Des Jarlais2, J. Wu3, K. Dombrowski4, B. Khan5, S. Braithwaite6, J. Kessler6, 1New York University, New York, NY, 2Beth Israel Medical Center, New York, NY, 3New York University School of Medicine, New York, NY, 4University of Nebraska, Lincoln, NE, 5John Jay College of Criminal Justice, New York, NY, 6New York University, New York, NY

3:00 HCV genotype distribution among injection drug users in Taiwan
Y. Lan1, Y. Yang1, T. Chi1, K. Chen1, R. Wang2, Y. Chiang3, C. Huang3, I. Ho3, Y. Hser4,1, 1Department of Health Risk Management, China Medical University, Taichung, Taiwan, 2Department of Public Health, China Medical University, Taichung, Taiwan, 3Center for Drug Abuse and Addiction, China Medical University Hospital, Taichung, Taiwan, 4Integrated Substance Abuse Program, UCLA, Los Angeles, CA

3:15 The impact of HIV testing policies and practices on HCV testing

3:30 Hepatitis C virus testing and treatment among HIV-infected people who inject drugs in St. Petersburg, Russia
J. Samet1,2, E. Krupitsky3,4, L. A. Wulach2, C. E. Chaisson1, J. Tsui1,2, 1Boston University, Boston, MA, 2Boston Medical Center, Boston, MA, 3First St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation, 4St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation

3:45 Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment
C. M. Denis, M. Fatseas, V. Beltran, J. Daulouede, M. Auriacombe, Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France

4:00 Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-C study
L. Maher1, B. White1, G. Dore1, A. Lloyd1, W. Rawlinson2, 1University of New South Wales, Sydney, NSW, Australia, 2Prince of Wales Hospital, Sydney, NSW, Australia
Sunday, June 15, 2014

4:15  Does effective combined prevention reduce racial/ethnic and sex disparities in HIV infection among PWID
D. C. Des Jarlais¹, K. Arasteh¹, C. McKnight¹, J. P. Feelemyer¹, H. L. Cooper², H. Hagan³, D. Perlman¹, ¹Beth Israel Medical Center, New York, NY, ²Emory University, Atlanta, GA, ³New York University, New York, NY

Symposium III

NEW BUPRENORPHINE FORMULATIONS AND DRUG COMBINATIONS IN CLINICAL DEVELOPMENT

Chairs: David McCann and Bob Walsh

2:30  The development of buprenorphine (Probuphine®) subdermal implants
Frank Vocci, Jr.¹, Behshad Sheldon², ¹Friends Research Institute, Inc., Baltimore, MD, ²Braeburn Pharmaceuticals, Inc, Princeton, NJ

2:50  CAM2038: Long-acting buprenorphine injection formulations in clinical development
Fredrik Tiberg, Camurus AB, Lund, Sweden

3:10  Development of the opioid modulator ALKS 5416: A sublingual co-formulation of buprenorphine and ALKS 33
Elliot Ehrich, Alkermes, Inc., Cambridge, MA

Oral Communications 2

BREAKING THE ICE: METHAMPHETAMINE TREATMENT TARGETS

Chairs: William W. Stoops and Walter Ling

3:45  Preclinical evaluation of JPC-141 as a novel treatment for methamphetamine abuse
J. R. Nickell¹, E. D. Denehy², J. P. Culver¹, P. A. Crooks³, M. T. Bardo², L. P. Dwoskin¹, ¹Pharmaceutical Sciences, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³University of Arkansas, Fayetteville, AR

4:00  Preclinical efficacy of an anti-methamphetamine vaccine with an E6020 adjuvant
R. Arora¹,², T. A. Kosten¹, R. S. Bennett¹,², B. M. Kinsey², F. M. Orson¹,², T. R. Kosten¹,², ¹Baylor College of Medicine, Houston, TX, ²MEDVAMC, Houston, TX, ³University of Houston, Houston, TX

4:15  Influence of bupropion, naltrexone and bupropion+naltrexone on methamphetamine self-administration in humans
W. W. Stoops¹,², E. Pike², L. R. Hays³, P. E. Glaser³, C. R. Rush¹,²,³, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY

4:30  Sustained-release methylphenidate for the treatment of methamphetamine dependence
W. Ling, M. P. Hillhouse, J. Jenkins, J. Hernandez, M. Olaer, S. Reed, L. Mooney, M. Torrington, D. Dickerson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
Sunday, June 15, 2014

Symposium IV

HOW TRANSLATIONAL IS BEHAVIORAL RESEARCH IN ADDICTION?

Chairs: F. Gerard Moeller and Kathryn A. Cunningham

5:00  What needs to be translated in addiction research?
Steven Grant, National Institute on Drug Abuse, NHS, HHS, Bethesda, MD

5:20  Cue reactivity in cocaine-dependent subjects, Relationship to impulsivity and 5-HT2C receptor genotype
F. Gerard Moeller, Virginia Commonwealth University Institute for Drug and Alcohol, Richmond, VA

5:40  5-HT2C receptor function, impulsivity and cocaine cue reactivity in rodents
Kathryn Cunningham, University of Texas Medical Branch, Galveston, TX

Symposium V

DSM-5 SUBSTANCE-RELATED AND ADDICTIVE DISORDERS: RATIONALE AND CONTROVERSIES

Chairs: Deborah S. Hasin and Wilson Compton

5:00  Combining abuse and dependence into a single disorder
Deborah S. Hasin, Columbia University, New York, NY

5:20  Cannabis, caffeine-related disorders, craving, and legal problems in DSM-5
Wilson Compton, National Institute on Drug Abuse, NHS, HHS, Bethesda, MD

5:40  Gambling disorder, Internet gaming disorder and other behavioral addictions in DSM-5
Marc Auriacombe, University of Bordeaux, Bordeaux, France

Oral Communications 3

BUZZ KILL: NEW DATA ON COMBINED ALCOHOL AND STIMULANTS

Chairs: Erin E. Bonar and Steven E. Meredith

5:00  Effects of chronic alcohol consumption on cocaine self-administration in rhesus monkeys
P. W. Czoty, Physiology & Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC

5:15  Energy drink use by adolescents and emerging adults seeking care in the emergency department: Alcohol, drugs, and other risk behaviors
E. E. Bonar, R. M. Cunningham, S. Polshkova, S. T. Chermack, F. C. Blow, M. A. Walton, University of Michigan, Ann Arbor, MI

5:30  Caffeine increases the reinforcing effects of alcohol in some social drinkers
S. E. Meredith, D. Evatt, E. C. Strain, R. R. Griffiths, The Johns Hopkins University School of Medicine, Baltimore, MD
Sunday, June 15, 2014

5:45  Modafinil and naltrexone for the treatment of comorbid cocaine and alcohol dependence

**Oral Communications 4**

**THE GAIN IN PAIN STAYS MAINLY ON THE WANE**

Chairs: Matthew J. Worley and Judith I. Tsui

5:00  *Hepatitis C virus infection, HIV and pain sensitivity in opioid-dependent patients*
J. Tsui¹, D. M. Cheng², M. C. Lira¹, M. R. Winter², D. Alford¹, J. Mao³, R. R. Edwards¹, J. Samet¹, ²Boston Medical Center; Boston University School of Medicine, Boston, MA, ³Harvard Medical School, Boston, MA

5:15  *Pain sensitivity and tolerance among individuals on opioid maintenance: Long-term effects*
A. Wachholtz, G. Gonzalez, Psychiatry, University of Massachusetts Medical School, Worcester, MA

5:30  *Chronic pain volatility predicts outcomes of buprenorphine-naloxone for prescription opioid dependence*
M. Worley¹, K. Heinzerling¹, S. Shoptaw¹, W. Ling², ¹Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, ²Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

5:45  *Cognitive behavioral therapy improves treatment outcome for prescription opioid users in primary-care based buprenorphine/naloxone treatment*
C. J. Cutter, B. A. Moore, D. Barry, L. E. Fiellin, R. S. Schottenfeld, D. Fiellin, P. O’Connor, Yale University School of Medicine, New Haven, CT

**Workshop I**

**THE EPIDEMIOLOGY OF NONMEDICAL USE OF PRESCRIPTION OPIOIDS AND OPIOID USE DISORDERS IN THE USA: RECENT TRENDS, LONGITUDINAL PATTERNS, AND TRANSITIONS TO HEROIN AND INJECTION DRUG USE**

Chairs: Silvia S. Martins and Sean E. McCabe

*Recent trends in nonmedical prescription opioid use and prescription opioid use disorder in the USA among adolescents and young adults*
Silvia S. Martins, Columbia University, New York, NY

*Longitudinal patterns of medical use, medical misuse, and nonmedical use of prescription opioids among adolescents in the United States*
Sean E. McCabe, University of Michigan, Ann Arbor, MI

*Risk of transition to heroin among non-opioid dependent illicit pharmaceutical opioid users*
Robert Carlson, Wright State University, Dayton, OH

*Injection drug use and other risk behaviors among rural prescription opioid users*
Jennifer R. Havens, University of Kentucky School of Medicine, Lexington, KY
Sunday, June 15, 2014

An epidemiologic investigation of the overlap between prescription opioid dependence and alcohol use disorders in the U.S
Howard Chilcoat, Purdue Pharma, Stamford, CT

Workshop II

INTEGRATION OF ADDICTION CARE INTO MEDICAL SETTINGS: THE STATE OF THE SCIENCE

7:00 - 9:00 PM

CHAIRS: Richard Saitz and Jeffrey Samet

Drug use among primary care patients with a positive screen for alcohol misuse
Kimberly Hepner, RAND Corporation, Santa Monica, CA

Health outcomes associated with decreases in illicit drug use in primary care
Tae Woo Park, Boston University, Boston, MA

Variability in primary care opioid prescribing practices
Jane M. Liebschutz, Boston Medical Center/Boston University, Boston, MA

Models of SBIRT for opioid dependence in emergency department patients
Gail D’Onofrio, Yale University School of Medicine, New Haven, CT

Discussant: Integration of addiction care into medical settings: The state of the science
Richard Saitz, Boston University School of Public Health, Boston, MA

Workshop III

GO/NO-GO DECISIONS IN MEDICATION DEVELOPMENT: WHY SOME COMPOUNDS SHOULD NOT GO FORWARD AND HOW DO WE IDENTIFY THEM?

7:00 - 9:00 PM

Chair: Jane B. Acri

Introduction and early stage toxicity testing in drug development: Examples of how predictions of toxicity are evaluated and can be used to guide SAR
Jane B. Acri, NIDA/NIH/DHHS, Bethesda, MD

Cardiovascular safety interaction testing and how it may kill a promising target
Nathan Appel, NIDA/NIH/DHHS, Bethesda, MD

Assessing anhedonia in drug development using intracranial self-stimulation: What it might predict and does it matter?
David A. White, NIDA/NIH/DHHS, Bethesda, MD
Sunday, June 15, 2014

**Workshop IV**

THE 20TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP (WILL INCLUDE PRESENTATIONS BY JUNIOR AND SENIOR INVESTIGATORS OF DATA FROM ONGOING STUDIES THAT INVOLVE CM)

Chairs: Steven Meredith and Kelly E. Dunn

*Some reflections on 20 years of research on the use of financial incentives to promote behavior change*

Stephen Higgins, University of Vermont, Burlington, VT

**Workshop V**

EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS FOR MINORITIES AND UNDER-REPRESENTED MINORITIES (CO-SPONSORED BY CPDD INTERNATIONAL PROGRAMS COMMITTEE)

Chairs: J. C. Anthony and Jan Copeland

*Just-in-time adaptive interventions delivered via smartphones*

Susan A. Murphy, The University of Michigan, Ann Arbor, MI

*The challenge of effective and culturally sensitive research methodologies: Australian Aboriginal and Torres Strait Islander communities*

Jan Copeland, UNSW Medicine University of New South Wales, Sydney, NSW, Australia

*The challenge of effective and culturally sensitive research methodologies in the United States: Lessons learned from the Collaborative Psychiatric Epidemiology Surveys and Other Health Disparities Research Projects*

Margarita Alegria, Cambridge Health Alliance & Harvard Medical School, Somerville, MA
Monday, June 16, 2014

Poster Session I
(Breakfast)

GRAN SALON
LOS ROSALES
8:00 - 10:00 AM

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Sunday 1:00 PM
Must be removed by Monday 12:00 Noon

STIMULANTS - HUMANS I

1 Caffeine withdrawal in college students: Differences by gender and beverage type
   D. Pomm, D. Svikis, P. Dillon, D. Dick, K. Kendler, Virginia Commonwealth University,
   Richmond, VA

2 Coffee and energy drink use in college freshmen: Is trouble brewing?
   D. Svikis1, P. Dillon1, L. Thacker1, S. Meredith2, K. M. Polak1, D. Dick1, S. Kornstein1,
   K. Kendler1, 1Virginia Commonwealth University, Richmond, VA, 2Johns Hopkins School of
   Medicine, Baltimore, MD

3 Understanding the buzz about energy drink use in college students
   University, Richmond, VA

4 Risk factors for consumption of energy drinks, alcohol and both among a sample of youth from
   10 U.S. metropolitan areas
   S. R. Khan, S. O. Lasopa, L. Cottler, C. W. Striley, Epidemiology, University of Florida,
   Gainesville, FL

5 Energy drink consumption and other drug use in male and female eighth, tenth, and twelfth
   graders
   K. M. Polak, P. Dillon, S. Girma, R. Koch, D. Svikis, Virginia Commonwealth University,
   Richmond, VA

6 Basal neuroendocrine status and cocaine craving measurements in active cocaine-dependent
   volunteers at admission and after 8 weeks of abstinence
   E. A. Ducat, B. M. Ray, J. Jackson, E. Butelman, M. Kreek, Laboratory of the Biology of
   Addictive Diseases, Rockefeller University, New York, NY

7 CRF versus AVP in human stress responsivity: Initial studies
   B. M. Ray, E. A. Ducat, B. Reed, J. Altschuler, M. Kreek, Laboratory of the Biology of
   Addictive Diseases, Rockefeller University, New York, NY

8 Oxidative stress, BDNF and severity of crack cocaine use in early withdrawal
   A. O. Sordi, F. Pechansky, F. Kessler, L. von Diemen, Psychiatry - Addiction, Center for Drug
   and Alcohol Research (CPAD), Hospital de Clinicas de Porto Alegre (HCPA), Universidade
   Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil, Porto Alegre, Brazil

9 BDNF levels of crack users are associated with clinical outcome during inpatient treatment
   L. von Diemen1, F. Kapcinski2, A. O. Sordi1, F. H. Kessler1, J. Narvaez1, F. P. Pechansky1,
   1Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Hospital
   de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2Instituto Nacional de Ciência e Tecnologia
   Translacional em Medicina (INCT), Hospital de Clinicas de Porto Alegre, Universidade
   Federal do Rio Grande do Sul, Porto Alegre, Brazil
10  
Prevalence of mild traumatic brain injury in cocaine-dependent research volunteers  
D. Ramesh1, L. A. Keyser-Marcus1, J. Schmitz2, S. D. Lane3, J. H. Marwitz2, J. S. Kreutzer2,  
F. Moeller1, 1Institute of Drug & Alcohol Studies, VCU, Richmond, VA, 2Physical Medicine  
& Rehabilitation, VCU, Richmond, VA, 3Psychiatry & Behavioral Sciences, UT-Houston,  
Houston, TX

11  
Distinctive types of executive dysfunction on cocaine dependence and ADHD compared to  
healthy controls  
P. D. Goncalves, M. Ometto, T. Chain, B. Santos, M. Silva, M. Louza, M. Cavallet,  
S. Caetano, A. Malbergier, S. Nicastri, A. Andrade, G. Busatto, P. J. Cunha, Institute &  
Department of Psychiatry, School of Medicine, University of São Paulo, São Paulo, Brazil

12  
Cocaine images impact inhibitory control: A within- and between-subjects comparison  
E. Pike1,2, W. W. Stoops1,2, C. R. Rush1,2,3, 1Psychology, University of Kentucky,  
Lexington, KY, 2Behavioral Science, University of Kentucky, Lexington, KY, 3Psychiatry,  
University of Kentucky, Lexington, KY

13  
Inhibitory control in patients with cocaine abuse is equally disrupted by generic and personally  
salient cocaine images  
G. J. DiGirolamo1,2, D. Smelson2, N. Guevremont, G. Gonzalez2, 1Psychology, College of  
the Holy Cross, Worcester, MA, 2Psychiatry, University of Massachusetts, Medical School,  
Worcester, MA

14  
Predicting the effects of d-amphetamine using measures of sensation seeking and impulsivity  
A. M. Harvanko1,2, C. Martin1,2, R. J. Charmigo2, J. S. Fogel1,2, J. A. Lile2, T. H. Kelly1,2,3,  
1Psychology, University of Kentucky, Lexington, KY, 2Behavioral Science, University of  
Kentucky, Lexington, KY, 3Psychiatry, University of Kentucky, Lexington, KY, 4Biostatistics,  
University of Kentucky, Lexington, KY

15  
Influence of sensation seeking on d-amphetamine reinforcement  
M. E. Patrick1, A. C. Meyer2, S. T. Higgins1,2, S. C. Sigmon1,2, 1Psychology, University of  
Vermont, Burlington, VT, 2Psychiatry, University of Vermont, Burlington, VT

16  
Low striatal dopamine D2/3 receptor availability predicts steeper delay discounting in  
methamphetamine abusers  
M. E. Ballard1, J. R. Monterosso1, A. C. Dean1, M. A. Mandelkern4,5, E. London1,2,  
1Psychiatry & Biobehavioral Neuroscience, University of California, Los Angeles, Los  
Angeles, CA, 2Molecular & Medical Pharmacology, University of California, Los Angeles,  
Los Angeles, CA, 3Psychology, University of Southern California, Los Angeles, CA,  
4Nuclear Medicine Service, Veterans Affairs Greater Los Angeles Healthcare System, Los  
Angeles, CA, 5Physics, University of California, Irvine, Irvine, CA

17  
The paradoxical effect of transcranial direct current stimulation on methamphetamine craving  
H. Ekhtiari1,2, A. Shahbabaie1, B. Zamanian2, M. Ebranlipoor1, M. Golesorkhi1, F. Keshvari1,  
V. Nejati1, 1Translational Neuroscience Program, Institute for Cognitive Science Studies,  
Tehran, Islamic Republic of Iran, 2Iranian National Center for Addiction Studies, Tehran,  
Islamic Republic of Iran

18  
Dependence on amphetamines increases Parkinson’s disease: Effect of gender  
G. R. Hanson, A. E. Fleckenstein, K. Curtin, University of Utah, Salt Lake City, UT

19  
Cardiovascular safety of ibudilast treatment with intravenous methamphetamine administration  
D. DeYoung1, K. G. Heinzerling1, A. Swanson2, J. Tsuang3, B. Furst3, Y. Yi4, Y. Wu4,  
S. Shoptaw1, 1Family Medicine, UCLA, Los Angeles, CA, 2Psychiatry, Stanford University,  
Stanford, CA, 3Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, 4Statistics, UCLA,  
Los Angeles, CA
20 Influence of buspirone on the cardiovascular and subject-rated effects of methamphetamine
C. R. Rush1,2,3, E. Pike2, W. W. Stoops1,2,1Behavioral Science, University of Kentucky, Lexington, KY, 2Psychology, University of Kentucky, Lexington, KY, 3Psychiatry, University of Kentucky, Lexington, KY

21 Cognitive and cardiovascular effects of carvedilol in recently abstinent, cocaine-dependent patients
M. J. Mancino1, S. Shervani1, J. D. Thostenson1, J. B. Guise1, J. McEachern1, T. R. Kosten2, A. Oliveto1, 1Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, 2Psychiatry, Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX

ADOLESCENT DRUG ABUSE I

22 Teens’ vulnerability to substance use disorder: Excess reward or deficient inhibition?
T. J. Crowley1, M. S. Dalwani1, S. K. Mikulich-Gilbertson1, S. Young1, S. K. McWilliams1, K. M. Raymond1, M. Roark1, M. T. Banich2, 1University of Colorado, Denver, CO, 2University of Colorado, Boulder, CO

23 Buffering effects of moral identity on the links between peer relationship quality and problem behaviors
C. Streit, G. Carlo, S. E. Killoren, M. E. Len-Rios, L. Cooper, A. Deutsch, A. N. Davis, University of Missouri, Columbia, MO

24 Longitudinal trajectories of disinhibitory personality and behavioral constructs across early to middle adolescence
V. Brown, A. Collado, J. Felton, J. M. Shadur, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, College Park, MD

25 Substance use trajectories from early adolescence through the college years
K. J. Dereffinko1, R. J. Charnigo1, R. Milich1, D. R. Lynam2, 1University of Kentucky, Lexington, KY, 2Purdue University, West Lafayette, IN

26 Personality traits and sex under the influence of alcohol during adolescence
M. Orgiles, A. Morales, M. T. Gonzalvez, A. Guillon, J. P. Espada, Miguel Hernandez University, Alicante, Spain

27 Perceived drinking risk and adolescent alcohol use over time: A dual latent growth curve analysis
J. M. Shadur, J. W. Felton, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD

28 Adolescent attachment and substance use: Concurrent and prospective links
J. D. Jones, N. Bouonou, L. Pandes-Carter, C. W. Lejuez, J. Cassidy, University of Maryland, College Park, College Park, MD

29 Beyond an adolescent’s first occasion of using prescription pain relievers extra-medically: Associations with sex and with alcohol involvement
M. A. Parker, J. C. Anthony, Michigan State University, East Lansing, MI

30 Initiation of nonmedical prescription opioid use and development of opioid dependence among young adults
P. Mateu-Gelabert, H. Guarino, Institute for Infectious Disease Research, NDRI, Inc., New York, NY

31 Effects of family relationships quality on drug use: Mediating effects of moral conviction
A. N. Davis, G. Carlo, C. Streit, University of Missouri, Columbia, MO
Monday, June 16, 2014

32  WITHDRAWN

33  Substance use trajectories among drug-using youth presenting to an urban ED
    M. A. Walton¹, J. E. Goldstick¹, Q. Epstein-Ngo¹, F. C. Blow¹, M. Zimmerman¹, B. M. Booth²,
    R. M. Cunningham¹, Departments of Psychiatry, Emergency Medicine, or School of Public
    Health, University of Michigan, Ann Arbor, MI,  ²University of Arkansas for Medical
    Sciences, Little Rock, AR

34  Understanding the service needs of assault-injured, drug-using youth presenting for care in an
    urban emergency department
    L. S. Massey², K. Bohnert², M. A. Walton², M. Ranney⁴, E. E. Bonar², F. C. Blow²,
    M. Zimmerman¹, B. M. Booth¹, R. M. Cunningham¹, Injury Center, University of Michigan,
    Ann Arbor, MI, ²Department of Psychiatry, University of Michigan, Ann Arbor, MI,
    ³University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Brown University, Providence, RI

35  Drug-using ED assault-injured youth: 2-year prospective study of violent injury and mortality
    R. Cunningham³, P. Carter¹, M. Zimmerman³, F. C. Blow², B. M. Booth¹, M. A. Walton²,
    ¹Univ of Arkansas, Little Rock, AR, ²Department of Psychiatry, Univ of Michigan, Ann
    Arbor, MI, ³Injury Center, Univ of Michigan, Ann Arbor, MI

36  The effect of neighborhood context on the relationship between substance misuse and weapons
    aggression in urban adolescents
    J. E. Goldstick¹, R. Lipton¹, P. Carter¹, M. Newton¹, S. A. Stoddard², M. A. Walton³,
    T. Reischl², M. Zimmerman², R. Cunningham¹-², ¹Emergency Medicine, University of
    Michigan, Ann Arbor, MI, ²Health Behavior and Health Education, University of Michigan,
    Ann Arbor, MI, ³Psychiatry, University of Michigan, Ann Arbor, MI

37  Exploring the effects of alcohol and marijuana use on experience of teen dating violence among
    high school students in Maryland
    E. Parker¹, C. Bradshaw¹-², K. Debnam¹, A. J. Milam¹-³, C. D. Furr-Holden¹, ¹Department of
    Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Curry
    School of Education, University of Virginia, Charlottesville, VA, ³School of Medicine, Wayne
    State University, Detroit, MI

38  Can a brief intervention be effective for adolescents with a severe-end drug problem?
    K. Winters, S. Lee, Psychiatry, University of Minnesota Medical School, Minneapolis, MN

39  Parent tobacco use, monitoring, and impulsive decision making: Predictors of post treatment
    youth substance use
    V. Noel, C. Stanger, A. J. Budney, Psychiatry, Geisel School of Medicine at Dartmouth,
    Lebanon, NH

40  Maternal impulsivity as a predictor of adolescent smoking status
    A. Herrick¹, S. Fields¹, B. Reynolds², P. Pirie³, ¹Psychology, Texas A&M University,
    College Station, TX, ²Behavioral Science, University of Kentucky College of Medicine,
    Lexington, KY, ³Ohio State University, Columbus, OH

41  Increasing the value of an alternative monetary reinforcer reduces cigarette choice in
    adolescents
    R. Cassidy, J. W. Tidey, C. W. Kahler, T. B. Wray, S. M. Colby, Center for Alcohol and
    Addiction Studies, Brown University, Providence, RI

NICOTINE I

42  Prenatal intravenous nicotine exposure enhances methamphetamine sensitization and alters
    BDNF levels in adult rat offspring
    R. T. Lacy¹, A. J. Morgan¹, R. W. Brown¹, M. K. Perna¹, S. B. Harrod¹, ¹Psychology,
    Davidson College, Davidson, NC, ²Psychology, University of S. Carolina, Columbia, SC,
    ³Psychology, E. Tennessee State University, Johnson City, TN
Monday, June 16, 2014

43  **Nicotine and stress: A role for the glutamate system**  
H. Philogene, C. S. Tallarida, S. Rawls, Center for Substance Abuse Research (CSAR), Temple University School of Medicine, Philadelphia, PA

44  **Opioid system located downstream of α7 nicotinic acetylcholine receptor participates in the development of physical dependence on nicotine in mice**  
S. Kishioka, N. Kiguchi, Y. Kobayashi, F. Saika, C. Yamamoto, Pharmacology, Wakayama Medical University, Wakayama, Japan

45  **Effects of extended release tramadol on cigarette smoking during opioid withdrawal**  
M. R. Lofwall¹,², S. Babalonis¹,³, L. Bennett⁴, P. A. Nuzzo³, S. L. Walsh¹,²,¹Behavioral Science, University of Kentucky College of Medicine (UK COM), Lexington, KY, ²Psychiatry, UK COM, Lexington, KY, ³Center on Drug and Alcohol Research, UK COM, Lexington, KY, ⁴Anesthesiology, UK COM, Lexington, KY

46  **Effects of anatabine at relevant human nicotinic receptor subtypes in vitro and on craving and C-reactive protein in heavy smokers**  

47  **Modeling potential mechanisms of differential treatment effects in osmotic-release methylphenidate for smoking cessation**  
S. X. Luo¹, M. M. Wall¹, L. S. Covey¹, M. Hu¹, F. R. Levin¹, E. V. Nunes¹, T. Winhusen², ¹Psychiatry, Columbia University, New York, NY, ²Psychiatry, University of Cincinnati, Cincinnati, OH

48  **Executive functioning and emotion dysregulation in ADHD and non-ADHD cigarette smokers**  
J. Mitchell¹, P. Dennis², J. Beckham², S. H. Kollins¹, ¹Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC, ²Durham Veterans Affairs Medical Center, Durham, NC

49  **Delay discounting predicts preference reversals by cigarette smokers**  
K. N. Tormohlen, A. K. Matusiewicz, A. Tyson, R. Yi, Center for Addictions, Personality and Emotion Research, Department of Psychology, University of Maryland, College Park, MD

50  **Examination of a recommended algorithm for eliminating nonsystematic delay discounting data**  
T. J. White¹,², R. Redner¹,², J. M. Skelly¹,³, S. T. Higgins¹,²,⁴, ¹Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, ²Psychiatry, University of Vermont, Burlington, VT, ³Medical Biostatistics, University of Vermont, Burlington, VT, ⁴Psychology, University of Vermont, Burlington, VT

51  **Influence of nicotine replacement therapy on heart rate variability and relapse**  
S. R. Vorel, M. Mahoney, A. Bisaga, Psychiatry, Columbia University/New York State Psychiatric Institute, New York, NY

52  **Online attentional re-training for smoking**  
R. Wiers¹, I. Elfriedali², T. W. Pronk¹, C. Bolman³, H. De Vries², ¹Addiction Development and Psychopathology (ADAPT) Lab, Psychology, University of Amsterdam, Amsterdam, Netherlands, ²Maastricht University, Maastricht, Netherlands, ³Open University, Heerlen, Netherlands

53  **Psychedelic-facilitated smoking cessation: An online survey**  
A. P. Garcia-Romeu, R. R. Griffiths, M. W. Johnson, Johns Hopkins School of Medicine, Baltimore, MD

54  **A novel behavioral activation intervention for smoking cessation; Mechanisms of change**  
C. Kopetz¹, L. MacPherson², A. Mitchell², A. Houston-Ludlam², R. W. Wiers², H. Larsen³, ¹Psychology, Wayne State University, Detroit, MI, ²Psychology, University of Maryland, College Park, MD, ³Psychology, University of Amsterdam, Amsterdam, Netherlands
55 Task persistence as a target for tobacco dependence treatment  
M. L. Steinberg, E. E. Epstein, N. F. Stahl, T. D. Budsock, J. M. Williams, Psychiatry, Rutgers University, New Brunswick, NJ; Center of Alcohol Studies, Rutgers University, Piscataway, NJ

56 CEASE quit smoking: A successful CBPR trial  
P. Sheikhattari, F. A. Wagner, Prevention Sciences Research Center, Morgan State University, Baltimore, MD; School of Community Health and Policy, Morgan State University, Baltimore, MD

57 CM of smoking abstinence vs. CM with shaping for smoking cessation among treatment-seeking patients  
R. Secades-Villa, C. López-Núñez, I. Pericot-Valverde, F. Alonso-Pérez, O. García-Rodríguez, Department of Psychology, University of Oviedo, Oviedo, Spain

58 Hookah use among college students: Prevalence, mental health and drug use  
A. Grinberg, C. L. Hart, J. Shapiro, D. Keith, F. Taha, M. P. McNeil, R. Goodwin, The Graduate Center (CUNY) at Queens College, Queens, NY; New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY; Mailman School of Public Health, Columbia University, New York, NY

THC AND CANNABINOIDS

59 Does marijuana increase risk for dating violence victimization or perpetration?: Results of a meta-analysis  
E. F. Rothman, R. M. Johnson, K. Pettoruto, M. Lavalley, Community Health Sciences, Boston University School of Public Health, Boston, MA; Biostatistics, Boston University School of Public Health, Boston, MA; Johns Hopkins University, Baltimore, MD

60 Monitoring marijuana use and risk perceptions with Google Trends data  
P. Cavazos-Rehg, M. Krauss, E. Spitznagel, S. Buckner-Petty, R. Grucza, L. Bierut, Washington University School of Medicine, St. Louis, MO

61 Does health status influence attitudes about and use of medical marijuana? Findings from a general population survey in California  
C. E. Grella, S. Cochran, V. Mays, Integrated Substance Abuse Programs, University of California, Los Angeles, CA; Public Health, University of California, Los Angeles, CA; Psychology, University of California, Los Angeles, CA

62 Medical marijuana: Stepping stone or protective effect?  
S. Lankenau, E. Iverson, Drexel University, Philadelphia, PA; Children’s Hospital Los Angeles, Los Angeles, CA

63 Recent cannabis use among adolescent and young adult immigrants in the Netherlands: The roles of acculturation strategy and linguistic acculturation  
M. Delforterie, H. Creemers, A. Huizink, Faculty of Psychology & EMGO, VU University, Amsterdam, Netherlands; Child Development and Education, University of Amsterdam, Amsterdam, Netherlands

64 Racial/ethnic differences in attentional bias and cue reactivity among individuals with marijuana use disorders  
L. M. Ruglass, R. Melara, Psychology, The City College of New York, New York, NY

65 Neighborhood environment and marijuana use in urban young adults  
66  Specialist ‘cannabis only’ clinics in NSW, Australia: Client and treatment characteristics and associations with treatment-seeking behavior
   J. Copeland, D. J. Allsop, National Cannabis Prevention and Information Centre, UNSW, Sydney, NSW, Australia
67  Evaluation of guanfacine administration on cognition in volunteers with cannabis-use disorder
   C. D. Verrico1,2, D. G. Thompson-Lake1,2, T. Iqbal1,2, J. Mahoney1,2, T. R. Kosten1,2, T. F. Newton1,2, R. De La Garza, II1,2, Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, 1Michael E. DeBakey VA Medical Center, Houston, TX
68  I-cut — an integrative group cessation intervention for co-smokers of tobacco and cannabis: Feasibility study
   J. Becker, M. P. Schaub, Swiss Research Institute for Public Health and Addiction, Zurich, Switzerland
69  Psychometric evaluation of the Marijuana Reduction Strategy Self-Efficacy Scale with a community sample of marijuana users
   A. K. Davis, N. Cross, K. Laruitsen, H. Rosenberg, L. Ashrafoun, Psychology, Bowling Green State University, Bowling Green, OH
70  WITHDRAWN
71  Daily marijuana use and craving in the academic setting: A study using ecological momentary assessment
   K. T. Phillips, M. M. Phillips, T. L. Lalonde, University of Northern Colorado, Greeley, CO
72  Initial validation of a marijuana purchase task
   E. Aston1, J. MacKillop3,1, R. Cassidy1, J. Metrick2,1, 1Center for Alcohol and Addiction Studies, Brown University, Providence, RI, 2Providence VA Medical Center, Providence, RI, 3Department of Psychology, University of Georgia, Athens, GA
73  Family environment as a mediator of relations between familial risk and impulsivity
   S. R. Ryan, C. W. Mathias, A. Acheson, D. M. Dougherty, Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX
74  Marijuana use and its relationship to impulsivity measured via delay discounting
   M. S. Sferra, S. Thamotharan, S. Fields, Psychology, Texas A&M University, College Station, TX
75  Measurement of attentional bias and stress in chronic marijuana users
   S. Liu1, N. Dias2, N. Rathnayaka2, J. H. Yoon3,1, J. Schmitz2, S. D. Lane2, 1Psychiatry, Baylor College of Medicine, Houston, TX, 2Psychiatry & Behavioral Sciences, UTHSC-Houston, Houston, TX
76  Marijuana use and FAAH genotype predict sleep quality in adolescents and emerging adults
   K. E. Maple, N. E. Wright, K. M. Lisdahl, Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI
77  THC (δ9-tetrahydrocannabinol) elicits persistent changes in expression of genes implicated in adolescent neurodevelopment
   B. K. Madras1, J. Zimmer1, L. M. Ogawa1, G. M. Miller1, S. V. Westmoreland1, E. Vallender1, Y. L. Hurd2, 1Psychiatry, Harvard Medical School-NEPRC, Southborough, MA, 2Mount Sinai Hospital, New York, NY
78  A study on neurotoxicity and dependence mechanisms of JWH-081 and JWH-210
79 Conditioned taste avoidance induced by Δ-9-tetrahydrocannabinol in the Fischer and Lewis rat strains
A. G. Wakeford, A. L. Riley, Psychology, American University, Washington, DC

CLUB DRUGS
80 Role of glycogen synthase kinase-3β in ketamine self-administration, cue and drug-induced reinstatement
X. Huang, K. Huang, W. Zheng, X. Li, W. Zhou, Y. Liu, Ningbo University School of Medicine, Ningbo, China

81 Substantial enantiomer-specific differences in the neurochemical and behavioral actions of the synthetic cathinone mephedrone
R. A. Gregg¹, M. H. Baumann², A. Vouga¹, C. Tallarida¹, S. Rawls¹, ¹Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, ²Medicinal Chemistry Section, NIDA Intramural Research Program, Baltimore, MD

82 Striatal dopamine dynamics in mice following acute and repeated toluene exposure
A. Apawu², T. Mathews², S. Bowen¹, ¹Psychology, Wayne State University, Detroit, MI, ²Chemistry, Wayne State University, Detroit, MI

83 Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology
T. M. Carbonaro¹, F. S. Barrett¹, M. P. Bradstreet¹, M. W. Johnson¹, K. A. MacLean¹, R. Jesse¹,², R. R. Griffiths¹,², ¹Psychiatry, Johns Hopkins University, Baltimore, MD, ²Neurosciences, Johns Hopkins University, Baltimore, MD, ³Council on Spiritual Practices, Baltimore, MD

84 The Challenging Experience Questionnaire: Characterization of acute adverse reactions to psilocybin
F. S. Barrett¹, M. P. Bradstreet¹, J. S. Leoutsakos¹, M. W. Johnson¹, K. A. MacLean¹, R. Jesse¹,², R. R. Griffiths¹,², ¹Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, ²Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, ³Council on Spiritual Practices, San Francisco, CA

85 Longitudinal patterns of ecstasy and other drug use among young adults
A. M. Arria, B. A. Bugbee, K. M. Caldeira, K. B. Vincent, K. E. O’Grady, Center on Young Adult Health and Development, Dept. of Behavioral and Community Health, University of Maryland School of Public Health, College Park, MD

86 K2 use at college entry and experimentation over college career

87 Synthetic cannabinoid use and awareness in a drug abuse treatment clinic
E. Disney, K. B. Stoller, R. Vandrey, Johns Hopkins University School of Medicine, Baltimore, MD

88 Synthetic cannabinoid use among treatment seeking substance users
M. A. Kelly, J. J. Mariani, A. Glass, M. Pavlicova, A. Radin, F. R. Levin, Psychiatry, Substance Abuse, Columbia/New York State Psychiatric Institute, New York, NY

CHEMISTRY AND PHARMACOKINETICS
89 Structure-activity relationship studies on the tetrahydroisoquinoline-based orexin 1 receptor antagonists: The 1-benzyl position
Y. Zhang, D. A. Perrey, D. L. Harris, N. A. German, A. M. Decker, B. P. Gilmour, B. F. Thomas, Research Triangle Institute, Research Triangle Park, NC
Monday, June 16, 2014

90 Targeting the serotonin (5-HT) 5-HT$_{2C}$ receptor: Rational design of small molecule allosteric modulators to treat psychostimulant use disorders
C. Wild, C. Ding, G. Zhang, N. Anastasio, J. Moncrief, T. Carbonaro, R. Fox, S. Stutz, R. Hartley, T. Smith, K. Cunningham, J. Zhou, Center for Addiction Research / Pharmacology, Univ of Texas Medical Branch, Galveston, TX

91 Chemical modifications to alter monoamine releasing activity of phenmetrazine analogs as potential treatments of stimulant addiction
O. A. Namjoshi$^1$, A. M. Decker$^1$, A. Landavazo$^1$, J. S. Partilla$^2$, M. H. Baumann$^2$, R. B. Rothman$^2$, B. E. Blough$^1$, 1Drug Discovery, RTI International, Research Triangle Park, NC, 2Medicinal Chemistry Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Health, Baltimore, MD

92 Plasma butyrylcholinesterase enzyme functional activity in cocaine addicts
D. A. Gorelick$^{1,2}$, J. R. Cashman$^1$, J. R. Schroeder$^1$, 1Intramural Resesarch Program, National Institute on Drug Abuse, NIH, Baltimore, MD, 2Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, 3Human BioMolecular Research Institute, San Diego, CA

93 Acetazolamide, a new adherence marker for clinical trials?
A. Hampson$^1$, S. Babaloni$^2$, M. R. Lofwall$^2$, P. A. Nuzzo$^2$, S. L. Walsh$^2$, 1Div. Pharmacotherapies, National Institute on Drug Abuse, NHS, HHS, Rockville, MD, 2Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

94 Quinine: A potential tracer for monitoring medication adherence
S. Babaloni$^1$$^2$, A. Hampson$^4$, M. R. Lofwall$^{1,2,3}$, P. A. Nuzzo$^2$, S. L. Walsh$^{1,2,3}$, 1Behavioral Science, University of Kentucky (UK), Lexington, KY, 2Center on Drug and Alcohol Research, UK, Lexington, KY, 3Psychiatry, UK, Lexington, KY, 4National Institute on Drug Abuse, Rockville, MD

95 Safety and pharmacokinetics of oxycodone DETERx administered intranasally in recreational opioid users

96 Pharmacokinetic-pharmacodynamic analyses in the assessment of abuse-deterrent opioid formulations
M. Shram$^1$, S. Colucci$^2$, S. Harris$^2$, P. J. Perrino$^2$, K. A. Schoedel$^1$, N. Levy-Cooperman$^1$, S. L. Walsh$^3$, 1Altheos Research Partners Inc., Toronto, ON, Canada, 2Purdue Pharma LP, Stamford, CT, 3Department Behavioral Science, University of Kentucky, Lexington, KY

BEHAVIOR

97 Aerobic exercise decreases speedball self-administration in female rats
J. C. Strickland, R. T. Lacy, M. K. Brophy, M. A. Witte, M. A. Smith, Davidson College, Davidson, KY

98 Modulation of behavioral effects of polydrug (cocaine/heroin) mixtures by alpha-2 agonists
R. D. Speelman$^1$, J. Bergman$^2$, 1Behavioral Biology-NERP, Harvard Medical School, Southborough, MA, 2Preclinical Pharmacology, McLean Hospital-Harvard Medical School, Belmont, MA

99 A novel 5HT2C-specific agonist/5HT2A-2B antagonist attenuates psychomotor behaviors induced by methamphetamine, oxycodone, and their combination
D. Morgan$^1$, C. E. Canal$^2$, P. C. Orza$^1$, J. L. Rose$^1$, M. S. Kim$^2$, R. G. Booth$^2$, 1Psychiatry, University of Florida, Gainesville, FL, 2Center for Drug Discovery, Northeastern University, Boston, MA
100 **Chronic, but not acute, low doses of pramipexole increased risk-taking behavior in rats**
S. E. Tedford\(^1,3\), N. A. Holtz\(^1\), A. L. Persons\(^1,3\), C. Napier\(^1,2,3\), \(^1\)Pharmacology, RUSH University, Chicago, IL, \(^2\)Psychiatry, RUSH University, Chicago, IL, \(^3\)Center for Compulsive Behavior and Addiction, RUSH University, Chicago, IL

101 **Choice self-administration in the HIV-1 transgenic rats: A perspective on compulsive behavior**
C. F. Mactutus, S. B. Harrod, S. J. Bertrand, A. J. Morgan, M. N. Cranston, R. M. Booze, Psychology, University of South Carolina, Columbia, SC

102 **HIV-1 transgenic rats exhibit attenuated cocaine-mediated increase in synaptosomal [3H]dopamine uptake in striatum following cocaine self-administration**
J. Zhu\(^1\), B. J. Bertrand\(^2\), S. B. Harrod\(^2\), C. F. Mactutus\(^3\), R. M. Booze\(^2\), \(^1\)Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, \(^2\)Psychology, University of South Carolina, Columbia, SC

103 **Is high fructose corn syrup addictive? Studies of operant intraoral self-administration in rats**
F. Leri, A. Levy, Psychology, University of Guelph, Guelph, ON, Canada

104 **The role of nociceptin in responding for palatable rewards**
I. A. Mendez, N. T. Maidment, N. P. Murphy, Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA

105 **Characterization of the discriminative stimulus effects of the NOP agonist Ro 64-6198 in non-human primates**
P. A. Saccone, K. A. Zelenock, A. Lindsey, M. E. Zaks, J. H. Woods, Pharmacology, University of Michigan Medical School, Ann Arbor, MI

106 **Characterization of morphine discriminative stimulus properties in C57BL/6 mice**
D. M. Walentiny, L. S. Harris, Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA

107 **Evaluation of intravenous self-administration of ALKS 33 in rats trained to self-administer morphine**
M. Sgro\(^1\), D. Modlin\(^1\), M. Todenkop\(^2\), D. Deaver\(^2\), M. Kallman\(^1\), \(^1\)Covance Laboratories, Greenfield, IN, \(^2\)Alkermes, Waltham, MA

108 **Oxycodone-induced conditioned place preference and locomotor activity in adult female C57BL/6J mice**
D. T. Collins, M. Kreek, Y. Zhang, The Laboratory of the Biology of Addictive Disease, The Rockefeller University, New York, NY

109 **Effect of opioid withdrawal on delay discounting of food in rhesus monkeys**
D. R. Maguire, L. R. Gerak, C. P. France, Pharmacology, UTHSCSA, San Antonio, TX

110 **Morphine and interleukin-1 receptor antagonist prevent the development of stress-enhanced fear learning**
M. Jones, C. Lebonville, D. Lysle, Psychology, UNC Chapel Hill, Chapel Hill, NC

111 **Oxytocin effects on human aggressive responding**
J. L. Alcorn, N. Dias, N. Rathnayaka, J. Schmitz, C. Green, S. D. Lane, Department of Psychiatry & Behavioral Sciences, School of Medicine, Program in Neuroscience, Graduate School of Biomedical Sciences University of Texas Health Science Center – Houston, Houston, TX

112 **Cocaine dependence and childhood maltreatment are associated with altered configurations of personality traits**
L. K. Brents, S. Tripathi, J. Young, G. James, C. D. Kilts, Helen L. Porter and James T. Dyke Brain Imaging Research Center, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR
Monday, June 16, 2014

113  Relationship between alexithymia and dopamine D2-type receptor availability: Methamphetamine-dependent subjects differ from healthy controls  
K. Okita¹, D. Ghahremani², D. Payer³, M. Mandelkern⁴, E. London¹,²,⁴, Laboratory of Molecular Neuroimaging, University of California, Los Angeles, Los Angeles, CA, ²Department of Psychiatry and Biobehavioral Neuroscience, University of California, Los Angeles, Los Angeles, CA, ³Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada, ⁴Nuclear Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁵Physics Department, University of California, Irvine, Irvine, CA

114  Varenicline improves information processing speed and verbal memory in methamphetamine-dependent participants  
A. Kalechstein¹,², J. Mahoney¹,², C. D. Verrico¹,², T. Iqbal¹,², R. De La Garza, II¹,², ¹Baylor College of Medicine, Houston, TX, ²Michael E. DeBakey VA Medical Center, Houston, TX

115  Total recall?: Researchers’ perceptions of the consent process  
K. L. Dugosh, D. Festinger, Treatment Research Institute, Philadelphia, PA

OPIOIDS

116  Gene variants of the opioid system - Relationship to heroin self-exposure, addiction, and treatment  
M. Randesi¹, O. Levran¹, E. Butelman¹, V. Yuferov¹, J. Ott², P. Blanken³, W. van den Brink³, J. M. van Ree³, M. Kreek¹, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, ²Institute of Psychology, Chinese Academy of Sciences, Beijing, China, ³Central Committee on the Treatment of Heroin Addicts (CCBH), Utrecht, Netherlands

117  Cognitive-behavioral therapy and educational counseling for chronic pain and opioid dependence  
D. T. Barry¹,², C. J. Cutter¹,², M. Beitel¹,², C. Liong², R. S. Schottenfeld¹, Psychiatry, Yale School of Medicine, New Haven, CT, ²APT Foundation Pain Treatment Services, New Haven, CT

118  Repeated exposure produces tolerance to some of the abuse-related subjective effects of oral tramadol in humans  
B. L. Bolin¹, C. R. Rush¹,², P. Glaser¹, W. W. Stoops¹, ¹Behavioral Science, University of Kentucky, College of Medicine, Lexington, KY, ²Psychiatry, University of Kentucky, College of Medicine, Lexington, KY

119  Comparison of impulsivity and decision making in ketamine, opioid and non-drug users  
H. Zeng¹, X. Zheng², H. Ye¹, The Research Center of Psychology and Brain Science, Guangzhou University, Guangzhou, China, ²School of Psychology, South China Normal University, Guangzhou, China

120  Effects of yohimbine and hydrocortisone pretreatment on opioid seeking, stress biomarkers, and learning in heroin-dependent volunteers  
M. K. Greenwald, L. H. Lundahl, V. Diwadkar, Wayne State University, Detroit, MI

121  WITHDRAWN

122  Real-time stress, craving and mood differences in polydrug-using methadone treatment responders and nonresponders  

123  Junkie habitus: Beyond disease and moral defect  
C. Gelpi-Acosta, Postdoctoral Fellow, NIDA Behavioral Science Training in Drug Abuse Research, National Development and Research Institute, New York City, NY
124 Increasing incidence of hospital admissions for opioid poisonings in adolescents and young adults: 2000-2009
   D. R. Camenga, J. R. Gaither, J. Leventhal, S. Ryan, Yale School of Medicine, New Haven, CT

125 Opioid deaths or polydrug/multi-cause deaths?
   J. G. Erensen, J. D. Haddox, Health Policy, Purdue Pharma L.P., Stamford, CT

126 Comparison of the risk of opioid overdose among patients prescribed immediate-release and extended-release opioid analgesics
   P. Coplan, A. DeVeaux-Geiss, A. Kadakia, G. Stiles, Risk Management and Epidemiology, Purdue Pharma, Stamford, CT

127 Risk factors associated with overdose among patients seeking treatment for opioid dependence
   E. L. Winstanley, A. Clark, Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, 2Nursing, University of Cincinnati, Cincinnati, OH

128 Detection of opioid overdoses and poisonings in electronic medical records as compared to medical chart reviews

129 Opioid overdose risk perception and naloxone acceptability among patients maintained on chronically prescribed opioids at the Cincinnati VA
   C. M. Wilder, S. C. Miller, E. Tiffany, T. Winhusen, Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, 2Substance Dependence Program - Mental Health, Cincinnati VA Medical Center, Cincinnati, OH

130 Is opioid dose a strong predictor of the risk of opioid overdose?: Important confounding factors that change the dose-overdose relationship
   A. DeVeaux-Geiss, P. Coplan, A. Kadakia, H. Chilcoat, Purdue Pharma LP, Stamford, CT

131 Brief guide to prevent overdose fatality for prescription opioid abusers: A harm reduction initiative
   L. E. Sandstrom, P. Coplan, H. Chilcoat, F. W. Brason, C. Leukefeld, L. A. Morris, Purdue Pharma, Stamford, CT, 2Project Lazarus, Moravian Falls, NC, 3University of Kentucky, Lexington, KY, 4Louis A Morris & Assoc., Dix Hills, NY

132 Overdose education and naloxone rescue kits for family members of opioid users: Characteristics, motivations and naloxone use
   S. Bagley, J. Peterson, D. M. Cheng, C. Jose, P. G. O’Connor, A. Y. Walley, Boston University Medical Center/Boston Medical Center, Boston, MA, 2Learn to Cope, Raynham, MA, 3Boston University School of Public Health, Boston, MA, 4Yale University School of Medicine, New Haven, CT

133 Mortality among patients accessing pharmacological treatment for opioid dependence in California, 2006-2010
   L. Li, E. Evans, D. Y. Huang, D. Urada, L. Liu, Y. Hser, B. Nosyk, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 2Feinberg School of Medicine, Northwestern University, Evanston, IL, 3British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, 4Simon Fraser University, Vancouver, BC, Canada

134 Comparison between former opiate addicts on methadone maintenance treatment and medication free for ≥10 years
   E. Peles, A. Sason, O. Tene, Y. Domany, S. Schreiber, Adelson Clinic for Drug Abuse Treatment & Research, Psychiatry, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel
Monday, June 16, 2014

135  Characterizing interpregnancy intervals of opioid-maintained women
C. L. Bergeria1, D. Hand2, M. Meyer1, S. T. Higgins1,2, S. C. Sigmon1,2, S. H. Heil1,2,
1Psychology, University of Vermont, Burlington, VT, 2Psychiatry, University of Vermont,
Burlington, VT, 3Obstetrics & Gynecology, University of Vermont College of Medicine,
Burlington, VT

136  Characteristics and quality of life of opioid-dependent pregnant women in Austria
V. Metz1,2, S. D. Comer1, J. Wuerzl1,2, A. Pribasniç1, G. Fischer1, 1Psychiatry, NYSPI &
Columbia University, New York, NY, 2Medical University of Vienna, Vienna, Austria

137  Stigma management for women in recovery
A. Gunn, 1University of Chicago, Chicago, IL, 2National Development Research Institutes,
Inc, New York, NY

138  Examining the association between methadone maintenance treatment and body mass index
S. C. Sigmon1, J. Fenn2, 1Psychiatry, University of Vermont, Burlington, VT, 2Nursing,
University of Vermont, Burlington, VT

139  Risk-taking behavior over 36-month follow-up treatment in outpatient opioid maintenance
treatment program
J. Daulouède1,2, C. M. Denis1, M. Fatseas1, V. Beltranc1,2, M. Auriacombe1,2, 1Addiction
Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, 2Addiction Treatment
Center, Bizia, Bayonne, France

140  Area-level attributes and program resources as predictors of methadone dosage patterns
D. Wutchiett, J. A. Frimpong, T. D’Aunno, Columbia University, New York, NY

141  Change of suicidality among heroin users: 1 month after methadone maintenance treatment
S. Wang1, C. Huang2, N. Y. Wang2, C. Chan1, Y. Liu1, C. Chen1, I. Ho2, 1Center for
Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan, 2China
Medical University and Hospital, Taichung, Taiwan, 3National Yang Ming University, Taipei,
Taiwan, 4Taoyuan Mental Hospital, Taoyuan, Taiwan

142  Trends in racial/ethnic differences in heroin use and heroin risk behaviors among nonmedical
users of prescription opioids from 2002 to 2011
S. S. Martins1, J. Santaella1, B. D. Marshall2, A. Maldonado1, M. Cerdá1, 1Epidemiology,
Columbia University, New York, NY, 2Epidemiology, Brown University, Providence, RI

143  Predictors of retention in methadone maintenance treatment differ by gender
A. R. Levine, L. H. Lundahl, D. M. Ledgerwood, M. K. Greenwald, Wayne State University,
Detroit, MI

144  The meaning of work: Perceptions among persons with maintenance treatment for opioid
addiction who are employed
M. Augustis1, D. Rosenberg2, H. Hillborg1, 1Research and Development, Sundsvall Hospital,
Sundsvall, Sweden, 2Department of Social Work, Umeå University, Umeå, Sweden,
3Research and Development, Sundsvall Hospital, Sundsvall, Sweden

HIV/HCV I

145  Perceptions of genetic testing and genomic medicine among urban drug users
D. Perlman1, C. Gelpi-Acosta2, S. R. Friedman2, A. E. Jordan2, H. Hagan3, 1Beth Israel
Medical Center, New York, NY, 2NDRI, Inc., New York, NY, 3New York University, New
York, NY

146  The effect of high stress on T-cell protein expression in chronic drug users: HIV implications
N. Boukli, S. Lopez, M. Rodriguez, E. Rios, Microbiology and Immunology, Universidad
Central Del Caribe, Bayamon
147 Effects of HIV infection and cocaine dependence on neurocognitive impairment  
S. Towe¹, K. Robertson², L. J. King¹, C. S. Meade¹, ¹Psychiatry and Behavioral Sciences, Duke University, Durham, NC, ²Department of Neurology, University of North Carolina, Chapel Hill, NC

148 The impact of prescription opioids on CD4 count in HIV: A longitudinal analysis  
E. J. Edelman¹, K. S. Gordon², W. Becker²,¹, J. R. Gaither¹, A. J. Gordon², J. Samet⁴, A. Justice²,¹, D. Fiellin¹, ¹Yale, New Haven, CT, ²VA CT, West Haven, CT, ³VA Pittsburgh and University of Pittsburgh, Pittsburgh, PA, ⁴Boston University, Boston, MA

149 Cerebrospinal fluid kynurenic acid and depressive symptoms in HIV-infected individuals  
N. Tanizaki¹, A. Franke², X. Li², N. Holmes¹, V. Douet¹, L. Chang¹, ¹Medicine, University of Hawaii at Manoa, Honolulu, HI, ²University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI

150 Formal and informal organizational activities of people who inject drugs  

151 Trends in care for persons who inject drugs in San Francisco  
P. O. Coffin¹,², H. Jin¹, E. Huriaux¹, H. Raymond¹,², ¹San Francisco Department of Public Health, San Francisco, CA, ²UCSF, San Francisco, CA

152 The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence  
B. Nosyk¹,², J. Min¹, G. Colley¹, V. Lima¹,², B. Yip¹, M. Milloy¹, E. Wood¹,³, J. Montaner¹,³, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, ³Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

153 Neighborhood disorder, HIV treatment access and ARV diversion: A mediation study of drug-involved HIV-positive individuals in South Florida  
C. L. O’Grady, H. Surratt, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL

154 Who in the world buys ARVs on the black market? The impact of drug use and ARV diversion on adherence  
K. Tsuyuki, H. Surratt, M. A. Levi Minzi, C. L. O’Grady, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL

155 Non-medical use of prescription drugs among HIV-positive individuals taking antiretroviral therapy  
H. Newville¹, J. Roley², J. Sorensen³, ¹St. Luke’s-Roosevelt Hospital, New York, NY, ²University of California, San Francisco, San Francisco, CA

156 Hepatitis C infection among Hispanics in California  
D. G. Fisher, G. L. Reynolds, E. Erlyana, C. Cummins, Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA

157 Primary drug use types and intervention-related self-monitoring in HIV patients  
E. Aharonovich¹,², D. S. Hasin¹,², ¹Psychiatry, Columbia University Medical Center, New York, NY, ²The New York State Psychiatric Institute, New York, NY

158 Comparative efficacy of a computer-based HIV testing video intervention in sites of varying HIV prevalence  
I. D. Aronson¹, S. Rajan³, L. A. Marsch², J. Koken¹, T. Bania³, ¹NDRI, New York, NY, ²Dartmouth, Lebanon, NH, ³Columbia, New York, NY
Monday, June 16, 2014

159 Drug use and response to alcohol intervention among HIV+ men and women
J. C. Elliott¹, E. Aharonovich¹, D. S. Hasin¹, ²Columbia University Medical Center, New York, NY, ²New York State Psychiatric Institute, New York, NY

160 Understanding drug use and the HIV cascade of care in San Juan, Puerto Rico
D. Hernández¹, Y. Fernández¹, F. Torres Cardona², P. Castellón³, J. Vargas Vidot², S. Miranda de Leon³, D. Feaster⁴, B. Schackman⁵, A. Rodriguez⁴, J. Santana⁶, L. Metsch¹, ¹Columbia University, New York, NY, ²Iniciativa Comunitaria de Investigación, San Juan, ³Puerto Rico Department of Health, San Juan, ⁴University of Miami, Miami, FL, ⁵Cornell University, New York, NY, ⁶University of Puerto Rico, Rio Piedras

161 Immediate impact of Hurricane Sandy on people who inject drugs in New York City

162 Support, traumatization, and employment differences in drug court outcomes
D. Morse¹, C. Cerulli¹, S. Bandyopadhyay², J. J. Guido², H. Yang², J. L. Wilson¹, F. Taxman³, ¹Psychiatry, University of Rochester School of Medicine, Rochester, NY, ²Biostatistics, University of Rochester School of Medicine, Rochester, NY, ³Criminology, Law & Society, George Mason University, Fairfax, VA

Symposium VI
SAN CRISTOBAL
10:00 - 12:00 PM
ACUTE AND CHRONIC STIMULANT EFFECTS ON MOTIVATION AND BEHAVIORAL CONTROL

Chairs: Scott H. Kollins and Iliyan Ivanov

10:00 Chronic effects of methylphenidate on reward signaling and behavior in animal models of ADHD
Peter Thanos, Stony Brook University, Stony Brook, NY

10:25 Methylphenidate and brain activity in a reward/conflict paradigm: The role of the insula in motivation and interference control: A human fMRI study
Iliyan Ivanov, Icahn School of Medicine at Mount Sinai, New York, NY

10:50 ADHD, smoking and stimulant medication: Preliminary results of a neuroimaging study of smokers with and without ADHD
F. Joseph McIeremon, Duke University Medical Center, Durham, NC

11:15 Moderators of alcohol and substance use outcomes from stimulant medication and ADHD
Steve Lee, UCLA, Los Angeles, CA

11:40 DISCUSSANT:
Nora D. Volkow, National Institute on Drug Abuse, Bethesda, MD

Symposium VII
BALLROOM B
10:00 - 12:00 PM
NEUROPEPTIDERIC TARGETS FOR CNS DISORDERS

Chairs: Ivy Carroll and Scott P. Runyon

10:00 Nociceptin/orphanin FQ opioid receptor functional selectivity, signaling and behavior
Michael Bruchas, Washington University School of Medicine, St. Louis, MO
Monday, June 16, 2014

10:25 Evaluation of ligand bias at the kappa opioid receptor: Spanning compound development to effects in neurons
Laura Bohn, The Scripps Research Institute, Jupiter, FL

10:50 Identification of neuropeptide S antagonists as pharmacotherapies for substance abuse
Scott P. Runyon, Research Triangle Institute, Research Triangle Park, NC

11:15 Neoclerodane diterpenes as novel treatments for drug abuse
Thomas E. Prisinzano, University of Kansas, Lawrence, KS

11:40 DISCUSSANT: Summary and analysis of neuropeptidogics targets for CNS disorders
Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC

Oral Communications 5

BALLROOM C
10:00 - 12:00 PM

PRISONERS OF ADDICTION: A GLOBAL VIEW

Chairs: David S. Festinger and Sarah Larney

10:00 Historical representation of drug related issues in a sample of Puerto Rican print media
G. D. Vega, S. Rivera, L. M. Torres, C. E. Albizu, University of Puerto Rico, San Juan

10:15 Residential mobility and housing instability among justice-involved African-American opioid abusers
A. Wooditch, F. Taxman, A. Murphy, Criminology, Law & Society, George Mason University, Fairfax, VA

10:30 Risk factors of psychosis among amphetamine users: A prospective study of clients in the Swedish criminal justice system
J. G. Brannness¹, E. B. Rognli¹, J. Berge², A. C. Håkansson², ¹Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, ²Department of Clinical Sciences Lund, Lund University, Lund, Sweden

10:45 Substance use, mental health and incarceration among Mexican-American young adult men with a history of gang membership
A. Cepeda¹, A. Valdez¹, K. M. Nowotny⁴, ¹School of Social Work, University of Southern California, Los Angeles, CA, ²Sociology, University of Southern California, Los Angeles, CA, ³Sociology, University of Colorado Boulder, Boulder, CO

11:00 Heroin and prescription opioid users: Characterization in a Canadian federal context
B. Brands¹,²,³, T. Thornton¹, M. Ternes⁴, M. Cheverie⁵, K. Thibault¹, A. Moser⁴, ¹Health Canada, Ottawa, ON, Canada, ²Centre for Addiction and Mental Health, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Correctional Services Canada, Ottawa, ON, Canada

11:15 Post-incarceration factors and relapse to opioid injection in St. Petersburg, Russia
J. A. Cepeda¹, A. Lyubimova², O. Levina², R. Heimer¹, ¹Epidemiology of Microbial Diseases, Yale University, New Haven, CT, ²NGO Stellit, St. Petersburg, Russian Federation

11:30 Opioid substitution therapy as a strategy to reduce deaths in prison: Retrospective cohort study
S. Larney¹,², N. Gisev¹, M. Farrell¹, T. Dobbins³, L. Burns¹, A. Gibson¹, J. Kimber¹, L. Degenhardt¹,⁵, ¹University of NSW, Sydney, NSW, Australia, ²Brown University, Providence, RI, ³University of Sydney, Sydney, NSW, Australia, ⁴University of Western Sydney, Sydney, NSW, Australia, ⁵University of Melbourne, Melbourne, NSW, Australia
Monday, June 16, 2014

11:45  The impact of opioid substitution therapy on mortality post-release from prison
L. Degenhardt1,2, S. Larney1,3, J. Kimber1, N. Gisev1, M. Farrell1, T. Dobbins4,
D. J. Weatherburn5, A. Gibson6, R. Mattick1, T. Butler7, L. Burns1, 1National Drug and
Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, 2School of Population
and Global Health, University of Melbourne, Melbourne, VIC, Australia, 3Alpert Medical
School, Brown University, Providence, RI, 4Sydney School of Public Health, University of
Sydney, Sydney, NSW, Australia, 5New South Wales Bureau of Crime Statistics and Research
(BOCSAR), Sydney, NSW, Australia, 6University of Western Sydney, Sydney, NSW,
Australia, 7Kirby Institute, University of New South Wales, Sydney, NSW, Australia

Oral Communications 6

SEX, DRUGS AND RANDOMIZED TRIALS

Chairs: Teresa Franklin and MacKenzie R. Peltier

10:00  Influence of sex on gray matter volume differences between smokers and nonsmokers
T. R. Franklin, R. Wetherill, K. Jagannathan, B. Johnson, J. Mumma, N. Hager, H. Rao,
A. Childress, University of Pennsylvania, Philadelphia, PA

10:15  Sex differences in impulsivity and brain volumes in methamphetamine users
S. Kogachi, L. Chang, C. Jiang, D. Alicata, T. Ernst, University of Hawaii, Honolulu, HI

10:30  Exploring gender in response to provocative stimuli in limbic regions of interest among cocaine
users
M. R. Peltier1,2, M. Canterberry2, C. A. Hanlon2, 1Louisiana State University, Baton
Rouge, LA, 2Medical University of South Carolina, Charleston, SC

10:45  Delay discounting in current, ex, and non-smokers: Interactions with gender
A. Quisenberry, C. Franck, M. N. Koffarnus, W. K. Bickel, Virginia Tech Carilion Research
Institute, Roanoke, VA

11:00  Sex differences in cognitive and motor impulsivity among users of different classes of drugs in
protracted abstinence
M. J. Wilson1, G. Vasileva2, F. Moeller3, J. Vassileva1, 1Psychiatry, University of Illinois at
Chicago, Chicago, IL, 2Bulgarian Addictions Institute, Sofia, Bulgaria, 3Psychiatry, Virginia
Commonwealth University, Richmond, VA

11:15  Gender differences in use of alternative tobacco products among daily and nondaily smokers
A. M. Allen1, C. Mathur2, T. S. Scheuermann3, N. Nollen3, D. Hatsukami4, J. Ahluwalia5,
1Family Medicine & Community Health, University of Minnesota, Minneapolis, MN,
2Internal Medicine, University of Minnesota, Minneapolis, MN, 3Preventive Medicine &
Public Health, University of Kansas, Kansas City, KS, 4Psychiatry, University of Minnesota,
Minneapolis, MN

11:30  Evidence of gender-specific telescoping effects in chronic, regular heroin users
University, Detroit, MI

11:45  Sex differences in depressive-like effects of kappa opioid receptor activation in rats
J. Mays, D. Puttick, S. Russell, E. Chartoff, Psychiatry, Harvard Medical School,
Belmont, MA
Monday, June 16, 2014

**Policy Forum**
(Brown Bag Lunch)

*BALLROOM B*
12:15 - 1:45 PM

Chairs: William L. Dewey and Martin Y. Iguchi

*Introduction:*
William L. Dewey, VCU, Richmond, VA

*Update from Capitol Hill*
Ed Long, VanScoyoc Associates, Washington, DC

*Panel on the Affordable Care Act: Implications for the substance abuse field*
Andrew Kessler, Slingshot Solutions, Annandale, VA

*The Affordable Care Act: A watershed moment for substance use disorders*
A. Thomas McLellan, Treatment Research Center, Philadelphia, PA

**Symposium VIII**

*THE EFFECTS, USE PATTERNS AND YOUTH PERCEPTION OF ELECTRONIC CIGARETTES*

*BALLROOM A*
2:00 - 4:00 PM

Chairs: Robert Balster and Thomas Eissenberg

2:00 *Acute effects of electronic cigarettes in adults: Nicotine delivery and abuse liability*
Thomas Eissenberg, Virginia Commonwealth University Institute for Drug and Alcohol, Richmond, VA

2:25 *Results from a large survey of electronic cigarette users*
Jonathan Foulds, Penn State University, Hershey, PA

2:50 *Perceptions about electronic cigarettes among adolescents and young adults*
Suchitra Krishnan-Sarin, Yale University, New Haven, CT

3:15 *Trajectories of electronic cigarette use among young adults*
Erin L. Sutfin, Wake Forest University, Winston-Salem, NC

3:40 *DISCUSSANT:*
Warren K. Bickel, Virginia Tech University, Roanoke, VA

**Symposium IX**

*NOVEL APPROACHES TO EXAMINING THE INTERTWINING EPIDEMICS OF HIV AND DRUG ABUSE: FROM DECISION-MAKING TO VIRAL LOAD*

*BALLROOM B*
2:00 - 4:00 PM

Chairs: Matthew W. Johnson and Steven Shoptaw

2:00 *Effects of acute alcohol, cocaine, and methamphetamine on the delay discounting of sexual consequences among drug users*
Matthew W. Johnson, Johns Hopkins University, Baltimore, MD

2:25 *Do laboratory-based measures of risk taking correlate with real-life HIV risk behavior in cocaine users?*
Christina S. Meade, Duke University Medical Center, Durham, NC
Monday, June 16, 2014

2:50 Using crowdsourcing technology to examine HIV risk, drug use, and sexual decision-making among men who have sex with men
   Evan S. Herrmann, Johns Hopkins University, Baltimore, MD

3:15 Partner stimulant use is independently associated with detectable HIV viral load among HIV-positive men in same-sex relationships
   Adam W. Carrico, University of California, San Francisco, San Francisco, CA

3:40 DISCUSSANT: Novel approaches to examining the intertwining epidemics of HIV and drug abuse: Summary and future directions
   Steven Shoptaw, University of California, Los Angeles, Los Angeles, CA

Oral Communications 7

WHAT’S THE BUZZ ON ALCOHOL?

Chairs: Kelly E. Dunn and Elise Weerts

2:00 Drinking during the first two weeks of a clinical trial significantly predicts drinking at the end of the trial
   K. E. Dunn, E. C. Strain, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD

2:15 Comparison of baclofen vs. naltrexone treatment during abstinence on reinstatement of alcohol self-administration in baboons
   E. Weerts, B. J. Kaminski, Johns Hopkins University School of Medicine, Baltimore, MD

2:30 Do medications impact treatment outcomes? XR-NTX in county-funded treatment
   D. A. Crevecoeur-MacPhail1, S. J. Cousins1, J. Barger2, D. Bennett1, E. Vasquez1, W. Sugita2, R. Rawson1, 1Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, 2Department of Public Health, Substance Abuse Prevention and Control, Alhambra, CA

2:45 Does the efficacy of medications for substance abuse treatment decrease over time?
   E. M. Klemperer, J. Hughes, Psychiatry, University of Vermont, Burlington, VT

3:00 Deconstructing clozapine further: Toward medication for alcohol use disorder in schizophrenia
   A. I. Green, J. Y. Khokhar, Psychiatry, Dartmouth College, Lebanon, NH

3:15 Alcohol drinking and related behaviors in hypothalamic-specific POMC-deficient mice
   Y. Zhou1, M. Rubinstein2, M. J. Low3, M. Kreek1, 1Rockefeller Univ, NY, NY, 2Univ Buenos Aires, Buenos Aires, Argentina, 3Univ Michigan, Ann Arbor, MI

3:30 The involvement of the CNR1 gene in impulsivity and stress response in alcohol-related behaviors
   M. Niculescu1, K. J. Cerullo1, K. Hess1, R. E. Rupslaukyte1, B. Stoothoff3, N. Enman1, K. Hesterberg2, L. Manza1, K. E. Hutchison2, 1Psychology, Lebanon Valley College, Annville, PA, 2Psychology and Neuroscience, University of Colorado, Boulder, CO

3:45 Alcohol dependence, gender, and cortisol response predict amygdala response pattern to fMRI stress task
   N. E. Wright1, C. B. Padula4, K. E. Maple1, R. Anthenelli2, E. Nelson5, K. M. Lisdahl1, 1Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI, 2University of California San Diego, San Diego, CA, 3University of Cincinnati, Cincinnati, OH, 4VA Palo Alto Health Care System, Palo Alto, CA
Oral Communications 8

SAY NO TO BLOW: COCAINE TREATMENT TARGETS

Chairs: Jun-Xu Li and Wilfrid N. Raby

2:00 Positive allosteric modulators of the serotonin 2C receptor as novel therapeutics for cocaine use disorder

2:15 Bi-directional effects of presynaptic and postsynaptic adenosine A2A receptor antagonism on cocaine seeking

2:30 The trace-amine-associated receptor 1 agonist RO5263397 attenuates abuse-related effects of cocaine in rats
   J. Li1, D. A. Thorn1, L. Jing1, Y. Zhang2, 1Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, 2Research Triangle Institute, Research Triangle Park, NC

2:45 Carvedilol treatment reduces cocaine use in methadone-maintained cocaine users
   M. Sofuoglu1,2, T. Babuscio3, K. M. Carroll1,2, 1Psychiatry, VA CT Healthcare System, West Haven, CT, 2Psychiatry, Yale University, New Haven, CT

3:00 Evaluation of lisdexamfetamine alone and lisdexamfetamine + modafinil for cocaine use disorder
   A. Brewer1, D. G. Thompson-Lake2, J. J. Mahoney2, T. F. Newton2, R. De La Garza, II1,2, 1Pharmacology, Baylor College of Medicine, Houston, TX, 2Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX

3:15 A multi-site, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence
   T. Winhusen1, D. Lewis1, G. Sharma2, S. Sparenborg3, 1University of Cincinnati, Cincinnati, OH, 2EMMES Corp., Rockville, MD, 3NIDA, Bethesda, MD

3:30 Prognostic relevance of dopamine beta-hydroxylase levels on disulfiram treatment at higher doses of cocaine dependence in methadone-stabilized patients: A secondary analysis
   R. Nahata1, M. J. Mancino1, H. Hendrickson1, L. Song1, J. D. Thostenson1, A. Oliveto1, 1Psychiatry, UAMS, Little Rock, AR, 2Biostatistics Faculty Support, UAMS, Little Rock, AR, 3College of Pharmacy, Bioanalytical, UAMS, Little Rock, AR

3:45 Absence of stress dysregulation predicts cocaine and mood outcomes in a study of mirtazapine for depressed cocaine-dependent patients
   W. N. Raby1,2, D. Bryon1, A. Glass1, M. Pavlikova3, E. V. Nunes1, H. D. Kleber1, 1Division on Substance Abuse, Department of Psychiatry, Columbia University, New York City, NY, 2Division on Substance Abuse, Department of Psychiatry, Albert Einstein College of Medicine, New York City, NY, 3Division of Biostatistics, Department of Public Health, Columbia University, New York City, NY
Monday, June 16, 2014

MARIAN W. FISCHMAN MEMORIAL AWARD LECTURE BALLROOM B 4:15 - 5:15 PM

Presentation of the Marian W. Fischman Award to Amy H. Newman

Introduction by Michael Nader

Lecture: What’s a nice girl like you doing in a field like this?
Amy H. Newman

Pre- and Post-Doctoral Trainees Networking Event LAS OLAS 5:15 - 6:45 PM

Workshop VI BALLROOM A 7:00 - 9:00 PM

KNOWLEDGE TRANSLATION IN ADDICTION SCIENCES: WHY AND HOW TO SHARE RESEARCH KNOWLEDGE BEYOND THE ACADEMIC COMMUNITY

Chairs: Doris Payer and Marc J. Kaufman

Introduction to knowledge translation in addiction sciences: Why and how
Doris Payer, Center for Addiction and Mental Health, Toronto, ON, Canada

Incorporating the Knowledge Translation Cycle in addictions treatment: Lessons from a nicotine-dependence clinic within an addictions hospital
Laurie Zawertailo, Centre for Addiction and Mental Health, Toronto, ON, Canada

Speaking to the media: Experiences and coaching for addiction researchers
Bertha K. Madras, Harvard Medical School, Southborough, MA

Social media and non-traditional strategies for drug-abuse science communication
Michael A. Taffe, The Scripps Research Institute, La Jolla, CA

Using academic research to inform public policy
Jane C. Maxwell, University of Texas School of Social Work, Austin, TX

Public outreach initiatives by CPDD: Past and future
Marc J. Kaufman, McLean Hospital, Belmont, MA

Workshop VII BALLROOM B 7:00 - 9:00 PM

HIGH RISK AND UNDERSTUDIED: ASSESSING ABUSE LIABILITY IN OPIOID-DEPENDENT SUBJECTS

Chairs: Sandra Comer and Kerri Schoedel

Evaluating abuse potential in the context of opioid dependence: Critical methodological considerations
Sharon L. Walsh, University of Kentucky College of Pharmacy, Lexington, KY
Monday, June 16, 2014

The assessment of tramadol’s pharmacological profile as an example of abuse liability testing in humans
Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

The use of opioid-dependent subjects to test abuse potential of agonist/antagonist ADFs: Contrast with recreational users
Naama Levy-Cooperman, Altreos Research Partners, Inc., Toronto, ON, Canada

Discussant: Role of agonist efficacy in abuse liability testing among opioid-dependent participants
Sandra Comer, Columbia University and NYSPI, New York, NY

Workshop VIII

EATING DISORDERS, ADDICTIONS AND SUBSTANCE USE DISORDERS: RESEARCH, CLINICAL AND TREATMENT ASPECTS

Chairs: Timothy Brewerton and Therese Killeen

Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects I
Timothy Brewerton, Medical University of South Carolina, Mt. Pleasant, SC

Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects II
A Matthews, The EMMES Corporation, Rockville, MD

Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects III
Therese Killeen, Medical University of South Carolina, Charleston, SC

Workshop IX

ADVANCES IN ADOLESCENT RECOVERY RESEARCH

Chairs: Michael L. Dennis and John F. Kelly

The role of 12-step mutual-help organizations in youth recovery: Benefits, moderators, and mechanisms
John F. Kelly, Massachusetts General Hospital, Boston, MA

Recovery schools as an aftercare pathway
Ken Winters, University of Minnesota, Minneapolis, MN

Using smartphones to manage adolescent recovery
Michael L. Dennis, Chestnut Health Systems, Normal, IL

Long-term trajectories of adolescent recovery and the factors that predict them
Sandra A. Brown, University of California San Diego, La Jolla, CA

Developing more recovery oriented systems of care for adolescents
Westley Clark, SAMHSA Center for Substance Abuse Treatment, Rockville, MD
Monday, June 16, 2014

2014 NIDA International Meeting Poster Session

SAN CRISTOBAL
7:00 – 9:00 PM

Chair: Steven W. Gust

BASIC SCIENCE

100. Human pharmacology of mephedrone: A dose-finding pilot study
M. Farré¹,², E. Papaseit¹,², C. Pérez-Maná¹,², M. Pujadas¹, F. Fonseca¹, M. Torrens¹,², R. de la Torre¹,³.¹ Hospital del Mar Medical Research Institute-IMIM and Drug Addiction Unit, Parc de Salut Mar, Spain; ²Universidad Autónoma de Barcelona, Spain; ³Universidad Pompeu Fabra, Spain

101. Brain perfusion and neurocognitive performance during cocaine withdrawal in patients with suicidal and depressive symptoms
C. Ibañez¹, T. Massardo¹, J. Véliz¹, J. Pallavicini¹, R. Jaimovich², R. Fernández¹, P. Flores², M. Servat¹, R. Chandía¹, J. Pereira².¹ Universidad de Chile, Chile; ²Pontificia Universidad Católica de Chile, Chile

102. Pharmacology and anti-addiction effects of Mesyl Sal B: A potent and long-acting analogue of Salvinorin A
B.M. Kivell¹, B. Simonson¹, A.S. Morani¹, N. Kumar¹, D. Simpson², T.E. Prisinzano².¹ School of Biological Science, Centre for Biodiscovery, Victoria University of Wellington, New Zealand; ²Department of Medicinal Chemistry, University of Kansas, United States

103. Neurochemical and behavioral profile of a rat model of depression and methamphetamine addiction comorbidity
J. Kucerova¹,², P. Amchova¹,², Z. Babinska¹,², T. Havlickova³, P. Jerabek³, P. Kacer⁴, M. Sustkova³, A. Sulcova¹.¹ Central European Institute of Technology, Masaryk University, Czech Republic; ²Department of Pharmacology, Masaryk University, Czech Republic; ³Department of Pharmacology, Charles University, Czech Republic; ⁴Institute of Chemical Technology, Czech Republic

104. Role of deep brain stimulation of medial prefrontal cortex on heroin-seeking behavior in rats
105. Molecular diversity of HIV-1 among drug users in Kenya
M.O. Oyaro¹, N. Padayachee²,³, K. Hiram²,³, T. Ndung'u²,³, K. Gounder²,³, J. Wylie⁴.
¹Immunology Unit, Department of Human Pathology, University of Nairobi, Kenya;
²HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of
KwaZulu-Natal, South Africa; ³KwaZulu-Natal Research Institute for Tuberculosis and
HIV, South Africa; ⁴Medical Microbiology Department, University of Manitoba,
Canada

106. Effect of nalbuphine on motor activity in opiate-dependent rats
R. Raghav¹, R. Jain¹, T.S. Roy², A. Dhawan¹, P. Kumar¹. ¹National Drug Dependence
Treatment Centre, India; ²Department of Anatomy, All India Institute of Medical
Sciences, India

107. Xylazine as a drug of abuse: Toxic effects to endothelial cells in combination with cocaine
and heroin
L.A. Silva-Torres¹,², C. Vélez³, J. Vargas-Vidot⁴, J.G. Ortiz¹, B. Zayas¹,³.
¹Pharmacology and Toxicology Department, School of Medicine, Medical Science
Campus, University of Puerto Rico, United States; ²Puerto Rico Institute of Forensic
Science, United States; ³School of Environmental Affairs, Universidad Metropolitana,
United States; ⁴Iniciativa Comunitaria, United States

108. A transgenerational ripple: How a puff during early development led to a global huff in
microRNA profiles as well as grand-offspring addictive behavior in Caenorhabditis
elegans
F. Taki, X. Pan, B. Zhang. East Carolina University, United States

109. Chronic administration of ketamine mimics the perturbed sense of body ownership
associated with schizophrenia
J. Tang¹, H.L. Morgan², Y. Liao¹, P.R. Corlett³, D. Wang¹, H. Li¹, Y. Tang⁴, J. Chen¹,
T. Liu¹, W. Hao¹, P.C. Fletcher², X. Chen¹,⁵. ¹Institute of Mental Health, the Second
Xiangya Hospital, Central South University, China; ²Department of Psychiatry,
University of Cambridge, Addenbrooke’s Hospital, United Kingdom; ³Department of
Psychiatry, Ribicoff Research Facility, Yale University, Connecticut Mental Health
Center, United States; ⁴Department of Psychiatry, The First Affiliated Hospital, China
Medical University, China; ⁵The State Key Laboratory of Medical Genetics, Central
South University, China

110. Unique and common neurocognitive effects of opiate and stimulant dependence persist
with protracted abstinence
J. Vassileva¹, F.G. Moeller², K. Bozgunov³, M. Wilson¹, G. Vasilev³. ¹University of
Illinois at Chicago, United States; ²Virginia Commonwealth University, United States;
³Bulgarian Addictions Institute, Bulgaria
111. *Alpha-1 adrenergic receptor modulation of ventral tegmental area dopamine neurons: Role in cocaine sensitization*
   M.C. Velásquez-Martínez, B. Santos-Vera, R. Vázquez-Torres, C.A. Jiménez-Rivera. 
   1Department of Physiology, Medical Sciences Campus, University of Puerto Rico, United States; 2Department de Ciencias Básicas, Escuela de Medicina, Universidad Industrial de Santander, Colombia

112. *Dorsal raphe serotonergic projections play a critical role in cocaine escalation*
   1Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Centre, The Netherlands; 2Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, United States; 3Department of Cellular Animal Physiology, Radboud University Nijmegen, The Netherlands

113. *Acute combined low/high bursts stimulation of the lateral habenula attenuates cue-induced heroin-seeking in rats*
   F. Zhang, S. Yang, H. Zhu, H. Liu, J. Gu, W. Zhou. Laboratory of Behavioral Neuroscience, Ningbo Addiction Research and Treatment Center, School of Medicine, Ningbo University, China

114. *Neuroimaging of adolescent drug users: Magnetic resonance spectroscopy metabolites variance in the anterior cingulate cortex reflects individual differences in personality traits*
   G. Zoccatelli, F. Alessandrini, C. Rimondo, G. Serpelloni.  
   1University Hospital of Verona, Italy; 2Addiction Department, ULSS 20 Verona, Italy; 3Antidrug Policies Department, Presidency of the Council of Ministers, Italy

115. *Characterization of the effects of α4β2* nACh receptor partial agonist cytisine in the two-choice serial reaction time task*
   E.E. Zvartau, G.S. Makshakov, O.A. Dravolina, A.Y. Bespalov, E.S. Kayukova, M.V. Dorofeikova. Valdman Institute of Pharmacology, First Pavlov State Medical University, Russia

**EPIDEMIOLOGY**

200. *Access to services for women with addiction in Eastern Europe*
   1National Institute for Infectious Diseases Prof. Dr. Matei Bals, ARENA OST Center, Romania; 2Clinic of Addictology, Medical Faculty, Charles University, Czech Republic; 3Center for Treatment of Drug Dependencies, Slovakia; 4Drug Outpatient and Prevention Center, Nyiro Gyula Hospital, Hungary; 5National Center for Addictions, Drug Demand Reduction Department, Bulgaria; 6Institute of Psychiatry and Neurology, Poland; 7Center for Addiction Treatment, Croatia; 8Center for Treatment of Drug Addiction, University Psychiatric Hospital, Slovenia
201. **Effect of cigarette smoking on blood sugar**  
R.I. Aqrawi. Research Department, Ministry of Health–Kurdistan, Iraq

202. **Prevalence of cigarette smoking or other form of tobacco use among university students**  
F. Bautista-Pérez. Research Department, Universidad Evangélica de El Salvador, El Salvador

203. **Risk of tobacco dependence for early and late alcohol first users in Peru**  
A. Burela¹, J. Beltran¹, M. Piazza¹,², F. Fiestas¹. ¹National Institute of Health, Peru; ²Universidad Peruana Cayetano Heredia, Peru

204. **Monitoring drug use through the Internet**  
L. Burns, J. Van Buskirk, A. Roxburgh. National Drug and Alcohol Research Centre, University of New South Wales, Australia

205. **Tobacco use and exposure to secondhand smoke in Mexican pregnant women**  
O. Campollo¹,², F. Hernandez², E. Angulo², A. Guzman², A. Munguia¹, M. Garcia¹, J.K. Cunningham³. ¹Center of Studies on Alcohol and Addictions, CUCS, Universidad de Guadalajara, Hospital Civil de Guadalajara, Mexico; ²Obstetrics Department, Antiguo Hospital Civil de Guadalajara, Mexico; ³Neonatology Department, Antiguo Hospital Civil de Guadalajara, Mexico; ⁴Department of Family and Community Medicine, The University of Arizona, United States

206. **Trend of accident-related health care expenditures in patients receiving treatment for opioid abuse or dependence in Taiwan**  
Y.-J. Chang¹, C.-Y. Peng², C.-H. Muo³. ¹National Taiwan Normal University, Taiwan; ²University of California, Los Angeles, United States; ³China Medical University Hospital, Taiwan

207. **Recent cannabis use among adolescent immigrants in The Netherlands—role of acculturation**  
M.J. Delforterie¹,², H.E. Creemers¹,², A.C. Huizink¹. ¹Institute for Health and Care Research (EMGO), Vrije Universiteit (VU University), The Netherlands; ²Research Institute of Child Development and Education, University of Amsterdam, The Netherlands

208. **Patterns of use of marijuana among university students in Bolivia, Colombia, Ecuador, and Peru**  
M. Demarco¹, M. Hynes², J.C. Araneda³, F. Cumsille¹. ¹Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United States; ²Latin American Network of Researchers on Drugs (REDLA), CICAD, OAS, United States; ³Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme–Latin America, United Nations Office on Drugs and Crime, Chile
209. **Secondhand smoke exposure among working women in a developing country: The Jordanian case**  
O. El-Shahawy1,2, L. Haddad3. 1School of Medicine, Virginia Commonwealth University, United States; 2General Medical Management, Ain Shams University, Egypt; 3School of Nursing, Virginia Commonwealth University, United States

210. **Increased emergency department visits associated with tramadol abuse are correlated with opioid-related overdose death in the United States**  
F. Fang1, Y. Wang2, J. Wu1. 1University of North Carolina, United States; 2Capital Medical University, China

211. **Male and female differences in the prevalence of ever use of illegal drugs in Peru**  
F. Fiestas1, J. Beltran1, A. Burela1, M. Piazza1,2. 1Instituto Nacional de Salud, Peru; 2Universidad Peruana Cayetano Heredia, Peru

212. **Measuring altruistic and solidaristic orientations toward others among people who inject drugs**  
S.R. Friedman1, E.R. Pouget1, M. Sandoval1, Y. Jones1, G. Nikolopoulos2, P. Mateu-Gelabert1. 1Institute for Infectious Disease Research, National Development and Research Institutes, Inc., United States; 2Transmission Reduction Intervention Project, Greece

213. **Urinary cannabis detection and mortality in a cohort of patients admitted for hospital detoxification**  
D. Fuster1, A. Sanvisens1, P. Zuluaga1, J. Tor1, I. Rivas2, R. Muga1. 1Internal Medicine Service, Hospital Germans Trias i Pujol, Spain; 2Municipal Centre for Substance Abuse Treatment, Centro Delta, IMSP, Spain

214. **A successful strategy for estimating the consumption of needles and syringes by Czech injecting drug users**  
R. Gabrhelik, J. Vacek, J. Mišta. Department of Addictology, Charles University in Prague, Czech Republic

215. **A complex image of social influences on adolescents’ illicit substance use**  
A. Gardikiotis1,2, D.W. Crano2. 1Aristotle University of Thessaloniki, Greece; 2Claremont Graduate University, United States

216. **Follow-up of crack users after hospital discharge based on probabilistic record linkage methodology**  
V.M. Gonçalves1,2,3, R.S. Pedroso1,2, A.M. dos Santos3, F. Pechansky1,2. 1Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Brazil; 2Hospital de Clínicas de Porto Alegre–Prof. Álvaro Alvim, Brazil; 3Informatics Department, Ministry of Health, Brazil
217. Prevalence and psychosocial correlates of Internet addiction among university students: A cross-sectional study  
S.H. Hassaan1,2, K.A. Elbeh1. 1Department of Psychiatry, Assiut University, Egypt; 2Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

218. A needs assessment study for the community of Cité Beau-Vallon, Mauritius  
M. Hennequin. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

219. Betel quid chewing, cigarette smoking, and alcohol consumption associate differently with metabolic biomarkers  
Y-W. Hsu1, H-Y. Li2, J-N. Wei1. 1Chia Nan University of Pharmacy and Science, Taiwan; 2Department of Internal Medicine, National Taiwan University, Taiwan

220. Online peer influence on Facebook, substance use attitudes, and offline behaviors among university students  
M.A. Jules1, D.M. Maynard1, N. Coulson2. 1University of the West Indies, Barbados; 2University of Nottingham, United Kingdom

221. Illicit drug use in Hunan Province, China: A profile of Chinese drug users in the general population  
Y. Liao1, J. Tang1, J. Wang2, T. Liu1, W. Hao1, X. Chen1. 1Mental Health Institute, the Second Xiangya Hospital of Central South University, China; 2Children’s National Medical Center, George Washington University, United States

222. Prevalence of khat use among Ethiopian HIV patients newly enrolled in care: Preliminary results  
A. Lifson1, S. Workneh2, H. Tekle2, B. Dame2, L. Bezabih1, K. Winters1, L. Slater3, T. Shenio1. 1University of Minnesotta, United States; 2Ethiopian National Alliance of State and Territorial AIDS Directors, Ethiopia; 3Global Program National Alliance of State and Territorial AIDS Directors, United States

223. Smoking behavior among college students of Bolivia  
R.G. Lopez. School of Psychology, Universidad Mayor de San Andres, Bolivia

224. Effects of immigration to the United States on alcohol, tobacco, and cannabis use among Colombian adolescents  
C. Lopez-Quintero, M. De La Rosa. The Center for Research on United States Latino HIV/AIDS and Drug Abuse, Florida International University, United States

225. Brazilian crack cocaine users: Preliminary results from a nationwide survey  
M. Malta1, N. Bertoni2, F.I. Bastos2. 1Social Science Department, Sergio Arouca School of Public Health, Oswaldo Cruz Foundation, Brazil; 2Institute of Scientific and Technological Communication and Information in Health, Oswaldo Cruz Foundation, Brazil
226. Development of the Multidimensional Attitudes Scale (2013) for measuring attitudes toward persons who abuse drugs in Latin America and the Caribbean
P.M. Martin¹, R. Basden², A. McKay³, A.D. Gallassi⁴, P.J. Concha⁵, C.A.D. Rivera⁶, S.A.A. Haughton⁷, T.D.J. Aleman Rivera⁸, R.F.P. Olano⁹, I.R. Bakari¹⁰, R. Mann¹¹, B. Brands¹¹, H. Hamilton¹¹, A. Kenti¹¹, G. Wright¹², I. Padilla¹². ¹University of Guyana, Guyana; ²University of the West Indies–Bahamas Campus, Bahamas; ³University of Belize, Belize; ⁴University of Brasilia, Brazil; ⁵University of Concepcion, Chile; ⁶Council for Control of Narcotic and Psychotropic Substances, Ecuador; ⁷University of the West Indies–Mona Campus, Jamaica; ⁸National Autonomous University of Nicaragua, Nicaragua; ⁹Universidad Peruana Cayetano Heredia, Peru; ¹⁰University of the Southern Caribbean, Trinidad and Tobago; ¹¹Center for Addiction and Mental Health, Canada; ¹²Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, United States

227. Pattern of drug abuse among street children in Dhaka City
J.H.B. Masud. Diabetic Association of Bangladesh, Bangladesh

228. Heroin production in Colombia: A time-bomb for a drug injection-driven HIV epidemic in Colombia?
P. Mateu-Gelabert¹, D. Berbesi², I.E.M. Motta³, H. Guarino¹, S. Harris¹. ¹National Development and Research Institutes, Inc., United States; ²CES University, Colombia; ³Pan American Health Organization, Columbia; ⁴Colombian Ministry of Health, Colombia

229. Barriers to accessing opioid substitution therapy among drug injectors in Ukraine
A. Mazhnaya¹, M.J. Bojko², J. Makarenko³, R. Marcus², S. Dvoryak³, Z. Islam¹, F.L. Altice⁴. ¹ICF International HIV/AIDS Alliance, Ukraine; ²School of Medicine AIDS Program, Yale University, United States; ³Ukrainian Institute for Public Health Policy, Ukraine

230. Application of outreach strategies to international collaborative research

231. Female cocaine users are at excess risk of becoming cocaine dependent soon after onset of cocaine use: Estimates for the United States, 2002–2011
A.M. Mohammed, J.C. Anthony. Research Training in Drug Dependence Epidemiology Program, Michigan State University, United States

232. Epidemiological and social factors of drug problems and other addictive behaviors in Spain
A.J. Molina Fernández¹, F. Rueda¹, M.J. Fernández-Serrano², E. Rueda¹, B. Aragón³, C. Mora¹. ¹Universidad Complutense de Madrid, Spain; ²University of Jaen, Spain
233. Disease outcomes in non-injecting cocaine-dependent patients seeking drug treatment in Barcelona, Spain
R. Muga\textsuperscript{1,2}, M. Torrens\textsuperscript{2,3}, P. Zuluaga\textsuperscript{1,2}, D. Fuster\textsuperscript{1}, F. Fonseca\textsuperscript{2,3}, F. Bolao\textsuperscript{4,5}, M. Pineda\textsuperscript{3}, I. Rivas\textsuperscript{6}, J. Tor\textsuperscript{1,2}, A. Sanvisens\textsuperscript{1}. \textsuperscript{1}Hospital Universitari Germans Trias i Pujol, Spain; \textsuperscript{2}Universitat Autònoma de Barcelona, Spain; \textsuperscript{3}Parc de Salut Mar, Spain; \textsuperscript{4}Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain; \textsuperscript{5}Universitat de Barcelona, Spain; \textsuperscript{6}Municipal Center for Substance Abuse Treatment (Centro Delta) IMSP, Spain

234. Cannabis use and criminal behavioral tendencies in young people: A study of Kaduna State, Nigeria
M.O. Onoja\textsuperscript{1}, A. Okoh\textsuperscript{2}, J.A. Ocheh\textsuperscript{1}. \textsuperscript{1}National Primary Health Care Development Agency, Nigeria; \textsuperscript{2}University of Jos–Plateau State, Nigeria

235. Herbal incenses, seizure latency, and anxiety
J.G. Ortiz\textsuperscript{1}, E.A. Suárez-Zayas\textsuperscript{2}, J.A. Peña Jiménez\textsuperscript{3}. \textsuperscript{1}Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, United States; \textsuperscript{2}Universidad Metropolitana–Cupey, United States; \textsuperscript{3}University of Puerto Rico–Río Piedras, United States

236. Psychiatric symptoms in a sample of young, sexual minority Brazilian ecstasy and LSD users
F. Pechansky\textsuperscript{1}, L.S. Remy\textsuperscript{1}, F. Kessler\textsuperscript{1}, L. Guimarães\textsuperscript{1}, H.L. Surratt\textsuperscript{2}, S. Kurtz\textsuperscript{2}. \textsuperscript{1}Center for Drug and Alcohol Research, Hospital of Clinics of Porto Alegre, Federal University of Rio Grande do Sul, Brazil; \textsuperscript{2}Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, United States

237. Association between highly active antiretroviral therapy nonadherence and tobacco use in women living with human immunodeficiency virus in public hospital in Lima, Peru
R.F. Pena-Olano\textsuperscript{1}, H. Maldonado-Ruiz\textsuperscript{1}, J.C. Bazo\textsuperscript{1}, J. Echevarría\textsuperscript{1,2,3}, E. Gotuzzo\textsuperscript{1,2,3}. \textsuperscript{1}Cayetano Heredia University, Peru; \textsuperscript{2}Cayetano Heredia National Hospital, Peru; \textsuperscript{3}Institute of Tropical Medicine “Alexander Von Humboldt”, Peru

238. Sex-related variation in patterns of tobacco dependence, alcohol, and drug abuse in the world mental health study in Peru
M. Piazza\textsuperscript{1,2}, F. Fiestas\textsuperscript{3}, A. Burela\textsuperscript{1}, J. Beltran\textsuperscript{1}. \textsuperscript{1}National Institute of Health, Peru; \textsuperscript{2}Universidad Peruana Cayetano Heredia, Peru

239. Tobacco chewing practice and oral health status of truck drivers of Karachi
A. Qureshi, A. Younus, N. Dawani. Department of Community Dentistry, Dr. Ishratulebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences, Pakistan
Monday, June 16, 2014

240. Prevalence and correlates of neck injection among people who inject drugs in Tijuana, Mexico
   C. Raffi1,2, K. Wagner1, P. Gonzalez-Zuniga1, G. Rangel1, S. Verdugo1, S.A. Strathdee1, 1University of California, San Diego, United States; 2San Diego State University, United States

241. Prevalence of prohibited drug use in the Philippines
   L.S. Ramiro. Department of Clinical Epidemiology, University of the Philippines, Philippines

242. Energy drink consumption and its association with substance abuse among college students in St. Petersburg, Russia
   M. Rusakova1,2, V. Odinokova2, P. Dillon3, D. Svikis3. 1St. Petersburg State University, Russia; 2NGO Stellit, Russia; 3Addiction and Women’s Health: Advancing Research and Evaluation Program, Virginia Commonwealth University, United States

243. Temperament and Lesch typology in the context of alcohol and heroin dependence
   B. Salem1,2,3, O. Lesch3. 1Integrated Substance Abuse Programs, University of California, Los Angeles, United States; 2Amal Hospital, Saudi Arabia; 3Department of Psychiatry and Psychotherapy, Vienna Medical University, Austria

244. Association of intimate partner violence with cigarette smoking before and during pregnancy, 2004–2008 births
   S. Salimi1, M. Terplan2, M. Chisolm3, D. Cheng4. 1Department of Medicine, School of Medicine, University of Maryland, United States; 2Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology and Public Health, School of Medicine, University of Maryland, United States; 3Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, United States; 4Maternal and Child Health Bureau, Maryland Department of Health and Mental Hygiene, United States

245. Methorphan in street heroin: Issues and challenges of the identification of a chiral compound in cases of opiate overdose in Italy
   G. Serpelloni1, C. Rimondo2, C. Seri2,3, M. Cavallini2, S. Strano Rossi4, F. Bortolotti3, R. Gottardo3, G. Musile3, F. Tagliaro3. 1Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; 2National Early Warning System, Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; 3Department of Public Health and Community Medicine, Unit of Forensic Medicine, University of Verona, Italy; 4Institute of Legal Medicine, Catholic University of Sacred Heart, Italy

246. Khat chewing and oral health status: A cross-sectional study on patients attending dental hospital in Jazan region
   K.A. Sheikh1, M. El-Setouhy1, R. Alansoy1, A.M. Al-Zailai2. 1Medical Research Center, Jazan University, Saudi Arabia; 2Jazan Dental Center, Jazan Province, Saudi Arabia
247. Do females and males behave differently on the road under the influence of alcohol and other drugs?
   T. Sousa¹, G. Pasa², J. Lunnen², F. Pechansky³. ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; ²Johns Hopkins International Injury Research Unit, Bloomberg School of Public Health, Johns Hopkins University, United States

248. Early evaluation of the experiences and opinions of pharmacists towards the Ontario Narcotics Monitoring System
   B. Sproule¹², K. Liu¹², J. Chundamala¹. ¹Centre for Addiction and Mental Health, Canada; ²University of Toronto, Canada

249. HIV risk-taking behaviors and psychological status among methadone patients using benzodiazepine in Jakarta
   H. Susami¹, D. Utami², R. Sarasvita³, A. Nurhidayat¹, M. Chawarski⁵, G. Woody⁶, D. Metzger⁶. ¹Special Working Group on HIV/AIDS, Faculty of Medicine, University of Indonesia, Indonesia; ²The Indonesian National Narcotics Board, Indonesia; ³Drug Abuse Division, Ministry of Health of Indonesia, Indonesia; ⁴Drug Dependence Hospital RSKO–Jakarta, Indonesia; ⁵Department of Psychiatry, Yale University, United States; ⁶Department of Psychiatry, University of Pennsylvania, United States

250. Socio-demographic and clinical characteristics of crack cocaine consumer pregnant and puerperal women
   C.M. Szobot¹, V. Mardini¹, G. Bocchese da Cunha², S.H.D.A. Martins-Costa¹, F. Guarienti¹, L. Manna³, T.G. Pianca¹, F. Pechansky¹, L.A.P. Rohde¹, F. Kapcinski¹, K. Cereres¹, M. L. Zavaschi¹. ¹Federal University of Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Brazil; ²Hospital Materno Infantil Presidente Vargas, Brazil; ³Lutheran University, Brazil

251. Substance-related knowledge and attitudes among adolescents in Kosovo
   Z. Tahiri, I. Mecini, V. Hashani. Main Family Medicine Center, Kosovo

252. Police bribery and access to methadone maintenance therapy within the context of drug policy reform in Tijuana, Mexico
   D. Werb¹, K. Wagner¹, L. Beletsky¹, P. Gonzalez-Zuniga¹, G. Rangel¹², M.E. Medina-Mora¹, S. Strathdee¹. ¹Division of Global Public Health, University of California, San Diego, United States; ²El Colegio de la Frontera del Norte, Mexico; ³Instituto Nacional de Psiquiatra Ramón de la Fuente, Mexico

253. Female opioid users may be at excess risk of becoming dependent soon after extra medical prescription pain reliever use in adolescence but not in young adulthood: Estimates for the United States, 2002–2011
   H-H. Yeh, J.C. Anthony. Department of Epidemiology and Biostatistics, Michigan State University, United States
254. Detecting a signal in the noise: Results of a pilot project to monitor the global spread of new drugs by monitoring media  
M.M Young¹, C. Dubequ⁴, K. Diedrich¹, O. Corazza², ¹Canadian Centre on Substance Abuse, Canada; ²Department of Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, United Kingdom

255. Viral hepatitis C and HIV in the Czech prison system: Prevalence, risk factors, and responses  
T. Zabranksy¹, B. Janikova¹, K. Grohmannova¹, M. Krejlova², ¹Department of Addictology, Charles University, Czech Republic; ²Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, Czech Republic

256. Social networks, spatial distance, and HIV risk among people who inject drugs in Malaysia  
A. Zelenev¹, E. Long², A. Bazazi³, F.L. Altice¹, ¹School of Medicine, Yale University, United States; ²School of Management, University of California, Los Angeles, United States; ³School of Public Health, Yale University, United States

OTHER

300. Lifetime substance use and medical costs among Baltimore medicare recipients  
P. Alexandre, S. Wang, W.E. Eaton. Johns Hopkins University, United States

301. Developing international information literacy competency standards for the addictions field  
N. Bryant. James Branch Cabell Library, Virginia Commonwealth University, United States

302. Analysis of policies affecting prevention and treatment of drug abuse in Burma (Myanmar)  
N.P.E. Kham, R.L. Balster. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

303. The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University  
J.R. Koch, R.L. Balster, A. Brelan, L.D. Hedges. Virginia Commonwealth University, United States

304. Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: One-year follow-up assessment  
O. Leonchuk¹, J.R. Koch², R.L. Balster², A. Brelan². ¹North Carolina State University, United States; ²Virginia Commonwealth University, United States

305. Physical and economic risk environments for HIV in compulsory drug addiction treatment centers: A study in Yunnan, China  
J. Meng¹, S. Burris². ¹Faculty of Law, Shantou University, China; ²James E. Beasley School of Law, Temple University, United States
306. *International Society of Addiction Journal Editors (ISAJE)*  
R. Pates. ISAJE, United Kingdom

**PREVENTION**

400. *Attitudes toward drug use mediated by social context and perception of drug effects among adolescents in Tijuana*  
N. Amador¹, C. Rafful²,³, J. Villatoro¹, M.E. Medina-Mora¹. ¹Mexican National Institute of Psychiatry, Mexico; ²University of California, San Diego, United States; ³San Diego State University, United States

401. *Risk reduction in antidrug abuse campaign*  
R. Ariel¹, V. Colondam¹, R. Rokhim², P.B. Hartanto². ¹YCAB Foundation, Indonesia; ²Universitas Indonesia, Indonesia

402. *Drug-using Tajikistan male migrants in Moscow: HIV risk behaviors, risk environment, and prevention needs*  
M. Bahromov¹, S. Weine², J. Jonbekov¹, J. Levy². ¹PRISMA Research Center, Tajikistan; ²University of Illinois at Chicago, United States

403. *Recruiting for a Short Message Service smoking cessation intervention in Peru: Pilot study results*  
D. Blitchtein, K. Zevallos, R. Samolski, M. Ybarra, J.C. Anthony. Research Training in Drug Dependence Epidemiology Program, Michigan State University, United States

404. *Parents’ self-fulfilling prophecy may influence children’s substance use*  
W.D. Crano, C.S. Lamb. Claremont Graduate University, United States

405. *Barriers to entry into medical care and antiretroviral therapy adherence among HIV-positive substance users in San Salvador, El Salvador*  
J. Dickson-Gomez¹, G. Bodnar², W. Cuellar², M.O. Zuniga², V. Navas², K. Johnson¹. ¹Medical College of Wisconsin, United States; ²Fundación Antidrogas de El Salvador, El Salvador

406. *Use trajectories of amphetamine-type stimulants in Shanghai, China*  
J. Du¹, D. Huang², M. Zhao¹, Y-I. Hser². ¹Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, China; ²Integrated Substance Abuse Programs, University of California, Los Angeles, United States

407. *Alcohol, drug abuse, and HIV infection among street children living in Kivulu slum in Kampala, Uganda*  
D. Elipu¹, H. Nakatudde¹, J. Kintu¹, M. Aweko¹, J. Akellot¹, B. Ayikoru². ¹Prevention of Alcohol, Drug Abuse, and HIV/AIDS Among Youth in Uganda, Uganda; ²Ministry of Gender, Labour and Social Development, Uganda
408. Uncomfortably numb: Substance use-associated elder mistreatment
D.V. Flores1,2,3, J. Burnett1,2,3, J. Booker2,3, C.B. Dyer1,2,3. 1University of Texas Medical School at Houston, University of Texas Health, United States; 2Texas Elder Abuse and Mistreatment Institute, United States; 3Harris Health System, United States

409. Identifying undiagnosed HIV infections among crack users in the metropolitan area of San Salvador
L.R. Glasman1, J. Dickson Gomez1, J. Lechuga2, G. Bodnar3, L. Rivas de Mendoza4, M.O. Zuniga1. 1Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, United States; 2Department of Psychology, University of Texas at El Paso, United States; 3Fundación Antidrogas de El Salvador, El Salvador; 4Universidad Centroamericana “José Simeón Cañas,” El Salvador

410. Study attrition among HIV-infected Russian risky drinkers
T. Kiriazova1,2,3, D.M. Cheng1, S.M. Coleman4, E. Blokhina4, E. Krupitsky4,5, M.C. Lira2, C. Bridden5, A. Raj6, J.H. Samet1,2. 1Boston University, United States; 2Boston Medical Center, United States; 3Future Without AIDS Foundation, Ukraine; 4First St. Petersburg Pavlov State Medical University, Russia; 5St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; 6University of California, San Diego, United States

411. Prevalence of pretreatment drug use among patients in a voluntary substance abuse treatment center in Malaysia
A. Krishnan1, S.E. Brown1, F. Khan1, M. Ghani1, A. Kamarulzaman2, F.L. Altice1. 1Yale University, United States; 2Centre of Excellence for Research in AIDS, University of Malaya, Malaysia

412. Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The hepatitis C incidence and transmission study
L. Maher1, B. White1, G.J. Dore1, A. Lloyd2, W. Rawlinson3. 1The Kirby Institute, University of New South Wales (UNSW), Australia; 2Inflammation and Infection Research Centre, School of Medical Sciences, UNSW, Australia; 3Virology Division, SEALS Microbiology, Prince of Wales Hospital, Australia

413. A review of substance abuse and related harms among indigenous women in Canada: Prevention, resilience, and treatment
D. Morisano1,2, R. Linklater1, S. Cunning1. 1Centre for Addiction and Mental Health, Canada; 2University of Toronto, Canada

414. Personality disorders among patients with substance use disorders in a treatment facility in Lagos
C.C. Okonkwo, A. Bamisile, O.F. Ajirinotu. Federal Neuropsychiatric Hospital, Nigeria
415. **Structural factors related to drug use and HIV vulnerability among men who have sex with men in the Mexico/Guatemala border region**  
E.R. Orellana¹, C. Fernandez-Casanueva², S. Morales-Miranda³, V.J. Mercer⁴, K.C. Brouwer⁴. ¹School of Social Work, Portland State University, United States; ²Centro de Investigaciones y Estudios Superiores en Antropología Social, Mexico; ³Universidad del Valle de Guatemala, Guatemala; ⁴Division of Global Public Health, University of California, San Diego, United States

416. **Prevalence of illicit drug use among patients of community health centers in East Los Angeles and Tijuana**  
M. Rico¹, M. Vahidi¹, J. Scholtz¹, M. García¹, G. Natera², R. Andersen³, I. Bojorquez⁴, J. Yacenda¹, M. Arroyo², M. González⁵, L. Gelberg¹,²,³, ¹Department of Family Medicine, University of California, Los Angeles, United States; ²National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico; ³School of Public Health, University of California, Los Angeles, United States; ⁴Department of Population Studies, El Colegio de la Frontera Norte, Mexico; ⁵Intersectoral Operations in Public Health, National Commission Against Addictions, Mexico

417. **Evaluation of the impact of the CHOICE program on truancy reduction among eighth graders in Chernihiv, Ukraine**  
V. Ryabukha. Chernihiv Region Charitable Organization “Aratta,” Ukraine

418. **Contraceptive practices and reproductive health needs among female sex workers who inject drugs in two Mexican-United States border cities**  
A. Servin. University of California, San Diego, United States

419. **A stepped-wedge randomized cluster trial assessing reductions in HIV risk and amphetamine-type stimulant use among women engaged in sex work in Cambodia**  
E. Stein¹, J. Evans¹, A. Carrico¹, M. Sokunny², C. Srean², A. Weissman², S. Ngak², C. Sophal³, N. Yuthea³, L. Maher⁵, K. Page¹. ¹University of California, San Francisco, United States; ²FHI 360, Cambodia; ³Royal Cambodian Government, Ministry of Health, Cambodia; ⁴National Authority to Combat Drugs, Cambodia; ⁵The Kirby Institute for Health and Immunity, University of New South Wales, Australia

420. **Results of the international ADHD in substance use disorder prevalence study**  
G. van de Glind¹,², W. van den Brink¹, International Collaboration on ADHD and Substance Abuse (ICASA) Research Group², F.R. Levin³. ¹University of Amsterdam, Netherlands; ²ICASA, The Netherlands; ³Columbia University, United States

421. **Factors associated with energy drinks among university students**  
F. Williams. Northern Caribbean University, Jamaica

422. **Factors associated with quality of life of Nicaraguan drug users in rehabilitation**  
P.I. Zeledon. Centre for Demographic Health Research, UNAN-León, Nicaragua
TREATMENT

500. A comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment centre
   Y.P.S. Balhara, Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India

501. The feasibility of implementing screening, brief intervention and referral to treatment in Peru
   J. Beltran-Puerta, J.P. Terashima, K.A. Hoffman, M. Calderón, L. García, F. Fiestas, J. Muench. 1Peruvian National Institute of Health, Peru; 2Oregon Health and Science University, United States

502. Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation
   E. Blokhina, E. Krupitsky, N. Bushara, T. Yaroslavtseva, A. Tiurina, V. Palatkin, E. Verbitskaya, E. Zvartau, G. Woody. 1Valdman Institute of Pharmacology, First Pavlov State Medical University of St. Petersburg, Russia; 2Department of Psychiatry, University of Pennsylvania, United States; 3Treatment Research Institute, United States

503. Effects of maternal opioid maintenance therapy on neonatal outcomes: Methadone versus buprenorphine
   L. Brandt, S. Fischberger, C. Aschauer, R. Jagsch, G. Fischer. 1Center for Public Health, Medical University of Vienna, Austria; 2Department for Psychiatry and Psychotherapy, Medical University of Vienna, Austria; 3Department of Applied Psychology, Health, Development, Enhancement and Intervention, University of Vienna, Austria

504. Problem cases and treatment denial: A qualitative study in institutional directors and supervisors in Buenos Aires
   J. Capece, M. Fanton. Programación Para la Prevención de la Drogadicción y lucha contra el Narcotráfico, Argentina

505. Screening and brief intervention for substance-using and delinquent adolescents from Cape Town, South Africa
   T. Carney, B. Myers, J. Louw, H. Carrara. 1Alcohol and Drug Abuse Research Unit, Medical Research Council, South Africa; 2Department of Psychiatry and Mental Health, University of Cape Town, South Africa; 3Department of Psychology, University of Cape Town, South Africa; 4Department of Public Health and Family Medicine, University of Cape Town, South Africa
506. **HIV transmission risk behaviors among patients of opioid maintenance treatment programs in Ukraine**
   V. Chtenguelov¹, S. Dvoriak², G. Prib³, ¹Department of Social Work and Applied Psychology, Academy of Labor, Social Relations and Tourism, Ukraine; ²Ukrainian Institute on Public Health Policy, Ukraine; ³Department of Psychology, Institute of Professional Training for Public Employment Service of Ukraine, Ukraine

507. **Comparison of expenditures in usual psychiatric care between Madrid and Boston hospital systems**
   B. Cook¹, E. Baca-Garcia², M. Alegria². ¹Center for Multicultural Mental Health Research, Cambridge Health Alliance, Department of Psychiatry, Harvard Medical School, United States; ²Fundación Jiménez Díaz, Spain

508. **Specialist “cannabis only” treatment clinics in New South Wales, Australia: Client and treatment characteristics and associations with treatment-seeking behavior**
   J. Copeland, D. Allsop. National Cannabis Prevention and Information Centre, University of New South Wales, Australia

509. **Performance measurement as a tool for improving substance abuse treatment in Brazil**
   F. De Conto¹,², J.R. Koch². ¹Florianópolis Department of Health and University Hospital, Brazil; ²Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

510. **The impact of opioid substitution therapy on mortality post-release from prison**
   L. Degenhardt¹,², S. Larney¹,³, J. Kimber¹, N. Gisev¹, M. Farrell¹, T. Dobbins⁴, D.J. Weatherburn⁵, A. Gibson⁶, R. Mattick¹, T. Butler⁷, L. Burns¹. ¹National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²School of Population and Global Health, University of Melbourne, Australia; ³Alpert Medical School, Brown University, United States; ⁴Cancer Epidemiology and Services Research, Sydney School of Public Health, Sydney Medical School, University of Sydney, Australia; ⁵New South Wales Bureau of Crime Statistics and Research, Australia; ⁶University of Western Sydney, Australia; ⁷The Kirby Institute, University of New South Wales, Australia

511. **The helping horse: How equine-assisted learning contributes to the well-being of First Nations youth in treatment for volatile substance misuse**
   C. Dell. University of Saskatchewan, Canada; University of Regina, Canada; University of Calgary, Canada; White Buffalo Youth Inhalant Treatment Program, Canada; Cartier Equine Learning Centre, Canada; Youth Solvent Addiction Committee, Canada; Canadian Centre on Substance Abuse, Canada; National Native Addictions Partnership Foundation, Canada; Saskatoon Community Youth Art Program, Canada
512. *A pilot implementation project of an integrated treatment for opioid addiction in Vietnam*
C. Denis¹, D. Metzger¹, G. Viretto², V. Trias², M. Auriacombe³, G. Raguin², S. Mai-Thi-Hoan⁴, G. Le-Truong⁴, J-P. Daulouëde²,³,⁵, C. O’Brien¹,¹Center for Studies of Addiction, University of Pennsylvania, United States; ²ESTHER, France; ³University Bordeaux Segalen, France; ⁴Ho Chi Minh City AIDS Committee, Vietnam; ⁵Bizia Addiction Clinic, France

513. *Treatment of women with substance use disorder at high risk of stigmatization*
P. Dolezalova. Clinic of Addictology, Charles University, Czech Republic

514. *Methadone treatment and antiretroviral therapy adherence among Kiev people who inject drugs*
S. Dvoriak¹, A. Karachevsk², G. Woody³,⁴¹Ukrainian Institute of Public Health Policy, Ukraine; ²Department of Psychiatry and Drug Abuse, O.O. Bogomolets National Medical University, Ukraine; ³Perelman School of Medicine, University of Pennsylvania, United States; ⁴Treatment Research Institute, United States

515. *A trend analysis on substance abuse treatment market in Iran using newspaper advertisements*
H. Ekhtiari¹,², S. Rezaee¹,³, S. Esmizadeh⁴, A. Deylamizadeh⁴.¹Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; ²Translational Neuroscience Program, Institute for Cognitive Science Studies, Iran; ³Cultural Studies Department, Faculty of Social Sciences and Communication, Allameh Tabatabai University, Iran; ⁴Rebirth Charity Organization, Iran

516. *Transitional effect of community-based addiction recovery meetings in Quezon City, Philippines*
L.R. Estacio, Jr.¹, M. Oda², J.M.D. Estacio³.¹University of the Philippines-Manila, Philippines; ²Asia-Pacific Addiction Research Institute, Philippines; ³Addictus-Philippines Inc., Philippines

517. *Crack cocaine users show low adherence rates in Brazilian public outpatient treatment*
S. Faller, A.R. Stolf, F. Pechansky, F. Kessler. Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil

518. *“Pasta base” cocaine and psychosocial deterioration: A comparative study in a local sample of drug users*
M. Fantoni¹, M. Ricciardi², R. Aldezábal², S. Azzollini³.¹Programación Para la Prevención de la Drogadicción y la Lucha contra el Narcotráfico, Argentina; ²Ministerio de Desarrollo Social, Gobierno de la Ciudad de Buenos Aires, Argentina; ³Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina
519. Safety reporting in randomized clinical trials for behavioral interventions in Mexico  
J. Fernández-Mondragón¹, V. Horigian², J. Graue-Moreno¹, E. Alonso², R. Verdeja², L. Bucay-Harari¹, A. De La Fuente Martín², C. Berlanga-Cisneros³, R. Marin-Navarrete¹.  
¹Clinical Trials Unit on Addiction and Mental Health, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico; ²Florida Node Alliance, University of Miami, United States; ³Direction of Clinical Research, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico

520. The level of anxiety among methamphetamine users at Drug Dependence Hospital RSKO-Jakarta  
F. Firdaus¹, M. Fadhilah¹, L. Hendarmin¹, A. Zaki¹, A. Nurhidayah¹. ¹UIN Syarif Hidayatullah University, Indonesia; ²Drug Dependence Hospital RSKO–Jakarta, Indonesia

521. Impact of comorbid psychiatric disorders on engagement in treatment after referral by an addiction liaison psychiatry unit  
F. Fonseca¹,², J. León¹, M. Llobet¹, P. Rossi¹,², D. Martínez-Sanvisens¹,², C. Tamarit¹,², M. Farré¹,²,³, M. Torrens¹,²,³. ¹Institut de Neuropsiquiatra i Addiccions, IMIM, Parc de Salut Mar, Spain; ²Institut Hospital Del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Spain; ³Facultad de Medicina, Universidad Autónoma de Barcelona, Spain

522. Baseline depressive symptoms and contingency management outcomes in smokers  

523. TREATNET: Quality standards for drug dependence treatment and care services  
G. Gerra, A. Busse, E. Saenz. Drug Prevention and Health Branch, Prevention, Treatment and Rehabilitation Section, United Nations Office on Drugs and Crime, Austria

524. Cytokines during acute abstinence of crack cocaine: The role of early life stress  

525. Predictors of receiving treatment for drug or alcohol problems among youth  
E. Haan¹, Y. Quevedo²,³, R. de Cerqueira Campos⁴, T. Mmolawa⁵, P. Alexandre⁶. ¹Public Health Department, Ministry of Social Affairs, Estonia; ²East Psychiatry Department, University of Chile, Chile; ³ Instituto Médico Schilkrut, Chile; ⁴Department of Health, Brazil; ⁵Department of Defense, Botswana; ⁶Johns Hopkins University, United States
526. Impact of substance abuse comorbidity on length of hospital stay for the treatment of psychosis in Egypt
W. Hassan\textsuperscript{1,2}, W.A. Alhaleem\textsuperscript{1}. \textsuperscript{1}Institute of Psychiatry, Ain Shams University, Egypt; \textsuperscript{2}Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

527. The gains of monetary cost and productivity with methadone maintenance treatment: One-year follow-up
C.Y. Hsiao\textsuperscript{1,2}, K.C. Chen\textsuperscript{1,2,3}, L-T. Lee\textsuperscript{1,2}, H.C. Tsai\textsuperscript{1,3}, W.H. Chang\textsuperscript{1,3}, I.H. Lee\textsuperscript{1,2}, P.S. Chen\textsuperscript{1,2}, R-B. Lu\textsuperscript{1,2,4}, Y.K. Yang\textsuperscript{1,2}. \textsuperscript{1}Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan; \textsuperscript{2}Addiction Research Center, National Cheng Kung University, Taiwan; \textsuperscript{3}Department of Psychiatry, National Cheng Kung University Hospital, Dou-Liou Branch, Taiwan; \textsuperscript{4}Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Taiwan

528. Retention and dropout of opioid substitution therapy program in Ukraine
Z. Islam, S. Filippovich, T. Prokhorova, A. Ghost. International HIV/AIDS Alliance, Ukraine

529. International collaboration between academic institutions: University Sains Malaysia and Yale School of Medicine
B.V. Kasinather\textsuperscript{1}, A. Desrosiers\textsuperscript{2}, R. Schottenfeld\textsuperscript{2}, M. Chawarski\textsuperscript{2}. \textsuperscript{1}Centre for Drug Research, Universiti Sains Malaysia, Malaysia; \textsuperscript{2}School of Medicine, Yale University, United States

530. Preliminary evidence of injecting drug reduction from a woman-focused random controlled trial in Republic of Georgia
I. Kirtadze\textsuperscript{1}, D. Otiaishvili\textsuperscript{1}, K. O’Grady\textsuperscript{2}, H. Jones\textsuperscript{3}, W. Zule\textsuperscript{4}, E. Krupitsky\textsuperscript{5}, W. Wechsberg\textsuperscript{4}. \textsuperscript{1}Addiction Research Center, Alternative Georgia, Georgia; \textsuperscript{2}Department of Psychology, University of Maryland, College Park, United States; \textsuperscript{3}University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States; \textsuperscript{4}RTI International, United States; \textsuperscript{5}Department of Addictions, Bekhterev Research Psychoneurological Institute, Russia

531. Development of an educational intervention to support primary care of alcohol problems among drug users
J. Klimas\textsuperscript{1,2}, K. Lally\textsuperscript{1}, L. Murphy\textsuperscript{1}, L. Crowley\textsuperscript{1}, R. Anderson\textsuperscript{3}, D. Meagher\textsuperscript{4}, B.P. Smyth\textsuperscript{4}, G. Bury\textsuperscript{2}, W. Cullen\textsuperscript{1}. \textsuperscript{1}Centre for Interventions in Infection, Immunity and Inflammation and Graduate Entry Medical School, Faculty of Education and Health Sciences, University of Limerick, Ireland; \textsuperscript{2}University College Dublin School of Medicine and Medical Science, Coombe Healthcare Centre, Ireland; \textsuperscript{3}The Charlemont Clinic, Ireland; \textsuperscript{4}Addiction Services, Health Services Executive, Ireland
532. Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting naltrexone implant
   E. Krupitsky¹, A. Kibitov², E. Zvartau³, E. Blokhina³, E. Verbitskaya³, V. Palatkin³, D. Nielsen⁴, T. Kosten⁴, G. Woody⁵. ¹St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; ²National Research Centre on Addictions, Russia; ³St. Petersburg State Pavlov Medical University, Russia; ⁴Baylor College of Medicine, United States; ⁵University of Pennsylvania, United States

533. Psychopathology among methadone patients at Drug Dependence Hospital RSKO–Jakarta
   M. Kurniawan¹², A. Nurhidayat¹, M. Fadhilah³, A. Rahayu², A. Zaki². ¹Institute of Mental Health, Addiction and Neuroscience, Indonesia; ²UIN Syarif Hidayatullah University, Indonesia; ³Drug Dependence Hospital RSKO–Jakarta, Indonesia

534. Specialized women’s track in methadone maintenance treatment clinic in Israel: Program description, client characteristics, and preliminary outcomes
   M. Lawental¹, H. Taylor², M. Blumenfeld², O. Zaslavsky³, T. Araten-Bergman¹. ¹School of Social Work, University of Haifa, Israel; ²Haifa Drug Abuse Treatment Center, Israel; ³School of Nursing, University of Haifa, Israel

535. Implementation of drug and HIV risk counseling in methadone maintenance treatment programs in Taiwan
   T. Szu-Hsien Lee¹, M. Chawarski², C-Y. Peng¹, C-C. Hung³, D. Metzger⁴. ¹Department of Health Promotion and Education, National Taiwan Normal University, Taiwan; ²School of Medicine, Yale University, United States; ³Taichung Veterans General Hospital, Taiwan; ⁴University of Pennsylvania, United States

536. The association between levels of plasma oxytocin and craving among heroin users
   S-H. Lin¹², P.S. Chen¹², L-T. Lee¹,², S-Y. Lee¹², H-C. Tsai¹,², K.C. Chen¹,²,³, I.H. Lee¹², R-B. Lu¹,²,⁴, Y.K. Yang¹,²,⁴. ¹Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan; ²Addiction Research Center, National Cheng Kung University, Taiwan; ³Department of Psychiatry, National Cheng Kung University Hospital, Dou-Liou Branch, Taiwan; ⁴Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Taiwan

537. Physiological and subjective responses after psychosocial stress among Uyghur heroin users in Xinjiang, China
   S. Liu¹, A. Abudula², A. Yashen², L. Zhang¹, Y. Cheng³, G. Song³, G. Yang⁴. ¹Shanghai University of Traditional Chinese Medicine, China; ²Addiction Treatment and Rehabilitation Center, Xinjiang Medical University, China; ³Xinjiang Medical University, China; ⁴Ningbo Addiction Research and Treatment Center, China
538. How increased information changed the attitude toward self-help groups in Russia for the last 5 years  
B. Lobodov¹, L. Rod², E. Chernyckii², P. Strogonov²; ¹Medical Center “Semya,” Russia; ²Voronezh State Regional Narcological Dispancer, Russia

539. Stigma and health care utilization among Russian HIV-infected drug users  
K. Lunze⁴, D. Lioznov³, D. Cheng¹, L. Forman¹, L. Wulach², A. Raj¹, E. Krupitsky³, J.H Samet¹,². ¹Boston University, United States; ²Boston Medical Center, United States; ³First St. Petersburg Pavlov State Medical University, Russia; ⁴University of California, San Diego, United States

540. Effectiveness and factors affecting drug use behavior among patients in methadone maintenance treatment program in Hai Phong and Ho Chi Minh City, Vietnam  
M.T.N. Mac¹, T.T.M. Nguyen¹, L.T. Nguyen¹, H. Tran², K. Soonthorndratha³. ¹Vietnam Authority of HIV/AIDS Control, Ministry of Health, Vietnam; ²Partners in Health Research, Vietnam; ³Institute for Population and Social Research, Mahidol University, Thailand

541. A multisite randomized controlled trial of motivational enhancement treatment in outpatient addiction care centers in Mexico  
R. Marín-Navarrete¹, V.E. Horigian², J. Fernández-Mondragón¹, R.E. Verdeja², E. Alonso², L. Templos-Nuñez¹, A. Eliosa-Hernández¹, D. Feaster², R. Sánchez-Huesca³, A. de la Fuente-Martín¹, C. Lima-Rodríguez⁴, C. Berlanga-Cisneros¹, M.E. Medina-Mora¹. ¹Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico; ²Florida Node Alliance, University of Miami, United States; ³Centros de Integración Juvenil, Mexico; ⁴Consejo Estatal Contra las Adicciones Puebla, Mexico

542. Continued methadone maintenance treatment among women: The first study on barriers  
Z.A. Mehrjerdi¹, A. Kiakojouri², K. Dolan¹, L. Arshad³, F. Rezaee⁴, H. Naranjiha². ¹Program of International Research and Training, National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²Peyman Opiate and Methamphetamine Use Treatment Clinic, Iran; ³Mikha Female-Specific Drop in Center, Iran; ⁴Sarzamin Khorshid Female-Specific Drop in Center, Iran; ⁵Darius Institute, University of Social Welfare and Rehabilitation Sciences, Iran

543. Correlates of perceived need for drug treatment among women from disadvantaged communities in Cape Town, South Africa, enrolled into a randomized field experiment  
B. Myers¹,², T.L. Kline³, I.A. Doherty³, T. Carney¹, W.M. Wechsberg⁴,⁵,⁶. ¹Alcohol and Drug Abuse Research Unit, South African Medical Research Council, South Africa; ²Department of Psychiatry and Mental Health, University of Cape Town, South Africa; ³RTI International, United States; ⁴Gillings Global School of Public Health, University of North Carolina, United States; ⁵Psychology in the Public Interest, North Carolina State University, United States; ⁶Psychiatry and Behavioral Sciences, Duke University School of Medicine, United States
544. **Pilot implementation of Screening, Brief Intervention, Referral, and Treatment at Tirana University Hospital “Mother Theresa” Center and private clinics in Albania**

E. Ngjelina, L. Cathers, C. Wagner. Center for Development and Social Initiatives, Albania; 2Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

545. **Treatment-seeking codeine users: A different kettle of fish?**

S. Nielsen, B. Murnion, A. Dunlop, L. Degenhardt, A. Demirko, N. Lintzeris. National Drug and Alcohol Centre, University of New South Wales, Australia; 2University of Sydney, Australia; 3Hunter New England Area Health Service, Australia; 4University of Newcastle, Australia; 5Centre for Population Health, Burnet Institute, Australia; 6South Eastern Sydney Local Health District, Australia

546. **Attitudes toward access to health care services among homeless and impoverished crack cocaine users in Saint Lucia**

L.R. Norman, M.P. Day. Ponce School of Medicine and Health Sciences, United States; 2Caribbean Drug Abuse Research Institute, Saint Lucia

547. **Incarceration as drug treatment: Insight from Georgian prison system**

D. Otiashvili, N. Balanchivadze, I. Kirtadze. Addiction Research Center, Alternative Georgia, Georgia

548. **Polydrug dependence among outpatients receiving treatment in Montevideo**

A. Pascale, C. Bares, F. Del Cioppo, C. Lopez, A. Usher. Grupo de Cavia Outpatient Treatment Program–Montevideo, Uruguay; 2School of Social Work, Virginia Commonwealth University, United States

549. **Effects of stress and drug-related cues among opiate-dependent individuals**

I. Pericot-Valverde, S.E. Back. Department of Psychology, University of Oviedo, Spain; 2Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States

550. **Evaluation of state opioid substitution treatment program in Republic of Georgia**


551. **Getting insight throughout treatment: Developing an instrument to measure addictive disease awareness**

Y. Quevedo, L. Arriagada, A. Borzutzky, N. Valdés. Instituto Médico Schilkrut, Chile

552. **Effects of omega-3 fatty acids on tobacco craving: A double-blind, randomized, placebo-controlled pilot study**

S. Rabinovitz-Shenkar. School of Criminology, University of Haifa, Israel
553. Clinician beliefs and behaviors regarding screening and brief intervention for drug use of their community health center patients
   A. Reddy, R. Andersen, L. Gelberg. University of California, Los Angeles, United States

554. United Nations Office on Drugs and Crime–World Health Organization Programme on Drug Dependence Treatment and Care: Jointly building treatment capacity in low- and middle-income countries
   E. Saenz¹, G. Gerra¹, A. Busse¹, N. Clark², V. Poznyak². ¹Health Branch, United Nations Office on Drugs and Crime, Austria; ²Management of Substance Abuse, World Health Organization, Switzerland

555. Contingency management of smoking abstinence versus contingency management with shaping for smoking cessation among treatment-seeking patients

556. Feasibility and acceptability of adding an opium tincture substitution treatment program to opioid substitution treatment clinics in Iran
   L. Seiri¹, A. Noroozi², A. Mokri², H. Dezhakam³. ¹Aftab Clinic, Iran; ²Iranian National Center for Addiction Studies, Iran; ³Congress 60, nonprofit organization, Iran

557. Role of stigma in self-esteem and well-being of people with substance use disorder
   S. Shahzad¹, N. Begum². ¹Institute of Clinical Psychology, University of Karachi, Pakistan; ²Area Study Centre for Europe, University of Karachi, Pakistan

558. Oxidative stress, brain-derived neurotrophic factor, and severity of crack cocaine use in early withdrawal
   A. Sordi, F. Kessler, F. Pechansky, L. von Diemen. Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil

559. Incubation of alcohol craving during abstinence in patients with alcohol dependence
   H-Q. Sun¹², P. Li¹, P. Wu¹, X. Xin³, Y-L. Fan⁴, G-B. Wang⁵, F. Wang⁴, M-Y. Ma⁴, M-M. Xue³, Y-X. Luo¹, F-D. Yang⁴, J. Shi¹, L. Lu¹². ¹National Institute on Drug Dependence, Peking University, China; ²Institute of Mental Health, Peking University, China; ³Department of Physiology, Basic Medical College, Inner Mongolia Medical University, China; ⁴Department of Alcohol and Drug Dependence, Beijing Hui-Long-Guan Hospital, Peking University, China; ⁵Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, China
560. **Benzodiazepine use among methadone maintenance treatment patients in Jakarta, Indonesia**
Z. Syarif\(^1\), H. Susami\(^2\), R. Sarasvita\(^4\), D. Utami\(^5\), A. Nurhidayat\(^6\), A. Desrosiers\(^2\), M. Chawarski\(^2\), G. Woody\(^7\), D. Metzger\(^7\). \(^1\)Addiction and AIDS Research Center, Indonesia; \(^2\)School of Medicine, Yale University, United States; \(^3\)Special Working Group on AIDS, Faculty of Medicine, University of Indonesia, Indonesia; \(^4\)Drug Abuse Division, Ministry of Health, Vietnam; \(^5\)The Indonesia National Narcotics Board, Indonesia; \(^6\)Drug Dependence Hospital RSKO–Jakarta, Indonesia; \(^7\)University of Pennsylvania, United States

561. **Factors affecting the retention of patients in a methadone maintenance treatment program in Vietnam**
N.T.M. Tam\(^1\), N.Q. Mai\(^1\), P.D. Manh\(^1\), N.T. Long\(^2\), H.H. Vu\(^3\). \(^1\)Vietnam Authority of HIV/AIDS Control, Vietnam; \(^2\)Ministry of Health, Vietnam; \(^3\)Substance Abuse and Mental Health Services Administration, United States Embassy, Vietnam

562. **Effectiveness of methadone maintenance treatment in “crocodile” users**
K. Todadze, S. Mosia, T. Qutateladze. Center for Mental Health and Prevention of Addiction, Georgia

563. **Acute stress response in cocaine-dependent subjects with comorbid depression**
M. Torrens\(^1\), R.R. Minguela\(^1\), D. Martinez-Sanvisens\(^1\), C. Pérez-Mañá\(^1\), E. Papaseit\(^1\), F. Fonseca\(^1\), M. Farre\(^1\). \(^1\)Institut Hospital Del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Spain; \(^2\)Institut de Neuropsiquiatria d’Addiccions, IMIM, Parc de Salut Mar, Spain; \(^3\)Facultad de Medicina, Universidad Autónoma de Barcelona, Spain

564. **Adherence and associated factors in methadone clinics in Nam Dinh Province, Vietnam**
Q. Tran\(^1\), H. Vu\(^2\). \(^1\)Provincial HIV/AIDS Center, Department of Health, Vietnam; \(^2\)Substance Abuse and Mental Health Services Administration, United States Embassy, Vietnam

565. **Hepatitis C virus testing and treatment among HIV-infected people who inject drugs in St. Petersburg Russia**
J.I. Tsui\(^1\), E. Krupitsky\(^3\), L. Wulach\(^2\), C.E. Chaisson\(^1\), J.H. Samet\(^1\). \(^1\)Boston University, United States; \(^2\)Boston Medical Center, United States; \(^3\)First St. Petersburg Pavlov State Medical University, Russia; \(^4\)St. Petersburg Bekhterev Research Psychoneurological Institute, Russia

566. **The use of drugs other than heroin by opiate-dependent patients in remission stabilized on naltrexone**
A. Tyurina\(^1\), E. Krupitsky\(^2\), E. Zvartau\(^1\), E. Blokhina\(^1\), E. Verbitskaya\(^1\), N. Bushara\(^1\), V. Palatkin\(^1\), G. Woody\(^3\). \(^1\)St. Petersburg State Pavlov Medical University, Russia; \(^2\)St. Petersburg V.M. Bekhterev Research Psychoneurological Institute, Russia; \(^3\)Department of Psychiatry, University of Pennsylvania, United States
567. **Brain-derived neurotrophic factor levels of crack users are associated with clinical outcome during inpatient treatment**

L. von Diemen\(^1\), F. Kapczinsky\(^2\), A. Orgle-Sordi\(^1\), F. Kessler\(^1\), J. Narvaez\(^1\), F. Pechansky\(^1\).

\(^1\)Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; \(^2\)Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil

568. **Fatal and nonfatal overdose after narcology hospital discharge among HIV-infected Russians**

A.Y. Walley\(^1\), E. Krupitsky\(^2\), D.M. Cheng\(^1,3\), E.K. Quinn\(^3\), L. Wulach\(^1\), P.O. Coffin\(^4\), J.H. Samet\(^5,3\).

\(^1\)Boston Medical Center, School of Medicine, Boston University, United States; \(^2\)Pavlov State University, Russia; \(^3\)School of Public Health, Boston University, United States; \(^4\)San Francisco Department of Public Health, United States

569. **A positron emission tomography imaging study of the effects of pharmacotherapy on brain mechanisms underlying cocaine dependence in cocaine and heroin-dependent patients.**

A. Weinstein\(^1,2\), N. Freedman\(^1\), I. Herman\(^3\), E. Mishani\(^1\), H. Atlan\(^1\), R. Chisin\(^1\).

\(^1\)Department of Medical Biophysics and Nuclear Medicine, The Human Biology Research Center, Hadassah Medical Center, Israel; \(^2\)Department of Behavioral Sciences, University of Ariel, Israel; \(^3\)Jaffa Treatment Center for Drug Victims, Israel

570. **Evaluation process for community-based drug treatment program in Indonesia**

E. Wijoyo\(^1\), R. Sarasvita\(^2\), A. Rachman\(^3\).

\(^1\)Kapeta Foundation, Indonesia; \(^2\)Indonesian Ministry of Health, Indonesia; \(^3\)National Aids Commission, Indonesia

571. **Take-home naloxone training: Comparing the effects on knowledge and attitudes between family members and drug users**

A.V. Williams, J. Marsden, J. Strang. Addictions Department, Institute of Psychiatry, King’s College London, United Kingdom

572. **Accreditation standards “patient rights”: Revision and current state in drug addiction treatment centers in Colombia**

M.A. Zapata. Group of Research in Mental Health, University CES, Colombia
Tuesday, June 17, 2014

Poster Session II
(Breakfast)

GRAN SALON
LOS ROSALES
8:00 - 10:00 AM

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Monday, 1 PM
Must be removed by Tuesday 12 Noon

SEX/GENDER 1

1 Sex differences in patterns of alcohol use among nightclub patrons in Brazil
   Z. M. Sanchez¹, S. Andreoni¹, A. Sanudo¹, S. S. Martins², ¹Department of Preventive
   Medicine, Universidade Federal de São Paulo, São Paulo, Brazil, ²Department of
   Epidemiology, Columbia University, New York, NY

2 Profiling alcoholic drinking and dating psychological abuse in a sample of college students in
   China
   Y. Liu¹, Y. Duan², W. Chen¹, M. Li¹, Y. Wang¹, Y. Ma¹, S. Liu³, J. Grady¹, H. Wu³, ¹School
   of Medicine, Ningbo University, Ningbo, China, ²Community Medicine & Healthcare,
   University of Connecticut Health Center (UCHC), Farmington, CT, ³Shanghai University
   of Traditional Chinese Medicine, Shanghai, China, ⁴Connecticut Institute for Clinical
   and Translational Science (CICATS), UCHC, Farmington, CT

3 Attitudes toward computer interventions for partner abuse and drug use among women in the
   emergency department
   E. Choo¹, M. Ranney¹, T. Wetle¹, K. Morrow², M. Mello¹, D. Squires⁴, A. Garro¹, C. Tape¹,
   C. Zlotnick², ¹Depart. of Emergency Medicine, ²Depart. of Psychiatry and Human Behavior,
   Warren Alpert Medical School of Brown University, Providence, RI, ³School of Public
   Health, Brown University, Providence, RI, ⁴Depart. of Behavioral and Social Sciences, Brown
   University, Providence, RI

4 Gender differences in hepatitis C risk behaviors
   A. Batchelder¹, C. L. Masson¹, J. Sorensen¹, D. Perlman², ¹University of California, San
   Francisco, CA, ²Beth Israel Medical Center, New York City, NY

5 Sex and HIV serostatus effects on high-risk decision making
   E. Martin¹, R. Gonzalez², J. Vassileva³, P. Makí³, A. Bechara⁴, M. Brand⁴, ¹Rush University
   Medical Center, Chicago, IL, ²Florida International University, Miami, FL, ³University of
   Illinois, Chicago, IL, ⁴University of Southern California, Los Angeles, CA, ⁵University of
   Duisberg-Essen, Duisberg, Germany

6 Emerging adult gender differences in sexual discounting and HIV risk behavior
   S. Thamotharan, S. Fields, Psychology, Texas A&M University, College Station, TX

7 Gender differences in the influence of child sexual abuse on drug use and related health risks
   during young adulthood: The moderating effects of DRD4
   K. M. Nowotny, J. D. Boardman, Department of Sociology & Population Program, University
   of Colorado at Boulder, Boulder, CO

8 Teen girls and boys of treated substance-abusing mothers
   A. Kadooka¹, H. Lanza², M. T. Schulte², L. Li², Y. Hser², ¹Hawaii School of Professional
   Psychology at Argosy University, Honolulu, HI, ²UCLA Integrated Substance Abuse
   Programs, Los Angeles, CA
9 Sex-differences in cognition and behaviors in children with family history of substance use disorders
  K. Lee1, L. Pritchett1, G. Løhaugen2,3, S. Kogachi1, E. Fukaya1, A. Hernandez1, C. Jiang1,
  D. Alicata1, T. Ernst1, L. Chang1, 1Medicine, University of Hawaii, Honolulu, HI, 2Pediatrics
  and Child Rehabilitation, Norwegian University of Science and Technology, Arendal,
  Norway, 3Laboratory Medicine, Norwegian University of Science and Technology,
  Trondheim, Norway

10 Predictors of the response to oral Δ9-THC in regular cannabis users: Focus on sex differences
  J. Fogel, T. Kelly, R. Charnigo, A. Harvanko, J. Lile, University of Kentucky, Lexington, KY

11 Sexually dimorphic effects of early life experience and adolescent Δ-9-tetrahydrocannabinol
  exposure in the rat
  L. Silva1, R. Black2, D. Dow-Edwards1, 1SUNY Downstate Medical Center, Brooklyn, NY,
  2Wellesley College, Wellesley, MA

12 Evaluation of sex differences in cannabinoid withdrawal in rats
  J. A. Marusich1, T. Lefever1, R. Craft2, J. L. Wiley1, 1RTI International, Research Triangle
  Park, NC, 2Washington State University, Pullman, WA

13 Progressive ratio responding for morphine is differentially altered in the presence of chronic
  peripheral neuropathy in male vs. female C57Bl/6 mice
  H. Neelakantan, S. J. Ward, E. A. Walker, Temple University, Philadelphia, PA

14 Effects of sex and remifentanil dose on the acquisition of responding for a remifentanil-
  associated stimulus
  J. W. Bertz, J. H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI

15 Effect of menstrual phase and social stress on cognitive performance of female monkeys
  S. A. Kromrey, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest School
  of Medicine, Winston Salem, NC

16 Region specific sexually dimorphic intracellular responses after cocaine-induced conditioned
  place preference expression
  S. K. Nygard1,2, A. Klambatsen1,2, V. Quinones-Jenab1,2, S. Jenab1,2, 1Psychology, Hunter
  College, CUNY, New York, NY, 2Biopsychology and Behavioral Neuroscience, The CUNY
  Graduate School and University Center, New York, NY

17 Sex differences in FosB expression in reward circuitry after administration of cocaine,
  methamphetamine, and cannabinoids
  C. Daly1,2, A. Toussaint1, M. Altubi1, J. Encarnacion1, S. Jenab1,2, V. Quinones-Jenab1,2,
  1Hunter College, New York, NY, 2Cuny Graduate Center, New York, NY

18 Long-term cocaine self-administration in female cynomolgus monkeys: Changes in behavior
  and in dopamine transporters and D2-like receptor availability
  M. C. Rowe1, S. H. Nader1, A. N. Duke1, R. VolP, L. Howell1, M. A. Nader1, 1Physiology &
  Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, 2Radiology,
  Emory University School of Medicine, Atlanta, GA, 3Psychiatry, Emory University School
  of Medicine, Atlanta, GA

19 Dopamine D3 receptor availability: Sex differences and effects of chronic drug exposure
  S. Martelle1, S. H. Nader1, P. W. Czoty1, W. S. John1, A. H. Newman2, M. A. Nader1,
  1Physiology and Pharmacology, WFUSM, Winston Salem, NC, 2Molecular Targets and
  Medications Discovery, NIDA-IRP, Baltimore, MD
20 Locus-specific epigenetic reprogramming for the study of reward pathology
E. Heller¹, H. Cates¹, H. Sun¹, C. J. Pena¹, D. Ferguson¹, S. Knight², F. Zhang³, S. Zhang⁴,
E. J. Nestler¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Sigma Aldrich,
Saint Louis, MO, ³MIT, Cambridge, MA, ⁴Sangamo Biosciences, Richmond, CA

21 Epigenetic regulation of cortical serotonin (5-HT) 5-HT₁A, 5-HT₂C receptor balance in
maladaptive impulsivity
N. C. Anastasio¹, J. L. Saavedra¹, A. L. Miller¹, R. B. Pyles¹, F. Moeller², K. Cunningham¹,
¹Ctr Addiction Res, UTMB, Galveston, TX, ²Psychiatry, VCU, Richmond, VA

22 Serotonin (5-HT) 2C receptor interaction with protein phosphatase and tensin homologue
results in distinct patterns of cortical ERK¹/² activation
C. Soto¹, ², N. C. Anastasio¹, ², R. Hartley¹, ², R. G. Fox¹, ², H. Du¹, S. Gilbertson³,
K. Cunningham¹, ², ¹Ctr for Addiction Res, UTMB, Galveston, TX, ²Dept Pharm&Tox,
UTMB, Galveston, TX, ³Dept Chem, Univ Houston, Houston, TX

23 Loss of serotonin (5-HT) 2C receptor (5-HT₂C-R) tone in the ventral tegmental area modulates
cocaine-related behaviors
S. E. Swinford-Jackson, N. C. Anastasio, R. G. Fox, S. J. Stutz, K. Cunningham, Center for
Addiction Research, UTMB, Galveston, TX

24 Effects of amygdalar CaMKII activity on extinction and reconsolidation of a cocaine-associated
memory
M. T. Rich¹, M. L. Bertholomey¹, L. E. Rupprecht¹, T. B. Abbott², E. E. Glucicek²,
K. L. Stone², L. Chung², C. M. Colangelo², J. R. Taylor², M. M. Torregrossa¹, ¹University of
Pittsburgh, Pittsburgh, PA, ²Yale University, New Haven, CT

25 Overexpression of miR-495 in nucleus accumbens attenuates cocaine intake on a progressive
ratio schedule of reinforcement
R. M. Bastle¹, R. J. Oliver², N. S. Pentkowski¹, A. S. Gardiner², N. I. Perrone-Bizzozero²,
J. L. Neisewander¹, ¹Arizona State Univ, Tempe, AZ, ²Univ New Mexico, Albuquerque, NM

26 Modulation of microRNA expression in the amygdala by binge cocaine and withdrawal
M. Doura¹, Y. Li², W. Cornwell³, T. J. Rogers³, E. Unterwald¹, ¹CSAR, Temple University,
Philadelphia, PA, ²Fox Chase Cancer Center, Philadelphia, PA, ³Center for Inflammation,
Translational and Clinical Lung Research, Temple University, Philadelphia, PA

27 Predisposing genetic differences contribute to vulnerability to escalate cocaine intake in rats
M. Valenza, R. Picetti, V. Yuferov, M. Kreek, The Laboratory of the Biology of Addictive
Diseases, The Rockefeller University, New York, NY

28 Genetic background influences the change from the discriminative stimulus to the rewarding
effects of psychostimulants in rats
T. Suzuki, D. Aikawa, A. Takanohashi, T. Saeki, M. Shibasaki, T. Mori, Department of
Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo,
Japan

29 Discrete-trial choice procedure: Methamphetamine vs. an alternative nondrug reward
D. Caprioli, L. Xuan, T. Zeric, N. Marchant, J. Bossert, Y. Shaham, Behavioral Neuroscience,
National Institute on Drug Abuse IRP, Baltimore, MD

30 96-Hour methamphetamine self-administration in male and female rats: Effects on brain reward
pathways
E. M. Cornett, N. E. Goeders, Pharmacology, Toxicology, Neuroscience, LSU Health
Sciences Center, Shreveport, LA
31 Social interaction may reduce amphetamine reward in male adolescent rats by activating mesocorticolimbic dopamine systems
V. G. Weiss, R. S. Hofford, J. R. Yates, M. T. Bardo, University of Kentucky, Lexington, KY

32 Methamphetamine self-administration in rats is diminished by wheel access in the prior 22 hours
M. A. Taffe, S. M. Aarde, K. Creehan, S. A. Vandewater, CNAD, The Scripps Research Institute, La Jolla, CA

33 Effects of the combination of exercise (wheel running) and atomoxetine on cocaine-seeking behavior in rats
N. Zlebnik, M. E. Carroll, University of Minnesota, Minneapolis, MN

34 mTOR-dependent plasticity: Don’t forget macroautophagy
C. A. Torres1,2, D. Garton3, W. Setlik4, M. Gershon4, D. Sulzer2, 1Integrated Program in Cellular, Molecular, and Biomedical Studies, Columbia University, New York, NY, 2Departments of Psychiatry, Neurology and Pharmacology, Columbia University, New York, NY, 3Columbia College, Columbia University, New York, NY, 4Department of Pathology, Columbia University, New York, NY

35 Exposure to fluoxetine during adolescence increases sensitivity to the rewarding effects of cocaine in adulthood
S. J. Nieto1, L. M. Riggs1, N. N. Zamora1, A. R. Zavala2, S. D. Iniguez1, 1Psychology, California State University, San Bernardino, CA, 2Psychology, California State University, Long Beach, CA

36 The effects of social learning on the acquisition of cocaine self-administration
M. A. Smith, R. T. Lacy, J. T. Strickland, Davidson College, Davidson, NC

37 Role of NR4A1 (Nur77) and NR4A3 (NOR-1) in the nucleus accumbens in conferring the protective addiction phenotype from environmental enrichment
E. Crofton1,2,3, Y. Zhang1,2, D. Li1,2, T. Green1,2, 1Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 2Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 3Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX

38 Overexpression of ΔFosB in rat nucleus accumbens shell mimics environmental enrichment in sucrose self-administration and cocaine seeking
Y. Zhang1,2, E. Crofton1,2,4, D. Li1,2, X. Fan1,2, E. J. Nestler1, T. Green1,2, 1Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 2Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 3Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, 4Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX

39 Behavioral and molecular factors contributing to beneficial effects of environmental enrichment and extinction training on cocaine relapse prevention
J. M. Gauthier1, A. Lin2, B. A. Nic Dhonnchadha1, H. Man2, K. M. Kantak1, 1Psychology, Boston University, Boston, MA, 2Biology, Boston University, Boston, MA

40 Cocaine-conditioned locomotor response: Modulating roles of environmental context and neural plasticity
J. Nguyen, M. B. Gatch, M. J. Forster, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
IMAGING

41 Temporal profile of fronto-striatal-limbic activity during implicit decisions in drug dependence
D. Yamamoto1, J. Reynolds3, T. Krmpotich1, M. Banich1, L. Thompson1, J. Tanabe1,
1University of Colorado Denver, Aurora, CO, 2University of Denver, Denver, CO, 3University of
Colorado Boulder, Boulder, CO

42 A hyper-connected and resilient small-world network in the cocaine-dependent brain
Z. Wang1, J. Suh1, Z. A. Monge1, C. P. O’Brien1, A. Childress1, 2Psychiatry, U of
Pennsylvania, Philadelphia, PA, 2VAMC, Philadelphia VA, Philadelphia, PA

43 Can we use cue-related brain responses to predict which cocaine patients will take more risks?
Z. A. Monge1, K. Jagannathan1, J. Suh1, R. Ehrman1, K. A. Young1, T. Franklin1,
D. Langleben1, 2, C. P. O’Brien1, A. Childress1, 2Psychiatry, University of Pennsylvania,
Philadelphia, PA, 2VA MIRECC, Philadelphia, PA

44 Self-regulation of craving-related brain activation in cocaine users via realtime fMRI
M. Canterberry, T. LeMatty, C. A. Hanlon, M. S. George, K. T. Brady, Medical University of
South Carolina, Charleston, SC

45 Modeling causal relationship between memory and craving-related brain networks in non-
treatment seeking cocaine smokers using IMaGES, a graph theoretic approach
S. Ray1, C. Hanson2, M. Haney3, B. Biswal4, S. J. Hanson2, 1CAS, Rutgers University,
Piscataway, NJ, 2RUBIC, Rutgers University, Newark, NJ, 3Columbia University, New
York, NY, 4New Jersey Institute of Technology, Newark, NJ

46 A PET imaging study on the effects of treatment with modafinil and topiramate on brain
mechanisms underlying cocaine dependence in concurrent cocaine-and heroin-dependent
patients
A. M. Weinstein1, 2, N. Freedman1, I. Herman3, E. Mishani1, H. Atlan1, R. Chisin1, 1Nuclear
Medicine and Medical Biophysics, Hadassah Hospital, Jerusalem, Israel, 2Behavioral
Sciences, University of Ariel, Ariel, Israel, 3Jaffa Treatment Center for Drug Victims, Jaffa,
Israel

47 Increased ventral striatum activation in response to heroin cues in heroin-dependent women
after extended-release naltrexone injection
A. Wang1, K. Jagannathan1, I. Elman2, A. R. Childress1, H. R. Kranzler1, C. P. O’Brien1,
D. Langleben1, 1University of Pennsylvania, Philadelphia, PA, 2Harvard University,
Cambridge, MA, 3Veterans Administration, Philadelphia, PA

48 Childhood maltreatment and amygdala connectivity in methamphetamine dependence
M. Kohno1, A. C. Dean1, G. Hellemann1, E. London1, 1Department of Psychiatry and
Biobehavioral Sciences and Semel Institute, David Geffen School of Medicine, University
of California, Los Angeles, CA, 2Department of Molecular and Medical Pharmacology,
University of California, Los Angeles, CA

49 Striatal dopamine D2/3 receptors in methamphetamine users: Recovery with exercise and
abstinence
C. Robertson1, 2, J. Chudzynski1, R. Rawson2, C. Cooper3, L. Mooney2, A. Brown5, 4
M. Mandelkern4, K. Ishibashi2, 4, E. London1, 3Pharmacology, UCLA, Los Angeles, CA,
3Psychiatry, UCLA, Los Angeles, CA, 3Physiology, UCLA, Los Angeles, CA, 4VA Health
System, Los Angeles, CA, 5Charles Drew Univ, Los Angeles, CA

50 Craving for methamphetamine is negatively associated with gray-matter volume
A. M. Morales1, M. Kohno1, A. Dean1, E. D. London3, 1Psychiatry and Biobehavioral
Sciences, UCLA, Los Angeles, CA, 2Molecular and Medical Pharmacology, UCLA, Los
Angeles, CA

60
51 Age of cigarette smoking onset is associated with P300 smoking cue reactivity: Preliminary EEG findings
Y. Mashhoon, S. L. Farmer, G. H. Trksak, S. E. Lukas, McLean Imaging Center, McLean Hospital | Harvard Medical School, Belmont, MA

52 d-Amphetamine effects and monetary incentive delay task performance: An fMRI Study
T. H. Kelly¹, A. Anderson¹, S. Jenkins¹, A. M. Harvanko¹, C. Martin¹, J. S. Fogel¹, J. Joseph², J. A. Lile¹, ¹University of Kentucky, Lexington, KY, ²Medical University of South Carolina, Charleston, SC

53 Real-time functional MRI feedback attenuates cue-induced craving in non-treatment-seeking nicotine-dependent smokers
K. T. Brady¹,², C. A. Hanlon¹, K. Hartwell¹,², J. Borekardt¹, J. Prisciandaro¹, M. Canterberry¹, X. Li¹, T. LeMatty¹, M. Owens¹, M. E. Saladin¹, M. Moran-Santa Maria¹, M. George¹,², ¹Psychiatry, Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VAMC, Charleston, SC

54 WITHDRAWN

55 Intending to quit smoking is associated with frontostriatal grey matter volume variation
P. McConnell¹, A. R. Mathew¹, E. Garland², J. McClernon³, B. Froeliger¹,², ¹Neurosciences, Medical University of South Carolina, Charleston, SC, ²Huntsman Cancer Institute, University of Utah, Salt Lake, UT, ³Psychiatry & Behavioral Medicine, Duke University, Durham, NC

56 Associations between gray matter volume, smoker status, and smoking heaviness
A. R. Mathew¹, P. McConnell¹, J. McClernon², B. Froeliger¹,², ¹Neurosciences, Medical University of South Carolina, Charleston, SC, ²Department of Psychiatry and Behavioral Medicine, Duke University Medical Center, Durham, NC

57 Effects of cannabis and cigarette smoking on gray matter volume: A voxel-based morphometry study

58 Prefrontal and parietal volumes and cognition in emerging adult marijuana users
J. S. Price¹, T. McQueen², S. Shollenbarger², E. L. Browning³, J. Wieser³, K. M. Lisdahl³, ¹Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA, ²Psychology, University of Cincinnati, Cincinnati, OH, ³Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI

59 Multimodal imaging reveals altered functional and structural connectivity of affective processing in alcohol dependence
C. B. Padula¹, R. M. Anthenelli², J. C. Elliassen¹, E. Nelson³, K. M. Lisdahl⁴, ¹VA Palo Alto Health Care System, Palo Alto, CA, ²VA San Diego Healthcare System, San Diego, CA, ³University of Cincinnati, Cincinnati, OH, ⁴University of Wisconsin Milwaukee, Milwaukee, WI

60 Development of error processing in children of alcoholics
J. Hardee, R. A. Zucker, M. Heitzeg, University of Michigan, Ann Arbor, MI
Exploring normative working memory variance to better understand disparities in risk for drug use disorders
T. Kearney-Ramos, J. Fausett, J. Gess, A. Reno, J. Peraza, C. Kilts, G. James, 1University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Virginia School of Medicine, Charlottesville, VA, 3University of New Mexico Medical School, Albuquerque, NM

ALCOHOL
The role of GABA_A receptors on ethanol-induced type 1 IP_3 receptor up-regulation
K. Mizuno, K. Kurokawa, T. Suzuki, S. Ohkuma, 1Department of Pharmacology, Kawasaki Medical School, Kurashiki, Japan, 2Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa, Japan

Sex-related differences in oral operant ethanol self-administration in C57BL/6J mice
A. M. Stafford, D. H. Brunzell, Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA

Ethanol metabolism in neural stem cells
E. McGrath, T. J. Dunn, J. Gao, P. Wu, Human Pathophysiology and Translational Medicine, University of Texas Medical Branch, Galveston, TX

Brain biomarkers of alcohol abuse at autopsy
M. Taherian, J. Jones, C. Williams, L. Duque, D. C. Mash, 1Neurology, UM Miller Medical School, Miami, FL, 2US Drug Testing Lab, Des Plaines, IL

The effects of intranasal oxytocin on social cognition, implicit preferences and craving in alcoholics

Unique factors associated with young women in substance use treatment: Craving, impulsivity, emotion regulation, and physiological response
C. Vinci, J. Schumacher, S. F. Coffey, 1University of Mississippi Medical Center, Jackson, MS, 2G.V. (Sonny) Montgomery VAMC, Jackson, MS

Affect and impulsivity in daily risky behavior
J. A. Bonsu, K. J. Derefinko, R. J. Charnigo, D. R. Lynam, R. Milich, 1University of Kentucky, Lexington, KY, 2Purdue University, West Lafayette, IN

Planned disinhibition? Risky sexual behavior, problematic alcohol use, and gender
R. MacLean, G. E. Shishkoff, S. J. Wilson, Psychology, Penn State, University Park, PA

How does binge drinking affect risky behaviors on the road?
G. Pasa, T. R. Sousa, J. Lunnen, F. P. Pechansky, 1Center for Drug and Alcohol Research - CPAD, Federal University of Rio Grande do Sul - UFRGS, Porto Alegre, Brazil, 2Johns Hopkins International Injury Research Unit, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Examining the risk for developing alcohol-related problems among adult children of alcoholics
E. M. Murphy, M. L. Kelley, Old Dominion University, Norfolk, VA

Maternal risk-taking propensity and children’s alcohol use: A latent growth curve approach
J. W. Felton, J. M. Shadur, A. Vijay, A. N. Banducci, R. Stadnik, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD

Model minority stereotype, psychological distress, substance use among Asian-American young adults
D. Iwamoto, C. W. Lejuez, E. Hamilton, M. Grivel, Univ. of Maryland, College Park, MD
Tuesday, June 17, 2014

74 Trajectories of neighborhood disorder, alcohol initiation, and alcohol use among urban adolescents
A. J. Milam1,2, C. M. Furr-Holden1, P. J. Leaf1, N. Ialongo1, 1Mental Health, Johns Hopkins School of Public Health, Baltimore, MD, 2School of Medicine, Wayne State University, Detroit, MI

75 Motives underlying the association of borderline personality disorder and alcohol-related problems
J. M. Loya, A. K. Matusiewicz, S. Z. Chen, C. W. Lejuez, CAPER/Psychology, University of Maryland, College Park, MD

76 Loss of self-control over drinking and the relationship of alexithymia to quality of life in alcohol-dependent patients
F. A. Thorberg1,2, R. M. Young3,5, M. Lyvers4, J. P. Connor6,5, R. Tyssen2, A. S. Landheim1, E. London2, G. Feeney5,6, 1Inlandet Hosp Trust, Brumunddal, Norway, 2Univ Oslo, Oslo, Norway, 3Qld Univ Technol, Brisbane, QLD, Australia, 4Bond Univ, Gold Coast, QLD, Australia, 5Princess Alexandra Hosp, Brisbane, QLD, Australia, 6Univ Qld, Brisbane, QLD, Australia, 7Univ Calif Los Angeles, Los Angeles, CA

77 The relationship between genetics and personality factors in peer-pressure susceptibility
R. S. Boyle, K. E. Siffin, M. B. Kitchens, M. Niculescu, Psychology, Lebanon Valley College, Annville, PA

78 Alcohol consumption and loneliness in mid- and late-life
S. L. Canham, P. M. Mauro, C. N. Kaufmann, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

79 What is the most cost-effective advertising strategy for alcohol pharmacotherapy clinical trials?
D. A. Tompkins, J. A. Harrison, E. C. Strain, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

80 Impact of heavy drinking among drug users identified by screening in primary care
C. Maynié-François, D. M. Cheng, J. H. Samet, C. A. Lloyd-Tavaglini, T. P. Palfai, J. A. Bernstein, R. Saitz, Boston University, Boston Medical Center, Boston, MA

81 Methods of pre-post analysis in the presence of missing data
A. Glass1, J. J. Mariani2, M. Pavlicova3, E. V. Nunes2, F. R. Levin2, M. M. Wall1,3, 1Biostatistics, New York State Psychiatric Institute, New York, NY, 2Psychiatry, Columbia University, New York, NY, 3Biostatistics, Columbia University, New York, NY

82 A brief behavioral telehealth intervention for veterans with alcohol use disorders in VA primary care: A pilot investigation
E. J. Santa Ana1,2, K. Lamb1,2, S. LaRowe1,2, P. Nietert1, 1MUSC, Charleston, SC, 2Charleston VAMC, Charleston, SC

83 The role of drinking motives among tobacco-using problem drinkers in terms of cognitive-based smoking processes and quit failure
L. Garey1, D. W. Foster2, M. J. Zvolensky4, J. W. Ditre5, N. B. Schmidt4, 1University of Houston, Houston, TX, 2Harvard University, Cambridge, MA, 3Syracuse University, Syracuse, NY, 4Florida State University, Tallahassee, FL

POLYDRUG ABUSE I

84 Caffeine and alcohol intake and nicotine dependence severity in female smokers
C. Riyad1, K. M. Gray1, M. E. Saladin2,1, 1Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 2Department of Health Science and Research, Medical University of South Carolina, Charleston, SC
85 Transitions in polydrug use among heroin and methamphetamine injectors in Tijuana, Mexico
M. C. Meacham1,2, K. D. Wagner1, T. Mackey1, T. L. Patterson1, S. Strathdee1, S. Roesch2,
1University of California San Diego, La Jolla, CA, 2San Diego State University, San
Diego, CA

86 Mood, alexithymia, dispositional mindfulness, sensitivity to reward and punishment, frontal
systems functioning and impulsivity in clients undergoing treatment for substance use disorders
M. Lyvers1, R. Hinton1, M. S. Edwards1, F. A. Thorberg2, 1Psychology, Bond University, Gold
Coast, QLD, Australia, 2Medicine, University of Oslo, Oslo, Norway

87 Associations of smoking history with cigarette smoking expectancies among adults in residential
substance use treatment
E. Hoffman, K. Long, J. Soldigner, L. MacPherson, Psychology, University of Maryland
College Park, College Park, MD

88 Non-heterosexual identity and substance use disorders: The mediating role of borderline
personality disorder features
L. R. Few1, C. A. Sloan2, N. G. Martin3, T. J. Trull4, A. Agrawal1, M. T. Lysney5,
1Washington University School of Medicine, Saint Louis, MO, 2VA Boston Healthcare
System, Boston, MA, 3QIMR Berghofer Medical Research Institute, Brisbane, QLD,
Australia, 4University of Missouri, Columbia, MO, 5King’s College London, London, United
Kingdom

89 Connecting states and traits: A look at personality and response to stress in real-time

90 Neuropsychological changes during residential substance use treatment
S. J. Lookatch1,2, E. Katz2, S. Anderson2, R. Shorey1,3, G. Stuart1, T. Moore1, 1Psychology,
University of Tennessee, Knoxville, TN, 2Psychology, Towson University, Towson, MD,
3Cornerstone of Recovery, Louisville, TN

91 Relationship between sleep problems and heavy/problem substance use in primary care patients
T. Moore1, T. Verno1, A. Werntz1, P. Dillon1, T. Gentry1, V. Walters2, S. R. Hursh2,3,
P. G. Roma2,3, B. Rybarczyk1, D. Svikis1, 1Virginia Commonwealth University,
Richmond, VA, 2Institutes for Behavior Resources, Baltimore, MD, 3Johns Hopkins
University School of Medicine, Baltimore, MD

92 Strategies to influence attitudes towards pharmacotherapies for alcohol and opioid use
disorders
K. Alanis-Hirsch1, R. Croff2, J. Ford3, L. Schmidt4, D. McCarty2, M. Chalk1, 1Treatment
Research Institute, Philadelphia, PA, 2Oregon Health & Science University, Portland, OR,
3Center for Health Enhancement System Studies, Madison, WI, 4University of California, San
Francisco, CA

93 Smoking crack might increase high risk injection practices among people who inject drugs
E. Roy1,2,3, C. Blanchette4, P. Leclerc5, M. Alrissette2,4, C. Morissette2,5, K. Blouin5, 1Sciences de la
santé communautaire, Université de Sherbrooke, Longueuil, QC, Canada, 2Institut National de
Santé Publique du Québec, Montréal, QC, Canada, 3Direction de Santé Publique de Montréal,
Montréal, QC, Canada, 4Département de médecine sociale et préventive, Université Laval,
Québec, QC, Canada

94 Factors associated with precursors to initiating other people into injection drug use
R. Bluthenthal1, L. Wenger2, J. Thing1, D. Chu1, J. Lorvick2, B. Quinn3, A. Kral1, 1Preventive
Medicine, University of Southern California, Los Angeles, CA, 2Urban Health, RTI
International, San Francisco, CA, 3Burnet Institute, Melbourne, VIC, Australia
Tuesday, June 17, 2014

95 Clinician beliefs and behaviors regarding screening and brief intervention for drug use of their community health center patients
   A. Reddy, L. Gelberg, R. Andersen, University of California Los Angeles, Los Angeles, CA

96 Feasibility of the Quit Using Drugs Intervention Trial
   M. Vahidi1, M. Rico1, J. Scholtz1, M. Garcia1, R. Andersen2, J. Yacenda1, L. Gelberg1,2,
   1Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA School of Public Health, Los Angeles, CA

97 Screening and brief treatment for illicit drug use in primary care: Feasibility and acceptability
   A. C. Brooks1, C. M. Carpenedo1, J. Lauby2, D. Metzger1,3, E. Byrne2, K. Favor4,
   K. C. Kirby1,3, 1Treatment Research Institute, Philadelphia, PA, 2Public Health Management Corporation, Philadelphia, PA, 3Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 4Department of Psychology, Lincoln University, Lincoln University, PA

98 RecoveryTrack-ExtendedCare™, a novel monitoring and outreach intervention
   J. Cacciol1,2, A. C. Brooks1, K. Kizina1, E. Moberg1, J. Berman1, G. DiGuiseppi1, 1Center on the Continuum of Care, Treatment Research Institute, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA

99 Computer vs. in-person brief intervention for drug misuse: 12-month outcomes
   R. P. Schwartz1, J. Gryczynski1, S. G. Mitchell1, A. Gonzales2, T. Peterson2, A. Moseley2,
   K. E. O’Grady3, S. J. Ondersma4, 1Friends Research Institute, Baltimore, MD, 2Sangre de Cristo Community Health Partnership, Santa Fe, NM, 3University of Maryland, College Park, MD, 4Wayne State University, Detroit, MI

100 An Internet-acquired recovery sample: Initial findings from the International Quit and Recovery Registry
   A. G. Wilson1, C. Franck2, M. N. Koffarnus1, R. Reese3, K. D. Bixel1, W. K. Bickel1, 1Virginia Tech Carilion Research Institute, Roanoke, VA, 2Virginia Tech, Blacksburg, VA, 3Jefferson College of Health Sciences, Roanoke, VA

101 Ecological momentary assessment to predict the risk of relapse
   M. L. Dennis, C. K. Scott, R. R. Funk, Chestnut Health Systems, Normal and Chicago, IL

102 Predicting mood and craving from real-time neighborhood surroundings
   K. L. Preston1, M. Tyburski1, K. A. Phillips1, M. L. Jobes1, C. D. Furr-Holden2,
   M. Vahabzadeh1, M. Mezghanni1, J. Lin1, D. H. Epstein1, 1NIDA Intramural Research Program, Baltimore, MD, 2Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

103 Uncomfortably numb: Substance use associated with elder mistreatment
   D. V. Flores1,2,3, J. Burnett1,2,3, J. Booker4,2, C. B. Dyer1,2,3, 1University of Texas Medical School, Houston, TX, 2Texas Elder Abuse and Mistreatment Institute, Houston, TX, 3Harris Health System, Houston, TX, 4Adult Protective Services Region 6, Houston, TX

104 Associations between childhood maltreatment, intimate partner violence, and substance use disorders
   K. Walsh, D. S. Hasin, Columbia University, New York, NY

105 Do social support and negative emotions condition the effect of child custody loss on drug use?
   K. Harp1,2, C. B. Oser2,3, 1Behavioral Science, University of Kentucky, Lexington, KY,
   2Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, 3Sociology, University of Kentucky, Lexington, KY
Tuesday, June 17, 2014

106  Childcare in families with SUD mothers or fathers  
H. R. Lawrence¹, M. L. Kelley², E. M. Murphy², G. M. D’Lima², R. J. Milletich², B. Hollis²,  
C. G. Cooke², M. Stockstad², ¹Department of Psychology, University of Maine, Orono, ME,  
²Department of Psychology, Old Dominion University, Norfolk, VA  
PSYCHIATRIC COMORBIDITY I

107  Family history of drug problems as a marker for other health risks in primary care patients  
A. Alvanzo¹, G. Villalobos², P. Dillon², S. Ondersma³, D. Svikis², ¹Johns Hopkins University,  
Baltimore, MD, ²Virginia Commonwealth University, Richmond, VA, ³Wayne State University, Detroit, MI

108  What predicts continued substance use among probationers?  
J. Lerch¹, F. Taxman¹, S. Walters², ¹George Mason University, Fairfax, VA, ²University of North Texas Health Science Center, Fort Worth, TX

109  Distress tolerance moderates the relationship between social rejection and major depressive disorder in inner-city substance users  
B. Ali, K. R. Hamilton, N. Bounoua, C. W. Lejuez, University of Maryland, College Park, MD

110  Perceived discrimination, depressive symptoms, and substance use among African-American and Afro-Caribbean young adults  
T. Clark¹, J. Brook², ¹School of Social Work, University of North Carolina, Chapel Hill, NC,  
²Psychiatry, New York University School of Medicine, New York, NY

111  Significantly lower prevalence of psychopathology in Asian compared to non-Asian methadone-maintained patients  
G. Bart, S. Lenz, Medicine, Hennepin County Medical Center, Minneapolis, MN

112  Gender differences in psychiatric symptoms among opiate-dependent patients in Russia  
A. Desrosiers¹, E. Blokhina², E. Krupitsky², M. C. Chawarski¹, ¹Yale School of Medicine,  
New Haven, CT, ²St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation

113  The impact of eye movement desensitization and reprocessing and schema therapy on addiction severity among a sample of French women suffering from PTSD and SUD  
B. Perez-Dandieu¹, H. Lenoir³, E. Othily², G. Tapia³, M. Cassen², J. Delille¹, ¹Addiction,  
CEID, Bordeaux, France, ²IMM, Cenon, France, ³EA4139, Laboratoire Psychologie, Santé et Qualité de Vie, Université de Bordeaux, Bordeaux, France

114  Past year non-medical opioid use and PTSD diagnosis: Interactions with gender and associations with symptom clusters  
S. A. Cercone¹, P. H. Smith², K. M. Smith³, G. G. Homish¹, S. McKee¹, ¹Community Health and Health Behavior, University at Buffalo, The State University of New York, Buffalo, NY,  
²Epidemiology and Public Health, Yale University, New Haven, CT, ³Department of Psychiatry, Yale University School of Medicine, New Haven, CT

115  Pathways to change: Trajectories following treatment in women with co-occurring PTSD and substance use disorders  
T. Lopez-Castro¹, M. Hu², D. A. Hien¹, ¹The City College of New York, NY, NY, ²NY State Psychiatric Institute, NY, NY

116  Incentivizing adherence to prolonged exposure for PTSD: Preliminary results  
J. M. Peice¹, R. L. Schacht², V. L. King¹, R. K. Brooner¹, ¹Psychiatry & Behavioral Sciences,  
Johns Hopkins University School of Medicine, Baltimore, MD, ²Psychology, University of Maryland, Baltimore County, Baltimore, MD
To reduce or abstain? Substance use goals in the treatment of veterans with substance use disorders and comorbid PTSD
B. E. Lozano1,2, D. Teer1, S. E. Back1,2, 1Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 2Mental Health Service, Ralph H. Johnson VAMC, Charleston, SC

How does change in alcohol misuse and depression comorbidity impact on neuropsychological test performance after 12 months?
S. A. Hunt, A. L. Baker, P. Michie, University of Newcastle, Newcastle, NSW, Australia

Relationship of alcohol and cocaine on mood episodes among HIV-infected adults with bipolar disorder and major depressive disorder
L. J. King, M. D. Key, S. Towe, C. S. Meade, Duke University, Durham, NC

Increasing psychiatric comorbidity in recent smoking birth-cohorts
A. Talati1, K. Keyes2, D. S. Hasin2,4, 1Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY, 2Epidemiology, Columbia University Mailman School of Public Health, New York, NY

Cigarette smoking and the onset and persistence of major depressive disorder among adults in the United States: 1994-2005
M. Zvolensky1,2, J. Bakhshaei1, R. Goodwin3,4, 1Psychology, University of Houston, Houston, TX, 2MD Anderson Cancer Center, Houston, TX, 3Psychology, Queens College, City University of New York, New York, NY, 4Epidemiology, Columbia University, New York, NY

Examining vulnerability to smokeless tobacco use among adolescents and adults with major depressive disorder
R. Redner1,2, T. J. White1,2, S. T. Higgins1,2,3, V. Harder2,3, 1Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, 2Psychiatry, University of Vermont, Burlington, VT, 3Psychology, University of Vermont, Burlington, VT

Changes in the prevalence of depression and anxiety disorders among daily smokers in the United States: 1990 to 2001
R. Goodwin1,2, S. Galea2, M. J. Zvolensky3,4, M. Wall5,6, Y. Nomura1,7, D. S. Hasin2,5,6, 1Psychology, City University of New York (CUNY), Flushing, NY, 2Epidemiology, Columbia University, New York, NY, 3Psychology, University of Houston, Houston, TX, 4Psychiatry, MD Anderson Cancer Center, Houston, TX, 5Psychiatry, Columbia University, New York, NY, 6Psychiatry, New York State Psychiatric Institute, New York, NY, 7Psychiatry, Mount Sinai School of Medicine, New York, NY

Depression, nicotine withdrawal, and smoking urges in smoking cessation
H. H. Reid1,2, D. M. Ledgerwood2, 1Psychology, Wayne State University, Detroit, MI, 2Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

Comparing smoking cessation interventions for persons with serious mental illness
P. Penn1, S. M. Gallagher2, E. Schindler3, W. K. Layne1, 1La Frontera Arizona, Tucson, AZ, 2S. Arizona VA, Tucson, AZ, 3Child & Family Resources, Tucson, AZ

Tobacco-related mortality among persons with mental health and substance abuse problems
F. Bandiera1, J. Gudyish1, B. Anteneh2, 1University of California, San Francisco, San Francisco, CA, 2Oregon Health Authority, Salem, OR
127 Individualized treatment for tobacco dependence in addictions treatment settings: The role of current depressive symptoms on outcomes at 3 and 6 months
L. Zawertailo1,2, D. Baliunas1, P. L. Selby1,3, Addictions Program, Centre for Addiction and Mental Health, Toronto, ON, Canada, 3Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, 3Family and Community Medicine, University of Toronto, Toronto, ON, Canada

128 Baseline depressive symptoms and contingency management outcomes in smokers
O. Garcia-Rodriguez, S. Weidberg, V. Martinez Loredo, J. R. Fernández-Hermida, R. Secades-Villa, Department of Psychology, University of Oviedo, Oviedo, Spain

129 Cannabis smoking may exacerbate depression-attributable functional impairment among recently active depressed cases
B. J. Fairman, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

PROGRAM DESCRIPTION
130 Disseminating information to psychologists on evidence-based practices to treat smoking in health priority populations
L. Beatty1, M. Iguchi2, F. Z. Belgrave3, G. Keita1, E. Andoh1, P. DiSandro1, 1American Psychological Association, Washington, DC, 2Georgetown University, Washington, DC, 3Virginia Commonwealth, Richmond, VA

131 Identification and evaluation of Internet forum discussion as a component of a post market-surveillance strategy for tobacco products
E. C. McNaughton, S. Bowman, K. McHugh, M. Behling, S. F. Butler, S. H. Budman, Inflexion, Inc, Newton, MA

132 Exploratory interviews with e-cigarette and snus users
S. Bowman, E. C. McNaughton, K. McHugh, M. Behling, S. F. Butler, S. H. Budman, Inflexion, Inc, Newton, MA

133 A pilot specialty jail diversion program for justice-involved veterans with co-occurring disorders
D. Smelson1,2, D. A. Pinals1,2, L. Sawh1,2,4, C. Fulwiler2, S. Singer2, K. O’Connor2, W. Fisher4, S. Hartwell3, G. Gonzalez2, 1Department of Veterans Affairs, Bedford, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Massachusetts Department of Mental Health, Boston, MA, 4University of Massachusetts Lowell, Lowell, MA, 5University of Massachusetts Boston, Boston, MA

134 The use of fingernail drug screening in multiply convicted OWI offenders in Kenosha County, WI
D. E. Lewis1, G. Brown2, I. Shu1, J. Jones1, 1U.S. Drug Testing Labs, Des Plaines, IL, 2Hope Council, Kenosha, WI

135 Studies on medications for addiction treatment in correctional settings
R. P. Schwartz2, J. D. Lee3, D. Farabee4, R. K. Chandler1, 1National Institute on Drug Abuse, North Bethesda, MD, 2Friends Research Institute, Baltimore, MA, 3New York University, New York City, NY, 4University of California - Los Angeles, Los Angeles, CA

136 Combining strategies: Using evidence-based interventions to build a more effective treatment program
J. Rhodes1, D. C. Lott1,2, 1Addiction Treatment Programs, Linden Oaks Hospital at Edward, Naperville, IL, 2Psychiatry, University of Illinois at Chicago, Chicago, IL
Tuesday, June 17, 2014

137 Developing an evidence-based intervention targeting high-risk migrant workers
R. Shrestha¹, M. Copenhaver², ¹Department of Community Medicine & Health Care, University of Connecticut, Farmington, CT, ²Department of Allied Health & Sciences, University of Connecticut, Storrs, CT

138 Web-based screening, brief intervention, and referral to treatment program in high schools
B. L. Curtis, A. T. McLellan, A. Woodworth, Treatment Research Institute, Philadelphia, PA

139 Navigating the world of adolescent substance abuse treatment through a web-based consumer guide

140 Web-based medical school education on substance use disorders
A. T. McLellan¹,², B. L. Curtis¹, B. Nordstrom¹, J. Skrajewski³, ¹Treatment Research Institute, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Dartmouth College, Hanover, NH, ⁴Betty Ford Institute, Rancho Mirage, CA

141 UNODC-WHO Program on Drug Dependence Treatment and Care: Building treatment capacity in low- and middle-income countries
E. Saenzer¹, G. Gerra¹, A. Busse², ¹Drug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria, ²Prevention, Treatment and Rehabilitation Section, United Nations Office on Drugs and Crime, Vienna, Austria

142 Implementing opioid overdose education and naloxone distribution in an outpatient community treatment program
D. C. Lott¹,², J. Rhodes¹, ¹Addiction Treatment Programs, Linden Oaks Hospital at Edward, Naperville, IL, ²Psychiatry, University of Illinois at Chicago, Chicago, IL

143 Implementation of drug and HIV risk counseling in MMT programs in Taiwan
T. Lee¹, M. C. Chawarski², C. Peng¹, C. Hung³, D. Metzer³, ¹National Taiwan Normal University, Taipei, Taiwan, ²Psychiatry, Yale School of Medicine, New Haven, CT, ³Taichung Veteran General Hospital, Taichung, Taiwan, ⁴University of Pennsylvania, Philadelphia, PA

144 Treatment of women with substance use disorder at high risk of stigmatization
P. Dolezalova, Clinic of Addictology, First Faculty of Medicine, Charles University, Prague, Czech Republic

PRESCRIPTION DRUGS

145 Evaluation of the relationship between pain level and craving of prescription opioids
L. Ashrafioon¹,², H. Rosenberg¹, ¹Psychology, Bowling Green State University, Bowling Green, OH, ²Mental Health Services, VA Ann Arbor Healthcare System, Ann Arbor, MI

146 Neurobiological and subjective stress reactivity among individuals with prescription opioid dependence: What is the role of interpersonal trauma exposure?
J. C. Hellmuth¹, J. L. McCauley¹, K. T. Brady¹,², S. E. Back¹,², ¹Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VAMC, Charleston, SC

147 Nonmedical use of oxycodone and other opiate analgesics in the US, 2004-2011: Are military veterans at increased risk?
R. Kato Price¹,², M. Shroff¹, C. van den Berk-Clark¹, G. Widner¹, S. Balan¹, E. Nelson¹, ¹Psychiatry, Washington University School of Medicine, Saint Louis, MO, ²Research and Development, VA St. Louis Health Care System, Saint Louis, MO

148 College student opinions about the use of non-medical prescription drugs
K. A. Parks, K. Levonyan-Radloff, S. Przybyla, A. Hequembourg, Research Institute on Addictions, University at Buffalo, Buffalo, NY
149 A typology of prescription drug misuse: A Latent Class Approach to contexts and risks  
B. C. Kelly\textsuperscript{1}, H. J. Rendina\textsuperscript{2}, B. E. Wells\textsuperscript{2}, J. T. Parsons\textsuperscript{2}, \textsuperscript{1}Purdue University, West Lafayette, IN, \textsuperscript{2}City University of New York, New York, NY

150 Correlates of prescription drug market involvement  
M. Vuolo\textsuperscript{1}, B. C. Kelly\textsuperscript{1}, B. E. Wells\textsuperscript{2}, J. T. Parsons\textsuperscript{2}, \textsuperscript{1}Purdue University, West Lafayette, IN, \textsuperscript{2}City University of New York, New York, NY

151 Comparison of adolescent self-reports of the nonmedical use of scheduled prescription medications in self-administered surveys vs. semi-structured interviews  
P. L. Ross-Durow, P. T. Veliz, S. E. McCabe, C. J. Boyd, Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI

152 Experiences of discrimination and psychosocial health problems as correlates of recent prescription drug misuse among YMSM: Evidence of a syndemic effect  
A. Keojevic, S. Lankenau, Drexel University School of Public Health, Philadelphia, PA

153 Prevalence and correlates of prescription stimulant misuse among youth in the emergency department  
L. K. Whiteside\textsuperscript{1}, R. Cunningham\textsuperscript{2}, E. E. Bonar\textsuperscript{2}, F. C. Blow\textsuperscript{2}, P. Ehrlich\textsuperscript{2}, M. Walton\textsuperscript{2}, \textsuperscript{1}Emergency Medicine, University of Washington, Seattle, WA, \textsuperscript{2}Psychiatry, Surgery and Emergency Medicine, University of Michigan, Ann Arbor, MI

154 Prescription opioid misuse among youth in primary care: A comparison of risk factors  
L. A. Lin, M. A. Walton, F. C. Blow, Department of Psychiatry, University of Michigan, Ann Arbor, MI

155 Identifying prescription drug misuse in primary care patients: A tale of two instruments  
M. Weaver, G. Villalobos, T. Moore, P. Dillon, D. Svikis, Virginia Commonwealth University, Richmond, VA

156 Primary care buprenorphine detoxification vs. maintenance for prescription opioid dependence  
D. Fiellin, C. J. Cutter, B. A. Moore, D. Barry, P. O’Connor, R. S. Schottenfeld, Yale, New Haven, CT

157 Patterns of concurrent substance use among prescription stimulant misusers: Results from the National Survey on Drug Use and Health  
L. Chen\textsuperscript{1}, R. Crum\textsuperscript{1,2,3}, C. N. Kaufmann\textsuperscript{1}, S. S. Martins\textsuperscript{4}, E. C. Strain\textsuperscript{2}, R. Mojtabai\textsuperscript{1,2}, \textsuperscript{1}Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, \textsuperscript{2}Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, \textsuperscript{3}Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, \textsuperscript{4}Epidemiology, Mailman School of Public Health, New York, NY

158 Global impact of prescription opioid misuse: Europe and U.S.  
J. L. Green\textsuperscript{1}, E. M. Martinez\textsuperscript{1}, A. Rosenblum\textsuperscript{1}, T. Cicero\textsuperscript{1}, R. C. Dart\textsuperscript{1}, S. Walcher\textsuperscript{2}, L. Somaini\textsuperscript{3}, G. Deruvo\textsuperscript{3}, H. Desel\textsuperscript{4}, G. Milanesi\textsuperscript{4}, F. Sesana\textsuperscript{5}, M. Guareschi\textsuperscript{6}, K. McBride\textsuperscript{1}, I. Maremmani\textsuperscript{7}, M. Parrino\textsuperscript{1}, \textsuperscript{1}RADARS(r) System, RMPDC, DHHA, Denver, CO, \textsuperscript{2}CONCEPT, Munich, Italy, \textsuperscript{3}SerT (Biella & Bitonto), Biella, Italy, \textsuperscript{4}GIZ-Nord Poisons Centre, Göttingen, Germany, \textsuperscript{5}Milan Poison Centre, Milan, Italy, \textsuperscript{6}AU-CNS, Pietrantsa, Italy, \textsuperscript{7}Santa Chiara University Hospital, Pisa, Italy

159 Strategies to reduce prescription opioid abuse in the United States: How have they influenced the epidemic?  
T. Green\textsuperscript{1,2}, S. Bowman\textsuperscript{1,2}, C. Los\textsuperscript{1}, K. McHugh\textsuperscript{1}, P. D. Friedmann\textsuperscript{2}, \textsuperscript{1}Inflexxion, Inc., Newton, MA, \textsuperscript{2}Rhode Island Hospital, Providence, RI

160 Prescription drug use, impairment warnings, and perceived risks among U.S. drivers  
R. Pollini, J. Yao, T. Kelley-Baker, Pacific Institute for Research and Evaluation, Calverton, MD
Tuesday, June 17, 2014

161 Florida’s prescription drug monitoring program and oxycodone-caused mortality: A monthly time series analysis, 2003-2012
   C. Delcher1,2,4, A. Wagenaar1,4, B. Goldberger3, M. Maldonado-Molina1,4, 1Health Outcome and Policy, University of Florida, Gainesville, FL, 2Epidemiology, University of Florida, Gainesville, FL, 3Pathology, University of Florida, Gainesville, FL, 4Institute of Child Health Policy, University of Florida, Gainesville, FL

162 Prescription opioid use is associated with increased mortality in the Reasons for Geographic and Racial Differences in Stroke study
   Y. Khodneva1, P. Muntner4, S. Kertesz2,1, G. Howard1, M. Safford1, 1UAB, Birmingham, AL, 2VAMC, Birmingham, AL

Symposium X

CB2 FUNCTIONS IN THE BRAIN AND THE PERIPHERY

Chairs: Toby K. Eisenstein and Vishnudutt Purohit

10:00 Differential CB2 receptor involvement in cocaine and nicotine reward
   Aron Lichtman, Virginia Commonwealth University, Richmond, VA

10:25 CB2 agonists and neuropathic pain
   Andrea G. Hohmann, Indiana University, Bloomington, IN

10:50 CB2 activation in brain endothelium: A new way to protect the blood brain barrier
   Yuri Persidsky, Temple University School of Medicine, Philadelphia, PA

11:15 CB2 agonists as immunosuppressants
   Toby K. Eisenstein, Temple University School of Medicine, Philadelphia, PA

11:40 DISCUSSANT: Assessing the potential of CB2 compounds as therapeutics for neuropathic pain, drug addiction, inflammation, and a leaky BBB
   Vishnudutt Purohit, National Institute on Drug Abuse, Bethesda, MD

Symposium XI

TRAJECTORIES OF HEROIN USE:
INSIGHTS FROM LONGITUDINAL STUDIES

Chairs: Linda Cottler and Christina Marel

10:00 Recovery from heroin addiction: Findings based on a 33-year follow-up study of heroin addicts
   Yih-Ing Hser, University of California, Los Angeles, Los Angeles, CA

10:25 Gender differences in 30-year trajectories of heroin and other drug use and health outcomes
   Christine E. Grella, University of California, Los Angeles, Los Angeles, CA

10:50 Using drug treatment outcome research to drive innovative treatment policy change
   Catherine Comiskey, Trinity College, Dublin, Dublin, Ireland

11:15 Longitudinal trajectories: New findings from the 11-year follow-up of the Australian Treatment Outcome Study
   Maree Teesson, University of New South Wales, Sydney, NSW, Australia

11:40 DISCUSSANT: Similarities across the globe
   Linda Cottler, University of Florida, Gainesville, FL
Oral Communications 9

BABY STEPS TOWARDS UNDERSTANDING PERINATAL
DRUG ABUSE

Chairs: Loretta P. Finnegan and Erin Fukaya

10:00  Perinatal substance use: A prospective evaluation of abstinence and relapse
A. Forray1, B. Merry1, J. P. Ruger2, K. A. Yonkers1, 1Yale School of Medicine, New
Haven, CT, 2Perelman School of Medicine, Philadelphia, PA

10:15  Growth models of maternal perinatal drinking patterns in a national sample
W. Liu1, E. Mumford1, H. Petras2, 1NORC at the Univ. of Chicago, Bethesda, MD, 2JBS
International, Inc., North Bethesda, MD

10:30  Drug and tobacco use during pregnancy transmit genetic influences on developmental risk for
substance use
K. Marceau1,2, V. Knopik2, D. Reiss1, D. Shaw4, M. Natsuaki5, P. Fisher6, L. D. Leve6,
J. M. Neiderhiser7, 1Brown University, Providence, RI, 2Rhode Island Hospital,
Providence, RI, 3Yale University, New Haven, CT, 4University of Pittsburgh, Pittsburgh, PA,
5University of California-Riverside, Riverside, CA, 6University of Oregon, Eugene, OR, 7Penn
State, State College, PA

10:45  Prenatal cigarette smoke exposure, childhood aggression and adolescent cigarette use
N. De Genna1, L. Goldschmidt2, M. Cornelius1,2, 1University of Pittsburgh School of
Medicine, Pittsburgh, PA, 2Western Psychiatric Institute and Clinic (WPIC), Pittsburgh, PA

11:00  Lower oxidative stress in umbilical blood cord of newborns exposed to crack during pregnancy
C. M. Szobot1, M. Zavaschi1, V. Mardini1, F. Kapczinski1, M. Kauer-Sant’anna1, G. Colpo1,
B. Aguiar1, G. Cunha1, L. Manna1, A. Childress2, D. Langleben2, K. M. Cereser1,
L. A. Rohde1, 1Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 2Treatment
Research Center, Philadelphia, PA

11:15  Motor development in children prenatally exposed to methamphetamine and tobacco
E. Fukaya1, J. Skranes2,3, G. Lohaugen2,3, C. Cloak1, C. Jiang1, L. Chang1, 1Univ of Hawaii
Manoa, Honolulu, HI, 2Children’s and Women’s Health, Norwegian Univ of Science and
Technology, Trondheim, Norway, 3Pediatrics, Sorlandet Hospital, Arendal, Norway

11:30  Effects of maternal opioid maintenance therapy on neonatal outcomes: Methadone vs.
buprenorphine
L. Brandt1, S. Fischberger2, R. Jagsch3, G. Fischer1,2, 1Center for Public Health, Medical
University of Vienna, Vienna, Austria, 2Psychiatry and Psychotherapy, Medical University of
Vienna, Vienna, Austria, 3Psychology, University of Vienna, Vienna, Austria

11:45  Reliability of pupil diameter measurements in neonates
S. H. Heil, D. J. Hand, C. L. Bergeria, D. E. Gaalema, G. J. Badger, A. M. Johnston,
University of Vermont, Burlington, VT
Oral Communications 10

JOIN THE CLUB: RESEARCH ON CLUB DRUGS

Chairs: Doris Payer and Michael H. Baumann

10:00 Pharmacology of “next generation” synthetic cathinones: The future is now
M. H. Baumann, K. R. Lehner, O. Bukhari, R. B. Rothman, J. S. Partilla, Designer Drug Research Unit, IRP, NIDA, NIH, Baltimore, MD

10:15 Human pharmacology of mephedrone: A dose-finding pilot study
E. Papaseit1,3, C. Perez-Mañá1,3, M. Pujadas1, F. Fonseca2, M. Torrens2,3, R. De La Torre1,4, M. Farre1,3, 1Human Pharmacology and Neurosciences, Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain, 2Drug Addiction Unit, Hospital del Mar-INAD, Barcelona, Spain, 3Universidad Autonoma de Barcelona-UAB, Barcelona, Spain, 4Universidad Pompeu Fabra-UPF, Barcelona, Spain

10:30 Exploring brain morphology in poly-stimulant abuse: Shape, volume, and surface area abnormalities in ecstasy-cocaine-and methamphetamine-preferring individuals
D. Payer1, M. Park1, S. Kish1, J. Lerch2, I. Boileau1,3, M. Chakravarty1,3, 1Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada, 2Medical Biophysics, University of Toronto, Toronto, ON, Canada, 3Psychiatry, University of Toronto, Toronto, ON, Canada

10:45 Psychiatric symptoms in a sample of young, sexual minority Brazilian ecstasy and LSD users
F. P. Pechansky1, L. S. Remy1, H. Surratt2, S. S. Kurtz2, 1Psychiatry, Center for Drug and Alcohol Studies - Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 2Center for Applied Research on Substance Use and Health Disparities Nova Southeastern University, Miami, FL

11:00 THC-like effects of novel synthetic cannabinoids found on the gray market
M. J. Forster, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX

11:15 Synthetic cannabinoid use in cannabis smokers
Z. D. Cooper, M. Haney, Psychiatry, Columbia University, NYSPI, New York, NY

11:30 Comparison of synthetic substances: Diffusion of Innovation framework
C. L. Arfken1, C. Madeja1, D. Owens2, 1Wayne State University, Detroit, MI, 2Southeast Michigan Community Alliance, Taylor, MI

11:45 Detecting a signal in the noise: Results of a pilot project to monitor the global spread of new drugs by monitoring media
M. M. Young1,2, C. Dubéau1, K. Diedrich1, O. Corazza3, 1Research and Policy, Canadian Centre on Substance Abuse, Ottawa, ON, Canada, 2Psychology, Carleton University, Ottawa, ON, Canada, 3Department of Postgraduate Medicine, University of Hertfordshire, Hatfield, United Kingdom
Animal Forum

HOW ANIMAL RESEARCHERS CAN HAVE A STRONGER VOICE

Chairs: Marilyn E. Carroll and Toby K. Eisenstein

Building the STAR Coalition with larger numbers, more visibility, more advocacy

Marilyn E. Carroll¹, Toby K. Eisenstein², ¹University of Minnesota, Minneapolis, MN,
²Temple University School of Medicine, Philadelphia, PA

Stop hiding: Engage in educational opportunities e.g., Cindy Buckmaster, on You Tube,
and working in different venues, from elementary school to vet school

Marilyn E. Carroll, University of Minnesota, Minneapolis, MN

How to deal with overzealous IACUC’s

Marilyn Carroll, Michael Gatch, Bert Weiss

Regulatory burden on federally funded research: The NSF Report

Toby K. Eisenstein, Michael Gatch, Bert Weiss

Reproducibility of Research Forum

IRREPRODUCIBLE RESEARCH: IS IT RELEVANT TO THE ADDICTION RESEARCH COMMUNITY? OR (REPRODUCIBILITY OF RESEARCH RESULTS: IS IT RELEVANT TO THE ADDICTION RESEARCH COMMUNITY?)

Chairs: Elena Koustova and Mark Swieter

Introduction and NIH update

Elena Koustova, NIDA/NIH/DHHS, Rockville, MD

NIDA’s Plans

Mark Swieter, NIDA/NIH/DHHS, Rockville, MD

Scientific Journal Editors

Media Forum

WHAT’S HOT: PIVOTAL RESEARCH IN CPDD 2014

Chairs: Bertha K. Madras and Anna Rose Childress

Introduction to media and format

Bertha K. Madras, Harvard Medical School-NEPRC, Southborough, MA

Introduction to each speaker

Anna Rose Childress, University of Pennsylvania, Philadelphia, PA
Tuesday, June 17, 2014

Grant-Writing Workshop  
(PRE-REGISTRANTS ONLY)  
LAS OLAS  
1:15 - 5:00 PM

Film Screening:  
Addiction Incorporated  
AUDITORIUM  
5:00 - 6:15 PM

Primm-Singleton Awardees Reception  
BOARDROOM 1  
5:00 - 6:30 PM

Workshop X  
BALLROOM A  
7:00 - 9:00 PM

THE USE OF GIS & GPS TECHNOLOGY IN ADDICTION RESEARCH


Biomapping: Future innovations in drug treatment research  
C. Debra M. Furr-Holden, Johns Hopkins University, Baltimore, MD

Advances in GIS methods for addiction research  
Adam J. Milam, Wayne State University School of Medicine, Detroit, MI

The use of GPS technology and electronic diary reports in drug treatment research  
David Epstein, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD

The role of gene environment interactions in substance use and dependence  
Brion Maher, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

DISCUSSANT: The future of GIS & GPS technology in addiction research  
Kenzie L. Preston, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD

Workshop XI  
BALLROOM B  
7:00 - 9:00 PM

IMPROVING THE WRITING OF EMERGING INVESTIGATORS IN ADDICTION SCIENCE: INNOVATIVE TRAINING, EVALUATION METHODS, AND RESOURCES

Chairs: James Sorensen and Joseph Guydish

Improvement of writing by integrating a professional skills development course and writers’ workgroup  
Christine E. Grella, University of California, Los Angeles, Los Angeles, CA

Getting on track: How to become an intrepid writer  
Adam Carrico, University of California, San Francisco, Los Angeles, CA

Improving the writing of emerging investigators in addiction science  
Helen Knudsen, University of Kentucky, Lexington, KY

Writers’ task force to improve writing and increase journal submissions of young investigators  
Carmen L. Masson, University of California, San Francisco, San Francisco, CA

Discussant: Writing manuscript reviews that assist both authors and editors  
Jeffrey Samet, Boston University Schools of Medicine and Public Health, Boston, MA
Tuesday, June 17, 2014

Workshop XII

UPDATE ON THE ABUSE-DETERRENT SCIENCE MEETING ON THE FDA DRAFT GUIDANCE FOR INDUSTRY ON ABUSE-DETERRENT OPIOIDS—EVALUATION AND LABELING

Chairs: Beatriz Rocha and Cynthia Arons

Lessons from the lab and the clinic: An academic perspective on the draft ADF guidance
Sharon L. Walsh, University of Kentucky, Lexington, KY

Considerations in abuse-liability testing: An industry perspective on the draft ADF guidance
Marta Sokolowska, Grunenthal USA, Inc., Bedminster, NJ

From evaluation to labeling: A regulatory perspective on the draft ADF guidance
Michael Klein, Controlled Substances Staff, Food and Drug Administration, Silver Spring, MD

DISCUSSANT: Opportunities and challenges in an emerging area of pharmaceutical and regulatory science
Beatriz Rocha, Covance, Princeton, NJ

Workshop XIII

ADDITION TREATMENT RESEARCH VS. USUAL CARE: WHAT ARE THE FORESEEABLE RISKS?

Chair: Andrew Saxon

Using treatment as usual in research: Current debate regarding disclosure of risks
Carmen Rosa, NIDA, Bethesda, MD

A cautionary tale: Do not include risks of usual care in study consent forms
Andrew Saxon, Veterans Affairs Puget Sound Health Care System, Seattle, WA

Treatment as usual in vulnerable populations: Case study of two clinical trials in HIV-infected participants
Todd Korthuis, Oregon Health and Science University, Portland, OR

Does research treatment always pose increased risk over usual care, and does it matter?
David A. Gorelick, University of Maryland, Baltimore, MD

Discussant
Collin O’Neil, New York University, New York, NY
Wednesday, June 18, 2014

Poster Session III
(Breakfast)

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Tuesday 1 PM
Must be removed by Wednesday 12 Noon

POLICY

1 Immunization increases the reinforcement threshold but not elasticity of demand for nicotine in an animal model of nicotine reduction policy
   M. G. LeSage\textsuperscript{1,2}, M. Staley\textsuperscript{1}, P. R. Pentel\textsuperscript{1,2}, \textsuperscript{1}Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, \textsuperscript{2}Medicine, University of Minnesota, Minneapolis, MN

2 Availability of smoking cessation services in SUD treatment in the context of health reform
   H. K. Knudsen\textsuperscript{1}, P. M. Roman\textsuperscript{2}, \textsuperscript{1}Behavioral Science, University of Kentucky, Lexington, KY, \textsuperscript{2}Sociology, University of Georgia, Athens, GA

3 Willingness to enter drug treatment: The role of treatment models, copays and financial incentives
   C. Barry\textsuperscript{1}, S. Busch\textsuperscript{2}, A. Epstein\textsuperscript{3}, D. Fiellin\textsuperscript{2}, \textsuperscript{1}Johns Hopkins, Baltimore, MD, \textsuperscript{2}Yale, New Haven, CT, \textsuperscript{3}University of Pennsylvania, Philadelphia, PA

4 Incentives in public addiction treatment payment systems: Intended and unintended effects
   S. Reif, M. Stewart, C. M. Horgan, B. Mohr, Institute for Behavioral Health, The Heller School, Brandeis University, Waltham, MA

5 FISCAL: An all-data approach to assessing financial capability in people with psychiatric disabilities and substance use
   M. Rosen\textsuperscript{1,2}, A. C. Black\textsuperscript{1,2}, C. M. Lazar\textsuperscript{1}, \textsuperscript{1}Yale University, New Haven, CT, \textsuperscript{2}VA Connecticut Healthcare, West Haven, CT

6 Using data mining of spontaneous adverse event reports and multivariate statistical methods for assessing abuse potential
   C. Arons\textsuperscript{1}, E. Hung\textsuperscript{2}, S. Ratcliffe\textsuperscript{1}, M. Hauben\textsuperscript{3}, \textsuperscript{1}Pfizer, Groton, CT, \textsuperscript{2}Pfizer, New York, NY

7 Assessing standards of evidence in evidence-based program registers for behavioral health treatments
   S. Magura, J. Burkhardt, D. Schroeter, S. Means, Y. Vladimirovna, C. Coryn, Western Michigan University, Kalamazoo, MI

8 Validation of the Substance Use Brief Screen in primary care
   J. McNeely\textsuperscript{1}, S. Strauss\textsuperscript{2}, P. N. Halkitis\textsuperscript{1,3}, R. Saitz\textsuperscript{4}, J. Rotrosen\textsuperscript{1}, D. Shelley\textsuperscript{1}, C. Cleland\textsuperscript{2}, M. N. Gourevitch\textsuperscript{1}, \textsuperscript{1}NYU School of Medicine, New York, NY, \textsuperscript{2}NYU College of Nursing, New York, NY, \textsuperscript{3}NYU Steinhardt School, New York, NY, \textsuperscript{4}Boston University, Boston, MA

9 Predictors of positive drug screens after deployment to Iraq or Afghanistan in the military drug testing program
   M. Larson\textsuperscript{1}, B. A. Mohr\textsuperscript{1}, R. Adams\textsuperscript{1}, T. V. Williams\textsuperscript{2}, \textsuperscript{1}Heller School for Social Policy and Management, Brandeis University, Waltham, MA, \textsuperscript{2}Defense Health Agency, Department of Defense, Falls Church, VA
Wednesday, June 18, 2014

10 Early evaluation of the experiences and opinions of pharmacists towards the Ontario Narcotics Monitoring System
   B. Sproule1,2, K. Liu1,2, J. Chundamala1, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

11 Estimated effect of state syringe policy on source of last-used injection equipment
   P. Janulis, J. C. Anthony, NIDA T32 Training Program, Michigan State University, East Lansing, MI

12 The impact of state medical marijuana legislation on adolescent marijuana use
   J. McConnell1, E. Choo1, N. Zaller2, M. Benz1, O. Warren1, K. Rising3, 1Department of Emergency Medicine, Brown University, Providence, RI, 2Department of Medicine, Brown University, Providence, RI, 3Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, 4Department of Emergency Medicine, Oregon Health & Science University, Portland, OR

13 Reported use of non-prescribed marijuana for biomedical and psychiatric conditions among regular marijuana users

14 Physician supply for the treatment of opioid use disorders: The influence of state policies
   B. D. Stein1,2, A. J. Gordon1,4, A. Dick2, R. M. Burns2, R. Pacula3, C. Farmer2, D. Leslie5,
   1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2RAND Corporation, Pittsburgh, PA, 3RAND Corporation, Santa Monica, CA, 4VA Pittsburgh Healthcare System, Pittsburgh, PA, 5Penn State College of Medicine, Hershey, PA

15 Expansion of buprenorphine opioid agonist therapy in the United States: Facility-level factors
   R. Liccardo Pacula3, A. J. Gordon1,4, A. W. Dick2, R. M. Burns2, C. Farmer2, D. Leslie5,
   M. Sorbero2, B. D. Stein1,2, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2RAND Corporation, Pittsburgh, PA, 3RAND Corporation, Santa Monica, CA, 4VA Pittsburgh Healthcare System, Pittsburgh, PA, 5Penn State College of Medicine, Hershey, PA

16 How does one measure buprenorphine diffusion? The challenges of alternative measures of success
   R. M. Burns2, R. Pacula3, A. W. Dick2, A. J. Gordon1,4, M. Sorbero2, D. L. Leslie5, C. Farmer2,
   B. D. Stein1,2, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2RAND Corporation, Pittsburgh, PA, 3RAND Corporation, Santa Monica, CA, 4VA Pittsburgh Healthcare System, Pittsburgh, PA, 5Penn State College of Medicine, Hershey, PA

17 Buprenorphine dissemination in the public sector: Social network analysis and institutional constraints of prescribers in New York City
   H. Hansen1, P. Bearman2, S. Mendoza1, J. Rotrosen1, 1Psychiatry, New York University, NY, NY, 2Sociology, Columbia University, NY, NY

18 Increasing access to opioid agonist treatment in U.S. treatment shortage areas
   A. Dick3, R. Pacula3, A. J. Gordon1,4, M. Sorbero2, R. M. Burns2, C. Farmer2, D. Leslie5,
   B. D. Stein1,2, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2RAND Corporation, Pittsburgh, PA, 3RAND Corporation, Santa Monica, CA, 4VA Pittsburgh Healthcare System, Pittsburgh, PA, 5Penn State College of Medicine, Hershey, PA

19 WITHDRAWN

OPIOIDS II

20 Predictors of sublingual buprenorphine induction and detoxification response among heroin-dependent adults
   E. A. Woodcock, M. K. Greenwald, L. H. Lundahl, Wayne State University, Detroit, MI

78
21 Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone vs. buprenorphine
M. A. Sullivan, A. Bisaga, K. Carpenter, J. J. Mariani, K. Mishlen, E. V. Nunes, Columbia University/ New York State Psychiatric Institute, New York, NY

22 Workforce attitudes regarding the implementation of extended release naltrexone to treat opioid dependence
L. Andrich1, K. T. Garvey1, E. M. Klemperer2,1, T. R. Rieckmann1, 1Oregon Health & Science University, Portland, OR, 2University of Vermont, Burlington, VT

23 Interest for treatment with extended-release naltrexone among Norwegian opiate users
K. S. Haase1,6, A. Opheim2, N. Kunoe1, L. S. Stavseth1, Z. Latif6, A. N. Mjolhus4, M. Møller5, L. Tanum3,1, 1Oslo University Hospitals, Norwegian Center for Addiction Research, Oslo, Norway, 2Bergen Hospital Trust, Bergen, Norway, 3Akershus University Hospital, Lorenskog, Norway, 4Stavanger University Hospitals, Stavanger, Norway, 5Ostfold Hospital Trust, Fredrikstad, Norway, 6University of Pennsylvania, Philadelphia, PA

24 Existential anxiety in first-time recipients of XR-NTX for opioid addiction
A. Opheim1, K. S. Haase2,3, L. Tanum4, N. Kunoe3, S. Nesvåg5, L. Stavseth4, H. Z. Latif6, A. L. Mjolhus4, M. Møller2, 1Haukeland University Hospital, Bergen, Norway, 2Norwegian Centre of Addiction Research, Oslo, Norway, 3Vestfold Hospital Trust, Tønsberg, Norway, 4Akershus University Hospital Trust, Oslo, Norway, 5Stavanger University Hospital, Stavanger, Norway, 6Oslo University Hospital, Oslo, Norway, 7Ostfold Hospital Trust, Fredrikstad, Norway

25 Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation
E. Blokhina2, E. Krupitsky2, N. Bushara2, T. Yaroslavtseva2, A. Tiurina2, V. Palatkin2, E. Verbitskaya2, E. Zvartau2, G. E. Woody1, 1University of Pennsylvania, Philadelphia, PA, 2St. Peters Inc Pavlov State Medical University, St. Petersburg, Russian Federation

26 Depot naltrexone as relapse prevention for opioid-dependent parolees

27 Feasibility of very low dose naltrexone and buprenorphine transition from opioid use to extended-release naltrexone
P. Mannelli, K. S. Peindl, L. Wu, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC

28 Naltrexone-facilitated discontinuation of buprenorphine
E. Dakwar, H. D. Kleber, Psychiatry, NYSPI/Columbia, New York, NY

29 Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone
W. Becker1,2, D. Ganoczy3, D. Fiellin2, A. S. Bohnert1, 1VA Connecticut, West Haven, CT, 2Yale University, New Haven, CT, 3Ann Arbor VA, Ann Arbor, MI

30 Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence?
R. Weiss1,2, K. McDermott1, M. L. Griffin1,2, E. Hilario1, H. Connery1,2, 1Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, 2Psychiatry, Harvard Medical School, Boston, MA
31 Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations
S. G. Severtson¹, E. M. Martinez¹, J. L. Green¹, R. C. Dart¹,², E. J. Lavonas¹,², ¹Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, ²Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO

32 Medicaid budget impact of generic buprenorphine / naloxone tablet
E. Clay², E. Kharitonova², S. Aballea¹, J. Ruby¹, V. Zah¹, ¹HEOR, ZRx Outcomes Research Inc., Toronto, ON, Canada, ²HEOR, Creativ-Ceutical, Chicago, IL, ³Medical Affairs, Reckitt Benckiser, Richmond, VA

33 Characteristics of buprenorphine opioid agonist treatment in a longitudinal U.S. Medicaid population
A. J. Gordon¹, ², W. Lo Ciganic¹, G. Cochran¹, W. F. Gellad¹,², J. M. Donohue¹, ¹University of Pittsburgh, Pittsburgh, PA, ³VA Pittsburgh Healthcare System, Pittsburgh, PA

34 Expanding access to MAT in Puerto Rico: Attitudes, perceptions and training needs of pharmacists and technicians toward dispensing buprenorphine for patients with opioid dependence
C. G. Grana Morales, J. Márquez, S. Rivera, J. Ruiz, J. Avilés, C. Albizu-Garcia, University of Puerto Rico, San Juan

35 Memantine improves buprenorphine treatment for opioid-dependent young adults
G. Gonzalez¹,²,³, G. DiGirolamo¹,², M. E. Kolodziej¹, D. Smelson¹, M. Romero-Gonzalez¹,³, ¹Division of Addiction Psychiatry, University of Massachusetts Medical School, Worcester, MA, ²Psychology, College of the Holy Cross, Worcester, MA, ³MAYU of New England, New Haven, CT

36 Differences between heroin and non-prescription opioid analgesics users in treatment-seeking opioid-dependent young adults
M. Romero-Gonzalez¹,², G. DiGirolamo¹, G. Gonzalez¹,², ¹Division of Addiction Psychiatry, University of Massachusetts Medical School, Worcester, MA, ²MAYU of New England, New Haven, CT

37 Health and social factors associated with alternate routes of administration of prescription opioids among young adult multdrug users
M. E. Buttram, S. P. Kurtz, Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL

38 Malmö treatment referral and intervention study: Effective referral from syringe exchange to treatment for heroin dependence
M. Bråbäck¹,², P. Isendahl¹,², S. Nilsson²,¹, A. Håkansson²,¹, ¹Psychiatry, Lund University, Lund, Sweden, ²Addiction Center Malmö, Psychiatry Skane, Malmö, Sweden

39 Mobile phone and text messaging in a public sector, office-based buprenorphine program
B. Tofghi¹, E. Grossman¹, E. Buirkle², J. D. Lee², ¹Population Health, New York University School of Medicine, New York City, NY, ²New York University School of Medicine, New York City, NY

40 Evaluation of an electronic information system to enhance practice at a medication-assisted opioid treatment program
L. S. Brown, S. Kritz, M. Lin, B. Louie, R. Zavala, START Treatment and Recovery Centers (formerly ARTC), Brooklyn, NY
Wednesday, June 18, 2014

41 Mobile interventions based on ecological momentary assessment: Perspectives of patients and providers in China, Taiwan, and the United States
Y. Hser¹, M. T. Schulte¹, F. Wu², Y. Lan¹, W. Tsay³, J. Du⁴, M. Zhao⁵, ¹UCLA, Los Angeles, CA, ²University of Maryland, College Park, MD, ³China Medical University, Taichung, Taiwan, ⁴Food & Drug Administration, Taipei, Taiwan, ⁵Shanghai Mental Health Center, Shanghai, China

42 Developing ecological momentary intervention content for relapse prevention
M. T. Schulte, Y. Hser, UCLA, Los Angeles, CA

43 Attitudes, beliefs, and barriers to adopting an automated naloxone delivery system to overcome opioid overdose: Interviews of opioid injectors and physicians
J. Mendelson¹, O. Clavier², D. Kynor², G. Galloway¹, ¹Addiction & Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, ²Creare, Inc., Hanover, NH

44 Smartphone-reported stress and drug events and day-end perceived stress, hassles, and mood in methadone-maintained individuals

45 Call behavior and reported drug use within an automated telephone-based treatment system for methadone patients
B. A. Moore¹, C. J. Cutter¹, A. P. Mahoney², N. Grandpre³, ¹Yale University School of Medicine, New Haven, CT, ²University of New Haven, New Haven, CT, ³University of Hartford, West Hartford, CT

PERINATAL DRUG ABUSE

46 Neonatal abstinence syndrome in methadone exposed infants: Role of genetic variability
A. L. Fielder¹, J. K. Coller², M. R. Hutchinson², R. R. Haslam³, N. Lu³, S. Adeniyi-Jones⁴, M. Ehrlich⁵, W. K. Kraft³, ¹Nursing & Midwifery, Sansom Institute, University of South Australia, Adelaide, SA, Australia, ²University of Adelaide, Adelaide, SA, Australia, ³Women’s & Children’s Hospital, Adelaide, SA, Australia, ⁴Thomas Jefferson University, Philadelphia, PA, ⁵Mt. Sinai School of Medicine, New York, NY

47 Correlates of risk for prenatal alcohol use among WIC recipients
Y. Washio¹, A. A. Mericle¹, H. Cassey², A. Daubert², K. C. Kirby¹, ¹Treatment Research Institute, Philadelphia, PA, ²Temple University, Philadelphia, PA

48 Cigarette smoking and other behavioral risk factors related to unintended pregnancy
D. J. Hand⁴, S. H. Heit¹,²,³, S. C. Sigmon¹,²,³, S. T. Higgins¹,²,³, ¹Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, ²Dept. of Psychiatry, University of Vermont, Burlington, VT, ³Dept. of Psychology, University of Vermont, Burlington, VT

49 Tobacco use and exposure to second-hand smoke in Mexican pregnant women
O. Campollo¹,², F. Hernandez³, E. Angulo³, A. Guzman³, A. Munguia³, M. Garcia¹, J. K. Cunningham³, ¹Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, ²Clinica para Dejar de Fumar, Hospital Civil de Guadalajara, Guadalajara, Mexico, ³Obstetrics, Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁴Neonatology, Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁵Family & Community Medicine, University of Arizona, Tucson, AZ
50 Evaluating potential moderators of efficacy for a single-session computer-delivered 5As intervention for smoking in pregnancy
S. J. Ondersma1,2, D. M. Ledgerwood1, D. Svikis3, 1Dept. of Psychiatry & Behavioral Neurosciences, Wayne State University, Detroit, MI, 2Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, 3Institute for Women’s Health; Psychology; Psychiatry; Ob/Gyn, Virginia Commonwealth University, Richmond, VA

51 The role of self-efficacy in predicting perinatal women’s ability to reduce smoking
J. Temple, V. D. Le, G. Hankins, M. S. Ahmed, T. Nanovskaya, Department of Obstetrics & Gynecology, UTMB, Galveston, TX

52 Predictors of changes in smoking from 3rd trimester to 9 months postpartum
S. Shisler1, G. G. Homish2, D. Molnar1, R. D. Eiden1, 1Research Institute on Addictions, SUNY Buffalo, Buffalo, NY, 2Community Health and Health Behavior, SUNY Buffalo, Buffalo, NY

53 Differences between recent quitters and current smokers during pregnancy
V. H. Coleman-Cowger1, V. Belur1, M. Terplan2, 1Lighthouse Institute, Chestnut Health Systems, Bloomington, IL, 2Department of Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD

54 The role of human placental transporters in the efflux of bupropion
S. Patrikeeva, D. Vernikovskaya, M. S. Ahmed, G. Hankins, T. Nanovskaya, Department of Obstetrics & Gynecology, UTMB, Galveston, TX

55 Determination of cotinine in the urine of pregnant patients enrolled in a clinical trial for the use of bupropion sustained-release as an aid for smoking cessation
V. M. Fokina1,2, X. Wang1, M. S. Ahmed1, G. Hankins1, T. Nanovskaya1, 1Obstetrics & Gynecology, UTMB, Galveston, TX, 2Pharmacology & Toxicology, UTMB, Galveston, TX

56 Prenatal stimulant exposure alters infant growth in term-born infants
A. Hernandez, R. Yamakawa, H. Johansen, C. Jiang, C. Cloak, T. Ernst, L. Chang, Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, HI

57 Behavior problems among cocaine-exposed children: Role of physiological regulation and parenting
B. Finger1, P. Schuetze3, R. Eiden2, 1Montana State University Billings, Billings, MT, 2Research Institute on Addictions, Buffalo, NY, 3Buffalo State College, Buffalo, NY

58 Cocaine use in late adolescence: Impact of prenatal cocaine exposure, sex/gender, and ongoing caregiver cocaine use
E. S. Bandstra1, V. H. Accornero1, D. C. Vidot2, E. Mansoor1, L. Xue1, C. Morrow1, J. C. Anthony3, 1Pediatrics, University of Miami Miller School of Medicine, Miami, FL, 2Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, 3Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

59 Differential influence of prenatal maternal aggression on childhood externalizing symptoms and adolescent substance use by gender
M. Horner, M. Cornelius, K. Kim, R. Tarter, University of Pittsburgh, Pittsburgh, PA

ADOLESCENT DRUG ABUSE II

60 Marijuana use, motives, and change intentions in adolescents
G. Dash, K. G. Anderson, Psychology, Reed College, Portland, OR
61 *Influences of behavior and academic problems at school entry on marijuana use during adolescence among African Americans*  
B. A. Reboussin¹, N. S. Ialongo¹, K. M. Green¹,¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³University of Maryland School of Public Health, College Park, MD

62 *Daily co-occurrences of marijuana use, alcohol use, and sexual intercourse among at-risk, truant adolescent girls*  
H. Graves, L. Hernandez, C. Kahler, A. Spirito, Brown University, Providence, RI

63 *Substance use and risk profiles of adolescent medical patients*  
M. Lightfoot, J. Morgan-Jackson, L. Pollack, Medicine, University of California, San Francisco, San Francisco, CA

64 *Effects of immigration to the United States on alcohol, tobacco and cannabis use among Colombian adolescents*  
C. Lopez-Quintero, M. De La Rosa, The Center for Research on U.S. Latino HIV/AIDS and Drug Abuse (CRUSADA), Florida International University, Miami, FL

65 *Results from the first nationwide survey of students in Collegiate Recovery Programs*  
A. B. Laudet¹, K. Harris², K. Winters³, D. Moberg⁴, T. Kimball⁵,¹NDRI, NYC, NY, ³Texas Tech, Lubbock, TX, ⁴University of Minnesota, Minneapolis, MN, ⁵University of Wisconsin, Milwaukee, WI

66 *A comparison of young adults seeking treatment for cannabis and opioid dependence*  
E. Evans, K. Mishlen, A. Glass, M. Pavlicova, J. J. Mariani, F. R. Levin, M. Sullivan, Psychiatry, Columbia University, New York State Psychiatric Institute, New York, NY

67 *Developmental heritability of internalizing symptoms and cigarette use co-occurrence*  
C. B. Bares¹, K. S. Kendler¹,², J. Silberg², ¹School of Social Work, Virginia Commonwealth University, Richmond, VA, ²Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, ³Department of Psychiatry, Virginia Commonwealth University, Richmond, VA

68 *Reasons for e-cigarette initiation and discontinuation among adolescents and young adults*  
G. Kong, D. R. Camenga, D. A. Cavallo, A. Palmer, M. Morean, S. Krishnan-Sarin, Yale University School of Medicine, New Haven, CT

69 *Cognitive bias modification combined with cognitive behavioral therapy: A smoking cessation intervention for adolescents*  
H. Larsen¹, G. Kong², D. Becker¹, D. A. Cavallo², J. Cousijn¹, E. Salemink¹, A. Collot D’Escurey-Koenigs¹, S. Krishnan-Sarin², R. Wiers¹, ¹Developmental Psychology, University of Amsterdam, Amsterdam, Netherlands, ²Psychiatry, Yale University School of Medicine, New Haven, CT

70 *Self-efficacy mediates treatment outcome in a smoking cessation program for adolescent smokers*  
P. Simon, C. Connell, G. Kong, M. E. Morean, D. A. Cavallo, D. Camenga, S. Krishnan-Sarin, Department of Psychiatry, Yale School of Medicine, New Haven, CT

71 *High rates of relapse in adolescent crack users after inpatient clinic discharge*  
72 Feasibility and acceptability of the implementation of Program Unplugged for the prevention of drug use among school adolescents in Brazil
D. R. Schneider, J. F. Hori, G. M. Peres, P. F. de Medeiros, J. I. Cruz, L. C. Oltramari, T. M. Grigolo, M. C. Prado, A. D. Pereira, Z. M. Sanchez, Universidade Federal de Santa Catarina, Florianópolis, Brazil, 2Universidade Federal de São Paulo, São Paulo, Brazil, Complexo de Ensino Superior de Santa Catarina, Florianópolis, Brazil

73 Evaluation of the Environmental Support Scale in adolescence
C. M. Risco, A. Collado-Rodriguez, E. Reynolds, C. W. Lejuez, L. MacPherson, Psychology, University of Maryland, College Park, MD, Child and Adolescent Psychiatry, The Johns Hopkins Hospital, Baltimore, MD

74 Identifying latent classes of adolescent drug treatment services: An outcomes analysis
M. Schuler, B. Griffin, E. Letourneau, E. Stuart, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, RAND, Arlington, VA, Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

75 Prevalence and predictors of driving under the influence in Spanish youngsters
M. González, A. Morales, K. W. Griffin, M. Orgiles, J. P. Espada, Universidad Miguel Hernandez, Elche, Spain, Weill Cornell Medical College, New York, NY

76 Alcohol use among traumatized youth in Zambia

77 Pathways from caregiver problematic alcohol use to child internalizing and externalizing behaviors in a child protective services sample
K. D. Seay, Brown School of Social Work, Washington University in St. Louis, St. Louis, MO

78 DSM-5 substance use disorder vs. DSM-IV substance abuse and dependence among pediatric patients
S. M. Kelly, K. E. O’Grady, J. Gryczynski, S. G. Mitchell, A. Kirk, R. P. Schwartz, Friends Research Institute, Baltimore, MD, Univ. of MD, College Park, MD, Total Health Care, Baltimore, MD

79 Brief tools for pediatricians to screen 9- to 12-year-olds in need of prevention for substance use disorder
T. Ridenour, M. D. Reynolds, Research Triangle Institute, Allison Park, PA, University of Pittsburgh, Pittsburgh, PA

80 Validation and performance of the Alcohol, Smoking, and Substance Involvement Screening Test in adolescent primary care patients
J. Gryczynski, S. M. Kelly, S. G. Mitchell, A. Kirk, K. E. O’Grady, R. P. Schwartz, Friends Research Institute, Baltimore, MD, Total Health Care, Baltimore, MD, University of Maryland, College Park, MD

POLYDRUG ABUSE II

81 Longitudinal predictors of 12-step attendance among substance-abusing women
D. D. Bowers, A. Murman, X. Guo, N. Slesnick, Ohio State University, Columbus, OH

82 Ancillary treatment use in the Stage II community-based Women’s Recovery Group therapy trial
D. Sugarman, S. Wigderson, H. Connery, G. Bailey, G. Fitzmaurice, S. F. Greenfield, McLean Hospital, Belmont, MA, Harvard Medical School, Cambridge, MA, Stanley Street Treatment & Resources, Fall River, MA, Brown University, Providence, RI
Wednesday, June 18, 2014

83 Factors associated with differential use of mental health services among women over 8 years after substance abuse treatment
E. Evans, L. Li, V. Lin, Y. Hser, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

84 Non-ETOH drug use among women in outpatient treatment for alcohol dependence
E. E. Epstein1, B. S. McCrady2, S. Cook1, N. Jensen1, A. Gaba1, M. L. Steinberg1, K. Bold1, 1Rutgers University, Piscataway, NJ, 2University of New Mexico, Albuquerque, NM

85 Availability of women-centered drug treatment services: An analysis of NSSATS 2002-2010
N. Longinaker1, L. Appel2, M. Terplan2, 1Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 2Department of Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD

86 Addiction services for women in Eastern Europe: What is available and where?
A. O. Abagi1, P. Dolezalova2, Z. Alexandercikova1, J. K. Csorba1, V. Bogdanova2, A. Kastelic6, 1National Institute for Infectious Diseases Prof. Dr. Matei Bals, OST ARENA Center, Bucharest, Romania, 2Clinic of Addictology, Prague, Czech Republic, 6Center for Treatment of Drug Dependencies, Bratislava, Slovakia, 4Drug Outpatient and Prevention Center, Gyula, Hungary, 6Drug Demand Reduction Department, Sofia, Bulgaria, 6Center for Treatment of Drug Addiction, Ljubljana, Slovenia

87 Preliminary evidence of injecting drug reduction from a woman-focused RCT in Republic of Georgia

88 Do chief complaints allow targeting of SBIRT in the emergency department?
R. P. McCormack1, P. Gauthier1, B. McClure1, L. Moy1, M. Hu2, M. Pavlicova2, E. V. Nunes2, D. Thompson3, M. Bogenschutz4, R. Mandler4, J. Rotrosen1, 1New York Univ. School of Medicine, New York, NY, 2Columbia Univ., New York, NY, 3Northwestern Univ., Chicago, IL, 4NIDA, Bethesda, MD, 5Univ. of New Mexico, Albuquerque, NM

89 Race and ethnicity differences in a MI-based brief intervention delivered in an ED setting
A. A. Forcehimes1, M. Bogenschutz1, G. Sharma2, R. Mandler2, 1UNM CASAA, Albuquerque, NM, 2EMMES, Rockville, MD, 3NIDA, Bethesda, MD

90 Correlates of drug use problems among substance users presenting in emergency departments: Results of a multi-site study
W. Macias Konstantopoulos1,2, J. A. Dreifuss1,3, K. A. McDermott3, B. A. Parry2, M. L. Howell2, R. N. Mandler2, M. Bogenschutz2, R. Weiss2, 1Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3McLean Hospital, Belmont, MA, 4NIDA, Bethesda, MD, 5University of New Mexico, Albuquerque, NM

91 A quality improvement innovation to establish a PCMH tailored to homeless veterans who utilize the ED
B. Patel1, R. Manchanda1, R. Andersen1,2, L. Altman1,2, L. Gelberg1,2, 1Department of Veterans Affairs, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

92 VA health service use for homeless and low-income veterans: A spotlight on Los Angeles’ VA Supportive Housing program
S. Gabrielian1,2, A. H. Yuan1, R. Andersen2,1, L. Rubenstein1,2, L. Gelberg2,1, 1VAGLA, Los Angeles, CA, 2UCLA, Los Angeles, CA
93 Trajectories of drug use frequency after substance abuse treatment among a sample of homeless youth
   X. Guo, N. Slesnick, X. Feng, The Ohio State University, Columbus, OH

94 Relations between psychopathy factors, substance use disorders, and treatment readiness among adults in inpatient substance use treatment
   K. Long1, L. MacPherson1, E. Verona2, C. W. Lejuez1, 1Psychology, University of Maryland, College Park, MD, 2Psychology, University of Illinois, Champaign, IL

95 Motivational enhancement, readiness to change, and treatment success in African-American substance users
   J. E. Korte1, L. Montgomery2, K. T. Brady1,3, K. Burlew3, 1Medical University of South Carolina, Charleston, SC, 2University of Cincinnati, Cincinnati, OH, 3Ralph H. Johnson VA Medical Center, Charleston, SC

96 Brazilian crack cocaine users: Preliminary results from a nationwide survey
   M. Malta, N. Bertoni, F. I. Bastos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

97 A multisite randomized controlled trial of Motivational Enhancement Treatment in outpatient addiction care centers in Mexico
   R. Marin-Navarrete1, V. E. Horigian2, J. C. Fernandez Mondragon1, R. Verdeja2, E. Alonso2, L. Templos-Nuñez1, A. Eliosa-Hernandez1, D. Feaster3, R. Sánchez-Huesca3, A. De la Fuente-Martin1, C. Lima-Rodriguez4, C. Berlnaga5, M. E. Medina-Mora5, 1Clinical Trials Unit on Addiction and Mental Health, National Institute of Psychiatry (Mexico), Distrito Federal, Mexico, 2Florida Node Alliance / NIDA-CTN, University of Miami, Miami FL, FL, 3Centros de Integración Juvenil AC (Mexico), Distrito Federal, Mexico, 4Florida Institute of Technology, Melbourne, FL, 5National Institute of Psychiatry (Mexico), Distrito Federal, Mexico

98 Employment-based reinforcement of opiate and cocaine abstinence in out-of-treatment injection drug users
   A. Holtyn1, M. N. Koffarnus2, A. DeFulio1, S. O. Sigurdsson3,1, E. C. Strain1, R. P. Schwartz4, K. Silverman1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Virginia Tech Carilion Research Institute, Roanoke, VA, 3Florida Institute of Technology, Melbourne, FL, 4Friends Research Institute, Baltimore, MD

99 Incentives and alerts for improving substance abuse treatment in Washington State
   D. W. Garnick1, C. M. Horgan1, A. Acevedo1, M. Lee1, E. L. Merrick1, G. Ritter1, L. Panas1, K. Campbell2, A. Huber3, E. Larson2, F. Wrede2, 1Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA, 2The Division of Behavioral Health and Recovery, Washington State Department of Social and Health Services, Olympia, WA, 3Dept. of Social and Health Services, Research and Data Analysis Division, Olympia, WA

100 Managing substance use treatment in private U.S. health plans
   E. L. Merrick, C. M. Horgan, S. Reif, A. Quinn, M. Stewart, D. W. Garnick, D. Hodgkin, A. Mateucci, Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA

101 Managing and improving behavioral health care quality in private health plans
102 Prevalence of illicit drug use among patients of community health centers in East Los Angeles and Tijuana

M. Garcia1, M. Rico1, J. Scholtz1, M. Vahidi1, G. Natera1, R. Andersen2, I. Bojorquez4, J. Yacenda1, M. Arroyo3, M. Gonzalez3, L. Gelberg1,2, 1Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA School of Public Health, Los Angeles, CA, 3National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, 4El Colegio de la Frontera Norte Department of Population Studies, Tijuana, Mexico, 5National Commission Against Addictions, Mexico City, Mexico

103 How important are counselor and client characteristics in determining overall client satisfaction with 12-Step focused community counseling groups?

R. Baroni1, D. Boyd1, A. Christmann1, E. Hutz1, C. M. Carpenedo1, A. C. Brooks1, A. B. Laudet1, K. C. Kirby1,2, 1Treatment Research Institute, Philadelphia, PA, 2National Development and Research Institutes, New York, NY, 3University of Pennsylvania School of Medicine, Philadelphia, PA

104 Effects of dissemination efforts to promote client engagement in recovery-oriented activities in community-based treatment

D. J. Knoblach1, A. Mericle2, E. Hutz2, A. C. Brooks2, A. B. Laudet3, D. Carise4, 1University of Maryland, Baltimore County, Catonsville, MD, 2Treatment Research Institute, Philadelphia, PA, 3National Development and Research Institutes, New York, NY, 4CRC Health Group, Inc., Cupertino, CA

105 Process evaluation of a community collaborative board: Using community-based participatory research to create a substance abuse/health intervention

A. Jemal1,2, V. C. Smith1, 1Rutgers University, New Brunswick, NJ, 2NDRI, New York, NY, 3Cabrini College, Radnor, PA

106 Strategies to increase family influence on patient decisions about medication-assisted treatment

R. Croff1, K. Alanis-Hirsch2, J. Ford3, L. Schmidt4, M. Chalk2, D. McCarty1, 1Oregon Health & Science University, Portland, OR, 2Treatment Research Institute, Philadelphia, PA, 3Center for Health Enhancement System Studies, Madison, WI, 4University of California, San Francisco, CA

107 Patients’ economic considerations of treatment for methamphetamine and opiate use at an innovative drug treatment center in Malaysia

S. Brown1, A. Krishnan1, M. Ghani2, F. Khan2, A. Kamarulzaman1,3, F. Altice1,3, 1Internal Medicine, Yale University School of Medicine, New Haven, CT, 2Yale College, New Haven, CT, 3Center of Excellence for Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia

108 Indigenous culture as intervention in addictions treatment

C. A. Dell1, S. Acoose2, 1Sociology & School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada, 2Indian Social Work, First Nations University of Canada, Saskatoon, SK, Canada

109 Nurses’ screening and referral behaviors and opinions about brief interventions before and after implementation of Project Engage

A. Pecoraro1, R. Mooney2, T. Horton2, G. E. Woody1, 1University of Pennsylvania, Philadelphia, PA, 2Christiana Hospital, Christiana, DE
HIV/HCV II

110 Substance use and sexual risk among men who have sex with men and women and their female partners
T. P. Dyer¹, M. R. Khan², M. Sandoval³, M. Bolyard⁴, S. R. Friedman⁵, ¹Epidemiology and Biostatistics, University of Maryland, College Park, MD, ²Epidemiology, University of Florida, Gainesville, FL, ³Institute for Infectious Disease Research, National Development and Research Institutes, New York, NY, ⁴Office of Institutional Research, Planning, and Effectiveness (OIRPE), Emory University, Atlanta, GA

111 HSV-2 and HIV among MSM who use cocaine and heroin in New York City
J. P. Feelemeyer¹, D. C. Des Jarlais¹, K. Arasteh¹, C. McKnight¹, H. L. Cooper¹, H. Hagan², R. Stall³, D. Perlman⁴, ¹The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, ²School of Nursing, New York University, New York, NY, ³Rollins School of Public Health, Emory University, Atlanta, GA, ⁴Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA

112 Drug use among male sex workers in Vietnam: Timing of initiation in relation to sex work
G. M. Le¹, M. Clatts², L. Goldsamt³, V. D. Vu¹, S. M. Nguyen¹, ¹Hanoi Medical University, Hanoi, Viet Nam, ²University of Puerto Rico, San Juan, ³National Development and Research Institutes, New York, NY

113 Sexual relationship power, victimization, and HIV risky sexual behavior in substance-abusing African-American women
C. Ahuama-Jonas, K. Burlew, Psychology, University of Cincinnati, Cincinnati, OH

114 Impaired executive function, drug and sex risk, and HIV infection in African-American men
W. W. Latimer¹, M. R. Khan², J. D. Scheidell², E. M. Dunne¹, ¹Clinical and Health Psychology, University of Florida, Gainesville, FL, ²Epidemiology, University of Florida, Gainesville, FL

115 The differential role of executive dysfunction on HIV risk behaviors among African-American drug users
A. Diggins¹, E. M. Dunne¹, B. E. Mancha¹, R. Trenz¹, K. Ritter², W. W. Latimer¹, ¹Clinical and Health Psychology, University of Florida, Gainesville, FL, ²University of Tennessee, Knoxville, TN

116 Characteristics of poly-substance users engaging in high HIV-risk behaviors
K. Williams, J. J. Stoltman, M. K. Greenwald, Psychiatry, Wayne State University, Detroit, MI

117 High dead-space syringe use among people who inject drugs in Tijuana, Mexico
C. Rafful¹,², W. Žule³, P. E. Gonzalez-Žuñiga¹, M. Medina-Mora¹, C. Magis-Rodriguez⁴, S. Strathdee¹, ¹Global Health, University of California San Diego, San Diego, CA, ²San Diego State University, San Diego, CA, ³RTI International, Research Triangle, NC, ⁴Mexican National Institute of Psychiatry, Mexico City, Mexico, ⁵CENSIDA, Mexico, Mexico City, Mexico

118 WITHDRAWN

119 Sex, drugs and healthcare utilization among HIV+ patients: The role of marijuana
L. H. Lundahl, D. M. Ledgerwood, C. L. Arfenk, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

120 Intoxication at last sexual intercourse and unprotected sex among HIV-positive and HIV-negative individuals in Uganda: An event-level analysis
B. Kerridge¹, P. Tran², D. S. Hasin¹, ¹Columbia University, New York City, NY, ²Medical School, St. George, True Blue, Grenada
121 Avoiding treatment due to fears of violence: The first report of gender-based and intimate partner violence in the community and in the hospital among female heroin users in Dar es Salaam, Tanzania
D. Balaji1, B. Lambdin2, J. Mbwambo3, O. Chang2, C. Nyandindi3, M. Copenhaver4, R. Bruce1,2, 1Yale University, New Haven, CT, 2Pangea Global AIDS Foundation, Oakland, CA, 3Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania, 4Allied Health Sciences, University of Connecticut, Storrs, CT

122 Fatal and non-fatal overdose after narcology hospital discharge among HIV-infected Russians
A. Y. Walley1, E. Krupitsky2, D. M. Cheng3,1, E. K. Quinn1, L. Wulach1, P. O. Coffin4, J. Samet1,2, 1Boston University School of Medicine/ Boston Medical Center, Boston, MA, 2Pavlov State University, St. Petersburg, Russian Federation, 3Boston University School of Public Health, Boston, MA, 4San Francisco Department of Public Health, San Francisco, CA

123 WITHDRAWN

124 Study attrition among HIV-infected Russian risky drinkers
T. Kiriazova1,2,3, D. M. Cheng1, S. Coleman1, E. Blokhina4, E. Krupitsky4,5, M. C. Lira2, C. Bridden2, A. Raj6, J. Samet1,2, 1Boston University, Boston, MA, 2Boston Medical Center, Boston, MA, 3Future without AIDS, Odessa, Ukraine, 4First Pavlov State Medical University, St. Petersburg, Russian Federation, 5Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, 6University of California San Diego, San Diego, CA

125 Using the VACS Index to track health outcomes associated with abstinence among HIV-infected patients receiving opioid agonist treatment
K. McGinnis1, E. J. Edelman2, J. Tate2, A. Justice2, D. Fiellin2, 1U Pittsburgh, Pittsburgh, PA, 2Yale, New Haven, CT

126 HIV stigma among substance-abusing PLWH: Implications for HIV treatment, ARV adherence and diversion
M. A. Levi Minzi, H. Surratt, Nova Southeastern University, Miami, FL

127 Receipt of opioid therapy guideline-concordant care among HIV+ and HIV- veterans
J. R. Gaither1, E. Edelman1, W. Becker1,2, S. Crystal4, K. Gordon2, J. Goulet1,2, R. Kerns1,2, M. Skanderson1, D. Weisberg1, K. Bryant6, A. Justice1,2, D. Fiellin1, 1Yale University, New Haven, CT, 2VA CT HCS, New Haven, CT, 3VA Pittsburgh HCS, New Haven, CT, 4Rutgers University, New Brunswick, NJ, 5NIH/NIAAA, Bethesda, MD

ABUSE LIABILITY

128 Assessment of human abuse potential of preladenant (a centrally-acting A2A antagonist) compared to phentermine and placebo in recreational stimulant users

129 The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone
J. D. Jones, M. Sullivan, J. M. Manubay, S. Mogali, V. Metz, S. Comer, Division of Substance Abuse, Columbia University, New York, NY

130 Effect of co-administration of naloxone on intravenous hydromorphone abuse potential in non-treatment-seeking, opioid-dependent drug users
N. Levy-Cooperman1, K. A. Schoedel1, J. Reiz2, D. Thompson2, B. Chakraborthy3, P. Geoffroy3, K. Michalko2, 1Altreos Research Partners, Toronto, ON, Canada, 2Purdue Pharma (Canada), Toronto, ON, Canada, 3INC Research, Toronto, ON, Canada
Preliminary report of THC influence on subject ability to discriminate between active opioid and placebo in human abuse liability study
M. Smith, J. Jenkins, M. Iverson, L. R. Webster, PRA (formerly CRI Lifetree), Salt Lake City, UT

Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates
R. C. Dart1, H. Surratt1, E. J. Lavonas1, E. M. Martinez1, S. G. Severtson2, T. Cicero1,
S. P. Kurtz1, A. Rosenblum1, J. L. Green1, 1Denver Health and Hospital Authority,
Denver, CO, 2Washington University School of Medicine, St. Louis, MO, 3Nova Southeastern University, Miami, FL, 4National Development and Research Institutes, New York, NY

The street prices of immediate- and extended-release tapentadol are lower than other Schedule II opioid tablets/capsules
M. C. Le Lait1, S. G. Severtson1, N. Dasgupta2, J. L. Green1, A. Hall1, R. C. Dart1,2
1RADARS(r) System, RMPDC, DHHA, Denver, CO, 2Epidemico, Boston, MA, 3U of Colorado Denver School of Medicine, Denver, CO

Comparing abuse of extended-release vs. immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose
S. F. Butler1, T. A. Cassidy1, P. Coplan2, 1Inflexxion, Inc., Newton, MA, 2Purdue Pharma, L.P, Stamford, CT

Evaluation of an ADF product’s route-of-administration profile
T. A. Cassidy, S. H. Budman, S. F. Butler, Inflexxion, Inc, Newton, MA

Routes of administration and frequency of abuse of OxyContin® and immediate-release oxycodone in a rural Kentucky county following introduction of reformulated OxyContin: Results from the first 71 follow-up interviews
J. R. Havens1, A. DeVeaux-Geiss2, C. Leukefeld1, H. Kale2, P. Coplan2, H. Chilcoat2,
1Behavioral Science, University of Kentucky, Lexington, KY, 2Purdue Pharma LP, Stamford, CT

Regional concentrations of Opana® ER abuse before and after introduction of a tamper-resistant formulation in 2012
S. G. Severtson1, M. C. Le Lait1, J. L. Green1, R. C. Dart1,2, 1RADARS(r) System, RMPDC,
DHHA, Denver, CO, 2University of Colorado Denver School of Medicine, Denver, CO

Trends in abuse and diversion in multiple surveillance systems three years after introduction of reformulated OxyContin
H. Chilcoat1, B. Bucher Bartelson2, S. G. Severtson2, S. F. Butler1, T. A. Cassidy3, P. Coplan1,
1Purdue Pharma, Stamford, CT, 2RADARS, Denver, CO, 3Inflexxion, Newton, MA

Epidemiology

iEpi. Epidemiology of one
G. Bobashev1, D. Liao1, J. Hampton1, J. Helzer2, L. Hoffer3, R. Morris1, 1RTI International,
Durham, NC, 2University of Vermont, Burlington, VT, 3Case Western Reserve University,
Cleveland, OH

The association between exposure to guns and gambling among community-recruited substance using women
K. Vaddiparti, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

Different dynamic relationship between stress and illicit drug use from pregnancy to postpartum among drug-using women
H. Wu1, E. Coman2, H. Tennen3, J. Grady3, 1Psychiatry, U Conn Health Center, Farmington, CT, 2TRIPP Center, UConn Health Center, Farmington, CT, 3Community Medicine and Health Care, U Conn Health Center, Farmington, CT
Female cocaine users are at excess risk of becoming cocaine dependent soon after onset of cocaine use: Estimates for the United States, 2002-2011
A. M. Mohammed, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

Patterns of crack use among drug-using females in Mexico City
N. Negi, A. Valdez, A. Cepeda, G. Naterra, 1 School of Social Work, University of Maryland, Baltimore, Baltimore, MD, 2School of Social Work, University of Southern California, Los Angeles, CA, 3Instituto de Psiquiatría, Ramón de la Fuente Muñiz, Mexico, Mexico

Follow up of crack users after hospital discharge based on probabilistic record linkage methodology
V. M. Gonçalves, R. S. Pedroso, A. M. dos Santos, F. P. Pechansky, 1Center for Drug and Alcohol Research, University of Rio Grande do Sul, Porto Alegre, Brazil, 2Informatics Department, Ministry of Health, Porto Alegre, Brazil

Addiction and barriers to treatment in a sample of community-recruited methamphetamine users in a South African township
C. S. Meade, S. Towe, M. H. Watt, D. Skinner, B. Myers, S. Kimani, J. C. MacFarlane, D. Pieterse, 1Duke University, Durham, NC, 2Stellenbosch University, Cape Town, South Africa, 3South African Medical Research Council, Cape Town, South Africa

A novel measure of assessing the frequency and route of administration of various substances of abuse
A. Ninnemann, J. Elmquist, J. Febres, H. Brasfield, R. C. Shorey, H. Zapor, C. Wolford-Celvenger, L. MacPherson, G. L. Stuart, 1University of Maryland, College Park, MD, 2University of Tennessee, Knoxville, TN

Associations between blood lead level and substance use among adults in the United States
H. Hu, J. Scheidell, A. Coatsworth, X. Xu, M. R. Khan, Department of Epidemiology, University of Florida, Gainesville, FL

Tobacco outlets and tobacco use in Baltimore City from 2004-2009

W. Xue, C. Lopez-Quintero, J. C. Anthony, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

Latinos’ access to online and formal mental health support
R. Parra-Cardona, J. C. Anthony, D. DeAndrea, 1Human Development and Family Studies, Michigan State University, East Lansing, MI, 2School of Communication, The Ohio State University, Columbus, OH

Effectiveness of Ambassador plus Navigator vs. Navigator alone to enroll current drug users in health studies
C. W. Striley, C. Ruktanonchai, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
Wednesday, June 18, 2014

154 Association between age, substance use and health service use in Medicare elderly prostate cancer patients
S. Chhatre¹, D. Metzger¹, G. E. Woody¹, R. Jayadevappa², ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²Medicine, University of Pennsylvania, Philadelphia, PA

155 Racial and ethnic disparities in substance use and outcomes in elderly prostate cancer patients
R. Jayadevappa², D. Metzger¹, G. E. Woody¹, S. Chhatre¹, ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²Medicine, University of Pennsylvania, Philadelphia, PA

156 Opioid use disorders: Trends and correlates
M. J. Dennis, M. L. Dennis, R. R. Funk, Chestnut Health Systems, Normal, IL

157 Opioid substitution therapy in New South Wales 2001-2012: Comparison between buprenorphine and methadone
L. Burns, N. Gisev, L. Degenhardt, S. Larney, NDARC, UNSW, Sydney, NSW, Australia

158 When less is more: A web-based study of user beliefs about buprenorphine dosing in self-treatment of opioid withdrawal symptoms
R. Daniulaityte¹, R. Carlson¹, D. Cameron², G. A. Smith², A. P. Sheth², ¹Community Health, Wright State University, Dayton, OH, ²Computer Science and Engineering, Wright State University, Dayton, OH

159 A latent class analysis of traumatic events experienced by drug users and their partners: Associations between distinct trauma patterns and psychiatric and substance use disorders, sex trade, and sexually transmitted infections
C. Cavanaugh¹, H. Petras²,³, W. W. Latimer⁴, ¹Psychology, Rutgers University, Camden, NJ, ²JBS International, North Bethesda, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Clinical and Health Psychology, University of Florida, Gainesville, FL

160 Factors associated with internalized injection drug user stigma among injection drug users in New York City
A. V. Rivera¹, J. DeCuir¹, N. D. Crawford², C. Fuller¹, ¹Epidemiology, Columbia University Mailman School of Public Health, New York, NY, ²Epidemiology and Biostatistics, Georgia State University School of Public Health, Atlanta, GA

161 Initiating people into illicit drug injection
A. Kral¹, L. Wenger¹, D. Chu³, B. Quinn³, J. Thing³, J. Lorvick¹, R. Bluthenthal³, ¹RTI International, San Francisco, CA, ²University of Southern California, Los Angeles, CA, ³Burnet Institute, Melbourne, VIC, Australia

162 Risk and protective factors for heroin initiation and re-initiation among rural prescription opioid users
J. P. Harp¹², J. R. Havens¹², ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

Symposium XII

BILL WOOLVERTON’S GREATEST HITS:
DRUGS, CHOICES, AND CONSEQUENCES

Chairs: James Rowlett and Michael A. Nader

10:00 The band plays on: Reinforcing efficacy, choice, and the music of Bill Woolverton
James Rowlett, University of Mississippi Medical Center, Jackson, MS

10:25 Animal models of cocaine choice: Drugs, environment, and social context
Michael A. Nader, Wake Forest University School of Medicine, Winston-Salem, NC
Wednesday, June 18, 2014

10:50 Delay discounting and the choice to take a drug  
Sally L. Huskinson, University of Mississippi Medical Center, Jackson, MS

11:15 Punishment of drug choice: Insights from the study of drugs as punishers  
Kevin B. Freeman, University of Mississippi Medical Center, Jackson, MS

11:40 DISCUSSANT: Across the Great Divide: Behavior meets pharmacology according to Bill Woolverton  
Robert Balster, Virginia Commonwealth University, Richmond, VA

Oral Communications 11  
BALLROOM A  
10:00 - 12:00 PM

ADDITION DEPICTION: IMAGING

Chairs: Anna Rose Childress and Daniel Langleben

10:00 Adolescents are driven by incentive valence, not magnitude, on the monetary incentive delay task  
J. Joseph¹, X. Zhu¹, C. Benca¹, G. Baik¹, F. Davies¹, T. H. Kelly², ¹Medical University of South Carolina, Charleston, SC, ²University of Kentucky, Lexington, KY

10:15 Choosing money over drugs: The underpinnings of rational choice in cocaine addicts  
M. J. Wesley¹, T. Lohrenz¹, M. N. Koffarnus¹, S. M. McClure², R. De La Garza II³, T. F. Newton³, W. K. Bickel¹, P. Montague¹, ¹Virginia Tech Carilion Research Institute, Roanoke, VA, ²Stanford University, Stanford, CA, ³Baylor College of Medicine, Houston, TX

10:30 Cocaine use-related temporal changes in white matter as detected by DTI  
L. Ma¹,², J. L. Steinberg¹,³, D. Ramesh¹,³, L. A. Keyser-Marcus¹,³, F. G. Moeller¹,³, ¹Institute for Drug and Alcohol Studies, Virginia Commonwealth University (VCU), Richmond, VA, ²Department of Radiology, VCU, Richmond, VA, ³Department of Psychiatry, VCU, Richmond, VA

10:45 “Destined for success”? Brain responses during drug cue exposure foretell clinical outcome in cocaine patients  
A. R. Childress¹,², J. Suh¹,², K. Jagannathan¹, K. A. Young¹, T. Franklin¹, R. Ehrman¹,², Z. Monge¹, D. Langleben¹,², K. M. Kampman¹, R. Wetherill¹, M. J. Gawrysiak², C. P. O’Brien¹, ¹Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²VA MIRECC, Philadelphia, PA

11:00 Use of real-time functional magnetic resonance imaging for facilitation of self-regulation of nucleus accumbens response in cocaine abusers  
M. Shane¹,², S. Posse³, ¹Forensic Psychology, University of Ontario Institute of Technology, Toronto, ON, Canada, ²Clinical Affective Neuroscience Laboratory, The Mind Research Network, Albuquerque, NM, ³Department of Neurology, University of New Mexico, Albuquerque, NM

11:15 Attenuated insular and frontocingulate decision-making related activation during an aversive interoceptive state in methamphetamine-dependent individuals  
J. L. Stewart¹, A. C. May¹, N. Poppa¹, P. W. Davenport¹, S. F. Tapert³, M. P. Paulus³, ¹Psychiatry, University of California, San Diego, La Jolla, CA, ²Clinical Affective Neuroscience Laboratory, The Mind Research Network, Albuquerque, NM, ³Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego, CA
Wednesday, June 18, 2014

11:30  Prefrontal and striatal fMRI response predicts adherence to injectable extended-release naltrexone in opioid dependence  

11:45  Neural function and structure among young men with cannabis dependence: Relationship to treatment response  
S. W. Yip, E. E. DeVito, H. Kober, K. M. Carroll, M. N. Potenza, Psychiatry, Yale School of Medicine, Yale, CT

Oral Communications 12

DANGEROUS DUO: PSYCHIATRIC COMORBIDITY

Chairs: Katherine Mills and Emma L. Barrett

10:00  Substance use during pregnancy among young women with symptoms of psychological stress and depression  
A. Pienta, J. Barber, J. Kusunoki, H. Gatny, University of Michigan, Ann Arbor, MI

10:15  Effects of smoking cessation on postpartum depression  
A. A. Lopez1,2,3, S. T. Higgins1,2,3, J. M. Skelly4, 1Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, 2Psychiatry, University of Vermont, Burlington, VT, 3Psychology, University of Vermont, Burlington, VT, 4Medical Biostatistics, University of Vermont, Burlington, VT

10:30  Evaluation of a brief smoking cessation intervention for inpatient substance users with elevated depressive symptoms  
A. N. Banducci, C. W. Lejuez, L. MacPherson, University of Maryland, College Park, MD

10:45  Acute stress response in cocaine-dependent subjects with comorbid depression  
M. Torrens1,2,3, R. R. Minguela1, D. Martinez-Sanvisens1,2,3, C. P. Perez-Mañã1,2,3, E. Papaseit1, F. Fonseca1,2, M. Farre1,3, 1Institut Hospital Del Mar d’Investigacions Mèdiques-IMIM, Parc de Salut Mar, Barcelona, Spain, 2Institut de Neuropsiquiatria i Addiccions (INAD), IMIM - Parc de Salut Mar, Barcelona, Spain, 3Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain

11:00  The long-term impact of post traumatic stress disorder on recovery from heroin dependence  
K. Mills1,2,3, C. Marel1,2, S. Darke1, J. Ross1,2, T. Slade1,2, L. Burns1,2, M. Teesson1,2, 1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, 2NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, Sydney, NSW, Australia

11:15  Post-traumatic stress disorder and change in drug and alcohol dependence among recent veterans  
A. S. Bennett, E. R. Pouget, A. Golub, National Development and Research Institutes, New York, NY

11:30  Enhancing the effects of cognitive behavioral therapy for PTSD and alcohol use disorders with antidepressant medication: A randomized clinical trial  
D. A. Hien1, F. R. Levin2, L. Ruglass1, T. Lopez-Castro1, 1The City College of New York, NY, NY, 2NY State Psychiatric Institute, NY, NY

11:45  Substance use and mental health consequences of childhood trauma: An epidemiological investigation  
Wednesday, June 18, 2014

Oral Communications 13

POT LUCK: THC RESEARCH

Chairs: Joshua Lile and Denise C. Vidot

10:00  
Current marijuana use and cardiometabolic disease risk in United States emerging adults, 2005-2010  
D. C. Vidot¹², K. L. Arheart¹, G. Prado¹, W. M. Hlaing¹, A. Acheampong³, S. E. Messiah¹²,  
¹Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,  
²Pediatrics, University of Miami Miller School of Medicine, Miami, FL, ³Epidemiology, University of Florida, Gainesville, FL

10:15  
Acute stress response in marijuana smokers and relapse to marijuana in the human laboratory  
R. Balter¹, G. Bedi¹², M. Haney¹², ¹Psychiatry, Columbia, New York, NY, ²NYSPI, New York, NY

10:30  
Cannabis self-administration in the laboratory and use in the natural environment during outpatient tiagabine maintenance  

10:45  
Marijuana use predicts cognitive impairment and white matter alterations  
S. A. Gruber¹², M. Dahlgren¹, K. Sagar¹, M. Dreman¹, M. Racine¹, A. Gonenc¹²,  
S. E. Lukas²³, ¹Imaging Center, McLean Hospital, Belmont, MA, ²Department of Psychiatry, Harvard Medical School, Boston, MA, ³Behavioral Psychopharmacology Research Lab, McLean Hospital, Belmont, MA

11:00  
A comparison of temporal discounting in adolescents and adults in treatment for cannabis use disorders  
D. C. Lee, C. Stanger, A. J. Budney, Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH

11:15  
A pilot study of zolpidem pharmacotherapy in the treatment of cannabis use disorders  
R. Vandrey¹, A. J. Budney², M. Smith¹, E. Herrmann¹, A. Hampson³, M. L. Stitzer¹, ¹Johns Hopkins University, Baltimore, MD, ²Dartmouth, Lebanon, NH, ³National Institute on Drug Abuse, Bethesda, MD

11:30  
Changes in cigarette and alcohol use during cannabis abstinence  
D. J. Allsop¹⁵, A. Dunlop²³, C. Sadler², G. Rivas⁴, J. Copeland¹, ¹National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia, ²Drug & Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW, Australia, ³School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia, ⁴Drug and Alcohol Services, New South Wales Ministry of Health, Sydney, NSW, Australia, ⁵School of Psychology, University of Sydney, Sydney, NSW, Australia

11:45  
Diabetes mellitus outcomes: Is cannabis smoking protective?  
O. Alshaarawy, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
Drug Evaluation History Forum  
(Brown Bag Lunch)  
THE DRUG EVALUATION PROGRAM OF THE CPDD: HISTORY AND SCOPE  

Chairs: James H. Woods and Kenner Rice

The NIH chemical synthesis program of CPDD  
Kenner Rice, NIDA/NIAAA, Rockville, MD

The academic-preclinical pharmacology program of CPDD  
James H. Woods, University of Michigan, Ann Arbor, MI

The human clinical drug assessment program of CPDD  
Charles W. Gorodetsky, Consultant, Kansas City, MO

Discussant  
Andrew Coop, University of Maryland, Baltimore, MD

Symposium XIII  
SAN CRISTOBAL  
2:30 - 4:30 PM

ENVIRONMENTAL AND PHYSIOLOGICAL FACTORS PREDISPOSING SUSCEPTIBILITY TO DRUG ABUSE

Chairs: Ellen Unterwald and Sari Izenwasser

2:30 Diet-induced obesity differentially alters drug reward in male and female rats  
Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL

2:55 Cocaine abuse susceptibility and dopamine dysfunction in a rodent model of PTSD  
Ellen Unterwald, Temple University School of Medicine, Philadelphia, PA

3:20 Adult cocaine abuse risk associated with adolescent treatment with ADHD medications  
Kathleen Kantak, Boston University, Boston, MA

3:45 Adolescent dopamine markers predict vulnerability to cocaine abuse and relapse in nonhuman primates  
Linda Porrino, Wake Forest University School of Medicine, North Carolina, NC

4:10 DISCUSSANT: Taking it to the streets: Implications for treatment and prevention  
Colleen A. Hanlon, Medical University of South Carolina, Charleston, SC

Oral Communications 14  
BALLROOM A  
2:30 - 4:30 PM

WHEN MORE IS LESS—STUDYING POLYSUBSTANCE ABUSE

Chairs: Shannon G. Mitchell and Sarah S. Dermody

2:30 Risk of polysubstance use and co-occurring internalizing and externalizing symptoms among adolescent sexual minority girls  
S. S. Dermody¹, M. P. Marshal², J. Cheong³, T. Chung², S. Stepp², A. Hipwell², ¹Department of Psychology, University of Pittsburgh, Pittsburgh, PA, ²Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, ³Department of Health Behavior, University of Alabama, Birmingham, AL
Wednesday, June 18, 2014

2:45  PlayForward: A videogame that increases drug, alcohol and sexual risk knowledge in teens  
L. E. Fiellin1, K. D. Hieftje1, T. Fakhouri1, L. R. Duncan2, B. Sawyer3, D. Fiellin1, 1Internal Medicine, Yale University School of Medicine, New Haven, CT, 2Department of Kinesiology, McGill University, Montreal, QC, Canada, 3Digitalmill, Inc., Portland, ME

3:00  The effect of marijuana commercialization on adolescent polysubstance use and treatment  
K. Belendiuk1, T. Black1, C. Thurstone1,2, 1Department of Psychiatry, University of Colorado, Aurora, CO, 2Denver Health and Hospital Authority, Denver, CO

3:15  Parent-teen drug use discussions: Associations with substance use  
T. M. Chaplin1, A. Hansen1, J. Simmons2, L. C. Mayes2, R. E. Hommer3, M. J. Crowley2, 1Psychology, George Mason University, Fairfax, VA, 2Yale University School of Medicine, New Haven, CT, 3National Institutes of Health, Bethesda, MD

3:30  Integrated treatment for mothers involved in child welfare for substance abuse  
L. Saldana1, P. Chamberlain1, A. Sheidow2, 1OSLC, Eugene, OR, 2MUSC, Charleston, SC

3:45  Adolescent SBIRT implementation in an urban FQHC: The first 6 months  
S. G. Mitchell1, K. Dusek1, J. Gryczynski1, M. Oros2, C. Hosler2, A. Kirk1, K. O’Grady4, B. Brown1, R. P. Schwartz1, 1Friends Research Institute, Baltimore, MD, 2Mosaic Group, Baltimore, MD, 3Total Health Care, Baltimore, MD, 4University of Maryland, College Park, MD

4:00  Caregiver and youth engagement in mandated juvenile drug treatment: Influence on substance use  
P. M. Mauro1, M. R. McCart2, S. Naeger1, A. J. Sheidow2, E. J. Letourneau1, 1Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Medical University of South Carolina, Charleston, SC

4:15  Delay discounting in polysubstance dependence  
L. Moody1,2, C. Franck1,3, L. Hatz1, W. K. Bickel1,2, 1Psychology, Virginia Tech Carilion Research Institute, Roanoke, VA, 2Psychology, Virginia Tech, Blacksburg, VA, 3Statistics, Virginia Tech, Blacksburg, VA

Oral Communications 15  BALLROOM B  2:30 - 4:30 PM

NO MORE “EXCUSEES”: EMERGING CUE RESEARCH

Chairs: Jesse Suh and Shervin Liddle

2:30  Attentional bias to alcohol-related stimuli and the self-reported desire to drink following a dose of alcohol  
W. Roberts, M. T. Fillmore, Psychology, University of Kentucky, Lexington, KY

2:45  Protracted abstinence influences the ‘Tug of War’ between pleasant and cocaine-related cues in addicted individuals: Evidence from a longitudinal ERP study  
M. A. Parvaz1, S. J. Moeller1, A. B. Konova2, G. H. Proudfit2, N. Alia-Klein1, R. Z. Goldstein1, 1Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 2Psychology, Stony Brook University, Stony Brook, NY

3:00  Poorer pre-potent response inhibition in cocaine-dependent patients vs. healthy controls during an affect-congruent Go-NoGo task  
J. Suh1,2, R. Ehrman1,2, M. Goldman1, Z. Singer1, T. Franklin1, K. Marquez1, C. P. O’Brien1, A. R. Childress1,2, 1University of Pennsylvania, Phila, PA, 2VAMC-MIRECC, Phila, PA
Wednesday, June 18, 2014

3:15 Changes in attentional bias to drug cues and fMRI stroop with behavioral treatment for cocaine dependence

3:30 Cocaine-dependent subjects display attentional bias toward cocaine-related but not alcohol-related stimuli
K. R. Marks1,2, W. W. Stoops1,2, C. R. Rush1,2,3, 1Behavioral Science, University of Kentucky, Lexington, KY, 2Psychiatry, University of Kentucky, Lexington, KY, 3Psychology, University of Kentucky, Lexington, KY

3:45 Strength of cocaine-associated memory: Acquisition, extinction and reinstatement
S. Liddie, Y. Itzhak, Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL

4:00 Long-access methamphetamine self-administration alters reactivity to novel cues: Implications for cue-induced relapse
J. Peters, M. Scafied, S. M. Ghee, C. M. Reichel, Department of Neurosciences, Medical University of South Carolina, Charleston, SC

4:15 Procedure-dependent effects of antagonism of nicotinic acetylcholine receptors on conditioned nicotine seeking in rat models of smoking relapse
X. Liu, University of Mississippi Medical Center, Jackson, MS

Oral Communications 16

Ballroom C

2:30 Stress-related genes and heroin addiction: A role for functional FKBP5 variants
O. Levran1, E. Peles2, M. Randesi1, Y. Li1, J. Rotrosen4, J. Ott5,1, M. Adelson6,2,1, M. Kreek1, 1Rockefeller University, New York, NY, 2Adelson Clinic for Drug Abuse Treatment and Research, Sourasky Medical Center, Tel Aviv, Israel, 3Shanxi University of Finance & Economics, Shanxi, China, 4NYU School of Medicine, New York, NY, 5Institute of Psychology, Chinese Academy of Sciences, Beijing, China, 6Adelson Clinic for Drug Abuse, Treatment and Research, Las Vegas, NV

2:45 Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting sustained-release naltrexone implant
E. Krupitsky1, A. Kibitov1, E. Zvartau1, E. Blokhina2, E. Verbitskaya2, V. Palatkin1, E. Nielsen4, T. Kosten5, G. E. Woody5, 1St. Petersburg State Pavlov Medical University, St. Petersburg, Russian Federation, 2St. Petersburg Bekhtrev Research Psychoneurological Institute, St. Petersburg, Russian Federation, 3National Research Center of Addictions, St. Petersburg, Russian Federation, 4Baylor College of Medicine, Waco, TX, 5University of Pennsylvania, Philadelphia, PA

3:00 Pharmacogenetics of buprenorphine therapy of cocaine addiction
D. A. Nielsen1,2, R. Walker1, S. C. Hamon3, M. H. Harding1,2, W. Ling4, T. R. Kosten1,2, 1Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, 2DeBakey VAMC, Houston, TX, 3UT Southwestern, Dallas, TX, 4The Rockefeller University, New York, NY, 5UCLA, Los Angeles, CA
Wednesday, June 18, 2014

3:15  Nicotine consumption and dependence: Genetic and environmental risk factors show indirect effects through nicotine craving
    D. Shmulewitz, J. L. Meyers, K. Keyes, E. Aharonovich, D. S. Hasin, Columbia University, New York, NY

3:30  CYP2A6 metabolism in the development of nicotine dependence in adolescents and young adults
    E. Olfson¹, J. Bloom¹, S. Bertelsen¹, J. Budde¹, V. Hesselbrock², J. Kramer³, A. Goate¹, L. Bierut¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Connecticut School of Medicine, Farmington, CT, ³University of Iowa Carver College of Medicine, Iowa City, IA

3:45  COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBT
    K. M. Carroll, A. Herman, E. E. DeVito, T. Frankforter, M. Sofuoglu, Psychiatry, Yale University School of Medicine, West Haven, CT

4:00  Novel genetic variant associated with substance use in two independent populations
    J. L. Meyers¹, L. Almli¹, S. Galea¹, A. E. Aiello², M. Uddin³, D. E. Wildman³, B. Bradley⁴, K. J. Ressler¹, K. C. Koenen¹, ¹Epidemiology and Psychiatry, Columbia University, New York, NY, ²Epidemiology, University of Michigan, Ann Arbor, MI, ³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, ⁴Psychiatry, Emory University, Atlanta, GA

4:15  The influence of dopamine β-hydroxylase gene polymorphism -1021C → T on levodopa/carbidopa treatment for cocaine dependence: A preliminary study
    J. Schmitz¹, S. Liu², C. Green¹, S. D. Lane¹, T. R. Kosten², F. Moeller¹, D. A. Nielsen², ¹University of Texas Medical School, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Virginia Commonwealth University Medical School, Richmond, VA

Late-Breaking Research

San Cristobal
4:45 - 5:45 PM

Business Meeting
(Members Only)

San Cristobal
6:00 - 7:00 PM

Dinner and Dancing

San Geronimo
7:30 - 10:30 PM

Badges must be worn for admission
Thursday, June 19, 2014

Poster Session IV
(Breakfast)

GRAN SALON
LOS ROSALES
8:00 - 10:00 AM

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Wednesday 1 PM
Must be removed by Thursday 12 Noon

CRIMINAL JUSTICE

1 Family, friend, and significant other support and HIV-related drug and sex risk prior to incarceration among African-American men in prison
   A. Coatsworth¹, D. Wohl², N. E. Whitehead¹, J. Scheidell¹, C. Golin³, S. Monk², S. Brown², M. R. Khan¹, ¹Department of Epidemiology, University of Florida, Gainesville, FL, ²School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Department of Clinical and Health Psychology, University of Florida, Gainesville, FL

2 Substance use and STI/HIV risk among African-American men incarcerated in North Carolina
   M. R. Khan¹, S. R. Friedman², A. Coatsworth¹, C. Golin³, A. Adimora³, J. D. Scheidell¹, L. Keen⁴, M. Hobbs³, D. Wohl³, ¹Epidemiology, University of Florida, Gainesville, FL, ²National Development and Research Institute, New York, NY, ³Department of Clinical and Health Psychology, University of Florida, Gainesville, FL

3 Examining HCV and other risks among rural women offenders
   C. Leukefeld¹, K. Harp¹, M. Webster¹, M. Staton-Tindall², C. B. Oser³, J. R. Havens¹, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Social Work, University of Kentucky, Lexington, KY, ³Sociology, University of Kentucky, Lexington, KY

4 Longitudinal gender differences in HIV and criminal justice outcomes
   J. P. Meyer, J. Cepeda, F. L. Altice, Yale, New Haven, CT

5 Prevalence of substance use disorders and HIV among female prisoners in Ukraine
   A. Krishnan¹, L. Azbel², J. A. Wickersham¹, F. L. Altice¹, ¹AIDS Program, Yale University School of Medicine, New Haven, CT, ²Ukrainian Institute on Public Health Policy, Kyiv, Ukraine

6 Borderline Personality Disorder symptoms and HIV risk behaviors among African-American incarcerated men
   J. D. Scheidell¹, C. Lejuez², D. Wohl³, C. Golin³, S. Monk³, G. Dockery³, M. R. Khan¹, ¹Epidemiology, University of Florida, Gainesville, FL, ²Psychology, University of Maryland, College Park, MD, ³University of North Carolina, Chapel Hill, NC

7 International rates of SUD and ADHD symptoms among prison inmates: Individual data and pooled effects
   R. González¹, A. Alicea¹, Y. Ginsberg², G. Gudjonsson¹, M. Konstenius², F. R. Levin⁴, M. Vélez¹, S. Young⁵, C. Albizu¹, ¹University of Puerto Rico, San Juan, ²Karolinska Institute, Solna, Sweden, ³Kings College, London, United Kingdom, ⁴Columbia University, New York, NY, ⁵Imperial College, London, United Kingdom

8 qEEG abnormalities in alcohol dependence offenders
   A. Calzada-Reyes, A. Alvarez Amador, Clinical Neurophysiology Department, Legal Medicine Institute, Havana, Cuba
9 Pre-military victimization and trauma among a sample of justice-involved veterans
   L. Sawh1,2,3, D. A. Pinals4,2, D. Smelson1,2, C. Fulwiler2, S. Singer2, K. O’Connor2, W. Fisher3,
   S. Hartwell2, G. Gonzalez2, 1Department of Veterans Affairs, Bedford, MA, 2University
   of Massachusetts Medical School, Worcester, MA, 3University of Massachusetts Lowell,
   Lowell, MA, 4Massachusetts Department of Mental Health, Boston, MA, 5University of
   Massachusetts Boston, Boston, MA

10 A needs comparison of justice-involved Iraq/Afghanistan veterans to other service eras
   K. O’Connor1,2, D. A. Pinals3,1, D. Smelson1,2, L. Sawh2,4,1, C. Fulwiler1, S. Singer1, W. Fisher4,
   S. Hartwell2, G. Gonzalez1, 1University of Massachusetts Medical School, Worcester, MA,
   2US Department of Veterans Affairs, Bedford, MA, 3Massachusetts Department of Mental
   Health, Boston, MA, 4University of Massachusetts, Lowell, Lowell, MA, 5University of
   Massachusetts Boston, Boston, MA

11 Mental health and HIV risk behavior among drug-using rural women in jail
   M. Staton-Tindall1, K. Harp2, C. B. Oser3, M. Webster2, J. R. Havens2, C. Leukefeld2, 1Social
   Work, University of Kentucky, Lexington, KY, 2Behavioral Science, University of Kentucky,
   Lexington, KY, 3Sociology, University of Kentucky, Lexington, KY

12 Psychiatric problems and sex-trading among drug-using African-American women: Does family
   support matter?
   D. Stevens-Watkins, C. Leukefeld, C. B. Oser, University of Kentucky, Lexington, KY

13 A comparison of outcomes by sexual orientation among women in integrated substance use and
   mental health disorder treatment
   H. Amaro2, J. Goldbach1, L. Duan1, S. E. Spear1, G. Prado3, 1Social Work, University of
   Southern California, Los Angeles, CA, 2Social Work and Preventive Medicine, University of
   Southern California, Los Angeles, CA, 3Department of Public Health Sciences, University of
   Miami, Miami, FL

14 Heightened vulnerability associated with criminal justice involvement among women who use
   drugs
   J. Lorvick1, M. L. Comfort1,2, B. Quinn3, C. Krebs4, A. Kral1, 1Urban Health Program,
   RTI International, San Francisco, CA, 2Center for AIDS Prevention Studies, University of
   California, San Francisco, CA, 3Burnet Institute, Melbourne, VIC, Australia, 4Crime, Violence
   and Justice Program, RTI International, Research Triangle Park, NC

15 Impaired driving histories among rural female drug-involved offenders
   M. Webster, M. Staton-Tindall, C. Leukefeld, J. R. Havens, C. B. Oser, K. Harp, Center on
   Drug and Alcohol Research, University of Kentucky, Lexington, KY

16 The size of African-American female’s health networks: The role of drug and criminal histories
   C. B. Oser, E. L. Pullen, C. Leukefeld, D. Stevens-Watkins, M. Staton-Tindall, J. R. Havens,
   Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

17 Predictors of sentenced inmates’ drug use transition from community to prison
   G. Caraballo-Correa, C. E. Albizu, R. Ramirez, J. J. Ruiz, Graduate School of Public Health,
   University of Puerto Rico, San Juan

18 Development and pilot testing of an online training to raise awareness among criminal justice
   professionals of medications used to treat opioid addiction
   J. Matejkowski1,2, K. L. Dugosh2, N. Clements3,2, D. S. Festinger2,4, 1University of Kansas,
   Lawrence, KS, 2Treatment Research Institute, Philadelphia, PA, 3St. Joseph’s University,
   Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA
19 WITHDRAWN

20 A brief behavioral activation treatment for substance use associated with lower rates of recidivism at a one-year follow-up
  C. Seitz-Brown¹, D. DeGeorge¹, E. Blevins¹, J. Williams¹, C. W. Lejuez¹, S. B. Daughters²,
  ¹University of Maryland, College Park, MD, ²University of North Carolina, Chapel Hill, NC

21 Improving outcomes for low-risk/low-need drug court clients: Life in the fast lane
  D. S. Festinger¹, K. L. Dugosh¹, D. Marlowe², ¹Treatment Research Institute, Philadelphia, PA, ²National Association of Drug Court Professionals, Alexandria, VA

SEX/GENDER II

22 Risky behaviors on the road: Do women and men act differently after drinking?
  T. R. Sousa¹, G. Pasa¹, J. Lunnen², F. P. Pechansky¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Johns Hopkins International Injury Research Unit, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

23 Prescription drug use in a national sample of female drivers
  T. Kelley-Baker, J. Yao, R. Pollini, Pacific Institute for Research and Evaluation, Calverton, MD

24 Gender differences in polysubstance use among those who misuse prescription opioids
  A. Acheampong¹, D. C. Vidot², L. Cottler¹, ¹Epidemiology, University of Florida, Gainesville, FL, ²Pediatrics, University of Miami, Miami, FL

25 Female opioid users may be at excess risk of becoming dependent soon after extra-medical prescription pain reliever use in adolescence but not in young adulthood: Estimates for the United States, 2002-2011
  H. H. Yeh, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

26 Characterizing sex differences among pain medication abusers

27 Gender differences in smoking and treatment outcome among opioid-maintained smokers

28 Is voluntary household smoking ban differentially effective for men’s and women’s smokeless tobacco use and addiction? Findings from the Global Adult Tobacco Survey in India
  S. Balan, S. Pandey, C. van den Berk-Clark, R. K. Price, Washington University in St. Louis, St. Louis, MO

29 Gender differences in laboratory stress response among prescription opioid-dependent individuals
  J. L. McCauley¹, M. A. Mercer¹, A. Teer¹, F. Beylotte¹, K. T. Brady¹,², S. E. Back¹,²,
  ¹Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC,
  ²Ralph H. Johnson VAMC, Charleston, SC

30 Effects of oral contraceptive use on stress response in acute smoking abstinence
  K. Harrison, A. M. Allen, S. Allen, M. al’Absi, University of Minnesota, Minneapolis, MN

31 “I take my refuge in tik”: Understanding gender differences in the initiation of methamphetamine use in South Africa
  A. L. Hobkirk¹, M. Watt¹, K. Guidera¹, S. Kimani¹, D. Skinner², D. Pieterse², C. S. Meade¹,
  ¹Duke Global Health Institute, Duke University, Durham, NC, ²Research on Health & Society, Stellenbosch University, Tygerberg, South Africa
32 Reproductive health needs among drug treatment clients
M. Bryant-Genevier¹, L. Appel¹, K. D. Mark¹, M. Terplan¹,², Obstetrics Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, ²Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD

33 Family/social problems as a greater barrier to treatment entry for women than men
A. M. Heads, R. Suchting, C. Green, J. Schmitz, N. Rathnayaka, S. D. Lane, University of Texas HSC at Houston, Houston, TX

34 How well do we understand older female substance abusers in the U.S.? An analysis of TEDS-D 2006-09
M. Terplan¹,², N. Longinaker¹, M. S. Chisolm², Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ²Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, ³Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD

35 Effects of alcohol intake on balance and stability in older adults: A pilot study
Y. Duan¹,², L. Barry³, J. Covault¹, A. Kenny¹, C. Oncken³, R. Bohannon¹, J. Grady⁵, H. Wu⁶, Community Medicine & Healthcare, University of Connecticut Health Center, Farmington, CT, ²Center on Aging, UCHC, Farmington, CT, ³Medicine, UCHC, Farmington, CT, ⁴Dept of Kinesiology, University of Connecticut, Storrs, CT, ⁵Connecticut Institute for Clinical and Translational Science (CICATS), University of Connecticut Health Center, Farmington, CT, ⁶Psychiatry, University of Connecticut Health Center, Farmington, CT

36 MOVED TO #3 ON TUESDAY POSTER SESSION

37 Gender differences in acceptability and treatment outcomes of Internet-based treatment for substance use disorders
A. Campbell¹, M. Hu³, S. F. Greenfield², E. Nunes¹, New York State Psychiatric Institute, New York, NY, ²Harvard Medical School, Boston, MA, ³Columbia University, New York, NY

38 Predictors of illicit drug use in low-income African-American women: A multilevel analysis of demographic and cultural factors
E. L. Pullen, C. B. Oser, Sociology, University of Kentucky, Lexington, KY

39 Gender differences in trauma and substance use characteristics among veterans with PTSD and substance use disorders
S. E. Back¹,², T. Killeen¹, A. Teer¹, F. Beylotte¹, J. L. McCauley¹, D. F. Gros¹,², J. Hellmuth¹, K. T. Brady¹,², ¹Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VA Medical Center, Charleston, SC

LITERATURE REVIEW

40 Role of the endogenous cannabinoid system in fear circuitry: Translational findings and clinical implications for post-traumatic stress disorder
S. Papini¹,², D. A. Hiem², Y. Neria³, F. Levin², ¹City College, New York, NY, ²New York State Psychiatric Institute, New York, NY
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Cannabis use among women and during pregnancy</td>
<td>F. Alharbi&lt;sup&gt;1,2&lt;/sup&gt;, N. El-guebaly&lt;sup&gt;1,4&lt;/sup&gt;, King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, University of Calgary, Calgary, AB, Canada, Alberta Health Services, Calgary, AB, Canada</td>
</tr>
<tr>
<td>42</td>
<td>The impact of cannabis use on opioid-dependence treatment: A systematic review</td>
<td>K. Z. Smith&lt;sup&gt;1,2&lt;/sup&gt;, S. Ravven&lt;sup&gt;1&lt;/sup&gt;, J. W. Boyd&lt;sup&gt;3,4&lt;/sup&gt;, Yale School of Medicine, New Haven, CT, Wayne State University, Detroit, MI, Cambridge Health Alliance, Cambridge, MA, Harvard Medical School, Cambridge, MA</td>
</tr>
<tr>
<td>43</td>
<td>Marijuana use among low-income urban youth: A systematic review</td>
<td>R. M. Johnson&lt;sup&gt;1&lt;/sup&gt;, C. Kaczmarsky&lt;sup&gt;2&lt;/sup&gt;, K. A. Power&lt;sup&gt;2&lt;/sup&gt;, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Community Health Sciences, Boston University School of Public Health, Boston, MA</td>
</tr>
<tr>
<td>45</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Effective HIV and substance abuse prevention programs for African-American women: Attending to culture and context</td>
<td>F. Z. Belgrave&lt;sup&gt;1&lt;/sup&gt;, D. Jones&lt;sup&gt;2&lt;/sup&gt;, J. Richardson&lt;sup&gt;1&lt;/sup&gt;, L. Beatty&lt;sup&gt;3&lt;/sup&gt;, Psychology, Virginia Commonwealth University, Richmond, VA, Service Research Branch, NIDA, Bethesda, MD, American Psychological Association, District of Columbia, DC</td>
</tr>
<tr>
<td>47</td>
<td>Time to first cigarette: A potential clinical screening tool for nicotine dependence and cancer risk</td>
<td>M. Mercincavage&lt;sup&gt;1&lt;/sup&gt;, S. A. Branstetter&lt;sup&gt;1&lt;/sup&gt;, J. E. Muscat&lt;sup&gt;2&lt;/sup&gt;, Biobehavioral Health, The Pennsylvania State University, University Park, PA, Public Health Sciences, Penn State College of Medicine, Hershey, PA</td>
</tr>
<tr>
<td>48</td>
<td>Smoking and cardiac rehabilitation participation</td>
<td>D. E. Gaalema&lt;sup&gt;1&lt;/sup&gt;, P. Ades&lt;sup&gt;2&lt;/sup&gt;, S. T. Higgins&lt;sup&gt;1&lt;/sup&gt;, University of Vermont, Burlington, VT, Fletcher Allen Health Care, Burlington, VT</td>
</tr>
<tr>
<td>49</td>
<td>A review of the relationship of drug dreams with craving and consumption</td>
<td>N. Cross, H. Rosenberg, Psychology, Bowling Green State University, Bowling Green, OH</td>
</tr>
<tr>
<td>50</td>
<td>Publication trends from 1950–2009: Opioids, benzodiazepines, barbiturates, and amphetamines</td>
<td>M. Zhang&lt;sup&gt;1,2&lt;/sup&gt;, B. Sproule&lt;sup&gt;1,2&lt;/sup&gt;, Centre for Addiction and Mental Health, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>51</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Influence of pharmacokinetics on the abuse liability of controlled-release opioid formulations: The case of oxycodone</td>
<td>B. Rafat&lt;sup&gt;1,2&lt;/sup&gt;, B. Sproule&lt;sup&gt;1,2&lt;/sup&gt;, Centre for Addiction and Mental Health, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>54</td>
<td>A systematic review of community opioid overdose prevention and naloxone distribution programs</td>
<td>A. K. Clark, E. L. Winstanley, C. M. Wilder, University of Cincinnati, Cincinnati, OH</td>
</tr>
</tbody>
</table>
55 Evaluation of the effectiveness of drug prevention programs: Analysis of the international scientific production (2002-2011)

56 WITHDRAWN

57 Understanding the predictive value of abuse potential assessments

SEDATIVE - HYPNOTICS

58 Misuse of alprazolam among people who inject drugs: A prescription for harm?
R. Bruno, S. Reddel, P. Dietze, B. de Graaff, S. Nielsen, L. Burns, School of Medicine, University of Tasmania, Hobart, TAS, Australia, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, Burnet Institute, Centre for Population Health, Melbourne, VIC, Australia

59 Benzodiazepine use among a sample of chronic pain patients prescribed opioids
S. Nielsen, R. Bruno, G. Campbell, M. Cohen, M. Farrell, W. Hall, B. Hoban, B. Larance, N. Lintzeris, R. Mattick, L. Degenhardt, National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia, University of Queensland, Herston, QLD, Australia, SESLHD, Surry Hills, NSW, Australia

60 Abuse potential of eslicarbazepine acetate in recreational sedative users

61 Abuse potential of a dual orexin receptor antagonist: A randomized, double-blind, crossover study in recreational drug users
E. M. Sellers, H. Cruz, J. Dingemanse, B. Chakaraborty, K. Schoedel, DL Global Partners, Inc, Toronto, ON, Canada, Aetelion Pharmaceuticals Ltd, Allschwil, Switzerland, INC Research, Toronto, ON, Canada, Altreos Research Partners Inc, Toronto, ON, Canada

62 Physical dependence liability of Retigabine in rats
M. Tessari, L. Dacone, M. Pilla, W. Rycroft, J. Prescott, A. Giarola, Safety Pharmacology, GlaxoSmithKline, Ware, United Kingdom, Preclinical Pharmacology, Aptuit Verona, Verona, Italy, Safety Assessment, GlaxoSmithKline, RTP, NC

63 Differential effects of the benzodiazepines alprazolam and oxazepam on methamphetamine-related behaviors in rats
A. Spence, G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology, & Neuroscience, LSU Health Sciences Center, Shreveport, LA

64 Effects of HZ-166, a novel a2 and a3 subunit-containing GABA4 receptor agonist, on inflammatory pain and operant behavior in mice
B. D. Fischer, C. Kroll, M. Poe, J. M. Cook, Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, WI
Involvement of mGlu5 receptor signal cascade in the enhancement of morphine-induced hyperlocomotion under chronic treatment with zolpidem
M. Shibasaki, K. Ishii, T. Mori, T. Suzuki, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

GluA1 phosphorylation: A potential mechanism to attenuate cocaine seeking in rats
C. Keller, M. F. Salvatore, G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology & Neuroscience, LSU Health Sciences Center, Shreveport, LA

The role of glutamate on incentive value attribution: Acquisition and expression
J. J. Chow, J. S. Beckmann, Psychology, University of Kentucky, Lexington, KY

Cocaine addiction: Role for glutamate, glia and chemokine
J. K. Kim, C. S. Tallarida, S. H. Ramirez, S. Rawls, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, Department of Pathology, Temple University School of Medicine, Philadelphia, PA

Orexin/hypocretin in the paraventricular nucleus of the thalamus mediates cocaine-seeking behavior in rats
A. Matzeu, T. M. Kerr, F. Weiss, R. Martin-Fardon, Molecular and Cellular Neuroscience Dept, The Scripps Research Institute, La Jolla, CA

Concomitant adrenal hormonal stress responses are required for cocaine-induced locomotor sensitization
D. F. Pena, L. M. Keller, C. B. Masterson, E. J. Cottor, J. R. Mantsch, Biomedical Sciences, Marquette University, Milwaukee, WI

Glucocorticoid-endocannabinoid interactions in the prelimbic cortex mediate stress-potentiated reinstatement of cocaine seeking
J. R. McReynolds, O. Vranjkovic, E. N. Graf, C. J. Hillard, J. R. Mantsch, Biomedical Sciences, Marquette University, Milwaukee, WI, Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI

Rearing environment modulates the effect of a glucocorticoid receptor antagonist on cocaine self-administration in rats
R. S. Hofford, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY

A re-engineered anticocaine monoclonal antibody: Determining h2E2 thermostability and thermodynamics of ligand binding
W. J. Ball, M. R. Tabet, N. Tabaja, N. Garbett, A. B. Norman, Pharmacology, University of Cincinnati, Cincinnati, OH, Molecular Genetics, University of Cincinnati, Cincinnati, OH, James B Brown Cancer Center, University of Louisville, Louisville, KY

Chronic treatment with the monoamine releaser phenmetrazine reduces cocaine self-administration and cocaine-induced reinstatement
L. N. Thomas, B. E. Blough, T. J. Beveridge, Phys Pharm, Wake Forest School of Medicine, Winston Salem, NC, Drug Discovery, RTI International, Research Triangle Park, NC

A procedure for rapid determination of delay discounting of drug and non-drug reinforcers in monkeys
S. L. Huskinson, L. Green, J. Myerson, K. B. Freeman, University of Mississippi Medical Center, Jackson, MS, Washington University, St. Louis, MO

Acute cocaine and concordance across measures of impulsive choice for food
J. R. Smethells, M. E. Carroll, Psychiatry, University of Minnesota, Minneapolis, MN
Persistent effects of tacrine on reinstatement of non-reinforced responding for cocaine
K. Grasing, S. He, Substance Abuse Research, VA Medical Center, Kansas City, MO

(±)-Modafinil potentiates cocaine self-administration but not the effects on DA levels in rodents
G. Tanda1,2, M. Mereu2, T. Hiranita2, A. H. Newman1,3, J. Katz2, 1Medications Development Program, NIDA/IRP, Baltimore, MD, 2Psychobiology Section, NIDA/IRP, Baltimore, MD, 3Medicinal Chemistry Section, NIDA/IRP, Baltimore, MD

Dopamine D2/D3 receptor modulation of food-drug choice in rhesus monkeys
W. S. John1, A. H. Newman2, M. A. Nader1, 1Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, 2Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD

Effects of the dopamine D3/D2 receptor antagonist buspirone on food/cocaine choice in socially housed male cynomolgus monkeys
M. Coller, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC

Effects of intramuscular and oral buspirone on physiology and behavior in monkeys
K. T. Szeli at, S. E. Martelle, M. A. Nader, Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC

Preference and c-fos activation of drug reward vs. natural reward: Are female pheromones more rewarding than cocaine?
K. Y. Salas-Ramirez1, K. Uribe2, L. Vidal1, E. Friedman1, 1Physiology, Pharmacology and Neuroscience, The Sophie Davis School of Biomedical Education at The City College of New York, New York, NY, 2Biology, The City College of New York, New York, NY

A progressive ratio determination of the relative reinforcing effect of methylphenidate versus cocaine by intravenous self-administration testing in rats
N. W. Buckley, J. Gosden, E. Johnson, S. L. Smith, D. J. Heal, RenaSci Ltd, Nottingham, United Kingdom

Effect of methylphenidate preexposure on methylphenidate-induced conditioned taste avoidance
M. Muller, B. B. Wetzell, S. M. Flax, H. E. King, A. L. Riley, Psychopharmacology Laboratory, Department of Psychology, American University, Washington, DC

A preclinical model of natural reward devaluation in cocaine addiction: Effects of dose
J. Green, L. Dykstra, R. M. Carelli, University of North Carolina, Chapel Hill, NC

MDPV-induced conditioned taste aversions in the F344/N and LEW rat strains
H. E. King1, K. Rice2, A. L. Riley1, 1Psychology, American University, Washington, DC, 2Chemical Biology Research Branch, National Institute on Drug Abuse, Bethesda, MD

Discriminative and locomotor effects of three synthetic cathinones
M. J. Forster, M. Rutledge, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX

Alpha-pyrrolidinovalerophenone (alpha-PVP): Self-administration and acute drug challenges in rats
S. M. Aarde, S. Vandewater, K. Creehan, M. A. Taffe, Committee on Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

STIMULANTS - HUMANS II

Methamphetamine dependence and intensive Motivational Interviewing
D. L. Polcin, R. A. Korcha, M. Nayak, J. Bond, Alcohol Research Group, Emeryville, CA
90  Contingency management and case management for out-of-treatment methamphetamine users  
K. F. Corsi, C. Garver-Apgar, R. E. Booth, Psychiatry, University of Colorado School of  
Medicine, Denver, CO  

91  Methamphetamine treatment-seeking women: Is referral source an indication of treatment  
retention?  
S. M. Stemmle, S. Shoptaw, Center for Behavioral and Addiction Medicine, UCLA, Los  
Angeles, CA  

92  Behavioral incentives to promote exercise compliance in cocaine-dependent women  
L. Islam, D. Svikis, Virginia Commonwealth University, Richmond, VA  

93  Cocaine-induced subjective effects differ between African Americans and Caucasians  
C. N. Haile1,2, D. G. Thompson-Lake1,2, J. J. Mahoney1,2, T. F. Newton1,2, R. De La Garza, II1,2,  
1Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, 2Michael E.  
DeBakey VAMC, Houston, TX  

94  Initial abstinence status and contingency management treatment outcomes: Does race matter?  
L. Montgomery1, K. Carroll2, N. Petry3, 1School of Human Services, University of Cincinnati,  
Cincinnati, OH, 2Psychiatry, Yale University, New Haven, CT, 3Psychiatry, University of  
Connecticut, Farmington, CT  

95  Race and ethnicity differences among adults with stimulant use disorders in a residential  
treatment setting: A baseline analysis of the STRIDE cohort  
K. Sanchez1,3, K. G. Chartier2, T. L. Greer1, R. Walker3, T. Carmody3, C. D. Rethorst3,  
K. M. Ring3, A. M. dela Cruz3, M. H. Trivedi3, 1School of Social Work, The University of  
Texas, Arlington, TX, 2School of Social Work, Virginia Commonwealth University,  
Richmond, VA, 3Department of Psychiatry, University of Texas Southwestern Medical Center,  
Dallas, TX  

96  Risk and protective correlates of METH-associated externalizing problems among European-  
American and U.S. Latino/a METH-dependent users  
G. Carlo1, J. Simpson2, K. Grant3, M. M. Martinez4, C. Pudiak4, R. Bevins4, 1University of  
Missouri, Columbia, MO, 2Midland University, Fremont, NE, 3VA Nebraska-Western Iowa  
Health Care System & University of Nebraska Medical Center, Omaha, NE, 4University of  
Nebraska-Lincoln, Lincoln, NE  

97  Patterns of consumption and medical complications of cocaine base paste use in Uruguay  
A. Pascale1,2, S. García1, A. Negri1,2, P. Yemini2, R. Ormaechea2, 1Department of Toxicology,  
School of Medicine, Montevideo, Uruguay, 2Drug Reference and Information Center “Portal  
Amarillo”, State Health Services Administration, Montevideo, Uruguay  

98  Sex and drugs in the lives of minority women: A multi-level analysis of smartphone-based daily  
diary data  
G. L. Reynolds1, D. G. Fisher1, J. Laurenceau2, 1California State University, Long Beach,  
Long Beach, CA, 2University of Delaware, Newark, DE  

99  Comparison of perceptions of HIV risk and risky sexual practices among heterosexual cocaine-  
dependent individuals  
D. G. Thompson-Lake1, K. Cooper1, J. J. Mahoney1, K. Gatchalian2, M. Koffarnus2, R. Salas1,  
T. Lohrenz2, W. Bickel2, P. R. Montague2, T. F. Newton1, R. De La Garza, II1, 1Psychiatry,  
Baylor College of Medicine, Houston, TX, 2Virginia Tech Carilion Research Institute,  
Roanoke, VA  

108
TREATMENT

100 Cocaine-dependent adults are more likely than controls to choose immediate unsafe sex over delayed safe sex
   M. N. Koffarnus¹, M. W. Johnson², M. J. Wesley¹, T. Lohrenz¹, P. R. Montague¹,
   W. K. Bickel¹, ¹Virginia Tech Carilion Research Institute, Virginia Tech, Roanoke, VA,
   ²Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine,
   Baltimore, MD

101 Depressive symptoms and impulsivity among trauma-exposed, cocaine-dependent adults: Associations with HIV-relevant drug and sex risk behaviors
   A. Vujanovic, R. Suchting, D. Atkinson, C. Green, J. Schmitz, Psychiatry and Behavioral
   Sciences, University of Texas Health Science Center at Houston, Houston, TX

102 Careless and overprotective fathers are associated with antisocial crack users
   M. Pettenon¹, L. P. Guimarães¹, R. S. Pedroso¹, G. E. Woody², F. P. Pechansky¹,
   F. P. Kessler¹, ¹CPAD-Centro de Pesquisa em Álcool e Drogas, UFRGS-Universidade Federal
   do Rio Grande do Sul, Porto Alegre, Brazil, ²University of Pennsylvania, Philadelphia, PA

103 Crack cocaine use and perceived life chances
   J. Davis, D. G. Fisher, G. L. Reynolds, L. Napper, S. A. Meyers, Center for Behavioral
   Research and Services, California State University, Long Beach, Long Beach, CA

104 Crack cocaine users show low adherence rates in Brazilian public outpatient treatment
   S. Faller, A. R. Stolf, F. P. Pechansky, F. Kessler, Center for Drug and Alcohol Research of
   the Federal University of Rio Grande do Sul (CPAD), Porto Alegre, Brazil

105 Adherence monitoring for substance abuse clinical trials
   R. Pal¹, G. Galloway¹, O. Clavier², K. Garrison¹, J. Mendelson¹, ¹Addiction & Pharmacology
   Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA,
   ²Creare, Inc., Hanover, NH

106 A remote wireless sensor network/electrocardiographic approach to discriminating cocaine use
   G. A. Angarita¹, A. Natarajan², E. C. Gaiser¹, A. Parate², B. Marlin², R. Gueorguieva³,
   D. Ganesan², R. T. Malison¹, ¹Psychiatry, Yale University School of Medicine, New
   Haven, CT, ²School of Computer Science, University of Massachusetts, Amherst, MA,
   ³Biostatistics, Yale University School of Medicine, New Haven, CT

107 Agreement between Timeline Follow-Back (TLFB) and Audio Computer-Assisted Self Interview
   (A-CASI) in HIV primary care patients: Assessment of days used primary drug
   D. S. Hasin¹,², E. Aharonovich¹,², ¹Columbia University Medical Center, New York, NY, ²New
   York State Psychiatric Institute, New York, NY

108 Frequency and intensity of craving among addicted patients during outpatient treatment
   H. Hurmic¹,², F. Serre¹,², M. Fatseas¹,², M. Alix¹,², M. Auriacombe¹,², ¹Addiction Psychiatry,
   Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, ²Addiction Treatment Center, CH Ch.
   Perrens et CHU Bordeaux, Bordeaux, France

109 Sleep quality in patients with SUD and behavioral addictions assessed by actigraphy: A prospective study
   C. Kervran¹, F. Serre¹, M. Fatseas¹, R. Debrabant¹, C. Trouba², J. Taillard², P. Philip¹,
   M. Auriacombe¹, ¹Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux,
   France, ²Sleep Clinic, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France

110 Training in contingency management: Effects on staff intervention delivery skill, knowledge, adoption readiness, and attitudes after 90 days of implementation experience
   B. Hartzler, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA
Thursday, June 19, 2014

111  **Effects of training and implementation experience on clinical skills involved in delivering contingency management**
B. E. Jones, B. Hartzler, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA

112  **Anxiety sensitivity and the discrepancy between motivation to change and perceived ability to change**
R. McHugh1,2, E. Hilario1, K. McDermott1, M. L. Griffin1,2, R. Weiss1,2, McLean Hospital, Belmont, MA, 1Harvard Medical School, Boston, MA

113  **Understanding organization readiness to use of technology-based treatment approaches**
S. E. Lord1, A. Ramsey2, 1Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, Lebanon, NH, 2Brown School, Washington University, St. Louis, MO

114  **Client predictors of treatment completion using a U.S. national sample**
G. Stahler1, J. P. DuCette1, Geography and Urban Studies, Temple University, Philadelphia, PA, 2Psychological Studies in Education, Temple University, Philadelphia, PA

115  **Predictors of substance use outcomes in mentorship for addiction problems**
K. Tracy1, M. Burton1, M. Warren1, D. Guzman1, M. Galanter1, T. Babuscio2, C. Nich2, 1Psychiatry, New York University School of Medicine, New York, NY, 2Psychiatry, Yale University School of Medicine, New Haven, CT

116  **Therapist turnover intentions: The predictive role of training satisfaction and evidence-based treatment perceptions**
B. Garner, L. Passetti, B. Hunter, M. Godley, Chestnut Health Systems, Normal, IL

117  **Social work students’ attitudes towards approaches to alcohol or other drug treatment**
S. K. Moore, NDRI, New York, NY

118  **ASAM treatment placement criteria for gambling disorder**
D. M. Ledgerwood, C. L. Arfken, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI

**PSYCHIATRIC COMORBIDITY II**

119  **Gambling behavior among gamblers with and without attention deficit/hyperactivity disorder**
J. Alexandre1,2, M. Fatseas1,2, G. Bouju1, C. Legauffre2, M. Valleur2, D. Magalon2, I. Chereau-Boudet2, M. Gorsane2, M. Auriacome1,2, J. Hardouin2, J. Venisse2, M. Grall-Bronnec2, 1Addiction Treatment Center, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, 2Gambling Cohort Group, Univ Nantes, Nantes, France

120  **Decision-making, impulsivity, and drug severity in co-occurring substance dependence and pathological gambling**
J. Tanabe1,2, T. Krmpotich1, S. Mikulich2, J. Sakai2, L. Thompson2, J. Reynolds3, M. T. Banich2, 1Radiology, University of Colorado, Denver, CO, 2Psychiatry, University of Colorado, Denver, CO, 3Psychology, University of Denver, Denver, CO

121  **Are sleep disturbances associated with craving intensity? What is the influence of psychiatric comorbidity and type of substance on this relationship? A computerized ambulatory monitoring study in patients beginning treatment for addiction**
F. Serre1, M. Fatseas1, J. Swendsen2, M. Auriacome1, 1Addiction Psychiatry, Univ. Bordeaux/ CNRS USR 3413, Bordeaux, France, 2CNRS UMR 5287 - INCIA, Univ. Bordeaux, Bordeaux, France

122  **Relationship of trait impulsivity and lifetime cocaine use consequences to current depression**
J. J. Lister, D. M. Ledgerwood, L. H. Lundahl, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
### Long-term patterns of heroin use and mental health: 11-Year follow-up of the Australian Treatment Outcome Study

C. Marel¹, M. Teesson¹, K. Mills¹, S. Darke¹, J. Ross¹, T. Slade¹, L. Burns¹, M. Lysnkey²,
¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia,
²Washington University, St Louis, MO

### Illicit drug use harms response to psychiatric treatment

V. L. King, J. M. Peirce, R. K. Brooner, M. S. Kidorf, Johns Hopkins School of Medicine, Baltimore, MD

### Early initiation of alcohol and illicit drug use: Associations with psychopathology among inpatient substance users

N. Bounoua, B. Ali, A. Lim, W. Lechner, J. M. Shadur, J. W. Felton, L. MacPherson, C. W. Lejuez, University of Maryland, College Park, College Park, MD

### “It’s like trying to change a flat tire when you got a blown engine.” Counselor views on treating clients with co-occurring medical conditions

L. A. Cathers¹, A. Armstrong¹, C. Hawley¹, J. Bradford², L. A. Keyser-Marcus¹, D. Svikis¹,
¹Virginia Commonwealth University, Richmond, VA, ²The Fenway Institute, Boston, MA

### Methamphetamine dependence, psychiatric disorders, and treatment outcomes in individuals treated with methylphenidate

L. Mooney, M. P. Hillhouse, A. Ang, J. Jenkins, W. Ling, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

### Preliminary results from a study evaluating creatine as a treatment option for depression in female methamphetamine users

T. Hellem¹², P. F. Renshaw¹, ¹Brain Institute, Univ of UT, SLC, UT, ²College of Nursing, Univ of UT, SLC, UT

### Impact of psychiatric comorbidity in engagement in treatment after referral by an Addiction Liaison Psychiatry Unit

F. Fonseca¹², J. León¹, M. Llobet¹, P. Rossi¹², D. Martinez-Sanvisens¹², C. Tamarit¹², M. Farre¹²³, M. Torrens¹²³, ¹Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain, ²Institut Hospital Del Mar d’Investigacions Mèdiques (IMIM), Parc de Salut Mar, Barcelona, Spain, ³Facultad de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain

### Comparing integrated care capacity among mental health and substance abuse treatment providers

M. Chaple, S. Sacks, NDRI, New York, NY

#### NICOTINE II

### Tobacco use in buprenorphine-maintained patients receiving primary care in a community mental health clinic

A. Harrington, M. E. Kolodziej, M. Hobart, G. Gonzalez, Psychiatry, University of Massachusetts, Worcester, MA

### Analyzing disparities on tobacco use through CBPR

S. A. Henry²¹, P. Sheikhattari¹², F. A. Wagner¹², ¹Prevention Sciences Research Center, Morgan State University, Baltimore, MD, ²School of Community Health and Policy, Morgan State University, Baltimore, MD

### Race as a moderator of the relationship between distress tolerance and cigarette smoking among Black and White women

J. R. Dahne¹, K. Stratton², R. Brown², A. Amstadter², C. W. Lejuez¹, L. MacPherson¹,
¹Psychology, University of Maryland, College Park, College Park, MD, ²Virginia Commonwealth University, Richmond, VA
134 Income variability by race in tobacco outlet density in Maryland
D. O. Fakunle¹, A. J. Milam¹,², C. D. Furr-Holden¹, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²School of Medicine, Wayne State University, Detroit, MI

135 Perceived risk of regular cigarette smoking and marijuana use in the U.S, 2002-2012
L. R. Pacek¹, P. M. Mauro², S. S. Martins¹,², ¹Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, ²Mental Health, Johns Hopkins University, Baltimore, MD, ³Epidemiology, Columbia University, New York, NY

136 Change in addiction treatment staff and client smoking following a statewide smoking ban
A. Pagano, J. Guydish, T. Le, B. Tajima, E. Passalacqua, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA

137 Smokers in addiction treatment see their risk of tobacco-related disease as lower than that of an average smoker
T. Le, J. Guydish, A. Pagano, B. Tajima, E. Passalacqua, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA

138 Quit attempt predictors among smokers in addiction treatment
C. Martinez¹,²,³, J. Guydish¹, T. Le¹, B. Tajima¹, E. Passalacqua¹, ¹Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, ²Cancer Prevention and Control Group, Institut d’Investigacio Biomedica de Bellvitge, Barcelona, Spain, ³Medicine and Health Sciences School, Universitat Internacional de Catalunya, Barcelona, Spain

139 Recruiting for an SMS smoking cessation intervention in Peru: Pilot study results
D. Blitchtein², K. Zevallos², M. R. Samolski², J. C. Anthony¹, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Salud Mental, Universidad Peruana Cayetano Heredia, Lima, Peru

140 Preliminary results of Project EX in Spain: A classroom-based smoking prevention and cessation program
J. P. Espada¹, M. T. Gonzalvez¹, M. Orgiles¹, A. Morales¹, S. Sussman², ¹Miguel Hernandez University, Alicante, Spain, ²University of Southern California, Los Angeles, CA

141 Role of substance abuse in physical and mental health trajectories throughout the deployment cycle: A National Guard study
C. van den Berk Clark¹, S. Balan¹, J. Scherrer², G. Widner¹, M. Shroff³, R. K. Price¹, ¹Psychiatry, Washington University, St. Louis, MO, ²Family and Community Medicine, St. Louis University, St. Louis, MO

142 Nicotine dependence among distinct smoking typologies
W. Pickworth, B. Koszowski, Z. Rosenberry, L. Viray, J. Potts, Health & Analytics, Battelle, Baltimore, MD

143 A non-parametric approach identifies a new gene-gene interaction associated with progression of nicotine dependence
M. Li¹, J. C. Gardiner², N. Breslau², J. C. Anthony², Q. Lu², ¹Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, ²Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

THEORETICAL/COMMENTARY

144 Monkey genomes: A paradigm shift for advancing preclinical research and medications development for addictions
G. M. Miller, E. J. Vallender, NEPRC, Harvard University, Southborough, MA
145 Functional approach in modeling drug dependence processes (theoretical overview midway to final results)
   O. Vsevolozhskaya, J. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

146 Methodological challenges with marijuana research in the U.S
   S. B. Farley, C. J. Reissig, Controlled Substance Staff (CSS), FDA, Silver Spring, MD

147 Posterior predictive power: A decision-making tool for clinical trial design
   N. Rathnayaka, R. Suchting, S. D. Lane, J. Schmitz, C. Green, Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX

148 Implications of decision-making processes for improving contingency management
   P. S. Regier¹, A. D. Redish², ¹Graduate Program of Neuroscience, University of Minnesota, Minneapolis, MN, ²Department of Neuroscience, University of Minnesota, Minneapolis, MN

149 Comprehensive women-centered treatment for substance use disorders in the Republic of Georgia: Current status and future directions
   D. Otiashvili¹, I. Kirtadze¹, K. E. O’Grady², W. Zule³, E. Krupitsky⁴, W. Wechsberg⁵, H. Jones⁶, ¹Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, ²Department of Psychology, University of Maryland, College Park, MD, ³RTI International, Research Triangle Park, NC, ⁴Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, ⁵UNC Horizons, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁶Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, School of Medicine, Johns Hopkins University, Baltimore, MD

150 The role of discrimination, ethnic identity, and acculturation in substance use patterns among Mexican origin transnational youth
   F. I. Soriano¹, J. C. Anthony¹,², F. Castro¹, I. Bojorquez¹, ¹Human Development, California State University San Marcos, San Marcos, CA, ²Department of Epidemiology, Michigan State University, East Lansing, MI, ³Department of Psychology, University of Texas, El Paso, TX

151 HIV among Puerto Rican people who inject drugs: Health disparities continue
   S. Deren¹, C. Gelpi-Acosta², C. Albizu-Garcia³, A. Gonzalez⁴, D. Des Jarlais⁴, S. Santiago-Negron⁵, ¹NYU, NY, NY, ²NDRI, NY, NY, ³UPR, San Juan, ⁴BIMC, NY, NY, ⁵ASSMCA, San Juan

152 Development of a workflow for screening for the hepatitis C virus in HIV-positive IV drug users
   E. Thomas, Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL

153 Statistical assessment for abuse deterrent formulation in clinical abuse potential studies
   L. Chen, Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD

154 FDA abuse-deterrent guidance. Assessing new technologies
   S. N. Calderon, J. M. Tolliver, M. Klein, Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD

155 Assessing stigma towards drug users among health care providers
   C. E. Albizu, J. N. Caraballo, G. Caraballo-Correa, S. Santiago, A. Mendez, S. Rivera-Suazo, University of Puerto Rico, San Juan

156 Stigmatizing experiences while in drug abuse treatment: A qualitative exploration of client’s perceptions
   S. Rivera-Suazo, C. E. Albizu, S. Santiago, C. Perez, University of Puerto Rico, San Juan
Symposium XIV

MEDICATIONS FOR DRUG ADDICTIONS: SEX DIFFERENCES IN OUTCOMES IN ANIMAL AND HUMAN LABORATORY STUDIES AND IN CLINICAL TRIALS

Chairs: Cora Lee Wetherington and Ivan Montoya

10:00  Differential antidepressant-like effects and potentiation of nicotinic-based antidepressants by guanfacine in males and females mice
Yann Mineur, Yale University School of Medicine, New Haven, CT

10:25  Targeting the noradrenergic system for gender-sensitive treatment development for substance dependence
Sherry McKee, Yale University School of Medicine, New Haven, CT

10:50  Progesterone to treat cocaine addiction: Results from animal and human studies
Marilyn E. Carroll, University of Minnesota, Minneapolis, MN

11:15  Oxytocin in cocaine and marijuana dependence
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC

11:40  DISCUSSANT: Ivan Montoya, National Institute on Drug Abuse, Bethesda, MD

Symposium XV

DEMYSTIFYING MEDICINAL CHEMISTRY AND DRUG DESIGN

Chairs: Andrew Coop and Thomas E. Prisinzano

10:00  Fundamental principles of drug design
Andrew Coop, University of Maryland School of Pharmacy, Baltimore, MD

10:30  Computer-aided drug design in the 21st century
Christopher W. Cunningham, Concordia University of Wisconsin School of Pharmacy, Mequon, WI

11:00  Drug discovery from the ocean
Kevin Tidgewell, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA

11:30  DISCUSSANT: The future of drug design and medicinal chemistry
Thomas E. Prisinzano, University of Kansas School of Pharmacy, Lawrence, KS

Oral Communications 17

RESEARCH AT A FEVERED PITCH: LATEST FINDINGS ON DRUGS AND NEUROINFLAMMATION

Chairs: Rae R. Matsumoto and Steven B. Harrod

10:00  Cytokines during acute abstinence of crack cocaine: The role of early life stress
R. Grassi-Oliveira¹, M. L. Levandowski¹, T. W. Viola¹, L. E. Wearick¹, J. Pezzi², M. E. Bauer¹, A. L. Teixeira¹, E. Bietzke¹, ¹Centre of Studies and Research in Traumatic Stress, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil, ²Pós Graduação em Ciências da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil
Thursday, June 19, 2014

10:15 Alteration of circulatory cytokine levels in alcohol-use disorder patients with or without comorbid major depression  
S. P. Neupane1, L. Lien1-2, P. Martinez3, P. Aukrust4, T. Ueland4, T. E. Mollnes4, K. Hestad2,6, J. G. Bramness7, 1Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, 2Innlandet Hospital Trust, Hamar, Norway, 3University of California, Berkeley, CA, 4Oslo University Hospital, Oslo, Norway, 5Oslo University Hospital, Oslo, Norway, 6The Norwegian University of Science and Technology, Trondheim, Norway, 7Norwegian Institute of Public Health, Oslo, Norway

10:30 The association between IL-6 and neurocognitive performance as a function of self-reported lifetime marijuana use  
L. Keen, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL

10:45 Interleukin-1β in the dorsal hippocampus and the conditioned immune effects of heroin  
C. Lebonville1, J. Szczytkowski-Thomson2, D. Lysle1, L. Hutson1, R. Fuchs3, 1Psychology, UNC-Chapel Hill, Chapel Hill, NC, 2Psychology, Messiah College, Grantham, PA

11:00 Binge-like ethanol consumption in C57BL/6J mice promotes site-specific increases of interleukin-1β expression in the area of the amygdala  
J. Casachahua, D. Lysle, T. Thiele, Psychology, UNC-CH, Chapel Hill, NC

11:15 HIV-1 transgenic rats exhibit attenuated motivation and escalation of cocaine self-administration  
S. B. Harrod, C. F. Mactutus, S. J. Bertrand, A. J. Morgan, R. M. Booze, Psychology, University of South Carolina, Columbia, SC

11:30 HIV-1 transgenic rat: Altered motivated behavior for natural reward  
S. J. Bertrand, C. F. Mactutus, S. B. Harrod, A. J. Morgan, R. M. Booze, Psychology, University of South Carolina, Columbia, SC

11:45 Attenuation of methamphetamine-induced striatal neurotoxicity involves both neuronal and glial mechanisms  
R. Matsumoto1, M. Robson1, R. Turner2, Z. Naser1, N. Kaushal1, C. McCurdy3, J. Huber1, J. O’Callaghan1, 1Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, 2Neurosurgery, West Virginia University, Morgantown, WV, 3Medicinal Chemistry, University of Mississippi, University, MS, 4Health Effects Laboratory Division, CDC/NIOSH, Morgantown, WV

Oral Communications 18

SAN CRISTOBAL
10:00 - 12:00 PM

NICOTINE

Chairs: Erin A. McClure and Diana Dow-Edwards

10:00 A trans-generational ripple: How a puff during early development led to a global huff in microRNA profiles as well as grand-offspring addictive behavior in Caenorhabditis elegans  
F. A. Taki, X. Pan, B. Zhang, Biology, East Carolina University, Greenville, NC

10:15 Nicotine alters behavior in pre-adolescent rats  
D. Dow-Edwards, A. Edwards, N. Konz, Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY
Increased weight gain and sucrose intake during extinction of nicotine self-administration in adult male rats
P. Grebenstein1,2, D. Burroughs1, C. Hernandez1, M. G. LeSage1,2, 1Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, 2Medicine, University of Minnesota, Minneapolis, MN

Contributions of glial glutamate transport and NMDA receptors in nicotine relapse
C. D. Gipson, N. Stankeviciute, Y. Kupchik, M. Scofield, P. W. Kalivas, Neurosciences, Medical University of South Carolina, Charleston, SC

Environmental enrichment decreases nicotine self-administration and attenuates nicotine-mediated enhancement of orexin-1 receptor gene expression and ERK1/2 activity in rat prefrontal cortex
A. M. Gomez1, D. Altomare1, S. B. Harrod2, K. E. Creek1, J. Zhu1, 1Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, 2Psychology, University of South Carolina, Columbia, SC

An open-label pilot trial of N-acetylcysteine and varenicline in cigarette smokers
E. A. McClure1, C. Gipson1, B. Froeliger1,2, P. Kalivas2, K. Gray1, 1Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 2Department of Neurosciences, Medical University of South Carolina, Charleston, SC

Effects of omega-3 fatty acids on tobacco craving: A double-blind, randomized, placebo-controlled pilot study
S. Rabinovitz, School of Criminology, University of Haifa, Haifa, Israel

Role of projections from ventral subiculum to nucleus accumbens shell in context-induced reinstatement of heroin seeking
J. M. Bossert, R. M. St. Laurent, N. J. Marchant, H. Wang, M. Morales, Y. Shaham, IRP/NIDA/NIH/ DHHS, Baltimore, MD

Reduction of adult hippocampal neurogenesis via cranial irradiation enhances morphine self-administration and morphine-induced locomotor sensitization
S. E. Bulin, D. R. Richardson, K. H. Song, T. D. Solberg, A. J. Eisch, University of Texas Southwestern Medical Center, Dallas, TX
Thursday, June 19, 2014

2:00  *Self-administration of oxycodone by adolescent and adult mice differentially affects hypothalamic mitochondrial metabolism gene expression*
M. Deutsch-Feldman¹, Y. Zhang¹, M. Buonora¹, A. Brownstein¹, K. Niikura¹, A. Ho¹, J. Ott²,³, M. Kreek¹, ¹The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²The Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, ³Institute of Psychology, Chinese Academy of Sciences, Beijing, China

2:15  *Self-administration of oxycodone alone or as a mixture with the kappa agonist, salvinorin A, by monkeys under a progressive-ratio schedule of reinforcement*
J. Naylor¹, T. Prisinzano³, K. Freeman¹, ¹Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, ³Medicinal Chemistry, The University of Kansas, Lawrence, KS

2:30  *Naltrexone inhibits the subjective effects of salvinorin-A in humans*
M. Valle¹, A. Maqueda²,³, J. Bouso¹, M. Puntes¹, M. Ballester¹, M. Garrido¹, M. González¹, J. Claramunt¹, D. Martínez¹, M. Martínez¹, G. Seguí¹, J. Coimbra¹, J. Pérez de los Cobos³, R. Antonijojan¹, J. Riba²,³, IIB Sant Pau, Barcelona, Spain, ²Human Neuropsychopharmacology Group, Barcelona, Spain, ³ICEERS, Barcelona, Spain, ⁴Hospital de Sant Pau, Barcelona, Spain

2:45  *Abuse potential study of intravenous oxycodone hydrochloride alone or in combination with intravenous naltrexone in nondependent, recreational opioid users*
B. Setnik¹, A. Bass¹, K. W. Somerville¹,², K. Matschke³, L. R. Webster¹, ¹Pfizer Inc, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Pfizer Inc, Collegeville, PA, ⁴CRI Lifetree, Salt Lake City, UT

3:00  *The misuse, abuse and diversion of opioid replacement therapies among street abusers*
S. P. Novak¹, L. Wenger², J. Lorvick², A. Kraľ², ¹RTI International, Research Triangle Park, NC, ²RTI International, Research Triangle Park, NC, ³RTI International, San Francisco, CA

3:15  *The association between benzodiazepine prescription and aberrant drug behaviors in primary care patients receiving chronic opioid therapy*
T. Park¹,², K. Nelson², Z. Xuan², K. E. Lasser², J. M. Liebschutz², R. Saitz², ¹VA Boston Healthcare System, Boston, MA, ²Boston University, Boston, MA

**Oral Communication 20**  
**BALLROOM B**  
**FOCUSBING ATTENTION ON ADHD AND ADDICTION**

Chairs: Frances R. Levin and Sonam O. Lasopa

1:30  *Adolescent atomoxetine, but not methylphenidate, decreases cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder*
C. J. Jordan¹, R. C. Harvey¹, B. M. Baskin¹, K. Rodriguez¹, A. Dellamorte¹, L. P. Dwoskin², K. M. Kantak¹, ¹Psychology, Boston University, Boston, MA, ²Pharmaceutical Sciences, University of Kentucky, Lexington, KY

1:45  *Decreased norepinephrine transporter function in the orbitofrontal cortex and enhanced cocaine abuse risk following adolescent methylphenidate treatment in a rat model of attention deficit hyperactivity disorder*
S. S. Somkuwar¹, K. Kantak², L. P. Dwoskin¹, ¹Pharmaceutical Sciences, University of Kentucky, Lexington, KY, ²Psychology, Boston University, Boston, MA
Thursday, June 19, 2014

2:00 Orbitofrontal connectivity in marijuana smoking youths with and without attention-deficit/hyperactivity disorder
M. P. Lopez-Larson1,2, J. Rogowska1, J. B. King1, D. Yurgelun-Todd1,2,3, 1The Brain Institute, University of Utah, Salt Lake City, UT, 2School of Medicine, University of Utah, Salt Lake City, UT, 3VISN 19, MIRREC, Salt Lake City, UT

2:15 ADHD as risk factor for early onset and later severity of illicit substance use: An accelerated gateway model

2:30 Mixed amphetamine salts-extended release for ADHD adults with cocaine use disorder
F. R. Levin1,3, J. J. Marianni1,3, A. Mahony3, D. J. Brooks3, L. Eberly2, Y. Bai2, S. Specker2, M. Mooney2, E. V. Nunes1,3, J. Grabowski2, 1Psychiatry, Columbia University, New York, NY, 2University of Minnesota, Minneapolis, MN, 3Substance Abuse, NYSPI, New York, NY

2:45 Gender differences in risk factors for nonmedical use of prescription stimulants among youth 10 to 18 years in the U.S
S. O. Lasopa, L. Cottler, K. Vaddiriparti, C. W. Striley, University of Florida, Gainesville, FL

3:00 Substance use patterns associated with adult ADHD in SUD treatment-seeking patients: Results from the Aquitaine Addiction Cohort Study
M. Fatseas1,2, H. Hurmic1,2, R. Debrabant1,2, F. Serre1,2, M. Auriacombe1,2, 1Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, 2Addiction Treatment Center, CH Ch. Perrens et CHU Bordeaux, Bordeaux, France

3:15 Osmotic-release methylphenidate randomized controlled trial for adolescents with attention-deficit/hyperactivity disorders and substance use disorders: A missing data sensitivity analysis
S. McPherson, M. Mamey, C. Barbosa-Leiker, S. M. Murphy, J. Roll, Washington State University, Spokane, WA

Oral Communications 21

BALLROOM C
1:30 - 3:30 PM

YOU’RE NOT THE BOSS OF ME: ADOLESCENT SUBSTANCE ABUSE

Chairs: Carol J. Boyd and Lora M. Cope

1:30 Disordered eating and substance use: Findings from a national sample of adolescents
K. Lange, S. Fields, Psychology, Texas A&M University, College Station, TX

1:45 A prospective study of youth’s nonmedical use of opioids, anxiolytics and sedatives
C. J. Boyd1,2, E. A. Meier1,2, P. T. Veliz2, Q. Epstein-Ngo2, S. E. McCabe2, 1School of Nursing, University of Michigan, Ann Arbor, MI, 2Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI

2:00 Impulsivity and early onset of alcohol and cigarette use in adolescents

2:15 Greater exposure to stressors during preadolescence predicts early adolescent substance use
N. E. Charles, A. Acheson, C. W. Mathias, D. Dougherty, The University of Texas Health Science Center at San Antonio, San Antonio, TX
Thursday, June 19, 2014

2:30  Childhood maltreatment and adolescent binge drinking: New findings on a longitudinal relationship  
S. Shin, School of Social Work, Virginia Commonwealth University, Richmond, VA

2:45  Differential incentive processing in youth before and after substance use initiation  
L. M. Cope, M. D. Tobias, J. E. Hardee, M. E. Soules, D. B. Steinberg, R. A. Zucker,  
M. M. Heitzeg, University of Michigan, Ann Arbor, MI

3:00  Effects of environmental enrichment on amphetamine self-administration under a fixed-ratio and progressive-ratio schedule following nicotine exposure  
D. J. Stairs, S. Ewin, M. Kangiser, C. Salvatore, M. Pfaff, PS, Creighton University,  
Omaha, NE

3:15  Age effects in methylphenidate-induced taste avoidance and BDNF/TrkB activity in the insular cortex  
B. B. Wetzell¹, M. M. Muller¹, J. L. Cobuzzi¹, Z. E. Hurwitz¹, K. DeCicco-Skinner²,  
A. L. Riley¹, ¹Psychopharmacology Lab, American University, Washington, DC, ²Department of Biology, American University, Washington, DC

SWEEPSTAKES DRAWING

BALLROOM B
3:35 - 3:55 PM

YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING AT 1:30 PM IN ORDER TO HAVE YOUR BADGE COLLECTED

HAVE A SAFE TRIP HOME!

SEE YOU IN PHOENIX, ARIZONA, JUNE 13-18, 2015
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aarde, S. M.</td>
<td>59, 107</td>
</tr>
<tr>
<td>Abagiu, A. O.</td>
<td>85</td>
</tr>
<tr>
<td>Aballea, S.</td>
<td>80</td>
</tr>
<tr>
<td>Abbott, T. B.</td>
<td>58</td>
</tr>
<tr>
<td>Accornero, V. H.</td>
<td>82</td>
</tr>
<tr>
<td>Acevedo, A.</td>
<td>86</td>
</tr>
<tr>
<td>Acheampong, A.</td>
<td>95, 102</td>
</tr>
<tr>
<td>Acheson, A.</td>
<td>15, 118</td>
</tr>
<tr>
<td>Acoose, S.</td>
<td>87</td>
</tr>
<tr>
<td>Acri, Jane B.</td>
<td>7</td>
</tr>
<tr>
<td>Adams, R.</td>
<td>77</td>
</tr>
<tr>
<td>Adelson, M.</td>
<td>20, 98</td>
</tr>
<tr>
<td>Adeniyi-Jones, S.</td>
<td>81</td>
</tr>
<tr>
<td>Ades, P.</td>
<td>104</td>
</tr>
<tr>
<td>Adimora, A.</td>
<td>100</td>
</tr>
<tr>
<td>Agrawal, Arpana</td>
<td>2, 64</td>
</tr>
<tr>
<td>Aguiar, B.</td>
<td>72</td>
</tr>
<tr>
<td>Aharonovich, E.</td>
<td>22, 23, 99, 109</td>
</tr>
<tr>
<td>Ahluwalia, J.</td>
<td>25</td>
</tr>
<tr>
<td>Ahmed, M. S.</td>
<td>82</td>
</tr>
<tr>
<td>Ahuama-Jonas, C.</td>
<td>88</td>
</tr>
<tr>
<td>Aiello, A. E.</td>
<td>99</td>
</tr>
<tr>
<td>Aikawa, D.</td>
<td>58</td>
</tr>
<tr>
<td>al' Absi, M.</td>
<td>102</td>
</tr>
<tr>
<td>Alanis-Hirsch, K.</td>
<td>64, 87</td>
</tr>
<tr>
<td>Alary, M.</td>
<td>64</td>
</tr>
<tr>
<td>Albizu-Garcia, C.</td>
<td>80, 100, 113</td>
</tr>
<tr>
<td>Albizu, C. E.</td>
<td>24, 101, 113</td>
</tr>
<tr>
<td>Alcorn, J. L.</td>
<td>18</td>
</tr>
<tr>
<td>Alegria, Margarita</td>
<td>8</td>
</tr>
<tr>
<td>Aleixandre-Benavent, R.</td>
<td>105</td>
</tr>
<tr>
<td>Alexandercikova, Z.</td>
<td>85</td>
</tr>
<tr>
<td>Alexandre, J.</td>
<td>110</td>
</tr>
<tr>
<td>Alford, D.</td>
<td>6</td>
</tr>
<tr>
<td>Alharbi, F.</td>
<td>104</td>
</tr>
<tr>
<td>Ali, B.</td>
<td>66, 111</td>
</tr>
<tr>
<td>Alia-Klein, N.</td>
<td>97</td>
</tr>
<tr>
<td>Alicata, D.</td>
<td>25, 57</td>
</tr>
<tr>
<td>Alicea, A.</td>
<td>100</td>
</tr>
<tr>
<td>Alix, M.</td>
<td>109</td>
</tr>
<tr>
<td>Allen, A. M.</td>
<td>25, 102</td>
</tr>
<tr>
<td>Allen, S.</td>
<td>102</td>
</tr>
<tr>
<td>Allsop, D. J.</td>
<td>15, 95</td>
</tr>
<tr>
<td>Almli, L.</td>
<td>99</td>
</tr>
<tr>
<td>Alonso-Pérez, F.</td>
<td>14</td>
</tr>
<tr>
<td>Alonso, E.</td>
<td>86</td>
</tr>
<tr>
<td>Alshaarawy, O.</td>
<td>95</td>
</tr>
<tr>
<td>Altice, E. L.</td>
<td>87, 100</td>
</tr>
<tr>
<td>Altman, L.</td>
<td>85</td>
</tr>
<tr>
<td>Altomare, D.</td>
<td>116</td>
</tr>
<tr>
<td>Altschuler, J.</td>
<td>9</td>
</tr>
<tr>
<td>Altubi, M.</td>
<td>57</td>
</tr>
<tr>
<td>Alvanzo, A.</td>
<td>66</td>
</tr>
<tr>
<td>Alvarez Amador, A.</td>
<td>100</td>
</tr>
<tr>
<td>Amaro, H.</td>
<td>101</td>
</tr>
<tr>
<td>Amstader, A.</td>
<td>111</td>
</tr>
<tr>
<td>Anastasio, N. C.</td>
<td>17, 28, 58</td>
</tr>
<tr>
<td>Andersen, R.</td>
<td>65, 85, 87</td>
</tr>
<tr>
<td>Anderson, A.</td>
<td>61</td>
</tr>
<tr>
<td>Anderson, K. G.</td>
<td>82</td>
</tr>
<tr>
<td>Anderson, S.</td>
<td>64</td>
</tr>
<tr>
<td>Andoh, E.</td>
<td>68</td>
</tr>
<tr>
<td>Andrade, A.</td>
<td>10</td>
</tr>
<tr>
<td>Andreoni, S.</td>
<td>56</td>
</tr>
<tr>
<td>Andrich, L.</td>
<td>79</td>
</tr>
<tr>
<td>Ang, A.</td>
<td>111</td>
</tr>
<tr>
<td>Angarita, G. A.</td>
<td>109</td>
</tr>
<tr>
<td>Angulo, E.</td>
<td>81</td>
</tr>
<tr>
<td>Anteneh, B.</td>
<td>67</td>
</tr>
<tr>
<td>Anthenelli, R. M.</td>
<td>27, 61</td>
</tr>
<tr>
<td>Anthony, James C.</td>
<td>1, 8, 11, 68, 78, 82, 91, 95, 102, 112, 113</td>
</tr>
<tr>
<td>Antonijoan, R.</td>
<td>117</td>
</tr>
<tr>
<td>Apawu, A.</td>
<td>16</td>
</tr>
<tr>
<td>Appel, L.</td>
<td>85, 103</td>
</tr>
<tr>
<td>Appel, Nathan</td>
<td>7</td>
</tr>
<tr>
<td>Arasteh, K.</td>
<td>4, 88</td>
</tr>
<tr>
<td>Arcuni, P.</td>
<td>62</td>
</tr>
<tr>
<td>Arfken, C. L.</td>
<td>73, 88, 110</td>
</tr>
<tr>
<td>Arheart, K. L.</td>
<td>95</td>
</tr>
<tr>
<td>Armstrong, A.</td>
<td>111</td>
</tr>
<tr>
<td>Arons, Cynthia</td>
<td>76, 77</td>
</tr>
<tr>
<td>Aronson, I. D.</td>
<td>22</td>
</tr>
<tr>
<td>Arora, R.</td>
<td>4</td>
</tr>
<tr>
<td>Arria, A. M.</td>
<td>16</td>
</tr>
<tr>
<td>Arroyo, M.</td>
<td>87</td>
</tr>
<tr>
<td>Ashrafion, L.</td>
<td>15, 69</td>
</tr>
<tr>
<td>Aston, E.</td>
<td>15</td>
</tr>
<tr>
<td>Atkinson, D.</td>
<td>109</td>
</tr>
<tr>
<td>Atlan, H.</td>
<td>60</td>
</tr>
<tr>
<td>Augutis, M.</td>
<td>21</td>
</tr>
<tr>
<td>Aukrust, P.</td>
<td>115</td>
</tr>
<tr>
<td>Auriacombe, Marc</td>
<td>3, 5, 21, 109, 110, 118</td>
</tr>
<tr>
<td>Avilés, J.</td>
<td>80</td>
</tr>
<tr>
<td>Azbel, L.</td>
<td>100</td>
</tr>
<tr>
<td>Babaloniis, S.</td>
<td>13, 17</td>
</tr>
<tr>
<td>Babuscio, T.</td>
<td>28, 110</td>
</tr>
<tr>
<td>Bachtel, R. K.</td>
<td>28</td>
</tr>
<tr>
<td>Back, Sudie E.</td>
<td>2, 67, 69, 102, 103</td>
</tr>
<tr>
<td>Badger, G. J.</td>
<td>72</td>
</tr>
<tr>
<td>Bagley, S.</td>
<td>20</td>
</tr>
<tr>
<td>Bai, Y.</td>
<td>118</td>
</tr>
<tr>
<td>Baker, A. L.</td>
<td>67</td>
</tr>
<tr>
<td>Bakhsheh, J.</td>
<td>67</td>
</tr>
<tr>
<td>Balaji, D.</td>
<td>89</td>
</tr>
<tr>
<td>Balan, S.</td>
<td>69, 102, 112</td>
</tr>
<tr>
<td>Balianas, D.</td>
<td>68</td>
</tr>
<tr>
<td>Bal, W. J.</td>
<td>106</td>
</tr>
<tr>
<td>Ballard, M. E.</td>
<td>10</td>
</tr>
<tr>
<td>Ballester, M.</td>
<td>117</td>
</tr>
<tr>
<td>Balster, Robert</td>
<td>26, 93</td>
</tr>
<tr>
<td>Balter, R.</td>
<td>95</td>
</tr>
<tr>
<td>Bandiera, F.</td>
<td>67</td>
</tr>
<tr>
<td>Bandstra, E. S.</td>
<td>82</td>
</tr>
<tr>
<td>Banducci, A. N.</td>
<td>62, 94</td>
</tr>
<tr>
<td>Bandopadhyay, S.</td>
<td>23</td>
</tr>
<tr>
<td>Bania, T.</td>
<td>22</td>
</tr>
<tr>
<td>Banich, M. T.</td>
<td>11, 60, 110</td>
</tr>
<tr>
<td>Barber, J.</td>
<td>94</td>
</tr>
<tr>
<td>Barbosa-Leiker, C.</td>
<td>118</td>
</tr>
<tr>
<td>Bardo, M. T.</td>
<td>4, 59, 106</td>
</tr>
<tr>
<td>Bares, C. B.</td>
<td>83</td>
</tr>
<tr>
<td>Bargerc, J.</td>
<td>27</td>
</tr>
<tr>
<td>Baroni, R.</td>
<td>87</td>
</tr>
<tr>
<td>Barrett, Emma L.</td>
<td>94</td>
</tr>
<tr>
<td>Barrett, F. S.</td>
<td>16</td>
</tr>
<tr>
<td>Barry, C.</td>
<td>77</td>
</tr>
<tr>
<td>Barry, D. T.</td>
<td>6, 19, 70</td>
</tr>
<tr>
<td>Barry, L.</td>
<td>103</td>
</tr>
<tr>
<td>Bart, G.</td>
<td>66</td>
</tr>
<tr>
<td>Baskin, B. M.</td>
<td>117</td>
</tr>
<tr>
<td>Bass, A.</td>
<td>117</td>
</tr>
<tr>
<td>Bass, J.</td>
<td>84</td>
</tr>
<tr>
<td>Basseches, P.</td>
<td>89</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Bastle, R. M. 58
Bastos, F. I. 86
Batchelder, A. 56
Bates, S. 69
Bauer, M. E. 114
Baumann, Michael H. 16, 17, 73
Bearman, P. 78
Beatty, L. 68, 104
Bechara, A. 56
Benedikt, K. 97
Belgrave, F. Z. 68, 104
Beltran, V. 3, 21
Bedi, G. 93
Bennett, A. S. 94
Bennett, D. 27
Bennett, L. 13
Bennett, R. S. 4
Benz, M. 78
Berge, J. 24
Bergaria, C. L. 21, 72
Bergman, J. 17
Berlenga, C. 86
Berman, J. 65
Bernstein, J. A. 63
Bertelsen, S. 99
Bertholomey, M. L. 58
Bertoni, N. 86
Bertrand, S. J. 18, 115
Betz, J. W. 57
Beveridge, T. J. 106
Bevins, R. 108
Beylotte, F. 105
Bickel, W. K. 25, 65, 93, 97, 108, 109
Bickel, Warren K. 26
Billick, Jean M. 1
Bierut, L. 14, 99
Bisaga, A. 13, 79, 116
Bissoli Jr, F. 105
Biswal, B. 60
Bixel, K. D. 65
Black, A. C. 77
Black, R. 57
Black, T. 97
Blanchette, C. 64
Blanken, P. 19
Blevins, E. 102
Blitchtein, D. 112
Blokhina, E. 66, 79, 89, 98
Bloom, J. 99
Blough, B. E. 17, 106
Blounin, K. 64
Blow, F. C. 5, 12, 70
Blum, D. 105
Bluthenthal, R. 64, 92
Boardman, J. D. 56
Bobashev, G. 90
Bogdanova, V. 85
Bogenschutz, M. 85
Bohannon, R. 103
Bohn, Laura 24
Bohnert, A. S. 79
Bohnert, K. 12
Boileau, I. 73
Bojorquez, G. 87, 113
Bolano-Pizarro, M. 105
Bol, K. 85
Bolin, B. L. 19
Bolman, C. 13
Bolton, P. 84
Bolyard, M. 88
Bonar, Erin E. 5, 12, 70
Bond, J. 107
Bonsu, J. A. 62
Booker, J. 65
Booth, B. M. 12
Booth, R. E. 108
Booth, R. G. 17
Booze, R. M. 18, 115
Borckardt, J. 61
Bosser, J. M. 58, 116
Bouju, G. 110
Bouklji, N. 21
Bounoua, N. 11, 66, 111
Bouso, J. 117
Bowen, S. 16
Bowers, D. D. 84
Bowman, S. 68, 70
Boyd, Carol J. 70, 118
Boyd, D. 87
Boyd, J. W. 104
Boyle, R. S. 63
Bråbäck, M. 80
Bradford, J. 111
Bradley, B. 99
Bradshaw, C. 12
Bradstreet, M. P. 16
Brady, Kathleen T. 60, 61, 69, 86, 102, 103, 114
Braithwaite, S. 3
Bramness, J. G. 24, 115
Brand, M. 56
Brands, B. 24
Brandt, L. 72
Branstetter, S. A. 104
Brasfield, H. 91
Brason, F. W. 20
Brents, L. K. 18
Breslau, N. 112
Brewer, A. 28
Brewerton, Timothy 30
Bridden, C. 89
Brietzke, E. 114
Brook, J. 66
Brooks, A. C. 65, 87
Brooks, D. J. 116, 118
Broonner, R. K. 66, 111
Brophy, M. K. 17
Brown, A. 60
Brown, B. 97
Brown, G. 68
Brown, L. S. 80
Brown, Q. L. 91
Brown, R. W. 12
Brown, S. 87, 100
Brown, Sandra A. 30
Brown, V. 11
Brown, V. L. 61
AUTHOR INDEX

Brownstein, A. 117
Bruce, R. 89
Bruchas, Michael 23
Bruno, R. 105
Bruzell, D. H. 62
Bryant-Genevier, M. 103
Bryant, K. 89
Bryon, D. 28
Bucher Bartelson, B. 90
Buckley, N. W. 107
Buckner-Petty, S. 14
Budde, J. 99
Budman, S. H. 68, 90
Budney, Alan J. 2, 12, 95
Budsock, T. D. 14
Bueno Cañigral, F. 105
Bugbee, B. A. 16
Buirkle, E. 80
Bukhari, O. 73
Bulin, S. E. 116
Buonora, M. 117
Burkhardt, J. 77
Burlew, K. 86, 88
Burnett, J. 65
Burns, L. 24, 25, 92, 94, 105, 111
Burns, R. M. 78
Burroughs, D. 116
Burton, M. 110
Busatto, G. 10
Busch, S. 77
Busse, A. 69
Butelman, E. 9, 19
Butler, S. F. 68, 90
Butler, T. 25
Butterfield, K. 89
Buttram, M. E. 80
Byrne, E. 65
Cacciola, J. 65, 69
Caetano, S. 10
Caldeira, K. M. 16
Calderon, S. N. 113
Calzada-Reyes, A. 100
Camenga, D. R. 20, 83
Cameron, D. 92
Campbell, A. 103
Campbell, C. 20
Campbell, G. 105
Campbell, K. 86
Campollo, O. 81
Canal, C. E. 17
Canham, S. L. 63
Canterberry, M. 25, 60, 61
Caprioli, D. 58
Caraballo-Corrales, G. 101, 113
Caraballo, J. N. 113
Carbonaro, T. M. 16, 17
Carelli, R. M. 107
Carise, D. 87
Carlo, G. 11, 108
Carlson, Robert 6, 92
Carmody, T. 108
Carpenedo, C. M. 65, 87
Carpenter, K. 79
Carragher, N. 94
Carrico, Adam W. 27, 75
Carroll, Ivy 23, 24
Carroll, K. M. 28, 94, 98, 99, 108
Carroll, Marilyn E. 59, 74, 106, 114
Carter, P. 12
Casacabana, J. 115
Cashman, J. R. 17
Cassen, M. 66
Cassey, H. 81
Cassidy, J. 11
Cassidy, R. 12, 15
Cassidy, T. A. 90
Castellon, P. 23
Castro, F. 113
Cates, H. 58
Cathers, L. A. 111
Cavallo, M. 10
Cavalcado, D. A. 83
Cavanaugh, C. 90
Cavazos-Rehg, P. 14
Cepeda, J. A. 24, 91, 100
Cercone, S. A. 66
Cerdá, M. 21
Cereser, K. M. 72
Cerulli, C. 23
Cerullo, K. J. 27
Cha, H. 15
Chain, T. 10
Chaisson, C. E. 3
Chakaraborty, B. 89, 105
Chakravarty, M. 73
Chalk, M. 64, 87
Chamberlain, P. 97
Chan, C. 21
Chandler, R. K. 68
Chang, L. 22, 25, 57, 72, 82
Chang, O. 89
Chapelle, M. 111
Chaplin, T. M. 97
Chapman, C. 94
Charles, N. E. 118
Charnigo, R. J. 10, 11, 57, 62, 95
Chartier, K. G. 108
Chartoff, E. 25
Chawarski, M. C. 66, 69
Chen, C. 21
Chen, K. 3
Chen, L. 70, 113
Chen, S. Z. 63
Chen, W. 56
Cheng, D. M. 6, 20, 63, 89
Cheng, H. 105
Cheong, J. 96
Chereau-Boudet, I. 110
Chermack, S. T. 5
Cheverie, M. 24
Chhatre, S. 92
Chi, T. 3
Chiang, Y. 3
Chilcoat, Howard 7, 20, 90
Childress, Anna Rose 1, 25, 60, 61, 72, 74, 93, 94, 97
Chisin, R. 60
Chisolm, M. S. 103
Choo, E. 78, 103
Chow, J. J. 106
Christmann, A. 87
Chu, D. 64, 92
Chudzynski, J. 60
Chundamala, J. 78
Chung, L. 58
AUTHOR INDEX

Chung, T. 96
Cicero, T. 70, 90
Claramunt, J. 117
Clark, A. K. 20, 104
Clark, T. 66
Clark, Westley 30
Clatts, M. 88
Clavier, O. 81, 109
Clay, E. 80
Cleland, C. 77
Clements, N. 101
Cloak, C. 72, 82
Coatsworth, A. 91, 100
Cobuzzi, J. L. 119
Cochran, G. 80
Cochran, S. 14
Coffey, S. F. 62
Coffin, P. O. 22, 89
Cohen, A. E. 13
Cohen, M. 105
Coimbra, J. 117
Colangelo, C. M. 58
Colby, S. M. 12
Coleman-Cowger, V. H. 82
Coleman, S. 89
Collado-Rodriguez, A. 84
Collado, A. 11
Coller, J. K. 81
Coller, M. 107
Colley, G. 22
Collins, D. T. 18
Collot D’Escury-Koenigs, A. 83
Colpo, G. 72
Colucci, S. 17
Coman, E. 90
Comer, Sandra D. 2, 21, 29, 30, 89
Comfort, M. L. 101
Comiskey, Catherine 71
Compton, Wilson 5
Connell, C. 83
Connery, H. 79, 84
Connor, J. P. 63
Cook, J. M. 105
Cook, S. 85
Cooke, C. G. 66
Coop, Andrew 2, 96, 114
Cooper, C. 60
Cooper, H. L. 4, 88
Cooper, K. 108
Cooper, L. 11
Cooper, Z. D. 73
Cope, Lora M. 118, 119
Copeland, Jan 8, 15, 95
Copenhaver, M. 69, 89
Coplan, P. 20, 90
Corazza, O. 73
Cornelius, M. 72, 82
Cortney, E. M. 58
Cornwell, W. 58
Corsi, K. F. 108
Coryn, C. 77
Cottler, Linda 9, 71, 90, 91, 102, 118
Cottor, E. J. 106
Cousijn, J. 83
Cousins, S. J. 27
Covault, J. 103
Covey, L. S. 13
Craft, R. 57
Cranston, M. N. 18
Crawford, N. D. 92
Creehan, K. 59, 107
Creek, K. E. 116
Creemers, H. 14
Crevecoeur-MacPhail, D. A. 27
Croft, R. 64, 87
Crofton, E. 59
Crooks, P. A. 4
Cross, N. 15, 78, 104
Crowley, M. J. 97
Crowley, T. J. 11
Crum, R. 70
Cruz, H. 105
Cruz, J. I. 84
Crystal, S. 89
Csorba, J. K. 85
Culver, J. P. 4
Cummins, C. 22
Cunha, G. 72
Cunha, P. J. 10
Cunning, S. 56
Cunningham, Christopher W. 114
Cunningham, J. K. 81
Cunningham, K.
Cunningham, Kathryn A. 5, 17,
28, 58
Cunningham, R. M. 5, 12, 70
Curley, L. E.
Curtin, K. 10
Curtis, B. L. 69
Cutter, C. J. 6, 19, 70, 81
Czoty, P. W. 5, 57, 107
D’Aunno, T. 3, 21
D’Lima, G. M. 66
D’Onofrio, Gail 7
Dacone, L. 105
Dahlgren, M. 95
Dahne, J. R. 111
Dakwar, E. 79
Dawani, M. S. 11
Daly, C. 57
Daniulaityte, R. 92
Darke, S. 94, 111
Dart, R. C. 70, 80, 90
Dasgupta, N. 90
Dash, G. 82
Daubert, A. 81
Daughters, S. B. 102
Daulouède, J. 3, 21
Davenport, P. W. 93
Davies, F. 93
Davis, A. K. 15, 78
Davis, A. N. 11
Davis, J. 109
De Genna, N. 72
de Graaff, B. 105
De la Fuente-Martin, A. 86
De La Garza, II, R. 15, 19, 28, 93,
108
De La Rosa, M. 83
De La Torre, R. 73
de Medeiros, P. F. 84
De Vries, H. 13
Dean, A. C. 10, 60
DeAndrea, D. 91
Deaver, D. 18
Degen, D. 18
Debinski, B. 16
# AUTHOR INDEX

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debnam, K.</td>
<td>12</td>
</tr>
<tr>
<td>Debrabant, R.</td>
<td>109, 118</td>
</tr>
<tr>
<td>DeCicco-Skinner, K.</td>
<td>119</td>
</tr>
<tr>
<td>Decker, A. M.</td>
<td>16, 17</td>
</tr>
<tr>
<td>DeCuin, J.</td>
<td>92</td>
</tr>
<tr>
<td>DeFulio, A.</td>
<td>86</td>
</tr>
<tr>
<td>Degenhardt, L.</td>
<td>24, 25, 92, 105</td>
</tr>
<tr>
<td>DeGeorge, D.</td>
<td>102</td>
</tr>
<tr>
<td>dela Cruz, A. M.</td>
<td>108</td>
</tr>
<tr>
<td>Delcher, C.</td>
<td>71</td>
</tr>
<tr>
<td>Delforterie, M.</td>
<td>14</td>
</tr>
<tr>
<td>Delile, J.</td>
<td>66</td>
</tr>
<tr>
<td>Dell, C. A.</td>
<td>87</td>
</tr>
<tr>
<td>Dellamorte, A.</td>
<td>117</td>
</tr>
<tr>
<td>Deney, E. D.</td>
<td>4</td>
</tr>
<tr>
<td>Denis, C. M.</td>
<td>3, 21</td>
</tr>
<tr>
<td>Dennis, Michael L.</td>
<td>30, 65, 92</td>
</tr>
<tr>
<td>Dennis, P.</td>
<td>13</td>
</tr>
<tr>
<td>Derefnko, K. J.</td>
<td>11, 62</td>
</tr>
<tr>
<td>Deren, S.</td>
<td>96</td>
</tr>
<tr>
<td>Dermody, Sarah S.</td>
<td>96</td>
</tr>
<tr>
<td>Deruvo, G.</td>
<td>70</td>
</tr>
<tr>
<td>Des Jarlais, Don C.</td>
<td>3, 4, 88, 113</td>
</tr>
<tr>
<td>Des Jarlais, Don C.</td>
<td>3, 4, 88, 113</td>
</tr>
<tr>
<td>Desel, H.</td>
<td>70</td>
</tr>
<tr>
<td>Desrosiers, A.</td>
<td>66</td>
</tr>
<tr>
<td>Deutsch-Feldman, M.</td>
<td>117</td>
</tr>
<tr>
<td>Deutsch, A.</td>
<td>11</td>
</tr>
<tr>
<td>DeVeaugh-Geiss, A.</td>
<td>20, 90</td>
</tr>
<tr>
<td>DeVito, E. E.</td>
<td>94, 98, 99</td>
</tr>
<tr>
<td>Dewey, William L.</td>
<td>26</td>
</tr>
<tr>
<td>DeYoung, D.</td>
<td>10</td>
</tr>
<tr>
<td>Dias, N.</td>
<td>15, 18</td>
</tr>
<tr>
<td>Dick, A. W.</td>
<td>78</td>
</tr>
<tr>
<td>Dick, D.</td>
<td>9</td>
</tr>
<tr>
<td>Dickerson, D.</td>
<td>4</td>
</tr>
<tr>
<td>Diedrich, K.</td>
<td>73</td>
</tr>
<tr>
<td>Dietze, P.</td>
<td>105</td>
</tr>
<tr>
<td>Diggins, A.</td>
<td>88</td>
</tr>
<tr>
<td>DiGirolamo, G. J.</td>
<td>10, 80</td>
</tr>
<tr>
<td>DiGuiseppi, G.</td>
<td>65</td>
</tr>
<tr>
<td>Dillon, P.</td>
<td>9, 64, 66, 70</td>
</tr>
<tr>
<td>Ding, C.</td>
<td>17, 28</td>
</tr>
<tr>
<td>Dingemanse, J.</td>
<td>105</td>
</tr>
<tr>
<td>DiSandro, P.</td>
<td>68</td>
</tr>
<tr>
<td>Disney, E.</td>
<td>16</td>
</tr>
<tr>
<td>Ditre, J. W.</td>
<td>63</td>
</tr>
<tr>
<td>Diwadkar, V.</td>
<td>19</td>
</tr>
<tr>
<td>Dobbins, T.</td>
<td>24, 25</td>
</tr>
<tr>
<td>Dockery, G.</td>
<td>100</td>
</tr>
<tr>
<td>Dolezalova, P.</td>
<td>69, 85</td>
</tr>
<tr>
<td>Domany, Y.</td>
<td>20</td>
</tr>
<tr>
<td>Dombrowski, K.</td>
<td>3</td>
</tr>
<tr>
<td>Donohue, J. M.</td>
<td>80</td>
</tr>
<tr>
<td>Dore, G.</td>
<td>3</td>
</tr>
<tr>
<td>dos Santos, A. M.</td>
<td>91</td>
</tr>
<tr>
<td>Douet, V.</td>
<td>22</td>
</tr>
<tr>
<td>Dougherty, D. M.</td>
<td>15, 118</td>
</tr>
<tr>
<td>Doura, M.</td>
<td>58</td>
</tr>
<tr>
<td>Dow-Edwards, Diana</td>
<td>57, 115</td>
</tr>
<tr>
<td>Dowd, E.</td>
<td>94</td>
</tr>
<tr>
<td>Dreifuss, J. A.</td>
<td>85</td>
</tr>
<tr>
<td>Dreman, M.</td>
<td>95</td>
</tr>
<tr>
<td>Du, H.</td>
<td>58</td>
</tr>
<tr>
<td>Du, J.</td>
<td>81</td>
</tr>
<tr>
<td>Duan, L.</td>
<td>101</td>
</tr>
<tr>
<td>Duan, Y.</td>
<td>56, 103</td>
</tr>
<tr>
<td>Dubeau, C.</td>
<td>73</td>
</tr>
<tr>
<td>Ducat, E. A.</td>
<td>9</td>
</tr>
<tr>
<td>DuCette, J. P.</td>
<td>110</td>
</tr>
<tr>
<td>Dugosh, K. L.</td>
<td>19, 101, 102</td>
</tr>
<tr>
<td>Duke, A. N.</td>
<td>57</td>
</tr>
<tr>
<td>Duncan, A.</td>
<td>14</td>
</tr>
<tr>
<td>Duncan, L. R.</td>
<td>97</td>
</tr>
<tr>
<td>Dunlop, A.</td>
<td>95</td>
</tr>
<tr>
<td>Dunn, Kelly E.</td>
<td>8, 27</td>
</tr>
<tr>
<td>Dunn, T. J.</td>
<td>62</td>
</tr>
<tr>
<td>Dunne, E. M.</td>
<td>88, 118</td>
</tr>
<tr>
<td>Duque, L.</td>
<td>62</td>
</tr>
<tr>
<td>Dusek, K.</td>
<td>97</td>
</tr>
<tr>
<td>Dwoskin, Linda P. 1, 4, 117</td>
<td>117</td>
</tr>
<tr>
<td>Dyer, C. B.</td>
<td>65</td>
</tr>
<tr>
<td>Dyer, T. P.</td>
<td>88</td>
</tr>
<tr>
<td>Dykstra, L.</td>
<td>107</td>
</tr>
<tr>
<td>Eberly, L.</td>
<td>118</td>
</tr>
<tr>
<td>Ebrahimpoor, M.</td>
<td>10</td>
</tr>
<tr>
<td>Edelman, E. J.</td>
<td>22, 89</td>
</tr>
<tr>
<td>Edwards, A.</td>
<td>115</td>
</tr>
<tr>
<td>Edwards, M. S.</td>
<td>64</td>
</tr>
<tr>
<td>Edwards, R. R.</td>
<td>6</td>
</tr>
<tr>
<td>Egan, K. L.</td>
<td>16</td>
</tr>
<tr>
<td>Ehrlich, Elliot</td>
<td>4</td>
</tr>
<tr>
<td>Ehrlich, M.</td>
<td>81</td>
</tr>
<tr>
<td>Ehrlich, P.</td>
<td>70</td>
</tr>
<tr>
<td>Ehrman, R.</td>
<td>60, 93, 97</td>
</tr>
<tr>
<td>Eiden, R. D.</td>
<td>82</td>
</tr>
<tr>
<td>Eisch, A. J.</td>
<td>116</td>
</tr>
<tr>
<td>Eisenstein, Toby K.</td>
<td>71, 74</td>
</tr>
<tr>
<td>Eissenberg, Thomas</td>
<td>26</td>
</tr>
<tr>
<td>Ekhtiari, H.</td>
<td>10</td>
</tr>
<tr>
<td>El-guebaly, N.</td>
<td>104</td>
</tr>
<tr>
<td>Elfeddali, I.</td>
<td>13</td>
</tr>
<tr>
<td>Eliosa-Hernandez, A.</td>
<td>86</td>
</tr>
<tr>
<td>Eliassen, J. C.</td>
<td>61</td>
</tr>
<tr>
<td>Elliott, J. C.</td>
<td>23</td>
</tr>
<tr>
<td>Elman, I.</td>
<td>60</td>
</tr>
<tr>
<td>Elmquist, J.</td>
<td>91</td>
</tr>
<tr>
<td>Encarnacion, J.</td>
<td>57</td>
</tr>
<tr>
<td>Enman, N.</td>
<td>27</td>
</tr>
<tr>
<td>Epstein, Epstein-Ngo, Q.</td>
<td>12, 118</td>
</tr>
<tr>
<td>Epstein, A.</td>
<td>77</td>
</tr>
<tr>
<td>Epstein, David H.</td>
<td>19, 64, 65, 75, 81</td>
</tr>
<tr>
<td>Epstein, E. E.</td>
<td>14, 85</td>
</tr>
<tr>
<td>Erensen, J. G.</td>
<td>20</td>
</tr>
<tr>
<td>Erlyana, E.</td>
<td>22</td>
</tr>
<tr>
<td>Ernst, T.</td>
<td>25, 57, 82</td>
</tr>
<tr>
<td>Espada, J. P.</td>
<td>11, 84, 112</td>
</tr>
<tr>
<td>Evans, E.</td>
<td>20, 83, 85</td>
</tr>
<tr>
<td>Evatt, D.</td>
<td>5</td>
</tr>
<tr>
<td>Ewin, S.</td>
<td>119</td>
</tr>
<tr>
<td>Fairman, B. J.</td>
<td>68</td>
</tr>
<tr>
<td>Fakhouri, T.</td>
<td>97</td>
</tr>
<tr>
<td>Fakunle, D. O.</td>
<td>112</td>
</tr>
<tr>
<td>Faller, S.</td>
<td>109</td>
</tr>
<tr>
<td>Fan, X.</td>
<td>59</td>
</tr>
<tr>
<td>Farabean, D.</td>
<td>68</td>
</tr>
<tr>
<td>Farley, S. B.</td>
<td>113</td>
</tr>
<tr>
<td>Farmer, C.</td>
<td>78</td>
</tr>
<tr>
<td>Farmer, S. L.</td>
<td>61</td>
</tr>
<tr>
<td>Farre, M.</td>
<td>73, 94, 111</td>
</tr>
<tr>
<td>Farrell, M.</td>
<td>24, 25, 105</td>
</tr>
<tr>
<td>Fateh, M.</td>
<td>3, 21, 109, 110, 118</td>
</tr>
<tr>
<td>Faulkner, J.</td>
<td>105</td>
</tr>
<tr>
<td>Fausett, J.</td>
<td>62</td>
</tr>
<tr>
<td>Favor, K.</td>
<td>65</td>
</tr>
<tr>
<td>Feaster, D.</td>
<td>23, 86</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Febres, J. 91
Feeleymer, J. P. 4, 88
Feeney, G. 63
Feeney, K. 6
Felton, J. 11
Felton, J. W. 11, 62, 111
Feng, X. 86
Fenn, J. 21
Ferguson, D. 58
Fernandez Mondragon, J. C. 86
Fernández-Artamendi, S. 118
Fernández, Y. 23
Festinger, D. S. 19, 101, 102
Festinger, David S. 24
Fielder, A. L. 81
Fields, S. 12, 15, 56, 118
Fiellin, D. 6, 22, 70, 77, 79, 89, 97
Fiellin, L. E. 6, 97
Fillmore, M. T. 97
Finger, B. 82
Finnegan, Loretta P. 72
Fischberger, S. 72
Fischer, B. D. 105
Fischer, G. 21, 72
Fisher, P. 72
Fisher, W. 68, 101
Fitzmaurice, G. 84
Flax, S. M. 107
Fleckenstein, A. E. 10
Fleming, A. B. 17
Flores, D. V. 65
Fogel, J. 57, 95
Fogel, J. S. 10, 61
Fokina, V. M. 82
Fonseca, F. 73, 94, 111
Forcenhimes, A. A. 85
Ford, J. 64, 87
Forray, A. 72
Forster, M. J. 59, 73, 107
Foster, D. W. 63
Foulds, Jonathan 26
Fox, R. G. 17, 28, 58
France, C. P. 18
Franck, C. 25, 65, 97
Franke, A. 22
Frankforter, T. 99
Franklin, Teresa R. 25, 60, 61, 93, 97
Freedman, N. 60
Freeman, Kevin B. 93, 106, 116, 117
Friedman, E. 107
Friedman, S. R. 21, 22, 23, 88, 100
Friedmann, P. D. 70, 79
Frimpong, J. A. 3, 21
Froeliger, B. 61, 116
Fuchs, R. 115
Fukaya, Erina 57, 72
Fuller, C. 92
Fulwiler, C. 68, 101
Funk, R. R. 65, 92
Furnari, M. A. 19
Furr-Holden, C. Debra M. 12, 14, 63, 65, 75, 91, 112
Furst, B. 10
Gaalema, D. E. 72, 104
Gaba, A. 85
Gabrielian, S. 85
Gaiser, E. C. 109
Gaither, J. R. 20, 22, 89
Galanter, M. 110
Galea, S. 67, 99
Gallagher, S. M. 67
Galloway, G. 81, 109
Ganesan, D. 109
Ganoczy, D. 79
Gao, J. 62
Garbett, N. 106
Garčia-Rodriguez, O. 14, 68, 118
García-Romeu, A. P. 13
Garzón, M. 65, 81, 87
Garzón, S. 108
Gardiner, A. S. 58
Gardiner, J. C. 112
Garey, L. 63
Garland, E. 61
Garner, B. 110
Garnick, D. W. 86
Garrido, M. 117
Garrison, K. 109
Garro, A. 103
Garton, D. 59
Garver-Apgar, C. 108
Garvey, K. T. 79
Gatch, Michael B. 59, 73, 74, 107
Gatchalian, K. 108
Gatny, H. 94
Gauthier, J. M. 59
Gauthier, P. 85
Gawrysiaik, M. J. 93
Gelberg, L. 65, 85, 87
Gellad, W. F. 80
Gelpi-Acosta, C. 19, 21, 113
Gentry, T. 64
Geoffroy, P. 89
George, M. S. 60, 61
Gera, L. R. 18
Gerr, N. A. 16
Gera, G. 69
Gerson, M. 59
Gess, J. 62
Ghahreman, D. 19
Ghan, M. 87
Ghee, S. M. 98
Giarola, A. 105
Gibson, A. 24, 25
Gibson, K. D. 13
Gilbertson, S. 58
Gilmour, B. P. 16
Ginsberg, Y. 100
Gintzler, Alan 74
Giovino, G. A. 91
Gipson, C. D. 116
Girma, S. 9
Gisev, N. 24, 25, 92
Glaser, P. E. 4, 19
Glass, A. 16, 25, 83, 83, 116
Glucicke, E. E. 58
Goate, A. 99
Godley, M. 110
Goeders, N. E. 58, 105, 106
Goldbach, J. 101
Goldberger, B. 71
Goldman, M. 97
AUTHOR INDEX

Goldsamt, L. 88
Goldschmidt, L. 72
Goldstein, R. Z. 97
Goldstick, J. E. 12
Golesorkhi, M. 10
Golin, C. 100
Golub, A. 94
Goncalves, P. D. 10
Gonçalves, V. M. 83, 91
Gonenc, A. 95
Gomez, A. M. 116
Gonzales, A. 113
Gonzalez, G. 6, 10, 68, 80, 101, 111
González, M. 87, 117
Gonzalez, R. 56
Gonzálvez, M. T. 11, 84, 112
Goodwin, R. 14, 67
Gordon, A. J. 22, 78, 80
Gordon, K. S. 22, 89
Gorelick, David A. 17, 76
Grabowski, J. 118
Grady, J. 56, 90, 103
Graf, E. N. 106
Grall-Bronnec, M. 110
Grana Morales, C. G. 80
Grandpre, N. 81
Grant, K. 108
Grant, Steven 5
Grasing, K. 107
Grassi-Oliveira, R. 114
Graves, H. 83
Gray, K. M. 63, 116
Grebenstein, P. 116
Green, A. I. 27
Green, C. 18, 20, 99, 103, 109, 113
Green, J. 107
Green, J. L. 70, 80, 90
Green, K. M. 83
Green, L. 106
Green, T. 59, 70
Greenfield, S. F. 84, 103
Greenwald, M. K. 19, 21, 25, 78, 88, 110
Greer, T. L. 108
Grell, Christine E. 14, 71, 75
Griffin, B. 84
Griffin, K. W. 84
Griffin, M. L. 79, 110
Griffiths, R. R. 5, 13, 16
Grigolo, T. M. 84
Grinberg, A. 14
Grivel, M. 62
Gros, D. F. 103
Grossman, E. 80
Gruber, S. A. 95
Gruczka, R. 14
Gryczynski, J. 65, 84, 97
Guaresehi, M. 70
Guarino, H. 11
Gudjonsson, G. 100
Gueorguieva, R. 109
Guerin, G. F. 105, 106
Guevremont, N. 10
Guidera, K. 102
Guido, J. J. 23
Guilien, A. 11
Guimarães, L. F. 109
Guimarães, L. S. 83
Guise, J. B. 11
Gunn, A. 21
Guo, X. 84, 86
Guydish, Joseph 67, 75, 112
Guzman, A. 81
Guzman, D. 110
Haase, K. S. 79
Haddox, J. D. 20
Hagan, H. 3, 4, 21, 88
Hager, N. 25
Haile, C. N. 108
Hákansson, A. C. 24, 80
Halkitis, P. N. 77
Hall, A. 90
Hall, W. 105
Hamilton, E. 62
Hamilton, K. R. 66
Hanson, S. C. 98
Hampson, A. 17, 95
Hampton, J. 90
Hand, D. J. 21, 72, 81
Haney, Margaret 2, 60, 73, 95
Hankins, G. 82
Hanlon, Colleen A. 25, 60, 61, 96
Hansen, A. 97
Hansen, H. 78
Hanson, C. 60
Hanson, G. R. 10
Hanson, S. J. 60
Hardee, J. E. 61, 119
Harder, V. 67
Harding, M. H. 98
Hardouin, J. 110
Harp, J. P. 92
Harp, K. 65, 100, 101
Harrington, A. 111
Harris, D. L. 16
Harris, K. 83
Harris, L. S. 18
Harris, S. 17
Harrison, J. A. 63
Harrison, K. 102
Harrold, Steven B. 12, 18, 114, 115, 116
Hart, C. L. 14
Hartley, R. 17, 28, 58
Hartwell, K. 61
Hartwell, S. 68, 101
Hartzler, B. 109, 110
Harvanko, A. M. 10, 57, 61, 95
Harvey, R. C. 117
Haslam, R. R. 81
Hatsukami, D. 25
Hatz, L. 97
Hauben, M. 77
Havens, Jennifer R. 6, 90, 92, 100, 101
Hawley, C. 111
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hays, L. R.</td>
<td>4, 95</td>
</tr>
<tr>
<td>He, S.</td>
<td>107</td>
</tr>
<tr>
<td>Heads, A. M.</td>
<td>103</td>
</tr>
<tr>
<td>Heal, D. J.</td>
<td>107</td>
</tr>
<tr>
<td>Hearn, L.</td>
<td>3, 118</td>
</tr>
<tr>
<td>Heilig, Markus</td>
<td>2</td>
</tr>
<tr>
<td>Heimer, R.</td>
<td>24</td>
</tr>
<tr>
<td>Heinzerling, K. G.</td>
<td>6, 10</td>
</tr>
<tr>
<td>Heitzeg, M. M.</td>
<td>61, 119</td>
</tr>
<tr>
<td>Helle, T.</td>
<td>111</td>
</tr>
<tr>
<td>Hellemann, G.</td>
<td>60</td>
</tr>
<tr>
<td>Heller, E.</td>
<td>58</td>
</tr>
<tr>
<td>Hellmuth, J. C.</td>
<td>69, 103</td>
</tr>
<tr>
<td>Herrmann, K. G.</td>
<td>6, 10</td>
</tr>
<tr>
<td>Hester, R.</td>
<td>61</td>
</tr>
<tr>
<td>Hellemann, G.</td>
<td>60</td>
</tr>
<tr>
<td>Helzer, J.</td>
<td>90</td>
</tr>
<tr>
<td>Hendrickson, H.</td>
<td>28</td>
</tr>
<tr>
<td>Henry, S. A.</td>
<td>111</td>
</tr>
<tr>
<td>Hepner, Kimberly</td>
<td>7</td>
</tr>
<tr>
<td>Hequembourg, A.</td>
<td>69</td>
</tr>
<tr>
<td>Herman, A.</td>
<td>99</td>
</tr>
<tr>
<td>Herman, I.</td>
<td>60</td>
</tr>
<tr>
<td>Hernandez, A.</td>
<td>57, 82</td>
</tr>
<tr>
<td>Hernández, D.</td>
<td>23</td>
</tr>
<tr>
<td>Hernández, C.</td>
<td>116</td>
</tr>
<tr>
<td>Hernandez, F.</td>
<td>81</td>
</tr>
<tr>
<td>Hernandez, J.</td>
<td>4</td>
</tr>
<tr>
<td>Hernandez, L.</td>
<td>83</td>
</tr>
<tr>
<td>Herrick, A.</td>
<td>12</td>
</tr>
<tr>
<td>Herrmann, Evan S.</td>
<td>27, 95</td>
</tr>
<tr>
<td>Hess, K.</td>
<td>27</td>
</tr>
<tr>
<td>Hesselbrock, V.</td>
<td>99</td>
</tr>
<tr>
<td>Hestad, K.</td>
<td>115</td>
</tr>
<tr>
<td>Hester, R.</td>
<td>61</td>
</tr>
<tr>
<td>Hesterberg, K.</td>
<td>27</td>
</tr>
<tr>
<td>Hewitt, D.</td>
<td>89</td>
</tr>
<tr>
<td>Hieftje, K. D.</td>
<td>97</td>
</tr>
<tr>
<td>Hien, D. A.</td>
<td>66, 94, 103</td>
</tr>
<tr>
<td>Higgins, Stephen T.</td>
<td>8, 10, 13, 21, 67, 81, 94, 102, 104</td>
</tr>
<tr>
<td>Hilario, E.</td>
<td>79, 110</td>
</tr>
<tr>
<td>Hillard, C. J.</td>
<td>106</td>
</tr>
<tr>
<td>Hillborg, H.</td>
<td>21</td>
</tr>
<tr>
<td>Hillhouse, M. P.</td>
<td>4, 111</td>
</tr>
<tr>
<td>Hinton, R.</td>
<td>64</td>
</tr>
<tr>
<td>Hipwell, A.</td>
<td>96</td>
</tr>
<tr>
<td>Hiranita, T.</td>
<td>107</td>
</tr>
<tr>
<td>Hlaing, W. M.</td>
<td>95</td>
</tr>
<tr>
<td>Ho, A.</td>
<td>117</td>
</tr>
<tr>
<td>Ho, I. 3, 21</td>
<td>105</td>
</tr>
<tr>
<td>Hobart, M.</td>
<td>111</td>
</tr>
<tr>
<td>Hobbs, M.</td>
<td>100</td>
</tr>
<tr>
<td>Hobbirk, A. L.</td>
<td>102</td>
</tr>
<tr>
<td>Hodgkin, D.</td>
<td>86</td>
</tr>
<tr>
<td>Hoffer, L.</td>
<td>90</td>
</tr>
<tr>
<td>Hoffman, E.</td>
<td>64</td>
</tr>
<tr>
<td>Hoffman, L.</td>
<td>102</td>
</tr>
<tr>
<td>Hofford, R. S.</td>
<td>59, 106</td>
</tr>
<tr>
<td>Hohmann, Andrea G.</td>
<td>71</td>
</tr>
<tr>
<td>Hollis, B.</td>
<td>66</td>
</tr>
<tr>
<td>Holmes, N.</td>
<td>22</td>
</tr>
<tr>
<td>Holty, A.</td>
<td>86</td>
</tr>
<tr>
<td>Holtz, N. A.</td>
<td>18</td>
</tr>
<tr>
<td>Homish, G. G.</td>
<td>66, 82</td>
</tr>
<tr>
<td>Hommer, R. E.</td>
<td>97</td>
</tr>
<tr>
<td>Hopyan, T.</td>
<td>105</td>
</tr>
<tr>
<td>Horgan, C. M.</td>
<td>77, 86</td>
</tr>
<tr>
<td>Horigian, V. E.</td>
<td>86</td>
</tr>
<tr>
<td>Horner, M.</td>
<td>82</td>
</tr>
<tr>
<td>Horr, J. F.</td>
<td>84</td>
</tr>
<tr>
<td>Horton, D. B.</td>
<td>105</td>
</tr>
<tr>
<td>Horton, T.</td>
<td>87</td>
</tr>
<tr>
<td>Hosler, C.</td>
<td>97</td>
</tr>
<tr>
<td>Houston-Ludlam, A.</td>
<td>13</td>
</tr>
<tr>
<td>Howard, G.</td>
<td>71</td>
</tr>
<tr>
<td>Howell, L.</td>
<td>57</td>
</tr>
<tr>
<td>Howell, M. L.</td>
<td>85</td>
</tr>
<tr>
<td>Hser, Y. 3, 20, 56, 81, 85</td>
<td></td>
</tr>
<tr>
<td>Hser, Yih-In Y.</td>
<td>71</td>
</tr>
<tr>
<td>Hu, H. 91</td>
<td></td>
</tr>
<tr>
<td>Hu, M. 13, 66, 85, 103</td>
<td></td>
</tr>
<tr>
<td>Huang, C. 3, 21</td>
<td></td>
</tr>
<tr>
<td>Huang, D. Y.</td>
<td>20</td>
</tr>
<tr>
<td>Huang, K.</td>
<td>16</td>
</tr>
<tr>
<td>Huang, X.</td>
<td>16</td>
</tr>
<tr>
<td>Huber, A.</td>
<td>86</td>
</tr>
<tr>
<td>Huber, J. 115</td>
<td></td>
</tr>
<tr>
<td>Hughes, J. 27</td>
<td></td>
</tr>
<tr>
<td>Huizink, A.</td>
<td>14</td>
</tr>
<tr>
<td>Hung, C. 69</td>
<td></td>
</tr>
<tr>
<td>Hung, E. 77</td>
<td></td>
</tr>
<tr>
<td>Hunt, S. A.</td>
<td>67</td>
</tr>
<tr>
<td>Hunter, B.</td>
<td>110</td>
</tr>
<tr>
<td>Hurd, Y. L.</td>
<td>15</td>
</tr>
<tr>
<td>Huriaux, E.</td>
<td>22</td>
</tr>
<tr>
<td>Hurmic, H.</td>
<td>109, 118</td>
</tr>
<tr>
<td>Hursh, S. R.</td>
<td>64</td>
</tr>
<tr>
<td>Hurwitz, Z. E.</td>
<td>119</td>
</tr>
<tr>
<td>Huskinson, Sally L.</td>
<td>93, 106</td>
</tr>
<tr>
<td>Hutchinson, M. R.</td>
<td>81</td>
</tr>
<tr>
<td>Hutchison, K. E.</td>
<td>27</td>
</tr>
<tr>
<td>Hutson, L.</td>
<td>115</td>
</tr>
<tr>
<td>Hutz, E.</td>
<td>87</td>
</tr>
<tr>
<td>Ialongo, N. S.</td>
<td>14, 63, 83</td>
</tr>
<tr>
<td>Iguchi, Martin Y.</td>
<td>26, 68</td>
</tr>
<tr>
<td>Iniguez, S. D.</td>
<td>59</td>
</tr>
<tr>
<td>Iqbal, T. 15, 19</td>
<td></td>
</tr>
<tr>
<td>Isendahl, P. 80</td>
<td></td>
</tr>
<tr>
<td>Ishibashi, K. 60</td>
<td></td>
</tr>
<tr>
<td>Ishii, K. 106</td>
<td></td>
</tr>
<tr>
<td>Islam, L. 108</td>
<td></td>
</tr>
<tr>
<td>Itzhak, Y. 98</td>
<td></td>
</tr>
<tr>
<td>Ivanov, IIiyan</td>
<td>23</td>
</tr>
<tr>
<td>Iverson, E.</td>
<td>14</td>
</tr>
<tr>
<td>Iverson, M. 90</td>
<td></td>
</tr>
<tr>
<td>Iwamoto, D. 62</td>
<td></td>
</tr>
<tr>
<td>Izenwasser, Sari</td>
<td>96</td>
</tr>
<tr>
<td>Jackson, J. 9</td>
<td></td>
</tr>
<tr>
<td>Jagannathan, K. 25, 60, 61, 93, 94</td>
<td></td>
</tr>
<tr>
<td>Jagsch, R. 72</td>
<td></td>
</tr>
<tr>
<td>James, G. 18, 62</td>
<td></td>
</tr>
<tr>
<td>Janoff, S. 20</td>
<td></td>
</tr>
<tr>
<td>Janulis, P. 78</td>
<td></td>
</tr>
<tr>
<td>Jasinski, Donald R.</td>
<td></td>
</tr>
<tr>
<td>Jayadevappa, R. 92</td>
<td></td>
</tr>
<tr>
<td>Jemal, A. 87</td>
<td></td>
</tr>
<tr>
<td>Jenab, S. 57</td>
<td></td>
</tr>
<tr>
<td>Jenkins, J. 4, 90, 111</td>
<td></td>
</tr>
<tr>
<td>Jenkins, S. 61</td>
<td></td>
</tr>
<tr>
<td>Jensen, N. 85</td>
<td></td>
</tr>
<tr>
<td>Jesse, R. 16</td>
<td></td>
</tr>
<tr>
<td>Jiang, C. 25, 57, 72, 82</td>
<td></td>
</tr>
<tr>
<td>Jin, H. 22</td>
<td></td>
</tr>
<tr>
<td>Jing, L. 28</td>
<td></td>
</tr>
<tr>
<td>Jobes, M. L. 19, 64, 65, 81</td>
<td></td>
</tr>
<tr>
<td>Johansen, H. 82</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
</tr>
<tr>
<td>John, W. S.</td>
<td>57, 107</td>
</tr>
<tr>
<td>Johnson, B.</td>
<td>25, 61</td>
</tr>
<tr>
<td>Johnson, E.</td>
<td>107</td>
</tr>
<tr>
<td>Johnson, Matthew W.</td>
<td>13, 16, 26, 109</td>
</tr>
<tr>
<td>Johnson, R. M.</td>
<td>14, 104</td>
</tr>
<tr>
<td>Johnston, A. M.</td>
<td>72</td>
</tr>
<tr>
<td>Jones, B. E.</td>
<td>110</td>
</tr>
<tr>
<td>Jones, H.</td>
<td>85, 113</td>
</tr>
<tr>
<td>Jones, J.</td>
<td>62, 68</td>
</tr>
<tr>
<td>Jones, J. D.</td>
<td>11, 89</td>
</tr>
<tr>
<td>Jones, M.</td>
<td>18</td>
</tr>
<tr>
<td>Jones, Y.</td>
<td>22</td>
</tr>
<tr>
<td>Jordan, A. E.</td>
<td>3, 21</td>
</tr>
<tr>
<td>Jordan, C. J.</td>
<td>117</td>
</tr>
<tr>
<td>Jose, C.</td>
<td>20</td>
</tr>
<tr>
<td>Joseph, J.</td>
<td>61, 93</td>
</tr>
<tr>
<td>Justice, A.</td>
<td>22, 89</td>
</tr>
<tr>
<td>Kaczmarsky, C.</td>
<td>104</td>
</tr>
<tr>
<td>Kadakia, A.</td>
<td>20</td>
</tr>
<tr>
<td>Kadooka, A.</td>
<td>56</td>
</tr>
<tr>
<td>Kahler, C. W.</td>
<td>12, 83</td>
</tr>
<tr>
<td>Kale, H.</td>
<td>90</td>
</tr>
<tr>
<td>Kalechstein, A.</td>
<td>19</td>
</tr>
<tr>
<td>Kalivas, P. W.</td>
<td>116</td>
</tr>
<tr>
<td>Kallman, Mary Jeanne</td>
<td>18, 88</td>
</tr>
<tr>
<td>Kamarulzaman, A.</td>
<td>87</td>
</tr>
<tr>
<td>Kaminski, B. J.</td>
<td>27</td>
</tr>
<tr>
<td>Kampman, K. M.</td>
<td>6, 93, 94</td>
</tr>
<tr>
<td>Kane, J. C.</td>
<td>84</td>
</tr>
<tr>
<td>Kang, H.</td>
<td>15</td>
</tr>
<tr>
<td>Kangiser, M.</td>
<td>119</td>
</tr>
<tr>
<td>Kantak, Kathleen M.</td>
<td>59, 96, 117</td>
</tr>
<tr>
<td>Kapczinski, F.</td>
<td>9, 72</td>
</tr>
<tr>
<td>Kastelic, A.</td>
<td>85</td>
</tr>
<tr>
<td>Kato Price, R.</td>
<td>69</td>
</tr>
<tr>
<td>Katz, E.</td>
<td>64</td>
</tr>
<tr>
<td>Katz, J.</td>
<td>107</td>
</tr>
<tr>
<td>Kauer-Sant'anna, M.</td>
<td>72</td>
</tr>
<tr>
<td>Kaufman, Marc J.</td>
<td>29</td>
</tr>
<tr>
<td>Kaufmann, C. N.</td>
<td>63, 70</td>
</tr>
<tr>
<td>Kaushal, N.</td>
<td>115</td>
</tr>
<tr>
<td>Kay-Lambkin, Frances</td>
<td>2, 3</td>
</tr>
<tr>
<td>Kearney-Ramos, T.</td>
<td>62</td>
</tr>
<tr>
<td>Kebojovic, A.</td>
<td>70</td>
</tr>
<tr>
<td>Keen, L.</td>
<td>100, 115</td>
</tr>
<tr>
<td>Keita, G.</td>
<td>68</td>
</tr>
<tr>
<td>Keith, D.</td>
<td>14</td>
</tr>
<tr>
<td>Keller, C.</td>
<td>106</td>
</tr>
<tr>
<td>Keller, L. M.</td>
<td>106</td>
</tr>
<tr>
<td>Kelley-Baker, T.</td>
<td>70, 102</td>
</tr>
<tr>
<td>Kelley, M. L.</td>
<td>62, 66</td>
</tr>
<tr>
<td>Kelly, B. C.</td>
<td>70</td>
</tr>
<tr>
<td>Kelly, John F.</td>
<td>30</td>
</tr>
<tr>
<td>Kelly, M. A.</td>
<td>16</td>
</tr>
<tr>
<td>Kelly, S. M.</td>
<td>84</td>
</tr>
<tr>
<td>Kelly, T. H.</td>
<td>10, 57, 61, 93, 95</td>
</tr>
<tr>
<td>Kendler, K. S.</td>
<td>9, 83</td>
</tr>
<tr>
<td>Kenny, A.</td>
<td>103</td>
</tr>
<tr>
<td>Kerns, R.</td>
<td>89</td>
</tr>
<tr>
<td>Kerr, T. M.</td>
<td>106</td>
</tr>
<tr>
<td>Kerridge, B.</td>
<td>88</td>
</tr>
<tr>
<td>Kertesz, S.</td>
<td>71</td>
</tr>
<tr>
<td>Kervran, C.</td>
<td>109</td>
</tr>
<tr>
<td>Keshvari, F.</td>
<td>10</td>
</tr>
<tr>
<td>Kessler, Andrew</td>
<td>26</td>
</tr>
<tr>
<td>Kessler, F. H.</td>
<td>9, 83, 109</td>
</tr>
<tr>
<td>Kessler, J.</td>
<td>3</td>
</tr>
<tr>
<td>Key, M. D.</td>
<td>67</td>
</tr>
<tr>
<td>Keyes, K.</td>
<td>67, 99</td>
</tr>
<tr>
<td>Keyser-Marcus, L. A.</td>
<td>10, 93, 111</td>
</tr>
<tr>
<td>Khan, B.</td>
<td>3</td>
</tr>
<tr>
<td>Khan, F.</td>
<td>87</td>
</tr>
<tr>
<td>Khan, M. R.</td>
<td>88, 91, 100</td>
</tr>
<tr>
<td>Khan, S. R.</td>
<td>9</td>
</tr>
<tr>
<td>Kharitonova, E.</td>
<td>80</td>
</tr>
<tr>
<td>Khodneva, Y.</td>
<td>71</td>
</tr>
<tr>
<td>Khokhar, J. Y.</td>
<td>27</td>
</tr>
<tr>
<td>Kibitov, A.</td>
<td>98</td>
</tr>
<tr>
<td>Kidorff, M. S.</td>
<td>111</td>
</tr>
<tr>
<td>Kiguchi, N.</td>
<td>13</td>
</tr>
<tr>
<td>Killeen, Therese</td>
<td>30, 103</td>
</tr>
<tr>
<td>Killoren, S. E.</td>
<td>11</td>
</tr>
<tr>
<td>Kilts, C. D.</td>
<td>18, 62</td>
</tr>
<tr>
<td>Kim, H.</td>
<td>15</td>
</tr>
<tr>
<td>Kim, J. K.</td>
<td>106</td>
</tr>
<tr>
<td>Kim, K.</td>
<td>82</td>
</tr>
<tr>
<td>Kim, M. S.</td>
<td>17</td>
</tr>
<tr>
<td>Kim, Y.</td>
<td>15</td>
</tr>
<tr>
<td>Kimani, S.</td>
<td>91, 102</td>
</tr>
<tr>
<td>Kimball, T.</td>
<td>83</td>
</tr>
<tr>
<td>Kimber, J.</td>
<td>24, 25</td>
</tr>
<tr>
<td>King, H. E.</td>
<td>107</td>
</tr>
<tr>
<td>King, J. B.</td>
<td>118</td>
</tr>
<tr>
<td>King, L. J.</td>
<td>22, 67</td>
</tr>
<tr>
<td>King, V. L.</td>
<td>66, 111</td>
</tr>
<tr>
<td>Kinlock, T. W.</td>
<td>79</td>
</tr>
<tr>
<td>Kinsey, B. M.</td>
<td>4</td>
</tr>
<tr>
<td>Kirby, K. C.</td>
<td>65, 69, 81, 87</td>
</tr>
<tr>
<td>Kiriazova, T.</td>
<td>89</td>
</tr>
<tr>
<td>Kirk, A.</td>
<td>84, 97</td>
</tr>
<tr>
<td>Kirk, I. J.</td>
<td>61</td>
</tr>
<tr>
<td>Kirtadze, I.</td>
<td>85, 113</td>
</tr>
<tr>
<td>Kish, S.</td>
<td>73</td>
</tr>
<tr>
<td>Kishioka, S.</td>
<td>13</td>
</tr>
<tr>
<td>Kitchens, M. B.</td>
<td>63</td>
</tr>
<tr>
<td>Kizina, K.</td>
<td>65</td>
</tr>
<tr>
<td>Klambatsen, A.</td>
<td>57</td>
</tr>
<tr>
<td>Kleber, H. D.</td>
<td>28, 79</td>
</tr>
<tr>
<td>Klein, Michael</td>
<td>76, 113</td>
</tr>
<tr>
<td>Klemperer, E. M.</td>
<td>27, 79</td>
</tr>
<tr>
<td>Knight, S.</td>
<td>58</td>
</tr>
<tr>
<td>Knoblauch, D. J.</td>
<td>87</td>
</tr>
<tr>
<td>Knopik, V.</td>
<td>72</td>
</tr>
<tr>
<td>Knudsen, Helen K.</td>
<td>75, 77</td>
</tr>
<tr>
<td>Kobayashi, Y.</td>
<td>13</td>
</tr>
<tr>
<td>Kober, H.</td>
<td>94</td>
</tr>
<tr>
<td>Koch, R.</td>
<td>9</td>
</tr>
<tr>
<td>Koenen, K. C.</td>
<td>99</td>
</tr>
<tr>
<td>Kogachi, S.</td>
<td>25, 57</td>
</tr>
<tr>
<td>Kohno, M.</td>
<td>60</td>
</tr>
<tr>
<td>Koken, J.</td>
<td>22</td>
</tr>
<tr>
<td>Kollins, Scott H.</td>
<td>13, 23</td>
</tr>
<tr>
<td>Kolodziej, M. E.</td>
<td>80, 111</td>
</tr>
<tr>
<td>Kong, G.</td>
<td>83</td>
</tr>
<tr>
<td>Konova, A. B.</td>
<td>97</td>
</tr>
<tr>
<td>Konstenius, M.</td>
<td>100</td>
</tr>
<tr>
<td>Konz, N.</td>
<td>115</td>
</tr>
<tr>
<td>Koob, George F.</td>
<td>1</td>
</tr>
<tr>
<td>Kopecky, E. A.</td>
<td>17</td>
</tr>
<tr>
<td>Kopetz, C.</td>
<td>13</td>
</tr>
<tr>
<td>Korcha, R. A.</td>
<td>107</td>
</tr>
<tr>
<td>Kornor, H.</td>
<td>104</td>
</tr>
<tr>
<td>Kornstein, S.</td>
<td>9</td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Korte, J. E.</td>
<td>86</td>
</tr>
<tr>
<td>Korthuis, Todd</td>
<td>76</td>
</tr>
<tr>
<td>Kosten, T.</td>
<td>98</td>
</tr>
<tr>
<td>Kosten, T. A.</td>
<td>4</td>
</tr>
<tr>
<td>Kosten, T. R.</td>
<td>11, 15, 98, 99</td>
</tr>
<tr>
<td>Koszowski, B.</td>
<td>112</td>
</tr>
<tr>
<td>Koustova, Elena</td>
<td>74</td>
</tr>
<tr>
<td>Kraft, W. K.</td>
<td>81</td>
</tr>
<tr>
<td>Kral, A.</td>
<td>64, 92, 101, 117</td>
</tr>
<tr>
<td>Kramer, J.</td>
<td>99</td>
</tr>
<tr>
<td>Kranzler, H. R.</td>
<td>60</td>
</tr>
<tr>
<td>Krauss, M.</td>
<td>14</td>
</tr>
<tr>
<td>Krebs, C.</td>
<td>101</td>
</tr>
<tr>
<td>Kreek, M.</td>
<td>9, 18, 19, 27, 58, 98, 117</td>
</tr>
<tr>
<td>Kreutzer, J. S.</td>
<td>10</td>
</tr>
<tr>
<td>Krishnan-Sarin, Suchitra</td>
<td>26, 83</td>
</tr>
<tr>
<td>Krishnan, A.</td>
<td>87, 100</td>
</tr>
<tr>
<td>Kritz, S.</td>
<td>80</td>
</tr>
<tr>
<td>Krmpotich, T.</td>
<td>60, 110</td>
</tr>
<tr>
<td>Kroll, C.</td>
<td>105</td>
</tr>
<tr>
<td>Kromrey, S. A.</td>
<td>57</td>
</tr>
<tr>
<td>Krupitsky, Eugeny</td>
<td>3, 66, 79, 85, 89, 98, 113</td>
</tr>
<tr>
<td>Kunoe, N.</td>
<td>79</td>
</tr>
<tr>
<td>Kupchik, Y.</td>
<td>116</td>
</tr>
<tr>
<td>Kurokawa, K.</td>
<td>62</td>
</tr>
<tr>
<td>Kurtz, S. P.</td>
<td>80, 90</td>
</tr>
<tr>
<td>Kurtz, S. S.</td>
<td>73</td>
</tr>
<tr>
<td>Kusunoki, J.</td>
<td>94</td>
</tr>
<tr>
<td>Kydd, R. R.</td>
<td>61</td>
</tr>
<tr>
<td>Kynor, D.</td>
<td>81</td>
</tr>
<tr>
<td>Lachewitz, J.</td>
<td>6</td>
</tr>
<tr>
<td>Lacy, R. T.</td>
<td>12, 17, 59</td>
</tr>
<tr>
<td>Lalonde, T. L.</td>
<td>15</td>
</tr>
<tr>
<td>Lamb, K.</td>
<td>63</td>
</tr>
<tr>
<td>Lambdin, B.</td>
<td>89</td>
</tr>
<tr>
<td>Lan, Y. 3, 81</td>
<td></td>
</tr>
<tr>
<td>Landavazo, A.</td>
<td>17</td>
</tr>
<tr>
<td>Landheim, A. S.</td>
<td>63</td>
</tr>
<tr>
<td>Lane, S. D.</td>
<td>10, 15, 18, 99, 103, 113</td>
</tr>
<tr>
<td>Lang, B. A.</td>
<td>78</td>
</tr>
<tr>
<td>Lange, K.</td>
<td>118</td>
</tr>
<tr>
<td>Langleben, Daniel</td>
<td>60, 72, 93, 94</td>
</tr>
<tr>
<td>Lanier, R. K.</td>
<td>13</td>
</tr>
<tr>
<td>Lankenau, S.</td>
<td>14, 70</td>
</tr>
<tr>
<td>Lanza, H.</td>
<td>56</td>
</tr>
<tr>
<td>Lariance, B.</td>
<td>105</td>
</tr>
<tr>
<td>Larney, Sarah</td>
<td>24, 25, 92</td>
</tr>
<tr>
<td>LaRowe, Sarah</td>
<td>63</td>
</tr>
<tr>
<td>Larsen, H.</td>
<td>13, 83</td>
</tr>
<tr>
<td>Larson, E.</td>
<td>86</td>
</tr>
<tr>
<td>Larson, M.</td>
<td>77</td>
</tr>
<tr>
<td>Larson, P.</td>
<td>89</td>
</tr>
<tr>
<td>Laruitsen, K.</td>
<td>15</td>
</tr>
<tr>
<td>Lasopa, Sonam O.</td>
<td>9, 117, 118</td>
</tr>
<tr>
<td>Lasser, K. E.</td>
<td>117</td>
</tr>
<tr>
<td>Latif, H. Z.</td>
<td>79</td>
</tr>
<tr>
<td>Latimer, W. W.</td>
<td>3, 88, 92, 115, 118</td>
</tr>
<tr>
<td>Lauby, J.</td>
<td>65</td>
</tr>
<tr>
<td>Laudet, A. B.</td>
<td>83, 87</td>
</tr>
<tr>
<td>Laurenceau, J.</td>
<td>108</td>
</tr>
<tr>
<td>Lauteritsen, K. J.</td>
<td>78</td>
</tr>
<tr>
<td>Lavalley, M.</td>
<td>14</td>
</tr>
<tr>
<td>Laxamana, J.</td>
<td>62</td>
</tr>
<tr>
<td>Layne, W. K.</td>
<td>67</td>
</tr>
<tr>
<td>Lazar, C. M.</td>
<td>77</td>
</tr>
<tr>
<td>Le Lait, M. C.</td>
<td>90</td>
</tr>
<tr>
<td>Le, G. M.</td>
<td>88</td>
</tr>
<tr>
<td>Le, T.</td>
<td>112</td>
</tr>
<tr>
<td>Le, V. D.</td>
<td>82</td>
</tr>
<tr>
<td>Leaf, P. J.</td>
<td>14, 63</td>
</tr>
<tr>
<td>Lebonville, C.</td>
<td>18, 115</td>
</tr>
<tr>
<td>Lechner, W.</td>
<td>111</td>
</tr>
<tr>
<td>Leclerc, P.</td>
<td>64</td>
</tr>
<tr>
<td>Ledgerwood, D. M.</td>
<td>21, 67, 82, 88, 110</td>
</tr>
<tr>
<td>Lee, Dustin C.</td>
<td>2, 95</td>
</tr>
<tr>
<td>Lee, J. D.</td>
<td>68, 79, 80</td>
</tr>
<tr>
<td>Lee, K. 15</td>
<td>57</td>
</tr>
<tr>
<td>Lee, M. 86</td>
<td></td>
</tr>
<tr>
<td>Lee, M. H. 14</td>
<td></td>
</tr>
<tr>
<td>Lee, S. 12</td>
<td></td>
</tr>
<tr>
<td>Lee, Steve 23</td>
<td></td>
</tr>
<tr>
<td>Lee, T. 69</td>
<td></td>
</tr>
<tr>
<td>Lefever, T. 57</td>
<td></td>
</tr>
<tr>
<td>Legauffre, C.</td>
<td>110</td>
</tr>
<tr>
<td>Lehner, K. R.</td>
<td>73</td>
</tr>
<tr>
<td>Lejuez, C.</td>
<td>100</td>
</tr>
<tr>
<td>Lejuez, C. 11</td>
<td>62, 63, 66, 84, 86</td>
</tr>
<tr>
<td>LeMarra, T. 60, 61</td>
<td></td>
</tr>
<tr>
<td>Len-Rios, M. E.</td>
<td>11</td>
</tr>
<tr>
<td>Lenoir, H.</td>
<td>66</td>
</tr>
<tr>
<td>Leu, D.</td>
<td>86</td>
</tr>
<tr>
<td>Leven, E. J.</td>
<td>97</td>
</tr>
<tr>
<td>Leukfeld, C. 20, 90, 100, 101</td>
<td></td>
</tr>
<tr>
<td>Levandowski, M. L.</td>
<td>114</td>
</tr>
<tr>
<td>Levine, E. D.</td>
<td>72</td>
</tr>
<tr>
<td>Levine, F.</td>
<td>103</td>
</tr>
<tr>
<td>Levin, F. R.</td>
<td>13, 16, 63, 83, 94, 100, 116, 118</td>
</tr>
<tr>
<td>Levin, Frances R.</td>
<td>117</td>
</tr>
<tr>
<td>Levina, O.</td>
<td>24</td>
</tr>
<tr>
<td>Levine, A. R.</td>
<td>21</td>
</tr>
<tr>
<td>Levis, S. C.</td>
<td>28</td>
</tr>
<tr>
<td>Levoyan-Radloff, K.</td>
<td>69</td>
</tr>
<tr>
<td>Levian, O. 19, 98</td>
<td></td>
</tr>
<tr>
<td>Levy-Cooperman, N.</td>
<td>17, 89, 105</td>
</tr>
<tr>
<td>Levy-Cooperman, Naama</td>
<td>30</td>
</tr>
<tr>
<td>Levy, A. 18</td>
<td></td>
</tr>
<tr>
<td>Lewis, B. 102</td>
<td></td>
</tr>
<tr>
<td>Lewis, D. 28</td>
<td></td>
</tr>
<tr>
<td>Lewis, D. E. 68</td>
<td></td>
</tr>
<tr>
<td>Li, D. 59</td>
<td></td>
</tr>
<tr>
<td>Li, Jun-Xu 28</td>
<td></td>
</tr>
<tr>
<td>Li, L. 20, 56, 85</td>
<td></td>
</tr>
<tr>
<td>Li, M. 56, 112</td>
<td></td>
</tr>
<tr>
<td>Li, X. 16, 22, 61</td>
<td></td>
</tr>
<tr>
<td>Li, Y. 58, 98</td>
<td></td>
</tr>
<tr>
<td>Liao, D. 90</td>
<td></td>
</tr>
<tr>
<td>Liccardo Pacula, R.</td>
<td>78</td>
</tr>
<tr>
<td>Lichtman, Aron</td>
<td>71</td>
</tr>
<tr>
<td>Liddie, S. 98</td>
<td></td>
</tr>
<tr>
<td>Liddie, Shervin</td>
<td>97</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Liebschutz, J. M.</td>
<td>117</td>
</tr>
<tr>
<td>Liebschutz, Jane M.</td>
<td>7</td>
</tr>
<tr>
<td>Lien, L.</td>
<td>115</td>
</tr>
<tr>
<td>Lightfoot, M.</td>
<td>83</td>
</tr>
<tr>
<td>Lile, J. 57, 95</td>
<td></td>
</tr>
<tr>
<td>Lile, J. A. 10, 61</td>
<td></td>
</tr>
<tr>
<td>Lile, Joshua 95</td>
<td></td>
</tr>
<tr>
<td>Lim, A. 111</td>
<td></td>
</tr>
<tr>
<td>Lima-Rodriguez, C. 86</td>
<td></td>
</tr>
<tr>
<td>Lima, V. 22</td>
<td></td>
</tr>
<tr>
<td>Lin, A. 59</td>
<td></td>
</tr>
<tr>
<td>Lin, J. 65</td>
<td></td>
</tr>
<tr>
<td>Lin, L. A. 70</td>
<td></td>
</tr>
<tr>
<td>Lin, M. 80</td>
<td></td>
</tr>
<tr>
<td>Lin, V. 85</td>
<td></td>
</tr>
<tr>
<td>Lindsey, A. 18</td>
<td></td>
</tr>
<tr>
<td>Ling, W. 4, 6, 98, 111</td>
<td></td>
</tr>
<tr>
<td>Ling, Walter 4</td>
<td></td>
</tr>
<tr>
<td>Linklater, R. 56</td>
<td></td>
</tr>
<tr>
<td>Lintzeris, N. 105</td>
<td></td>
</tr>
<tr>
<td>Liong, C. 19</td>
<td></td>
</tr>
<tr>
<td>Lipton, R. 12</td>
<td></td>
</tr>
<tr>
<td>Lira, M. C. 6, 89</td>
<td></td>
</tr>
<tr>
<td>Lisdahl, K. M. 15, 27</td>
<td></td>
</tr>
<tr>
<td>Lister, J. 110</td>
<td></td>
</tr>
<tr>
<td>Liu, K. 78</td>
<td></td>
</tr>
<tr>
<td>Liu, L. 20</td>
<td></td>
</tr>
<tr>
<td>Liu, S. 15, 56, 99</td>
<td></td>
</tr>
<tr>
<td>Liu, W. 72</td>
<td></td>
</tr>
<tr>
<td>Liu, X. 98</td>
<td></td>
</tr>
<tr>
<td>Liu, Y. 16, 21, 56</td>
<td></td>
</tr>
<tr>
<td>Llobet, M. 111</td>
<td></td>
</tr>
<tr>
<td>Lloyd-Tavaglini, C. A. 63</td>
<td></td>
</tr>
<tr>
<td>Lloyd, A. 3</td>
<td></td>
</tr>
<tr>
<td>Lo Ciganic, W. 80</td>
<td></td>
</tr>
<tr>
<td>Lobmaier, P. P. 104</td>
<td></td>
</tr>
<tr>
<td>Loescher, J. L. 13</td>
<td></td>
</tr>
<tr>
<td>Lofwall, M. R. 13, 17</td>
<td></td>
</tr>
<tr>
<td>Løhaugen, G. 57, 72</td>
<td></td>
</tr>
<tr>
<td>Lohrenz, T. 93, 108, 109</td>
<td></td>
</tr>
<tr>
<td>London, E. D. 10, 19, 60, 63</td>
<td></td>
</tr>
<tr>
<td>Long, Ed 26</td>
<td></td>
</tr>
<tr>
<td>Long, K. 64, 86</td>
<td></td>
</tr>
<tr>
<td>Longinaker, N. 85, 103</td>
<td></td>
</tr>
<tr>
<td>Lookatch, S. J. 64</td>
<td></td>
</tr>
<tr>
<td>Lopez-Castro, T. 66, 94</td>
<td></td>
</tr>
<tr>
<td>Lopez-Larson, M. P. 118</td>
<td></td>
</tr>
<tr>
<td>López-Núñez, C. 14</td>
<td></td>
</tr>
<tr>
<td>Lopez-Quintero, C. 83, 91</td>
<td></td>
</tr>
<tr>
<td>Lopez, A. A. 94</td>
<td></td>
</tr>
<tr>
<td>Lopez, S. 21</td>
<td></td>
</tr>
<tr>
<td>Lord, S. E. 110</td>
<td></td>
</tr>
<tr>
<td>Lorvick, J. 64, 92, 101, 117</td>
<td></td>
</tr>
<tr>
<td>Los, C. 70</td>
<td></td>
</tr>
<tr>
<td>Lott, D. C. 68, 69</td>
<td></td>
</tr>
<tr>
<td>Louie, B. 80</td>
<td></td>
</tr>
<tr>
<td>Louza, M. 10</td>
<td></td>
</tr>
<tr>
<td>Low, M. J. 27</td>
<td></td>
</tr>
<tr>
<td>Loya, J. M. 63</td>
<td></td>
</tr>
<tr>
<td>Lozano, B. E. 67</td>
<td></td>
</tr>
<tr>
<td>Lu, N. 81</td>
<td></td>
</tr>
<tr>
<td>Lu, Q. 112</td>
<td></td>
</tr>
<tr>
<td>Lukas, S. E. 61, 95</td>
<td></td>
</tr>
<tr>
<td>Lundahl, L. H. 19, 21, 25, 78, 88, 110</td>
<td></td>
</tr>
<tr>
<td>Lunnen, J. 62, 102</td>
<td></td>
</tr>
<tr>
<td>Luo, S. X. 13</td>
<td></td>
</tr>
<tr>
<td>Lynam, D. R. 11, 62</td>
<td></td>
</tr>
<tr>
<td>Lynch, K. G. 6</td>
<td></td>
</tr>
<tr>
<td>Lynskey, M. T. 64, 111</td>
<td></td>
</tr>
<tr>
<td>Lysle, D. 18, 115</td>
<td></td>
</tr>
<tr>
<td>Lyubimova, A. 24</td>
<td></td>
</tr>
<tr>
<td>Lyvers, M. 63, 64</td>
<td></td>
</tr>
<tr>
<td>Ma, L. 93</td>
<td></td>
</tr>
<tr>
<td>Ma, Y. 56</td>
<td></td>
</tr>
<tr>
<td>MacFarlane, J. C. 91</td>
<td></td>
</tr>
<tr>
<td>Macias Konstantopoulos, W. 85</td>
<td></td>
</tr>
<tr>
<td>Mackey, T. 64</td>
<td></td>
</tr>
<tr>
<td>MacKillop, J. 15</td>
<td></td>
</tr>
<tr>
<td>MacLean, K. A. 16</td>
<td></td>
</tr>
<tr>
<td>MacLean, R. 62</td>
<td></td>
</tr>
<tr>
<td>MacPherson, L. 11, 13, 62, 64, 84, 86, 91, 94, 111</td>
<td></td>
</tr>
<tr>
<td>Mactutus, C. F. 18, 115</td>
<td></td>
</tr>
<tr>
<td>Madeja, C. 73</td>
<td></td>
</tr>
<tr>
<td>Madras, Bertha K. 1, 15, 29, 74</td>
<td></td>
</tr>
<tr>
<td>Magalon, D. 110</td>
<td></td>
</tr>
<tr>
<td>Magis-Rodriguez, C. 88</td>
<td></td>
</tr>
<tr>
<td>Maguire, D. R. 18</td>
<td></td>
</tr>
<tr>
<td>Magura, S. 77</td>
<td></td>
</tr>
<tr>
<td>Maher, Brion 75</td>
<td></td>
</tr>
<tr>
<td>Maher, L. 3</td>
<td></td>
</tr>
<tr>
<td>Mahoney, A. P. 81</td>
<td></td>
</tr>
<tr>
<td>Mahoney, J. J. 15, 19, 28, 108</td>
<td></td>
</tr>
<tr>
<td>Mahoney, M. 13</td>
<td></td>
</tr>
<tr>
<td>Mahony, A. 118</td>
<td></td>
</tr>
<tr>
<td>Maidment, N. T. 18</td>
<td></td>
</tr>
<tr>
<td>Maki, P. 56</td>
<td></td>
</tr>
<tr>
<td>Malbergier, A. 10</td>
<td></td>
</tr>
<tr>
<td>Maldonado-Molina, M. 71</td>
<td></td>
</tr>
<tr>
<td>Maldonado, A. 21</td>
<td></td>
</tr>
<tr>
<td>Malison, R. T. 109</td>
<td></td>
</tr>
<tr>
<td>Malta, M. 86</td>
<td></td>
</tr>
<tr>
<td>Maney, M. 118</td>
<td></td>
</tr>
<tr>
<td>Man, H. 59</td>
<td></td>
</tr>
<tr>
<td>Mancha, B. E. 88</td>
<td></td>
</tr>
<tr>
<td>Manchanda, R. 85</td>
<td></td>
</tr>
<tr>
<td>Mancino, M. J. 11, 28</td>
<td></td>
</tr>
<tr>
<td>Mandelkern, M. A. 10, 19, 60</td>
<td></td>
</tr>
<tr>
<td>Mandler, R. N. 85</td>
<td></td>
</tr>
<tr>
<td>Manna, L. 72</td>
<td></td>
</tr>
<tr>
<td>Mannelli, P. 79</td>
<td></td>
</tr>
<tr>
<td>Mansoor, E. 82</td>
<td></td>
</tr>
<tr>
<td>Mantsch, John R. 2, 106</td>
<td></td>
</tr>
<tr>
<td>Manubay, J. M. 89</td>
<td></td>
</tr>
<tr>
<td>Manza, L. 27</td>
<td></td>
</tr>
<tr>
<td>Mao, J. 6</td>
<td></td>
</tr>
<tr>
<td>Maple, K. E. 15, 27</td>
<td></td>
</tr>
<tr>
<td>Maqueda, A. 117</td>
<td></td>
</tr>
<tr>
<td>Marceau, K. 72</td>
<td></td>
</tr>
<tr>
<td>Marchant, N. J. 58, 116</td>
<td></td>
</tr>
<tr>
<td>Mardini, V. 72</td>
<td></td>
</tr>
<tr>
<td>Mare, Christina 71, 94, 111</td>
<td></td>
</tr>
<tr>
<td>Maremmanni, I. 70</td>
<td></td>
</tr>
<tr>
<td>Mariani, J. J. 16, 63, 79, 83, 116, 118</td>
<td></td>
</tr>
<tr>
<td>Marín-Navarrete, R. 86</td>
<td></td>
</tr>
<tr>
<td>Mark, K. D. 103</td>
<td></td>
</tr>
<tr>
<td>Marks, K. R. 98</td>
<td></td>
</tr>
<tr>
<td>Marlin, B. 109</td>
<td></td>
</tr>
<tr>
<td>Marlowe, D. 102</td>
<td></td>
</tr>
<tr>
<td>Márquez, J. 80</td>
<td></td>
</tr>
<tr>
<td>Marquez, K. 97</td>
<td></td>
</tr>
<tr>
<td>Marsch, L. A. 22</td>
<td></td>
</tr>
<tr>
<td>Marshall, M. P. 96</td>
<td></td>
</tr>
<tr>
<td>Marshall, B. D. 21</td>
<td></td>
</tr>
<tr>
<td>Martelle, S. E. 57, 107</td>
<td></td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Martin-Fardon, R. 106
Martin, C. 10, 61
Martin, E. 56
Martin, N. G. 64
Martínez-Loredo, V. 68, 118
Martínez-Sanvisens, D. 94, 111
Martínez, C. 112
Martínez, D. 117
Martínez, E. M. 70, 80, 90
Martínez, M. 117
Martínez, M. M. 108
Martinez, P. 115
Martins, Silvia S. 6, 21, 56, 70, 112
Marusich, J. A. 57
Marwitz, J. H. 10
Mash, D. C. 62
Mashhoon, Y. 61
Massey, L. S. 12
Masson, Carmen L. 56, 75
Masterson, C. B. 106
Matejkowski, J. 101
Mateu-Gelabert, P. 11
Mateucci, A. 86
Mathew, A. R. 61
Mathews, T. 16
Mathias, C. W. 15, 118
Mathur, C. 25
Matschke, K. 117
Matsumoto, Rae R. 114, 115
Matthews, A 30
Mattick, R. 25, 105
Matusiewicz, A. K. 13, 63
Matzeu, A. 106
Mauro, P. M. 63, 97, 112
Maxwell, Jane C. 29
May, A. C. 93
Mayes, L. C. 97
Maynié-François, C. 63
Mays, J. 25
Mays, V. 14
Mazure, C. M. 91
Mazzom, M. 83
Mbwambo, J. 89
McBride, K. 70
McCabe, Sean E. 6, 70, 118
McCann, David 1, 4
McCart, M. R. 97
McCarty, D. 64, 87
McCaulley, J. L. 69, 102, 103
McClernon, F. Joseph 23
McClernon, J. 61
McClure, B. 85
McClure, Erin A. 115, 116
McClure, S. M. 93
McConnell, J. 78
McConnell, P. 61
McCormack, R. P. 85
McCready, B. S. 85
McCurdy, C. 115
McDermott, K. 79, 110
McDermott, K. A. 85
McGaul, J. 11
McGinnis, K. 89
McGrath, E. 62
McHugh, K. 68, 70
McHugh, R. 110
McKee, S. 66
McKee, Sherry 91, 114
McKnight, C. 4, 88
McLellan, A. Thomas 26, 69
McNaughton, E. C. 68
McNeely, J. 77
McNeil, M. P. 14
McPherson, S. 118
McQueeney, T. 61
McReynolds, J. R. 106
McWilliams, S. K. 11
Meacham, M. C. 64
Mead, A. N. 105
Meade, Christina S. 22, 26, 67, 91, 102, 104
Means, S. 77
Medina-Mora, M. E. 86, 88
Meier, E. A. 118
Melara, R. 14
Mello, M. 103
Mendelson, J. 81, 109
Mendez, I. A. 18, 113
Mendoza, S. 78
Mercer, M. A. 102
Mencincavage, M. 104
Meredith, S. 9
Meredith, S. E. 5
Meredith, Steven 8
Meredith, Steven E. 5
Mereu, M. 107
Mericle, A. 87
Mericle, A. A. 81
Merrick, E. L. 86
Merry, B. 72
Messiah, S. E. 95
Metrik, J. 15
Metsch, L. 23
Metsch, L. R. 3
Metz, V. 21, 89
Metzger, D. 65, 69, 92
Meyer, A. C. 10, 102
Meyer, J. P. 100
Meyer, M. 21
Meyers, J. L. 99
Meyers, K. 69
Meyers, S. A. 109
Mezghanni, M. 65
Michalko, K. 89
Michalopoulos, L. 84
Michie, P. 67
Mikulich-Gilbertson, S. K. 11
Mikulich, S. 110
Milam, A. J. 12, 14, 63, 91, 112
Milam, Adam J. 75
Milanesi, G. 70
Millich, R. 11, 62
Miller, A. L. 58
Miller, G. M. 15, 112
Miller, S. C. 20
Milletitch, R. J. 66
Milloy, M. 22
Mills, K. 94, 111
Mills, Katherine 94
Min, J. 22
Mineur, Yann 114
Minguela, R. R. 94
Miranda de Leon, S. 23
Mishani, E. 60
Mishlen, K. 79, 83
Mitchell, A. 13
Mitchell, J. 13, 62
Mitchell, S. G. 65, 84, 97
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell, Shannon G.</td>
<td>96</td>
</tr>
<tr>
<td>Mizuno, K.</td>
<td>62</td>
</tr>
<tr>
<td>Mjølhus, A. L.</td>
<td>79</td>
</tr>
<tr>
<td>Mjølhus, A. N.</td>
<td>79</td>
</tr>
<tr>
<td>Moberg, D.</td>
<td>83</td>
</tr>
<tr>
<td>Moberg, E.</td>
<td>65</td>
</tr>
<tr>
<td>Modlin, D.</td>
<td>18</td>
</tr>
<tr>
<td>Moeller, F. Gerard</td>
<td>5, 10, 25, 58, 93, 99</td>
</tr>
<tr>
<td>Moeller, S. J.</td>
<td>97</td>
</tr>
<tr>
<td>Mogali, S.</td>
<td>89</td>
</tr>
<tr>
<td>Mohammed, A. M.</td>
<td>91</td>
</tr>
<tr>
<td>Mohr, B. A.</td>
<td>77</td>
</tr>
<tr>
<td>Mojtabai, R.</td>
<td>70</td>
</tr>
<tr>
<td>Møller, M.</td>
<td>79</td>
</tr>
<tr>
<td>Mollnes, T. E.</td>
<td>115</td>
</tr>
<tr>
<td>Molnar, D.</td>
<td>82</td>
</tr>
<tr>
<td>Moncrief, J.</td>
<td>17, 28</td>
</tr>
<tr>
<td>Monge, Z. A.</td>
<td>60, 93</td>
</tr>
<tr>
<td>Monk, S.</td>
<td>100</td>
</tr>
<tr>
<td>Montague, P. R.</td>
<td>93, 108, 109</td>
</tr>
<tr>
<td>Montaner, J.</td>
<td>22</td>
</tr>
<tr>
<td>Monterosso, J. R.</td>
<td>10</td>
</tr>
<tr>
<td>Montgomery, L.</td>
<td>86, 108</td>
</tr>
<tr>
<td>Montoya, Ivan</td>
<td>114</td>
</tr>
<tr>
<td>Moody, L.</td>
<td>97</td>
</tr>
<tr>
<td>Mooney, L.</td>
<td>4, 60, 111</td>
</tr>
<tr>
<td>Mooney, M.</td>
<td>118</td>
</tr>
<tr>
<td>Mooney, R.</td>
<td>87</td>
</tr>
<tr>
<td>Moore, B. A. 6, 70, 81</td>
<td></td>
</tr>
<tr>
<td>Moore, S. K.</td>
<td>110</td>
</tr>
<tr>
<td>Moore, T. 64, 70</td>
<td></td>
</tr>
<tr>
<td>Morales, A. 11, 84, 112</td>
<td></td>
</tr>
<tr>
<td>Morales, A. M. 60</td>
<td></td>
</tr>
<tr>
<td>Morales, M. 116</td>
<td></td>
</tr>
<tr>
<td>Moran-Santa Maria, M. 61</td>
<td></td>
</tr>
<tr>
<td>Morean, M. E. 83</td>
<td></td>
</tr>
<tr>
<td>Morgan-Jackson, J. 83</td>
<td></td>
</tr>
<tr>
<td>Morgan, A. J. 12, 18, 115</td>
<td></td>
</tr>
<tr>
<td>Morgan, D.</td>
<td>17</td>
</tr>
<tr>
<td>Mori, T. 58, 106</td>
<td></td>
</tr>
<tr>
<td>Morisano, Dominique</td>
<td></td>
</tr>
<tr>
<td>Morissette, C. 64</td>
<td></td>
</tr>
<tr>
<td>Morris, L. A. 20</td>
<td></td>
</tr>
<tr>
<td>Morris, R. 90</td>
<td></td>
</tr>
<tr>
<td>Morrow, C. 82</td>
<td></td>
</tr>
<tr>
<td>Morrow, K. 103</td>
<td></td>
</tr>
<tr>
<td>Morse, D. 23</td>
<td></td>
</tr>
<tr>
<td>Moseley, A. 65</td>
<td></td>
</tr>
<tr>
<td>Moser, A. 24</td>
<td></td>
</tr>
<tr>
<td>Moy, L. 85</td>
<td></td>
</tr>
<tr>
<td>Muller, M. 107</td>
<td></td>
</tr>
<tr>
<td>Muller, M. M. 119</td>
<td></td>
</tr>
<tr>
<td>Mumford, E. 72</td>
<td></td>
</tr>
<tr>
<td>Mumma, J. 25, 61</td>
<td></td>
</tr>
<tr>
<td>Munguia, A. 81</td>
<td></td>
</tr>
<tr>
<td>Muntner, P. 71</td>
<td></td>
</tr>
<tr>
<td>Murna, A. 84</td>
<td></td>
</tr>
<tr>
<td>Murphy, A. 24</td>
<td></td>
</tr>
<tr>
<td>Murphy, E. M. 62, 66</td>
<td></td>
</tr>
<tr>
<td>Murphy, N. P. 18</td>
<td></td>
</tr>
<tr>
<td>Murphy, S. M. 118</td>
<td></td>
</tr>
<tr>
<td>Murphy, Susan A. 8</td>
<td></td>
</tr>
<tr>
<td>Murray, L. 84</td>
<td></td>
</tr>
<tr>
<td>Muscat, J. E. 104</td>
<td></td>
</tr>
<tr>
<td>Myers, B. 91</td>
<td></td>
</tr>
<tr>
<td>Myerson, J. 106</td>
<td></td>
</tr>
<tr>
<td>Nader, Michael A. 29, 57, 92, 107</td>
<td></td>
</tr>
<tr>
<td>Nader, S. H. 57</td>
<td></td>
</tr>
<tr>
<td>Naegger, S. 97</td>
<td></td>
</tr>
<tr>
<td>Namjoshi, O. A. 17</td>
<td></td>
</tr>
<tr>
<td>Nanovskaya, T. 82</td>
<td></td>
</tr>
<tr>
<td>Napier, C. 18</td>
<td></td>
</tr>
<tr>
<td>Napper, L. 109</td>
<td></td>
</tr>
<tr>
<td>Narvaez, J. 9</td>
<td></td>
</tr>
<tr>
<td>Naser, Z. 115</td>
<td></td>
</tr>
<tr>
<td>Natarajan, A. 109</td>
<td></td>
</tr>
<tr>
<td>Natera, G. 87, 91</td>
<td></td>
</tr>
<tr>
<td>Natsuki, M. 72</td>
<td></td>
</tr>
<tr>
<td>Nayak, M. 107</td>
<td></td>
</tr>
<tr>
<td>Naylor, J. 117</td>
<td></td>
</tr>
<tr>
<td>Neelakantan, H. 57</td>
<td></td>
</tr>
<tr>
<td>Negi, N. 91</td>
<td></td>
</tr>
<tr>
<td>Negrin, A. 108</td>
<td></td>
</tr>
<tr>
<td>Neiderhisuer, J. M. 72</td>
<td></td>
</tr>
<tr>
<td>Neisewander, Janet 1, 58</td>
<td></td>
</tr>
<tr>
<td>Nejati, V. 10</td>
<td></td>
</tr>
<tr>
<td>Nelson, E. 27, 61, 69</td>
<td></td>
</tr>
<tr>
<td>Nelson, K. 117</td>
<td></td>
</tr>
<tr>
<td>Neria, Y. 103</td>
<td></td>
</tr>
<tr>
<td>Nestler, E. J. 58, 59</td>
<td></td>
</tr>
<tr>
<td>Nesvåg, S. 79</td>
<td></td>
</tr>
<tr>
<td>Neupane, S. P. 115</td>
<td></td>
</tr>
<tr>
<td>Neurer, J. 3</td>
<td></td>
</tr>
<tr>
<td>Newman, Amy H. 29, 57, 107</td>
<td></td>
</tr>
<tr>
<td>Newton, M. 12</td>
<td></td>
</tr>
<tr>
<td>Newton, T. F. 15, 28, 93, 108</td>
<td></td>
</tr>
<tr>
<td>Newville, H. 22</td>
<td></td>
</tr>
<tr>
<td>Nguyen, J. 59</td>
<td></td>
</tr>
<tr>
<td>Nguyen, S. M. 88</td>
<td></td>
</tr>
<tr>
<td>Nic Dhonchadh, B. A. 59</td>
<td></td>
</tr>
<tr>
<td>Nicastr, S. 10</td>
<td></td>
</tr>
<tr>
<td>Nich, C. 98, 110</td>
<td></td>
</tr>
<tr>
<td>Nickell, J. R. 4</td>
<td></td>
</tr>
<tr>
<td>Niculescu, M. 27, 63</td>
<td></td>
</tr>
<tr>
<td>Nielsen, D. A. 98, 99</td>
<td></td>
</tr>
<tr>
<td>Nielsen, E. 98</td>
<td></td>
</tr>
<tr>
<td>Nielsen, S. 105</td>
<td></td>
</tr>
<tr>
<td>Niertert, P. 63</td>
<td></td>
</tr>
<tr>
<td>Nieto, S. J. 59</td>
<td></td>
</tr>
<tr>
<td>Niikura, K. 117</td>
<td></td>
</tr>
<tr>
<td>Nikolopoulos, G. K. 23</td>
<td></td>
</tr>
<tr>
<td>Nilsson, S. 80</td>
<td></td>
</tr>
<tr>
<td>Ninnemann, A. 91</td>
<td></td>
</tr>
<tr>
<td>Nixon, S. J. 102</td>
<td></td>
</tr>
<tr>
<td>Noel, V. 12</td>
<td></td>
</tr>
<tr>
<td>Nollen, N. 25</td>
<td></td>
</tr>
<tr>
<td>Nomura, Y. 67</td>
<td></td>
</tr>
<tr>
<td>Noonan, P. K. 17</td>
<td></td>
</tr>
<tr>
<td>Nordstrom, B. 69</td>
<td></td>
</tr>
<tr>
<td>Norman, A. B. 106</td>
<td></td>
</tr>
<tr>
<td>Nosyk, B. 20, 22</td>
<td></td>
</tr>
<tr>
<td>Novak, S. P. 117</td>
<td></td>
</tr>
<tr>
<td>Nowotny, K. M. 24, 56</td>
<td></td>
</tr>
<tr>
<td>Nunes, E. V. 13, 28, 63, 79, 85, 103, 116, 118</td>
<td></td>
</tr>
<tr>
<td>Nuzzo, P. A. 13, 17</td>
<td></td>
</tr>
<tr>
<td>Nyandindi, C. 89</td>
<td></td>
</tr>
<tr>
<td>Nygard, S. K. 57</td>
<td></td>
</tr>
<tr>
<td>O’Brien, Charles P. 1, 6, 60, 79, 93, 94, 97</td>
<td></td>
</tr>
<tr>
<td>O’Callaghan, J. 115</td>
<td></td>
</tr>
<tr>
<td>O’Connor, K. 68, 101</td>
<td></td>
</tr>
<tr>
<td>O’Connor, P. G. 6, 20, 70</td>
<td></td>
</tr>
<tr>
<td>O’Grady, C. L. 22</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>O'Grady, K. E.</td>
<td>16, 65, 84, 85, 97, 113</td>
</tr>
<tr>
<td>O'Neil, Collin E.</td>
<td>28, 76</td>
</tr>
<tr>
<td>Ogawa, L. M.</td>
<td>15</td>
</tr>
<tr>
<td>Okita, K.</td>
<td>19</td>
</tr>
<tr>
<td>Olaer, M.</td>
<td>4</td>
</tr>
<tr>
<td>Olfsen, E.</td>
<td>99</td>
</tr>
<tr>
<td>Oliver, R. J.</td>
<td>58</td>
</tr>
<tr>
<td>Oliveto, A.</td>
<td>11, 28</td>
</tr>
<tr>
<td>Oltramari, L. C.</td>
<td>84</td>
</tr>
<tr>
<td>Ometto, M.</td>
<td>10</td>
</tr>
<tr>
<td>Oncken, C.</td>
<td>103</td>
</tr>
<tr>
<td>Ondersma, S. J.</td>
<td>65, 66, 82</td>
</tr>
<tr>
<td>Opheim, A.</td>
<td>79</td>
</tr>
<tr>
<td>Orgiles, M.</td>
<td>11, 84, 112</td>
</tr>
<tr>
<td>Ormaechea, R.</td>
<td>108</td>
</tr>
<tr>
<td>Oros, M.</td>
<td>97</td>
</tr>
<tr>
<td>Orson, F. M.</td>
<td>4</td>
</tr>
<tr>
<td>Orza, P. C.</td>
<td>17</td>
</tr>
<tr>
<td>Osborn, L. A.</td>
<td>78</td>
</tr>
<tr>
<td>Oser, C. B.</td>
<td>65, 100, 101, 103</td>
</tr>
<tr>
<td>Othily, E.</td>
<td>66</td>
</tr>
<tr>
<td>Otiashvili, D.</td>
<td>85, 113</td>
</tr>
<tr>
<td>Ott, J.</td>
<td>19, 98, 117</td>
</tr>
<tr>
<td>Owens, D.</td>
<td>73</td>
</tr>
<tr>
<td>Owens, M.</td>
<td>61</td>
</tr>
<tr>
<td>Pacek, L. R.</td>
<td>112</td>
</tr>
<tr>
<td>Pacula, R.</td>
<td>78</td>
</tr>
<tr>
<td>Padula, C. B.</td>
<td>27, 61</td>
</tr>
<tr>
<td>Pagano, A.</td>
<td>112</td>
</tr>
<tr>
<td>Pal, R.</td>
<td>109</td>
</tr>
<tr>
<td>Palatkin, V.</td>
<td>79, 98</td>
</tr>
<tr>
<td>Palfai, T. P.</td>
<td>63</td>
</tr>
<tr>
<td>Palmer, A.</td>
<td>83</td>
</tr>
<tr>
<td>Pan, X.</td>
<td>115</td>
</tr>
<tr>
<td>Panas, L.</td>
<td>86</td>
</tr>
<tr>
<td>Pande-Carter, L.</td>
<td>11</td>
</tr>
<tr>
<td>Pandey, S.</td>
<td>102</td>
</tr>
<tr>
<td>Papaseit, E.</td>
<td>73, 94</td>
</tr>
<tr>
<td>Papini, S.</td>
<td>103</td>
</tr>
<tr>
<td>Parate, A.</td>
<td>109</td>
</tr>
<tr>
<td>Park, M.</td>
<td>73</td>
</tr>
<tr>
<td>Park, T.</td>
<td>117</td>
</tr>
<tr>
<td>Park, Tae Woo</td>
<td>7, 116</td>
</tr>
<tr>
<td>Parker, E.</td>
<td>12</td>
</tr>
<tr>
<td>Parker, M. A.</td>
<td>11</td>
</tr>
<tr>
<td>Parks, K. A.</td>
<td>69</td>
</tr>
<tr>
<td>Parra-Cardona, R.</td>
<td>91</td>
</tr>
<tr>
<td>Parrino, M.</td>
<td>70</td>
</tr>
<tr>
<td>Parry, B. A.</td>
<td>85</td>
</tr>
<tr>
<td>Parsons, J. T.</td>
<td>70</td>
</tr>
<tr>
<td>Partilla, J. S.</td>
<td>17, 73</td>
</tr>
<tr>
<td>Parvaz, M. A.</td>
<td>97</td>
</tr>
<tr>
<td>Pasa, G.</td>
<td>62, 102</td>
</tr>
<tr>
<td>Pascale, A.</td>
<td>108</td>
</tr>
<tr>
<td>Passalacqua, E.</td>
<td>112</td>
</tr>
<tr>
<td>Passetti, L.</td>
<td>110</td>
</tr>
<tr>
<td>Patel, B.</td>
<td>85</td>
</tr>
<tr>
<td>Patrick, M. E.</td>
<td>10, 102</td>
</tr>
<tr>
<td>Patrikeeva, S.</td>
<td>82</td>
</tr>
<tr>
<td>Patterson, T. L.</td>
<td>64</td>
</tr>
<tr>
<td>Paulus, M. P.</td>
<td>93</td>
</tr>
<tr>
<td>Pavlicova, M.</td>
<td>16, 63, 83, 85, 116</td>
</tr>
<tr>
<td>Pavlikova, M.</td>
<td>28</td>
</tr>
<tr>
<td>Payer, Doris</td>
<td>19, 29, 73</td>
</tr>
<tr>
<td>Pechansky, F. P.</td>
<td>9, 62, 73, 83, 91, 102, 109</td>
</tr>
<tr>
<td>Pecoraro, A.</td>
<td>87</td>
</tr>
<tr>
<td>Pedrosa, R. S.</td>
<td>83, 91, 109</td>
</tr>
<tr>
<td>Peindl, K. S.</td>
<td>79</td>
</tr>
<tr>
<td>Peirce, J. M.</td>
<td>66, 111</td>
</tr>
<tr>
<td>Peles, E.</td>
<td>20, 98</td>
</tr>
<tr>
<td>Peltier, MacKenzie R.</td>
<td>25</td>
</tr>
<tr>
<td>Pena, C. J.</td>
<td>58</td>
</tr>
<tr>
<td>Pena, D. F.</td>
<td>106</td>
</tr>
<tr>
<td>Peng, C.</td>
<td>69</td>
</tr>
<tr>
<td>Penn, P.</td>
<td>67</td>
</tr>
<tr>
<td>Pentel, P. R.</td>
<td>77</td>
</tr>
<tr>
<td>Pentkowski, N. S.</td>
<td>58</td>
</tr>
<tr>
<td>Peraza, J.</td>
<td>62</td>
</tr>
<tr>
<td>Pereira, A. D.</td>
<td>84</td>
</tr>
<tr>
<td>Peres, G. M.</td>
<td>84</td>
</tr>
<tr>
<td>Pérez de los Cobos Peris,</td>
<td>105, 117</td>
</tr>
<tr>
<td>Pérez-Dandieu, B.</td>
<td>66</td>
</tr>
<tr>
<td>Pérez-Manà, C.</td>
<td>73, 94</td>
</tr>
<tr>
<td>Perez, C.</td>
<td>113</td>
</tr>
<tr>
<td>Pericot-Valverde, I.</td>
<td>14</td>
</tr>
<tr>
<td>Perlman, D.</td>
<td>4, 21, 56, 88</td>
</tr>
<tr>
<td>Perna, M. K.</td>
<td>12</td>
</tr>
<tr>
<td>Perrey, D. A.</td>
<td>16</td>
</tr>
<tr>
<td>Perrin, N.</td>
<td>20</td>
</tr>
<tr>
<td>Perrino, P. J.</td>
<td>17</td>
</tr>
<tr>
<td>Perrone-Bizozero, N. I.</td>
<td>58</td>
</tr>
<tr>
<td>Persidsky, Yuri</td>
<td>71</td>
</tr>
<tr>
<td>Persons, A. L.</td>
<td>18</td>
</tr>
<tr>
<td>Peters, J.</td>
<td>98</td>
</tr>
<tr>
<td>Peterson, J.</td>
<td>20</td>
</tr>
<tr>
<td>Peterson, T.</td>
<td>65</td>
</tr>
<tr>
<td>Petras, H. 72, 92</td>
<td>108</td>
</tr>
<tr>
<td>Petry, N.</td>
<td>108</td>
</tr>
<tr>
<td>Pettenon, M.</td>
<td>83, 109</td>
</tr>
<tr>
<td>Pettinati, H. M.</td>
<td>6</td>
</tr>
<tr>
<td>Pettoruto, K.</td>
<td>14</td>
</tr>
<tr>
<td>Pezzi, J.</td>
<td>114</td>
</tr>
<tr>
<td>Pfaff, M.</td>
<td>119</td>
</tr>
<tr>
<td>Philip, P.</td>
<td>109</td>
</tr>
<tr>
<td>Phillips, K. A.</td>
<td>19, 64, 65, 81</td>
</tr>
<tr>
<td>Phillips, K. T.</td>
<td>15</td>
</tr>
<tr>
<td>Phillips, M. M.</td>
<td>15</td>
</tr>
<tr>
<td>Philogene, H.</td>
<td>13</td>
</tr>
<tr>
<td>Pianca, T. G.</td>
<td>83</td>
</tr>
<tr>
<td>Picetti, R.</td>
<td>58</td>
</tr>
<tr>
<td>Pickworth, W.</td>
<td>112</td>
</tr>
<tr>
<td>Pienta, A.</td>
<td>94</td>
</tr>
<tr>
<td>Pieterse, D.</td>
<td>91, 102</td>
</tr>
<tr>
<td>Pike, E.</td>
<td>4, 10, 11</td>
</tr>
<tr>
<td>Pilla, M.</td>
<td>105</td>
</tr>
<tr>
<td>Pinals, D. A.</td>
<td>68, 101</td>
</tr>
<tr>
<td>Pirie, P.</td>
<td>12</td>
</tr>
<tr>
<td>Plebani, J. G.</td>
<td>6</td>
</tr>
<tr>
<td>Poe, M.</td>
<td>105</td>
</tr>
<tr>
<td>Polak, K. M.</td>
<td>9</td>
</tr>
<tr>
<td>Polcin, D. L.</td>
<td>107</td>
</tr>
<tr>
<td>Pollack, L.</td>
<td>83</td>
</tr>
<tr>
<td>Pollini, R. 70, 102</td>
<td>102</td>
</tr>
<tr>
<td>Polishkova, S.</td>
<td>5</td>
</tr>
<tr>
<td>Pomm, D.</td>
<td>9</td>
</tr>
<tr>
<td>Poppa, N.</td>
<td>93</td>
</tr>
<tr>
<td>Porrino, Linda</td>
<td>96</td>
</tr>
<tr>
<td>Posse, S.</td>
<td>93</td>
</tr>
<tr>
<td>Potenza, M. N.</td>
<td>94, 98</td>
</tr>
<tr>
<td>Potts, J.</td>
<td>112</td>
</tr>
<tr>
<td>Pouget, E. R. 22, 23, 94</td>
<td>108</td>
</tr>
<tr>
<td>Power, K. A.</td>
<td>104</td>
</tr>
<tr>
<td>Prado, G.</td>
<td>95, 101</td>
</tr>
<tr>
<td>Author</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Prado, M. C.</td>
<td>84</td>
</tr>
<tr>
<td>Prescott, J.</td>
<td>105</td>
</tr>
<tr>
<td>Preston, Kenzie L.</td>
<td>64, 65, 75, 81</td>
</tr>
<tr>
<td>Pribasnig, A.</td>
<td>21</td>
</tr>
<tr>
<td>Price, J. S.</td>
<td>61</td>
</tr>
<tr>
<td>Price, R. K. 102, 112</td>
<td></td>
</tr>
<tr>
<td>Prisciandaro, J.</td>
<td>61</td>
</tr>
<tr>
<td>Prisinzano, Thomas E.</td>
<td>114, 117</td>
</tr>
<tr>
<td>Pritchett, L.</td>
<td>57</td>
</tr>
<tr>
<td>Pronk, T. W.</td>
<td>13</td>
</tr>
<tr>
<td>Proud[t, G. H.</td>
<td>97</td>
</tr>
<tr>
<td>Przybyla, S.</td>
<td>69</td>
</tr>
<tr>
<td>Pudiaik, C.</td>
<td>108</td>
</tr>
<tr>
<td>Pujadas, M.</td>
<td>73</td>
</tr>
<tr>
<td>Pullen, E. L. 101, 103</td>
<td></td>
</tr>
<tr>
<td>Puntes, M.</td>
<td>117</td>
</tr>
<tr>
<td>Purohit, Vishnudutt</td>
<td>71</td>
</tr>
<tr>
<td>Puttick, D.</td>
<td>25</td>
</tr>
<tr>
<td>Pyles, R. B. 58</td>
<td></td>
</tr>
<tr>
<td>Quinn, A.</td>
<td>86</td>
</tr>
<tr>
<td>Quinn, B. 64, 92, 101</td>
<td></td>
</tr>
<tr>
<td>Quinn, E. K.</td>
<td>89</td>
</tr>
<tr>
<td>Quinones-Jenab, V.</td>
<td>57</td>
</tr>
<tr>
<td>Quisenberry, A.</td>
<td>25</td>
</tr>
<tr>
<td>Rabinovitz, S.</td>
<td>116</td>
</tr>
<tr>
<td>Rabj, Wilfrid N.</td>
<td>28</td>
</tr>
<tr>
<td>Racine, M.</td>
<td>95</td>
</tr>
<tr>
<td>Rabin, A.</td>
<td>16</td>
</tr>
<tr>
<td>Rafat, B. 104</td>
<td></td>
</tr>
<tr>
<td>Rafful, C. 88</td>
<td></td>
</tr>
<tr>
<td>Raj, A. 89</td>
<td></td>
</tr>
<tr>
<td>Rajan, S. 22</td>
<td></td>
</tr>
<tr>
<td>Ramesh, D. 10, 93</td>
<td></td>
</tr>
<tr>
<td>Ramirez, R. 101</td>
<td></td>
</tr>
<tr>
<td>Ramirez, S. H. 106</td>
<td></td>
</tr>
<tr>
<td>Ramos, C. 86</td>
<td></td>
</tr>
<tr>
<td>Ramsey, A. 110</td>
<td></td>
</tr>
<tr>
<td>Randesi, M. 19, 98</td>
<td></td>
</tr>
<tr>
<td>Ranney, M. 12, 103</td>
<td></td>
</tr>
<tr>
<td>Rao, H. 25, 61</td>
<td></td>
</tr>
<tr>
<td>Ratcliffe, S. 77</td>
<td></td>
</tr>
<tr>
<td>Rathnayaka, N. 15, 18, 103, 113</td>
<td></td>
</tr>
<tr>
<td>Ravven, S. 104</td>
<td></td>
</tr>
<tr>
<td>Rawlinson, W. 3</td>
<td></td>
</tr>
<tr>
<td>Rawls, S. 13, 16, 106</td>
<td></td>
</tr>
<tr>
<td>Rawson, R. 27, 60</td>
<td></td>
</tr>
<tr>
<td>Ray, B. M. 9</td>
<td></td>
</tr>
<tr>
<td>Ray, S. 60</td>
<td></td>
</tr>
<tr>
<td>Ray, T. 20</td>
<td></td>
</tr>
<tr>
<td>Raymond, H. 22</td>
<td></td>
</tr>
<tr>
<td>Raymond, K. M. 11</td>
<td></td>
</tr>
<tr>
<td>Rebossin, B. A. 16, 83</td>
<td></td>
</tr>
<tr>
<td>Reddel, S. 105</td>
<td></td>
</tr>
<tr>
<td>Reddy, A. 65</td>
<td></td>
</tr>
<tr>
<td>Redish, A. D. 113</td>
<td></td>
</tr>
<tr>
<td>Redner, R. 13, 67</td>
<td></td>
</tr>
<tr>
<td>Reed, B. 9</td>
<td></td>
</tr>
<tr>
<td>Reed, S. 4</td>
<td></td>
</tr>
<tr>
<td>Reese, R. 65</td>
<td></td>
</tr>
<tr>
<td>Regier, P. S. 113</td>
<td></td>
</tr>
<tr>
<td>Reichel, C. M. 98</td>
<td></td>
</tr>
<tr>
<td>Reid, H. H. 67</td>
<td></td>
</tr>
<tr>
<td>Reif, S. 77, 86</td>
<td></td>
</tr>
<tr>
<td>Reischl, T. 12</td>
<td></td>
</tr>
<tr>
<td>Reiss, D. 72</td>
<td></td>
</tr>
<tr>
<td>Reissig, C. J. 104, 113</td>
<td></td>
</tr>
<tr>
<td>Reiz, J. 89</td>
<td></td>
</tr>
<tr>
<td>Remy, L. S. 73</td>
<td></td>
</tr>
<tr>
<td>Renda, H. J. 70</td>
<td></td>
</tr>
<tr>
<td>Reno, A. 62</td>
<td></td>
</tr>
<tr>
<td>Renshaw, P. F. 111</td>
<td></td>
</tr>
<tr>
<td>Ressler, K. J. 99</td>
<td></td>
</tr>
<tr>
<td>Rethorst, C. D. 108</td>
<td></td>
</tr>
<tr>
<td>Reynolds, B. 12</td>
<td></td>
</tr>
<tr>
<td>Reynolds, E. 84</td>
<td></td>
</tr>
<tr>
<td>Reynolds, J. 60, 110</td>
<td></td>
</tr>
<tr>
<td>Reynolds, M. D. 84</td>
<td></td>
</tr>
<tr>
<td>Rhodes, J. 68, 69</td>
<td></td>
</tr>
<tr>
<td>Riba, J. 117</td>
<td></td>
</tr>
<tr>
<td>Ribeiro Schneider, D. 105</td>
<td></td>
</tr>
<tr>
<td>Rice, Kenner 96, 107</td>
<td></td>
</tr>
<tr>
<td>Rich, M. T. 58</td>
<td></td>
</tr>
<tr>
<td>Richardson, D. R. 116</td>
<td></td>
</tr>
<tr>
<td>Richardson, J. 104</td>
<td></td>
</tr>
<tr>
<td>Rico, M. 65, 87</td>
<td></td>
</tr>
<tr>
<td>Ridenour, T. 84</td>
<td></td>
</tr>
<tr>
<td>Rieckmann, T. R. 79</td>
<td></td>
</tr>
<tr>
<td>Riggs, L. M. 59</td>
<td></td>
</tr>
<tr>
<td>Riggs, Paula D. 3</td>
<td></td>
</tr>
<tr>
<td>Riley, A. L. 16, 107, 119</td>
<td></td>
</tr>
<tr>
<td>Ring, K. M. 108</td>
<td></td>
</tr>
<tr>
<td>Rios, E. 21</td>
<td></td>
</tr>
<tr>
<td>Risco, C. M. 84</td>
<td></td>
</tr>
<tr>
<td>Rising, K. 78</td>
<td></td>
</tr>
<tr>
<td>Ritter, G. 86</td>
<td></td>
</tr>
<tr>
<td>Ritter, K. 88</td>
<td></td>
</tr>
<tr>
<td>Rivas, G. 95</td>
<td></td>
</tr>
<tr>
<td>Rivera, A. V. 92</td>
<td></td>
</tr>
<tr>
<td>Rivera, S. 24, 80</td>
<td></td>
</tr>
<tr>
<td>Riyad, C. 63</td>
<td></td>
</tr>
<tr>
<td>Roark, M. 11</td>
<td></td>
</tr>
<tr>
<td>Roberts, M. 20</td>
<td></td>
</tr>
<tr>
<td>Roberts, W. 97</td>
<td></td>
</tr>
<tr>
<td>Robertson, C. 60</td>
<td></td>
</tr>
<tr>
<td>Robertson, K. 22</td>
<td></td>
</tr>
<tr>
<td>Robson, M. 115</td>
<td></td>
</tr>
<tr>
<td>Rocha, Beatriz 1, 76</td>
<td></td>
</tr>
<tr>
<td>Rodriguez, A. 23</td>
<td></td>
</tr>
<tr>
<td>Rodriguez, K. 117</td>
<td></td>
</tr>
<tr>
<td>Rodriguez, L. 6</td>
<td></td>
</tr>
<tr>
<td>Rodriguez, M. 21</td>
<td></td>
</tr>
<tr>
<td>Roesch, S. 64</td>
<td></td>
</tr>
<tr>
<td>Rogers, T. J. 58</td>
<td></td>
</tr>
<tr>
<td>Rognli, E. B. 24</td>
<td></td>
</tr>
<tr>
<td>Rogowska, J. 118</td>
<td></td>
</tr>
<tr>
<td>Rohde, L. A. 72</td>
<td></td>
</tr>
<tr>
<td>Roley, J. 22</td>
<td></td>
</tr>
<tr>
<td>Roll, J. 118</td>
<td></td>
</tr>
<tr>
<td>Roma, P. G. 64</td>
<td></td>
</tr>
<tr>
<td>Roman, P. M. 77</td>
<td></td>
</tr>
<tr>
<td>Romero-Gonzalez, M. 80</td>
<td></td>
</tr>
<tr>
<td>Rosa, Carmen 76</td>
<td></td>
</tr>
<tr>
<td>Rosa, R. L. 83</td>
<td></td>
</tr>
<tr>
<td>Rose, J. 118</td>
<td></td>
</tr>
<tr>
<td>Rose, J. L. 17</td>
<td></td>
</tr>
<tr>
<td>Rose, J. S. 91</td>
<td></td>
</tr>
<tr>
<td>Rosen, M. 77</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, D. 21</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, H. 15, 69, 78, 104</td>
<td></td>
</tr>
<tr>
<td>Rosenblerry, Z. 112</td>
<td></td>
</tr>
<tr>
<td>Rosenblum, A. 70, 90</td>
<td></td>
</tr>
<tr>
<td>Ross-Durow, P. L. 70</td>
<td></td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Ross, J. 94, 111
Rossi, P. 111
Rothman, E. F. 14
Rothman, R. B. 17, 73
Rotrosen, J. 77, 78, 85, 98
Rowe, M. C. 57
Rowlett, James 92
Roy, E. 64
Rubenstein, L. 85
Rubinstein, M. 27
Ruby, J. 80
Ruglass, L. M. 14, 94
Ruiz, J. J. 80
Ruktanonchai, C. 91
Runyon, Scott P. 23, 24
Rupprecht, L. E. 58
Rupslaukyte, R. E. 27
Rush, C. R. 4, 10, 11, 19, 98
Russell, B. R. 61
Ryan, S. 20
Ryan, S. R. 15
Rybarczyk, B. 64
Rycroft, W. 105
Saavedra, J. L. 58
Sacco, P. A. 18
Sacks, S. 111
Sadler, C. 95
Saeki, T. 58
Saenz, E. 69
Safford, M. 71
Sagar, K. 95
Saika, F. 13
Saitz, Richard 7, 63, 77, 117
Sakai, J. 110
Saladin, M. E. 61, 63
Salas-Ramirez, K. Y. 107
Salas, R. 108
Saldana, L. 97
Salemink, E. 83
Salvatore, C. 119
Salvatore, M. F. 106
Samet, J. 3, 6, 22, 89
Samet, Jeffrey H. 3, 7, 63, 75
Samolski, M. R. 112
Sanchez-Huesca, R. 86
Sanchez, K. 108
Sanchez, Z. M. 56, 84
Sandoval, M. 22, 23, 88
Sandstrom, L. E. 20
Santa Ana, E. J. 63
Santaella, J. 21
Santana, J. 23
Santiago-Negron, S. 113
Santos, B. 10
Sanudo, A. 56
Sason, A. 20
Sawh, L. 68, 101
Sawyer, B. 97
Saxon, Andrew 76
Schacht, R. L. 66
Schackman, B. 23
Schaub, M. P. 15
Scheidell, J. 91, 100
Scheidell, J. D. 88, 100
Scherrer, J. 112
Scheuermann, T. S. 25
Schindler, E. 67
Schmidt, L. 64, 87
Schmidt, N. B. 63
Schmitz, Joy 10, 15, 18, 98, 99, 103, 109, 113
Schneider, D. R. 84
Schoedel, Kerri A. 17, 29, 89, 105
Scholtz, J. 65, 87
Schottenfeld, R. S. 6, 19, 70
Schreiber, S. 20
Schreiner, D. 28
Schroeder, J. R. 17
Schroeter, D. 77
Schuetze, P. 82
Schuler, M. 84
Schulte, M. T. 56, 81
Schumacher, J. 62
Schwartz, R. P. 65, 68, 84, 86, 97
Scofield, M. 98, 116
Scott, C. K. 65
Seay, K. D. 84
Secades-Villa, R. 14, 68, 118
Seguí, G. 117
Seitz-Brown, C. 102
Selby, P. L. 68
Sellers, E. M. 89, 105
Seong, W. 15
Serre, F. 109, 110, 118
Sesana, F. 70
Setlik, W. 59
Setnik, Beatrice 1, 117
Severtson, S. G. 80, 90
Sferra, M. S. 15
Sgro, M. 18
Shadur, J. M. 11, 62, 111
Shaham, Yavin 2, 58, 116
Shahbabaie, A. 10
Shane, M. 93
Shapiro, J. 14
Sharma, G. 28, 85
Shaw, D. 72
Shelldow, A. J. 97
Sheikhattari, P. 14, 111
Sheldon, Behshad 4
Shelley, D. 77
Shervani, S. 11
Sheth, A. P. 92
Shibasaki, M. 58, 106
Shin, J. 15
Shin, S. 119
Shishkoff, G. E. 62
Shisler, S. 82
Shmulewitz, D. 99
Shollenbarger, S. 61
Shoptaw, Steven 6, 10, 26, 27, 108
Shorey, R. C. 64, 91
Shram, M. 17
Shrestha, R. 69
Shroff, M. 69, 112
Shu, I. 68
Shuster, E. 20
Siffin, K. E. 63
Sigmon, S. C. 10, 21, 81, 102
Sigurdsson, S. O. 86
Sikkema, K. 104
Silberg, J. 83
Silber, J. 83
Silva, L. 57
Silva, M. 10
Silverman, K. 86
Simmons, J. 97
Simon, P. 83
Simpson, J. 108
Singer, S. 68, 101
Singer, Z. 97
Sinha, Rajita 2
Skalski, L. 104
Skanderson, M. 89
Skelly, J. M. 13, 94
Skinner, D. 91, 102
Skrajewski, J. 69
Skranes, J. 72
Slade, T. 94, 111
Slesnick, N. 84, 86
Sloan, C. A. 64
Smelson, D. 10, 68, 80, 101
Smethells, J. R. 106
Smith, G. A. 92
Smith, K. M. 66
Smith, K. Z. 104
Smith, M. 90, 95
Smith, M. A. 17, 59
Smith, P. H. 66, 91
Smith, S. L. 107
Smith, T. 17
Smith, V. C. 87
Sofuoglu, M. 28, 99
Sokolowska, Marta 76
Solberg, T. D. 116
Soldigner, J. 64
Somaini, L. 70
Somkuwar, S. S. 117
Sommerville, K. W. 117
Song, K. H. 116
Song, L. 28
Song, M. 15
Sorbero, M. 78
Sordi, A. O. 9
Sorensen, James 22, 56, 75
Soriano, F. I. 113
Soto, C. 58
Soules, M. E. 119
Souza, T. R. 62, 102
Spangler, J. 16
Sparenborg, S. 28
 Spealman, R. D. 17
Spear, S. E. 101
Specker, S. 118
Spence, A. 105
Spirito, A. 83
Spitznagel, E. 14
Sproule, B. 78, 104
Squires, D. 103
St. Laurent, R. M. 116
Stadnik, R. 62
Stafford, A. M. 62
Stahl, N. F. 14
Stahler, G. 110
Stairs, D. J. 119
Staley, M. 77
Stall, R. 88
Stanger, C. 12, 95
Stankeviciute, N. 116
Staton-Tindall, M. 100, 101
Stavseth, L. S. 79
Stein, B. D. 78
Steinberg, D. B. 119
Steinberg, J. L. 93
Steinberg, M. L. 14, 85
Stemmier, S. M. 108
Stepp, S. 96
Stevens-Watkins, D. 101
Stewart, J. L. 93
Stewart, M. 77, 86
Stiles, G. 20
Stitzer, M. L. 95
Stockstad, M. 66
Stoddard, S. A. 12
Stolf, A. R. 109
Stoller, K. B. 16
Stoltman, J. J. 25, 88
Stone, K. L. 58
Stoops, William W. 4, 10, 11, 19, 95, 98
Stoohoff, B. 27
Strain, Eric C. 5, 27, 30, 63, 70, 86
Strathdee, S. 64, 88
Stratton, K. 111
Strauss, S. 77
Streit, C. 11
Strickland, J. C. 17
Strickland, J. T. 59
Striley, C. W. 9, 90, 91, 118
Stuart, E. 84
Stuart, G. L. 64, 91
Stutz, S. J. 17, 28, 58
Suchting, R. 103, 109, 113
Suerken, C. K. 16
Sugarman, D. 84
Sugita, W. 27
Suh, Jesse 60, 93, 94, 97
Sullivan, M. A. 79, 83, 89
Sulzer, D. 59
Sun, H. 58
Surratt, H. 22, 73, 89, 90
Sussman, S. 112
Sutfin, Erin L. 16, 26
Suzuki, T. 58, 62, 106
Svikis, D. 9, 64, 66, 70, 82, 108, 111
Swanson, A. 10
Swendsen, J. 110
Swieter, Mark 74
Swinford-Jackson, S. E. 58
Szczytkowski-Thomson, J. 115
Szeliga, K. T. 107
Szobot, C. M. 72
Tabaja, N. 106
Tabet, M. R. 106
Taffe, Michael A. 29, 59, 107
Taha, F. 14
Taherian, M. 62
Taillard, J. 109
Tajima, B. 112
Takanohashi, A. 58
Taki, F. A. 115
Talati, A. 67
Tallarida, C. S. 13, 16, 106
Tamarit, C. 111
Tanabe, J. 60, 110
Tanda, G. 107
Tanizaki, N. 22
Tanum, L. 79
Tape, C. 103
Tapert, S. F. 93
Tapia, G. 66
AUTHOR INDEX

Tarter, R. 82
Tate, J. 89
Taxman, F. 23, 24, 66
Taylor, J. R. 58
Tedford, S. E. 18
Teer, A. 102, 103
Teer, D. 67
Teesson, Maree 71, 94, 111
Teitell, S. 104
Teixeira, A. L. 114
Temple, J. 82
Templos-Nuñez, L. 86
Tene, O. 20
Tennent, H. 90
Ternes, M. 24
Terplan, M. 82, 85, 103
Tessari, M. 105
Thacker, L. 9
Thamotharan, S. 15, 56
Thanos, Peter 23
Thibault, K. 24
Thiele, T. 115
Thing, J. 64, 92
Thomas, B. F. 16
Thomas, E. 113
Thomas, L. N. 106
Thompson-Lake, D. G. 15, 28, 108
Thompson, D. 85, 89
Thompson, L. 60, 110
Thorber, F. A. 63, 64
Thorn, D. A. 28
Thornton, T. 24
Thostenson, J. D. 11, 28
Thurstone, C. 97
Tiberg, Fredrik 4
Tidey, J. W. 12
Tidgewell, Kevin 114
Tiffany, E. 20
Tirurina, A. 79
Tobias, M. D. 119
Todenkopf, M. 18
Töfghi, B. 80
Toliver, J. M. 113
Tomkins, D. A. 63
Tormohlen, K. N. 13
Torregrossa, M. M. 58
Torrens, M. 73, 94, 111
Torres Cardona, F. 23
Torres, C. A. 59
Torres, L. M. 24
Torrington, M. 4
Toussaint, A. 57
Towe, S. 22, 67, 91, 104
Tracy, K. 110
Tran, P. 88
Trenz, R. 88
Tripathi, S. 18
Tripathi, M. H. 108
Trivedi, G. H. 61
Trouba, C. 109
Troyer, M. 89
Trull, T. J. 64
Tsay, W. 81
Tsang, J. 10
Tsui, Judith I. 3, 6
Tsuyuki, K. 22
Turner, R. 115
Tyburski, M. 65
Tyson, A. 13
Tyssen, R. 63
Uddin, M. 99
Udel de Haes, J. 89
Ueland, T. 115
Unterwald, Ellen M. 58, 96
Urada, D. 20
Uribé, K. 107
Vaddiparti, K. 90, 118
Vahabzadeh, M. 65
Vahidi, M. 65, 87
Valdez, A. 24, 91
Valenzuela, M. 58
Valle, M. 117
Vallender, E. J. 15, 112
Vallette, M. 110
van den Berk-Clark, C. 69, 102, 112
van den Brink, W. 19
van Ree, J. M. 19
Vandewater, S. A. 59, 107
Vandrey, R. 16, 95
Varga, M. 13
Vargas Vidot, J. 23
Vasilev, G. 25
Vasquez, E. 27
Vassileva, J. 25, 56
Vaughan, B. 116
Vega, G. D. 24
Vélez, M. 100
Veliz, P. T. 70, 118
Vensisse, J. 110
Verbitskaya, E. 79, 98
Verdeja, R. 86
Vernikovskaya, D. 82
Verno, T. 64
Verona, E. 86
Verrico, C. D. 15, 19
Vidal, L. 107
Vidot, Denise C. 82, 95, 102
Vijay, A. 62
Villalobos, G. 66, 70
Vincent, K. B. 16
Vinci, C. 62
Viola, T. W. 114
Viray, L. 112
Vladimirovna, Y. 77
Voci, Jr., Frank 1, 4
Vojtech, J. M. 104
Volkow, Nora D. 1, 23
Voll, R. 57
von Diemen, L. 9
Vorel, S. R. 13
Vouga, A. 16
Vranjkovic, O. 106
Vsevolozhskaya, O. 113
Vu, V. D. 88
Vujanovic, A. 109
Vuolo, M. 70
Wachholtz, A. 6
Wagenaar, A. 71
Wagner, F. A. 14, 111
Wagner, K. O. 64
Wagoner, K. G. 16
Wakeford, A. G. 16
Walcher, S. 70
Valentiny, D. M. 18
AUTHOR INDEX

Walker, E. A. 57
Walker, R. 98, 108
Wall, M. 67
Walley, A. Y. 20, 89
Walsh, Bob 4
Walsh, K. 65
Walsh, Sharon L. 13, 17, 29, 76
Walters, S. 66
Walters, V. 64
Walton, M. A. 5, 12, 70
Wang, A. 60, 94
Wang, H. 116
Wang, N. Y. 21
Wang, R. 3
Wang, S. 21
Wang, X. 82
Wang, Y. 56
Wang, Z. 60
Ward, S. J. 57
Warren, M. 110
Warren, O. 78
Washio, Y. 81
Watt, M. 102
Watt, M. H. 91
Wearick, L. E. 114
Weatherburn, D. J. 25
Weaver, D. 70
Webster, L. R. 90, 117
Webster, M. 100, 101
Wechsberg, W. 85, 113
Weerts, E. 27
Weerts, Elise 27
Weidberg, S. 68
Weinstein, A. M. 60
Weinstein, D. 62
Weisberg, D. 89
Weiss, F. 106
Weiss, R. 79, 85, 110
Weiss, V. G. 59
Wells, B. E. 70
Wenger, L. 64, 92, 117
Wernitz, A. 64
Wesley, M. J. 93, 109
Westmoreland, S. V. 15
Wetherill, R. R. 25, 61, 93
Wetherington, Cora Lee 114
Wetle, T. 103
Wetzell, B. B. 107, 119
Wheeler, P. 3
White, B. 3
White, David A. 7
White, T. J. 13, 67
Whitehead, N. E. 3, 100
Whiteside, L. K. 70
Wickersham, J. A. 100
Widner, G. 69, 112
Wiers, R. W. 13, 83
Wieser, J. 61
Wigderson, S. 84
Wild, C. 17, 28
Wild, C. M. 20, 104
Wildman, D. E. 99
Wiley, J. L. 57
Williams, C. 62
Williams, J. 102
Williams, J. M. 14
Williams, K. 88
Williams, T. V. 77
Wilson, A. G. 65
Wilson, J. L. 23
Wilson, M. J. 25
Wilson, S. J. 62
Winhusen, T. 13, 20, 28
Winstanley, E. L. 20, 104
Winter, M. R. 6
Winters, Ken 12, 30, 83
Witte, M. A. 17
Wohl, D. 100
Wolford-Celvenger, C. 91
Wolffson, M. 16
Wood, E. 22
Woodcock, E. A. 25, 78
Wooditch, A. 24
Woods, James H. 18, 57, 96
Woodworth, A. 69
Woody, G. E. 79, 87, 92, 98, 109
Woolley, J. 62
Worley, Matthew J. 6
Wray, T. B. 12
Wrede, F. 86
Wright IV, C. 13

Wright, N. E. 15, 27
Wu, E. 81
Wu, H. 56, 90, 103
Wu, J. 3
Wu, L. 79
Wu, P. 62
Wu, Y. 10
Wuerzl, J. 21
Wulach, L. 89
Wulach, L. A. 3
Wutchiett, D. M. 3, 21
Xu, X. 91
Xuan, L. 58
Xuan, Z. 117
Xue, L. 82
Xue, W. 91

Yacenda, J. 65, 87
Yamakawa, R. 82
Yamamoto, C. 13
Yamamoto, D. 60
Yang, H. 23
Yang, Y. 3
Yao, J. 70, 102
Yaroslatseva, T. 79
Yates, J. R. 59
Ye, H. 19
Yeh, H. H. 102
Yemini, P. 108
Yi, R. 13
Yi, Y. 10
Yip, B. 22
Yip, S. W. 94
Yonkers, K. A. 72
Yoon, J. H. 15
Young, J. 18
Young, K. A. 60, 93
Young, M. M. 73
Young, R. M. 63
Young, S. 11, 100
Yuan, A. H. 85
Yuferov, V. 19, 58
Yurgelun-Todd, D. 118
Zah, V. 80
AUTHOR INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zaks, M. E.</td>
<td>18</td>
</tr>
<tr>
<td>Zaller, N.</td>
<td>78</td>
</tr>
<tr>
<td>Zamanian, B.</td>
<td>10</td>
</tr>
<tr>
<td>Zamora, N. N.</td>
<td>59</td>
</tr>
<tr>
<td>Zanetello, L. B.</td>
<td>83</td>
</tr>
<tr>
<td>Zapor, H.</td>
<td>91</td>
</tr>
<tr>
<td>Zavala, A. R.</td>
<td>59</td>
</tr>
<tr>
<td>Zavala, R.</td>
<td>80</td>
</tr>
<tr>
<td>Zavaschi, M.</td>
<td>72</td>
</tr>
<tr>
<td>Zawertailo, Laurie</td>
<td>29, 68</td>
</tr>
<tr>
<td>Zelenock, K. A.</td>
<td>18</td>
</tr>
<tr>
<td>Zeng, H.</td>
<td>19</td>
</tr>
<tr>
<td>Zeric, T.</td>
<td>58</td>
</tr>
<tr>
<td>Zevallos, K.</td>
<td>112</td>
</tr>
<tr>
<td>Zhang, B.</td>
<td>115</td>
</tr>
<tr>
<td>Zhang, F.</td>
<td>58</td>
</tr>
<tr>
<td>Zhang, G.</td>
<td>17, 28</td>
</tr>
<tr>
<td>Zhang, M.</td>
<td>104</td>
</tr>
<tr>
<td>Zhang, S.</td>
<td>58</td>
</tr>
<tr>
<td>Zhang, Y.</td>
<td>16, 18, 28, 59, 117</td>
</tr>
<tr>
<td>Zhao, M.</td>
<td>81</td>
</tr>
<tr>
<td>Zheng, W.</td>
<td>16</td>
</tr>
<tr>
<td>Zheng, X.</td>
<td>19</td>
</tr>
<tr>
<td>Zhou, J.</td>
<td>17, 28</td>
</tr>
<tr>
<td>Zhou, W.</td>
<td>16</td>
</tr>
<tr>
<td>Zhou, Y.</td>
<td>27</td>
</tr>
<tr>
<td>Zhu, J.</td>
<td>18, 116</td>
</tr>
<tr>
<td>Zhu, X.</td>
<td>93</td>
</tr>
<tr>
<td>Zimmer, J.</td>
<td>15</td>
</tr>
<tr>
<td>Zimmerman, M.</td>
<td>12</td>
</tr>
<tr>
<td>Zlebnik, N.</td>
<td>59</td>
</tr>
<tr>
<td>Zlotnick, C.</td>
<td>103</td>
</tr>
<tr>
<td>Zucker, R. A.</td>
<td>61, 119</td>
</tr>
<tr>
<td>Zule, W.</td>
<td>85, 88, 113</td>
</tr>
<tr>
<td>Zvartau, E.</td>
<td>79, 98</td>
</tr>
<tr>
<td>Zvolensky, M. J.</td>
<td>63, 67</td>
</tr>
</tbody>
</table>
SYMPOSIA

Sunday, June 15

I. Stress and relapse to drug use: From animal models to clinical trials
   Chairs: John Mantsch and Yavin Shaham

The pervasive and uncontrollable nature of stress makes the ability of stressful life events to promote drug use and relapse highly problematic for addicts. Therefore, understanding the neurobiological processes that underlie stress-related relapse to drug use is important for the development of new and more effective therapeutic approaches. Research on this topic has relied heavily on preclinical rodent models. However, such models are only useful insofar as they have predictive validity (i.e., the ability to model the human condition and to identify effective treatments). This symposium brings together preclinical and clinical addiction researchers to explore how findings from studies using rodent models of stress-induced drug relapse relate to human drug addiction. The results of rodent studies investigating stress-induced relapse and the underlying neurobiological mechanisms will be presented and their ability to inform drug development and treatment efforts will be discussed. These results will be related to research findings in human populations examining the dysregulation of the stress response in drug-dependent individuals, the relationship between stress-induced craving and relapse risk, the influence of early-life trauma and co-morbid stress-related pathology on drug use and relapse, and targeted medications to prevent stress-induced drug craving and relapse. The goal of the symposium is to promote dialogue and collaboration among preclinical and clinical researchers with the hope that it will guide the establishment of more effective treatment strategies, particularly those aimed at minimizing the contribution of stress to drug addiction and relapse.

II. Up in smoke: Cannabis and tobacco, linked at the hip and double trouble
   Chairs: Alan J. Budney and Frances Kay-Lambkin

High prevalence of concurrent use of cannabis and tobacco among adolescents and adults raises multiple public health concerns. There remains a pressing need for more scientific attention to this pattern of substance use, particularly with an increased societal focus on marijuana legalization. This symposium will enhance the audience’s understanding of the associations between and consequences of concurrent use of cannabis and tobacco, with outcomes from laboratory and clinical studies illustrating its complexities and challenges. The role of shared genetic influences on cannabis and tobacco during its earliest stages of use (initial reactions and age of onset) and later stages (withdrawal and dependence) will be reviewed. Data from laboratory studies showing that daily marijuana smokers who smoke tobacco are more likely to relapse to marijuana, with subsequent studies showing that active tobacco smoking does not significantly influence marijuana relapse relative to tobacco abstinence will be presented. Other topics examined will include patterns of co-use and alternative clinical approaches for intervention; initial findings from a clinical trial will demonstrate variations in expected outcomes; the especially high rates of concurrent use among those with other psychiatric disorders, and findings illustrating how integrated treatments for cannabis use and psychiatric symptoms are effective, but may inadvertently increase tobacco use; and conversely, how tobacco-focused treatments may improve psychiatric symptoms, cannabis and tobacco use. Implications of concurrent use on adolescents, with special attention to how marijuana legalization impacts such concerns will be discussed.
SYMPOSIA

Sunday, June 15

III. New buprenorphine formulations and drug combinations in clinical development
   Chairs: David McCann and Bob Walsh

This symposium will summarize data from the ongoing clinical development of three new buprenorphine-containing products: 1) buprenorphine subdermal implants (Probuphine®); 2) CAM2038 long-acting buprenorphine injection; and 3) ALKS 5461 sublingual tablets. The buprenorphine implant and long-acting injection products may prove especially useful in treating opioid-dependent patients who are non-adherent with daily dosing. In addition, these products appear to have very low potential for diversion and abuse by patients. Probuphine® implants may be effective for up to six months. There are two different CAM2038 formulations: one is intended for weekly injections and the other for monthly injections. Unlike other buprenorphine-containing products, ALKS 5461 also contains a potent, systemically bioavailable mu-opioid receptor antagonist, ALKS 33. The two active agents, in 1:1 (wt:wt) ratio, are co-formulated in a sublingual tablet. The inclusion of ALKS 33 in ALKS 5461 is intended to render the resulting combination devoid of addictive potential. In human clinical pharmacology studies, ALKS 33 has been shown to counteract the actions of buprenorphine at mu-opioid receptors. In phase I and phase II clinical studies, ALKS 5461 has shown efficacy in the adjunctive treatment of major depressive disorder (MDD) in patients showing inadequate response to standard therapies, an indication for which the FDA has granted “fast track status.” ALKS5461 is also viewed as a potential treatment for multiple substance use disorders, and a human laboratory cocaine/ALKS 5461 interaction study has been completed.

IV. How translational is behavioral research in addiction
   Chairs: F. Gerard Moeller and Kathryn A. Cunningham

One of the strengths of research in addictions compared with other psychiatric disorders is the existence of animal models with significant face validity. However, in spite of these animal models, there have been a number of medications identified in preclinical studies that have not shown efficacy in clinical trials. The aim of this symposium is to discuss translational (and non-translational) aspects of preclinical and clinical models of addictions. The study of cocaine cue reactivity in rodents and human cocaine-dependent subjects will serve as a case in point to foster discussion on the broader topic of translational behavioral research. With a history of cocaine use, environmental contexts and stimuli (e.g., paraphernalia) become reliably associated with its use leading to durable conditioned responses (“cue reactivity”) that can predict relapse as well as treatment success. Drug cue reactivity is the attentional orientation toward such drug-associated cues that are measurable as conditioned physiological effects (e.g., heart rate), subjective properties (e.g., craving), appetitive approach behaviors (e.g., drug-seeking) and activation of specific corticostriatal sub-circuits. Cocaine cue reactivity is frequently measured as attentional bias (attentional orienting response in a computerized cocaine-word Stroop task) while appetitive approach behavior (lever presses in self-administration context) is assessed in animals under conditions of extinction or forced abstinence. Data will be presented on the overlapping neurobiology of cue reactivity in rodents self-administering cocaine and human cocaine dependent subjects. Differences and similarities between preclinical and clinical research will be discussed in relation to the ultimate goal of development of new treatments for addictions.
SYMPOSIA

Sunday, June 15

V. DSM-5 substance-related and addictive disorders: Rationale and controversies
Chairs: Deborah Hasin and Wilson Compton

Substance use disorders in DSM-IV had many strengths, but also problems that required change. The DSM-5 Substance-Related Workgroup recommended changes to preserve the strengths while solving the problems, based on research evidence from over 200,000 participants and much feedback from the field. In this symposium, DSM-5 changes in substance-related disorders, their rationale, and clinical implications will be presented. DSM-IV had two disorders, dependence and abuse, with abuse diagnosed only when dependence was not present. In DSM-5, the two disorders were replaced with a single disorder, indicated by at least two of eleven criteria (7 DSM-IV dependence, 3 DSM-IV abuse and one new criterion: craving). The diagnostic threshold was chosen to maintain consistency in prevalence of substance use disorders between DSM-IV and DSM-5. DSM-5 also includes severity indicators based on the number of criteria (2-3, 4-5 and 6+ for mild, moderate and severe). New criteria for cannabis and caffeine withdrawal were introduced, and criteria for tobacco disorders aligned with the other substances. The rationale for moving gambling disorders to the same chapter as substance disorders will be reviewed, as well as the status of other non-substance, behavioral "addictions". While future studies are needed to address issues that remain, the recommended changes are intended to overcome many problems and reduce clinician burden, given the need to consider only one main disorder rather than two. Reactions of the press and the field to the DSM-5 SUD will be reviewed, as well as alternative diagnostic approaches and how DSM-5 will affect ongoing research.

Monday, June 16

VI. Acute and chronic stimulant effects on motivation and behavioral control
Chairs: Scott Kollins and Iliyan Ivanov

This panel will present new data from animal, human neuroimaging and pharmacological clinical trials. The presentations aim to address in depth new findings and controversies related to the purported effects of stimulants (e.g. methylphenidate, amphetamines, cocaine) on modulating brain activations related to motivation and behavioral control. These controversies stem from various studies in animals and humans some suggesting that despite their well-documented clinical safety prescription stimulants may have effects on brain structures and functions that could be linked to potentially deleterious long term outcomes. The clinical implications of such neurobiological effects, however, remains poorly understood. For instance, available evidence suggests that the positive effects of prescription stimulants on symptoms of inattention and impulsivity are not sustained over longer periods. In addition, some have hypothesized that stimulant exposure in early life may activate pathways that facilitate the development of later substance use problems. The studies that will be presented in this panel will address the questions of acute effects of stimulants specifically focusing on motivational drives and behavioral control assessed by variety of tasks in animal models as well as humans studied with functional magnetic resonance (fMRI). These reports will provide information about neuroanatomical and neurophysiological changes associated with behavioral modulations resulting from both stimulant challenge and treatment with prescription stimulants. Further, new information will be presented to address questions related to long-term neurobiological effects of stimulants exposure in animals and the clinical outcomes of long-term stimulant treatments in youths and adults with attentional and impulsivity syndromes specifically looking at the relationship between stimulant treatment and later substance use problems.
Monday, June 16

VII. Neuropeptidergic targets for CNS disorders
Chair: Ivy Carroll and Scott P. Runyon

This symposium will include studies directed toward: (1) evaluation of ligand bias at the kappa opioid receptor (KOR), where the evaluation of novel compounds that preferentially engage G protein versus β-arrestin 2 interaction with KOR will be discussed; (2) nociceptin/orphanin FQ receptor functional selectivity, signaling, and behavior which will discuss NOPR signaling in vitro as it relates to C-terminal regulation; (3) neoclerodane diterpenes as novel treatments for drug abuse, where studies directed toward the development of novel treatments for drug abuse based on salvinorin A will be discussed; and (4) identification of neuropeptide S antagonists as pharmacotherapies for substances which will present the development of novel neuropeptide S antagonists that are active in rodent models of relapse to cocaine self-administration. The basic research information presented in these four presentations will provide a better understanding of how four different neuropeptidergic targets will lead to potential pharmacotherapies for treatment of various substance abuse problems and other CNS disorders.

VIII. The effects, use patterns and youth perception of electronic cigarettes
Chairs: Robert L. Balster and Thomas Eissenberg

There is an explosion of interest in the use of e-cigarettes (ECIGS). The symposium will provide an overview of ECIGS, how they work, and data on how design features of the various products affect their nicotine and toxicant yield, as well as an overview of data on the acute effects of ECIGS, with a primary focus on results of laboratory studies. Results of a comprehensive online survey of a large sample of ECIG users will describe the progression of product use over time, the extent and pattern of smoking cessation and continued dual tobacco use, and the perceived dependence on ECIGS versus cigarettes. Youth perception of ECIGS and results from a qualitative study in adolescents and young adults, grouped by smoking status and gender will be presented, along with the results of a 4-year longitudinal study of college students from 11 colleges in North Carolina and Virginia. Changes in rates of ECIG use over time and on longitudinal trajectories of electronic cigarette use, including initiation, transitions to and from conventional cigarettes and dual use will be reported. Regulatory implications of the research for possible FDA regulation of these products will also be discussed.

IX. Novel approaches to examining the intertwining epidemics of HIV and drug abuse:
From decision-making to viral load
Chair: Matthew W. Johnson and Steven Shoptaw

Drug abuse and HIV infection are complex, intertwined epidemics. Both the epidemiology of HIV transmission and our scientific understanding of the behavioral and biological factors that underlie HIV infection and related outcomes have evolved over time. These changes have prompted the development of new research methodologies in effort to more fully understand the causal factors that underlie the relationship between drug use and HIV infection. This symposium brings together four independent research teams to discuss novel methods of examining HIV risk behavior among drug users. Topics include: 1) laboratory investigations of sexual decision making after acute administration of alcohol, cocaine, and methamphetamine, 2) a laboratory examination of relationships between measures of risk-taking, real-life HIV risk behavior, and HIV infection among cocaine users 3), using crowdsourcing technology to examine sexual decision-making, substance abuse, and HIV infection among a difficult-to-reach population of men who have sex with men (MSM), and 4), individual and partner-level correlates
of stimulant use, antiretroviral therapy (ART) adherence, and viral load among MSM. This program spans from basic rigorous laboratory studies to population-level assessment, providing a unique opportunity for integration of laboratory science and clinical research.

Tuesday, June 17

X. CB2 functions in the brain and the periphery
Chairs: Toby K. Eisenstein and Vishnutt Purohit

New discoveries are showing that the CB2 receptor has a multitude of functions. It was originally recognized that this receptor is abundantly expressed in the immune system and only sparsely in the brain. Recent discoveries suggest that CB2 receptors are present in neurons. Exploration of its functions is revealing that CB2 does not produce the same psychoactive effects as ligation of CB1, but it does modulate effects of neuronal processes involved in addiction. Further, it has a role in neuropathic pain. Newer evidence indicates that the CB2 receptor is expressed on endothelial cells of the blood-brain barrier, and CB2 agonists alter the BBB permeability. In the immune system, CB2-selective agonists are emerging as a powerful class of immunosuppressive compounds. This symposium presents new developments in this rapidly emerging field and explores the potential role of CB2 receptor activation in the treatment of pain, drug addiction, inflammation, and preservation of BBB integrity.

XI. Trajectories of heroin use: Insights from longitudinal studies
Chairs: Linda Cottler and Christina Marel

Longitudinal naturalistic studies of heroin dependence provide the unique opportunity to examine predictors of remission, criminality, mortality, psychopathology and long-term treatment outcomes. Indeed, although there has been much research examining heroin dependence from cross-sectional perspectives, the comparably few longitudinal cohort studies allow long-term trajectories of heroin use, abstinence and other comorbid disorders to be examined. Long-term patterns and trajectories of heroin use have important implications for treatment responses, clinical practice and policy. This symposium examines long-term trajectories of heroin use across three countries: USA, Ireland and Australia, and discusses the implications for clinical practice and policy. From Australia, the 11-year follow-up of ATOS will be completed in December 2013, on a sample of 615 treatment and non-treatment seeking heroin users who were recruited into the study in 2001. Over 66% of the cohort has been interviewed to date, and we have accounted for over 88% (including those who are deceased, refusals, and incarcerated). ATOS trajectories data will be presented for the first time, with a particular focus on the relationship of heroin use trajectories, PTSD and depression, and how these disorders affect patterns of heroin use and abstinence. Longitudinal findings from the ROSIE study in Ireland, and from the US, studies on recovery from heroin addiction, based on 33-year findings. Gender differences in 30-year trajectories of heroin and other drug use will also be reported.
Considerable progress in the understanding of drug abuse has been made through the use of animal models. This symposium describes animal research homologous to the human condition and highlights the profound insights by one of CPDD’s long-time members, Bill Woolverton, who died recently after a brief illness. In honor of Bill’s legacy, the speakers are his postdoctoral mentor and former postdoctoral mentees. Bill was passionate about the concept of reinforcing efficacy (or strength) and the choice to take drugs as a determinant of persistent drug use. The efficacy/strength of drugs as reinforcers “pulls” behavior away from other reinforcers, so that the abuser engages in choice for drugs over essentially everything else. A better understanding of these concepts would enhance our ability to develop treatments for drug abuse and other disorders involving dysfunctional consumption. The aims of this symposium are to provide CPDD members with an understanding of the concept of reinforcing efficacy and its impact in medication development, to describe how factors such as environmental context, cost, pharmacology, and social context influence drug choice, to learn about recent advances in delay discounting, in which the extent to which a subject chooses a reinforcer of lower magnitude with no delay over a reinforcer of larger magnitude with a delay provides an analogue of the concept of “impulsive choice”, and how punishers of drug choice have clinical potential. Finally, the discussion will allow opportunity for lively discourse and reflection on Bill’s substantial legacy to drug abuse research.

XIII. Environmental and physiological factors predisposing susceptibility to drug abuse

Many factors influence an individual’s susceptibility to substance use disorders. Findings from preclinical and clinical studies will be presented that implicate environmental and physiological factors that impact the vulnerability to drug abuse. Data will be shown demonstrating that diet-induced obesity increases cocaine reward in males, whereas females have increased reward when a high-fat diet is removed. High-fat diets also produce sex-related differences in dopaminergic transmission and hormones involved in feeding. Another presentation will address altered dopaminergic function and reward sensitivity in a rodent model of PTSD. In this model, PTSD causes dysregulation of reward circuits as reflected by anhedonia and reduced reward function, and is accompanied by alterations in the dopamine system. Investigation of adolescent methylphenidate and atomoxetine treatments on adult cocaine self-administration and DAT/NET function in an ADHD model will be presented. Rats with an ADHD phenotype show enhanced cocaine self-administration after adolescent methylphenidate, but not atomoxetine. Although both medications acutely enhance DA and NE in prefrontal cortex, DAT and NET function are altered in opposing ways. How dopamine markers (DAT and D2 receptor availability) measured in early adolescence can predict vulnerability to development of cocaine abuse and relapse in nonhuman primates will be presented. Clinical and translational implications of these studies, including possible targets for the development of therapeutic interventions and prevention efforts will be discussed, as will potential translational studies bridging between these findings and their clinical impact. Collectively, these studies identify specific factors that affect susceptibility to substance use disorders, elucidate underlying mechanisms and suggest avenues of translational importance.
Thursday, June 19

XIV. Medications for drug addictions: Sex differences in outcomes in animal and human laboratory studies and in clinical trials
Chair: Cora Lee Wetherington and Ivan Montoya

There are no FDA-approved medications to treat cocaine and marijuana addiction and treatment medications for nicotine and alcohol addiction often have lower success rates in women than men. This translational symposium will feature data from animal models, human laboratory and clinical trial research demonstrating promise of several medications to treat cocaine, marijuana, nicotine and alcohol addiction. Speakers will review extant studies and highlight their recent findings and differential outcomes and mechanisms in males and females. Mice data showing that guanfacine, an alpha2-adrenergic autoreceptor agonist, has differential antidepressant-like effects in males and females, and that simultaneously targeting noradrenergic and cholinergic systems could be especially useful in smoking cessation treatment, particularly those with depressive symptoms will be presented. Human laboratory and clinical outcomes demonstrating that guanfacine preferentially targets drug craving and stress reactivity in women versus men across separate samples of cocaine and tobacco dependent adults will also be discussed. Human and animal model data suggesting possible use of progesterone to treat cocaine addiction, including new rodent data showing that progesterone’s effectiveness in reducing drug seeking is enhanced by exercise will be reviewed, in addition to animal studies investigating oxytocin and noradrenergic drugs as potential medications for cocaine addiction, and human laboratory research investigating oxytocin for treatment of marijuana and cocaine dependence, including fMRI and stress data. The discussant will synthesize the findings and discuss issues regarding sex differences in outcomes of medications being investigated to treat substance use disorders.

XV. Demystifying medicinal chemistry and drug design
Chair: Andrew Coop and Thomas E. Prisinzano

An educational symposium for all members of CPDD focused on the approaches, techniques, and interdisciplinary nature of medicinal chemistry and drug design as applied to treatments for drug dependence. The vision of the symposium is to provide an overview of medicinal chemistry, accessible to all members of the College, with the aim of improving communication and reducing barriers caused by “cultural” misunderstandings. The ultimate goal is to foster collaborative endeavors towards the development of new medications for the treatment of substance abuse and dependence. The overview and discussant by two senior leaders in the field will be complemented by three junior independent researchers demonstrating the application of principles to their own research programs. In addition to providing an educational experience for all at CPDD, this provides a unique opportunity to introduce three junior independent medicinal chemists to the CPDD and NIDA community, and ensure this important component of the CPDD interdisciplinary community continues to grow and prosper.
WORKSHOPS

Sunday, June 15

I. The epidemiology of nonmedical use of prescription opioids and opioid use disorders in the USA: Recent trends, longitudinal patterns, and transitions to heroin and injection drug use

   Chairs: Silvia S. Martins and Sean E. McCabe

Nonmedical use of prescription opioids (NMUPO) and prescription opioid (PO) disorder is a national public health crisis in the USA as well as in other countries. This workshop brings together leaders in the field of NMUPO who will present recent findings on a) NMUPO and opioid use disorder secondary to NMUPO in adolescents and young adults based upon data from the 2002-2011 U.S. National Survey on Drug Use and Health (NSDUH); b) longitudinal patterns of NMUPO based on four waves of U.S. regional (Secondary Student Life Survey) and national samples (Monitoring the Future data) of middle and high school students; c) the risk of transition to heroin use among 396 U.S. young adult NMUPO users in the community followed for 36 months (data from Ohio); d) patterns of injection drug use and other risk behaviors among a longitudinal cohort of 500 rural Appalachian NMUPO followed since 2008; and e) the overlap of alcohol use disorders and opioid dependence using data from the two waves U.S. National Epidemiologic Study on Alcohol and Related Conditions (NESARC). By the end of this session participants will be able to better understand the prescription opioid epidemic as well as longitudinal patterns of NMUPO, prevalence and trends on opioid use disorders, the transition from NMUPO to heroin and injection drug use and the association of NMUPO with other risk behaviors. The presented findings have implications for both prevention and treatment.

II. Integration of addiction care into medical settings: The state of the science

   Chairs: Richard Saitz and Jeffrey Samet

To address barriers to addiction treatment, integration of care into medical settings is advocated and being disseminated. Few studies address integration in medical settings. This workshop will discuss 1) identification of drug use in primary care by using results of alcohol screening, highlighting characteristics and predictors of drug use among those who screen positive for alcohol misuse and implications for improving identification of drug use; 2) results of a cohort analysis in primary care, the aim of which was to determine the effects of reduction of drug use (versus abstinence and no change), which showed that among cocaine and opioid users but not marijuana users, abstinence, but not use reductions, was associated with fewer drug use consequences; 3) a large study of variability in opioid prescribing in urban community health centers and a safety-net hospital that determined the effects of prescribing practices and a nurse care manager on outcomes (risk for opioid misuse (e.g. early refills) and guideline concordant care (e.g. opioid agreements, urine drug testing); 4) results of a randomized trial for opioid dependence, comparing referral, to brief intervention (BI) with referral to specialized care, or BI with initiation of buprenorphine and referral to a primary care maintenance program. The state of the science for integration of addiction treatment in medical settings, including results of two large randomized trials—screening and brief intervention for drug use, and chronic care management for addiction in primary care, will be reviewed.
WORKSHOPS

Sunday, June 15

III. Go/No-Go decisions in medication development: Why some compounds should NOT go forward and how do we identify them
Chair: Jane B. Acri

Marketed drugs in the US and Europe are sometimes discovered to have adverse side effects after they have gone through the rigorous safety and efficacy testing required for approval. Sometimes the adverse effects were missed in early stages of development because they did not occur in preclinical testing, or they were not apparent until the compound had been taken by sufficiently large numbers of individuals to show rare, but serious side effects. Because the possible manifestation of toxic side effects might result in life-threatening risks to the patient population as well as a huge loss of investment, it is important to assess a compound’s potential to produce adverse effects at all stages in the development process. This workshop will highlight evaluation procedures used to assist in lead selection during the Structure Activity Relationship (SAR) stage by eliminating compounds with carcinogenic potential and cardiovascular risks, using examples from the NIDA Medication Development Program. For compounds that pass early safety hurdles, we will discuss late stage in vivo tests designed to identify those compounds that may exacerbate cardiovascular effects of cocaine, or that might have the potential to produce severe negative mood states. The procedures, and examples, both from the literature and from recent failures in NIDA’s medication candidate pipeline will be presented and discussed.

IV. The 20th Annual Contingency Management Working Group
Chairs: Steven Meredith and Kelly Dunn

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 20th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

V. Epidemiology and public health research methods for minorities and under-represented minorities (Co-Sponsored by CPDD International Programs Committee)
Chairs: James Anthony and Jan Copeland

This year, the annual workshop is co-sponsored by the CPDD International Programs Committee. As in the past, the focus is on methods issues pertinent to epidemiology, biostatistics, and public health research generally. There will be a talk about adaptive designs for clinical research with a special focus on smartphone interventions. Thereafter, focus will shift to methodological challenges in minority health disparities and equity research.
WORKSHOPS

Monday, June 16

VI. Knowledge translation in addiction sciences: Why and how to share research knowledge beyond the academic community
Chair: Doris Payer and Marc Kaufman

Evidence suggests that despite the wealth of important research information produced in the health sciences, there is a gap between what is known within academic circles and what is practiced outside of these circles by knowledge users (e.g., clinicians, policy-makers, educators, healthcare administrators, community leaders, patients, or the public). There is increasing acknowledgement among scientists and funding agencies that more can be done to bridge this “know-do gap,” resulting in increasing investment in the practice of Knowledge Translation (KT), i.e., the pro-active dissemination of research knowledge to facilitate real-world implementation. This practice seems especially important in the field of addictions, where clinical success rates, policy decisions, and even public opinion stand to benefit greatly from scientific support. In turn, an interest in KT can increase funding success for scientists, and help researchers understand the real-world differences their work can make. This workshop, organized by members of the CPDD “Education, Outreach, & Public Policy” and “Media” committees, aims to raise awareness about KT among addiction scientists and encourage adoption of KT strategies in their research. Workshop presentations will explain the importance and benefits of KT to researchers and to the field, present theoretical models, strategies, and tools for actual practice, and share the experiences of individuals already actively engaged in some of this work.

VII: High risk and understudied: Assessing abuse liability in opioid-dependent subjects
Chairs: Sandra D. Comer and Kerri A. Schoedel

Literature reviews and FDA draft guidance on the assessment of drug abuse potential and abuse-deterrent formulations describe methodology for evaluating abuse potential clinically in recreational drug users. Both FDA guidance documents indicate that subjects should not be those diagnosed with dependence, in treatment for substance use disorders, or in the case of the opioids, physically dependent. However, opioid-dependent individuals represent a population at very high risk for abusing, misusing and tampering with prescription opioids, as well as using these drugs by alternative routes, such as intranasal or intravenous administration. Because of their high-risk behavior, opioid-dependent individuals may also be disproportionately represented in negative medical and societal outcomes of abuse, such as emergency department visits. Hence, these subjects represent both an ‘at-risk’ population, as well as a relatively understudied one. Therefore, assessment of opioid-dependent subjects, along with recreational drug users, may provide a more comprehensive picture with improved predictive validity for translating outcomes to the post-market setting. The aim of this workshop is to provide an overview and critical discussion of methods of evaluating the abuse liability of opioids in opioid-dependent subject models. Specific methodological issues, such as the use of detoxification and/or maintenance drugs in non-treatment-seeking subjects or patients in treatment (methadone-, buprenorphine-maintained), subject management, appropriate measures/endpoints, and ethical concerns, will be discussed. The strengths and challenges associated with these subject populations will be contrasted with studies performed in recreational drug users.
Monday, June 16

VIII. Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects  
Chairs: Timothy D. Brewerton and Therese K. Killeen

Patients with eating disorders (EDs), particularly those with bulimic symptoms, have high rates of substance use disorders (SUD), and conversely, patients with SUD have higher rates of EDs. EDs often involve the abuse of substances as well as the compulsive engagement in maladaptive behaviors (dieting, exercising, binge eating, vomiting) that are addictive in nature. Substances are used to promote vomiting (emetics), retard absorption (lipase inhibitors), promote elimination (laxatives, diuretics), and suppress appetite (stimulants, caffeine, alcohol, nicotine, herbs). Highly palatable foods have been found to act much like substances of abuse in the brains of both animals and humans. Specifically, high concentrations of refined sugar, fat, salt, and caffeine have been reported to have addictive properties. Animal and human experiments confirm that both food ingestion and drug use cause dopamine release in brain areas that mediate pleasure and emotion, and the amount of dopamine release correlates with the sense of subjective reward or experience of pleasure from both food and drug use. Similar patterns of brain activation as seen on fMRI in response to food and drug cues have also been found. In addition, food stimulates the opiate system and there are striking similarities in use and withdrawal patterns of sugar and of classic drugs of abuse. Furthermore, there often appear to be reciprocal relationships among food and other substances. Taken together, these observations support the conclusion that food, ED behaviors and classic addictive substances compete for the same brain pathways and may serve the same purposes psychologically.

IX. Advances in adolescent recovery research  
Chairs: Michael L. Dennis and John F. Kelly

Over 90% of people with substance use disorders (SUD) started using under age 18 and met diagnostic criteria by age 21. Intervention in the first 9 years of use is associated with cutting the years of use before achieving a year of abstinence by over 57%. But only 8% of adolescent with SUD enter treatment and over half of those stay less than 90 days, are discharged negatively, and relapse within 90 days. In addition to improving access and treatment effectiveness, a comprehensive solution also requires a better understanding of adolescent recovery and how it can be managed better (which is the focus of this workshop). The workshop will describe 1) the role of 12-step mutual-help organizations in youth recovery and then examine their benefits, moderators, and mechanisms; evolution of the recovery school movement and its role as an aftercare pathway to maintain recovery; how smartphones can be used to manage adolescent recovery through increased self-monitoring, immediate access to interventions, and predicting the risk of relapse.
Tuesday, June 17

X. The use of GIS & GPS technology in addiction research  
Chair: C. Debra Furr-Holden and Kenzie Preston

There is a growing body of evidence that place matters with respect to opportunities to use drugs, decisions about what drugs to use, and success in recovery from addiction and drug dependence. Geographic Information Systems (GIS) provide a valuable framework and a set of analytic tools for understanding and empirically clarifying how the environment influences the addiction process. Global Positioning System (GPS) technology has also advanced such that we are able to continuously monitor where people are and combine this data with added information from electronic diary entries to understand the interaction between place, self-reported stress, drug cravings, intentions to use drugs, and actual drug use. Combined, these methods open new avenues for research that offers great promise for drug prevention, treatment intervention, and recovery from addiction. The workshop will discuss the use of both GIS- & GPS-based technology in understanding the addiction process. Specifically, recent advancement in GIS methods will be explored including the use of remote sensing to classify environmental risk for substance use, application of geospatial analytic techniques and tools within a GIS framework, and multi-level modeling with geographic data. In addition, ongoing studies that use GPS-based technology to understand how place influences drug cravings, decisions about drug use, and success in drug treatment will be discussed.

XI. Improving the writing of emerging investigators in addiction science:  
Innovative training, evaluation methods, and resources  
Chairs: James L. Sorensen and Joseph Guydish

The addiction research field needs increasingly productive investigators who create high-quality scientific reports. At the 2013 meeting we presented a workshop focusing on how emerging researchers can publish their manuscripts. This year we focus on training methods and resources to improve the writing of emerging investigators. Presenters are investigators spanning both preclinical and clinical research, and include three current editors of addiction research journals. All presenters suggest both conceptual and practical guidelines. While the workshop is aimed at assisting those providing training to young investigators, both junior and senior colleagues can benefit and provide their perspective. In this interactive workshop, one third of the time is reserved for audience questions, comments, and discussion. The workshop spans both manuscript and proposal writing, with learning levels from fellows to faculty. The first presenter emphasizes that you really can't succeed as a researcher if you can't write well (and quickly); she explains how her training program integrates publication issues into a Professional Development seminar that is followed by participation in an ongoing Writers’ Workgroup. The second presenter describes an innovative Writers’ Task Force that focuses junior investigators on completing manuscripts; since the seminar’s inception in 1992, a total of 207 papers have been supported, 73% of these have been submitted for publication, and 65% have been published to date. The third presenter, a scientist and journal editor, describes an innovative editorial internship program that has developed editorial skills among developing investigators. The fourth presenter, a clinical laboratory researcher, describes training to help new investigators develop high-quality manuscripts.
WORKSHOPS

Tuesday, June 17

XII: Update on the Abuse-Deterrent Science Meeting on the FDA draft Guidance for industry on abuse-deterrent opioids—evaluation and labeling

Chairs: Beatriz Rocha and Cynthia Arons

This workshop is sponsored by CPDD’s Committee on Industry, Academia, and Government Relations. The FDA issued a draft Guidance on Evaluation and Labeling of Abuse-Deterrent Opioids in January 2013. It outlined four Categories of testing of opioid formulations that are designed to deter abuse (three pre-approval, one post-marketing). The draft then discussed four tiers of labeling language, ranging from claims that the drug formulation incorporates physiochemical barriers to abuse to claims that the product has actually reduced abuse in the real world setting. The FDA expressed an interest in encouraging and stimulating scientific input from non-governmental experts on the draft Guidance. In response to the interest expressed by the FDA, a two-day meeting was held in the fall of 2013 where over 200 participants from FDA, industry, and academia discussed and deliberated study-design considerations, data interpretation, and potential criteria for each section of the draft Guidance, as well as how to apply the principles to an ANDA referencing a listed drug that had some approved abuse-deterrence labeling. This workshop will summarize and synthesize the key points of the 2013 meeting from the perspectives of academia, industry, and government; update the audience with new developments in this emerging science; present a moderated panel discussion amongst the speakers; and provide for audience interaction with the speakers.

XIII. Addiction treatment research vs. usual care: What are the foreseeable risks?

Chair: Andrew Saxon

The Office for Human Research Protections (OHRP), part of the US Department of Health and Human Services, is seeking advice from all stakeholders on how to assess the risks to people in randomized studies that involve existing treatments. Addiction treatment trials that include ‘standard of care’ (or “treatment as usual”) are conducted in community health care settings (i.e. hospitals, primary care, treatment clinics). Such trials are being done currently and are likely to become more widespread. Researchers, clinicians, and bioethicists have differing opinions regarding how best to protect participants; some may insist that all risks, including those of usual care, be included in the informed consent process, even though patients with a particular condition would be taking one or the other treatment anyway. How best to assess and present these risks is a complex issue. The main questions include: What are the treatment-as-usual risks? Are they more than minimal risk? How does one assess risks of combined research and usual treatments? (especially with potentially vulnerable populations such as those with substance use and addiction). These issues will be addressed by a panel of experts in addiction treatment, clinical research, and bioethics, including membership on institutional review boards (IRB). Panelists will attempt to shed some light and provide recommendations that will assist clinical investigators designing and conducting future addiction treatment clinical trials.
Acknowledgements and Advertisements

The following organizations have financially supported the work of the CPDD organization during the past year

Collegium Pharmaceutical, Inc.

Grunenthal USA, Inc

NIDA (National Institute on Drug Abuse)

The Harris Family Foundation

Vince & Associates Clinical Research

Funding for this conference was made possible (in part) by Grant Agreement # R13 DA 013192 from NIDA.

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government